Making headway with the molecular and clinical definition of rare genetic disorders with intellectual disability by Willemsen, M.H.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/108606
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Making Headway with 
the Molecular and Clinical Definition 
of Rare Genetic Disorders with 
Intellectual Disability
Marjolein H Willemsen
Making Headway with the Molecular and Clinical Definition of Rare genetic 
Disorders with Intellectual Disability 
The studies presented in this thesis were performed at the Department of Human 
Genetics, Radboud University Medical Centre, Nijmegen, The Netherlands, and 
supported by grants from the Consortium ‘’Stronger on your own feet’’.
ISBN/EAN 978-90-9026995-5
© M.H. Willemsen
All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any 
means, electronic or mechanical, by print or otherwise, without permission in writing from the author
Cover design and lay-out: In Zicht Grafisch Ontwerp, Arnhem
Image by: Ghislaine Collard from Jans Pakhuys, de Amerpoort, Amersfoort
Printed by: Ipskamp Drukkers, Enschede
Making Headway with 
the Molecular and Clinical Definition 
of Rare Genetic Disorders with 
Intellectual Disability
Proefschrift
ter verkrijging van de graad van doctor 
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. mr. S.C.J.J. Kortmann, 
volgens besluit van het college van decanen 
in het openbaar te verdedigen op woensdag 17 oktober 2012 
om 13.30 uur precies
door 
 Marjolein Hanna Willemsen
geboren op 28 februari 1981
te Nijmegen
Promotoren
 Prof. dr. B.C.J. Hamel
 Prof. dr. ir. J.H.L.M. van Bokhoven
 Mw. prof. dr. H.M.J. van Schrojenstein Lantman-de Valk
Copromotor 
 Mw. dr. T. Kleefstra
 
Manuscriptcommissie
 Prof. dr. B.G.M. van Engelen (voorzitter)
 Prof. dr. J.A.M. Smeitink
 Mw. prof. dr. H. van Esch (UZ Leuven)
Voor papa
Contents
Abbreviations   9
Chapter 1  General introduction and outline of this thesis 11
 1.1  Intellectual disability or mental retardation, what is in a name? 13
 1.2  Intellectual disability, an issue of major personal and social impact 14
 1.3  The importance of a causal diagnosis 14
 1.4  Yield of previous cohort studies on aetiology of intellectual disability 15
 1.5  Historical hallmarks in genetic diagnostics of intellectual disability 20
 1.6  Scope and outline of this thesis  23
Chapter 2  Study design and patient cohort 29
 2.1  Organization 31
 2.2  Total pre-selection cohort 31
 2.3  Patient selection and recruitment 32
 2.4  Included subjects 35
 2.5  Genetic diagnostic assessment 35
Chapter 3  Identification and characterization of chromosomal disorders with ID 45
 3.1  Microscopic chromosomal aberrations 45
  3.1.1   Further Molecular and Clinical Delineation of the  47 
Wisconsin Syndrome Phenotype associated with Interstitial  
3q24q25 Deletions
  3.1.2   Clinical and molecular characterization of two patients with  63 
a 6.75 Mb  deletion in 8p12p21 with two candidate loci for  
congenital heart defects
 3.2  Submicroscopic chromosomal aberrations 79
  3.2.1   Identification of ANKRD11 and ZNF778 as candidate genes  79 
for autism and variable cognitive impairment in the novel 16q24.3 
microdeletion syndrome
  3.2.2   Chromosome 1p21.3 microdeletions comprising DPYD and  99 
MIR137 are associated with intellectual disability
  3.2.3   Interpretation of clinical relevance of X-chromosome copy  121 
number variations identified in a large cohort of individuals with 
cognitive disorders and/or congenital anomalies 
Chapter 4 Further phenotypic delineation of well known ID syndromes 153
 4.1  Kleefstra syndrome 153
  4.1.1  Update on Kleefstra syndrome 155
  4.1.2   Familial Kleefstra syndrome due to maternal somatic mosaicism  177 
for interstitial 9q34.3 microdeletions
 4.2  Adult phenotypes in Angelman- and Rett-like syndromes 193
Chapter 5 Exome sequencing in sporadic and familial ID 237
 5.1   Mutations in DYNC1H1 cause severe intellectual disability with  239 
neuronal migration defects and peripheral neuropathy
 5.2   Diagnostic exome sequencing in patients with severe intellectual  251 
disability 
 5.3   Involvement of the kinesin family members KIF4A and KIF5C in  273 
intellectual disability and synaptic function 
Chapter 6 General overview of results 289
 6.1  Diagnostic phase  291
 6.2  Diagnostic related research phase 303
 6.3  Total yield of diagnostic phase and diagnostic related research phase 313
 6.4  Comparison between patients with and without a diagnosis 313
Chapter 7 General discussion and future prospects 319
 7.1  Yield of present-day genetic diagnostic assessment 321
 7.2  Further phenotypic delineation of known ID syndromes 324
 7.3  Identification and definition of novel ID syndromes 325
 7.4  Challenges in clinical interpretation 326
 7.5   Implementation in clinical practice: outpatient clinic  327 
‘’Zeldzaam’’ (‘’Unique’’)
 7.6  Future prospects 329
 Summary/Samenvatting 337
 Dankwoord 345
 List of publications 349
 Curriculum vitae 351
 Appendix (Color Figures) 353 
9abbreviations
List of abbreviations
AAIDD American Association on Intellectual and Developmental Disabilities
AD Autosomal dominant
ADHD Attention Deficit Hyperactivity Disorder
AR Autosomal recessive
ASD Autism spectrum disorder
ATRX Alpha-thalassemia/mental retardation syndrome
CA Congenital anomaly
CD Cognitive disorders
CMT Charcot-Marie-Tooth
CNV Copy number variation
CNS Central nervous system
CT Computer tomography
DD Developmental delay
DECIPHER DatabasE of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources
DGV Database of Genomic Variants
ECARUCA European Cytogeneticists Association Register of Unbalanced Chromosome Aberrations
EEG Electroencephalogram
FISH Fluorescent in situ hybridization
HMM Hidden Markov model
HPO Human Phenotype Ontology
ICD International Classification of Diseases
ID Intellectual disability
IQ Intelligence quotient
IUGR Intra-uterine growth retardation
kb kilobase (thousand base pairs)
KIF Kinesin family 
KS Kleefstra Syndrome
Mb Megabase (million base pairs)
MCA Multiple congenital anomalies 
MLPA Multiplex Ligation Probe Amplification
MRI Magnetic resonance imaging
NGS Next generation sequencing
OMIM Online Mendelian Inheritance in Man
SNP Single Nucleotide Polymorphism
UPD Uniparental disomy
WES Whole exome sequencing
WGS Whole genome sequencing
WHO World health organization
XL X-linked
General introduction and outline of this thesis
1.1  Intellectual disability or mental retardation, what is in a name?
1.2  Intellectual disability, an issue of major personal and social impact
1.3  The importance of a causal diagnosis
1.4  Yield of previous cohort studies on aetiology of intellectual disability
1.5  Historical hallmarks in genetic diagnostics of intellectual disability
1.6  Scope and outline of this thesis
1
13
general introduction and outline of this thesis
1
1.1   Intellectual disability or mental retardation,  
what is in a name?
The nomenclature of intellectual disability (ID) has frequently been an issue of 
debate. The terminology to describe individuals with impaired intellectual 
functioning has changed many times over the years. These name changes reflect 
the tendency in the attitude of the society to use more respectful and less offensive 
terms.1-7 Intellectual disability and mental retardation are two different descriptions 
of the same phenomenon. The term ‘’mental retardation’’ was introduced around 
1960.1, 2 During the last decade the term ‘’intellectual disability’’ is increasingly 
being used and actually has generally replaced the term ‘’mental retardation.’’3, 4 
This transition in nomenclature was initiated by organizations that provide health 
care and social support to people with ID and increasingly gained ground in other 
areas, such a public authorities and more recently in (clinical) genetics as well. In 
2006 the American Association on Mental Retardation (AAMR) changed her name 
to the American Association on Intellectual and Developmental Disabilities 
(AAIDD).4 Furthermore, in October 2010 President Obama signed ‘’Rosa’s law’’, 
mandating that the term ‘’mental retardation’’ should be replaced by ‘’intellectual 
disability’’ in the federal statutes (http://blogs.suntimes.com/sweet/2010/10/
obama_signs_rosas_law_mental_r.html). 
One of the voiced arguments to change the name is, that it would be less offensive 
and a better reflection of how we look at people with ID in their social-ecological 
context. The term ‘’intellectual disability’’ would better meet the conception that the 
condition is not an absolute, fixed state, but is rather the result of an interplay 
between the cognitive abilities of an individual on the one hand, and his or her 
environment and personalized support on the other hand.3-5 Opponents of the 
name change state that the new name is less accurate, because it does not indicate 
that it is a developmental problem, and that it causes confusion, because it is not 
associated with a change in the definition.6 Most international classification systems, 
such as the Diagnostic and Statistical Manual of Mental Disorders, Fourth revision 
(DSM-IV) of the American Psychiatric Association and the International Classification 
of Diseases, Tenth Revision (ICD-10) of the World Health Organization (WHO) are 
based on the definition by the AAIDD. This definition comprises three criteria: 1) a 
significant limitation in intellectual functioning, 2) a significant limitation in adaptive 
behaviour, like social and practical skills, and 3) an origin before the age of 18 
years.4 Generally, an intellectual quotient (IQ) score equal to or below 70 is used as 
an indication for presence of ID, though, as is reflected by the definition, just an IQ 
level equal to or below 70 is not sufficient to speak of ID. 
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often undervalued. ‘’What is the benefit for the affected individual him- or herself to 
know the cause?’’ is a frequently asked question. However, knowing the cause is of 
great importance to both affected individuals and their families. It may provide 
insight in comorbidity, associated behaviour problems, prognosis and lifespan, 
and recurrence risk, and thereby gives answers to important questions from involved 
families and health care providers. Identification of a genetic cause precludes 
further unnecessary and often incriminating testing, and fruitless interventions. 
Instead, knowing the cause enables specific anticipation on associated health and 
behavioural problems, since the extreme heterogeneity in aetiology and clinical 
presentation goes along with diverse prognoses and variable needs. Besides, the 
emotional impact on affected individuals and/or their families of just getting an 
explanation why this happened to him/her, to their son, daughter, brother or sister, 
is enormous in many cases. It is often a great relief when a diagnosis is established 
and all pieces come together, sometimes after many years of uncertainty and 
searching for a diagnosis. In addition it enables counselling of recurrence risk, and 
prenatal testing if indicated and desirable. Moreover, the identification of genetic 
defects associated with ID provides insight in the underlying pathological 
mechanisms, which is the first crucial step that opens the way towards the future 
development of treatment strategies.31, 32
1.4   Yield of previous cohort studies on aetiology of 
intellectual disability
Causes of ID can be divided into genetic causes and acquired, environmental 
causes. In individual cases, the overall phenotype may also be the result of the 
interplay of both genetic and environmental influences. Most severe forms of ID 
(IQ<50) have a genetic cause.11 By contrast, mild forms of ID, especially those with 
IQ levels around 70, are thought to represent the lower end of the normal IQ 
distribution and to be more commonly the result of the combined contribution of 
several genetic factors as well as environmental factors.11 Genetic causes of ID can 
be roughly subdivided in chromosomal aberrations, monogenic defects (including 
autosomal recessive metabolic disorders) and imprinting/epigenetic disorders. A 
special subgroup of metabolic disorders includes disorders caused by mitochondrial 
DNA defects. In epigenetic disorders, mutations in a single gene can lead to 
distortion of the expression of several other genes, without affecting the genomic 
architecture of these genes. Imprinting is another mechanisms involved in 
epigenetic disorders and refers to a parent of origin effect on the expression of 
genes. Chromosomal aberrations can be further subdivided into microscopically 
visible (numerical or large structural abnormalities) and submicroscopic aberrations. 
1.2   Intellectual disability, an issue of major 
personal and social impact
Based on the normal distribution of IQ values in the general population, 2-3% of the 
individuals have an IQ level equal to or below 70. But, as mentioned above, ID is 
more than just a limitation in intellectual functioning. 
In previous prevalence studies estimations range from 0.2 to 8%. This broad range 
is caused by differences in study design, study population and definition of ID.8-11 
The estimated prevalence of ID in the Netherlands is 0.7%.12 The prevalence of 
severe (IQ<50) ID is lower than the prevalence of mild ID (IQ>50) and is less 
variable between the different prevalence studies. Most studies report a prevalence 
of severe ID in the range of 0.3-0.5%.8-11, 13 
Prevalence studies of ID in the Netherlands are mostly based on registration 
databases of health care providers, including general practice databases and 
databases of ID care services.12, 14 Wullink et al. used extrapolation methods to 
calculate the prevalence of ID in the Netherlands based on the prevalence in 
Limburg, the Netherlands.12 The most recent estimate of the prevalence by Ras et 
al.15 also incorporates insights from international literature and calculated a total 
prevalence of at least 120.000 individuals (0.75%), including 60.000 (0.38%) people 
with an IQ<50 and at least 60.000 (0.38%) people with an IQ between 50 and 70. It 
is expected that the latter category in fact should include many more individuals, 
but they are more difficult to trace in care service registries.8-11 Most individuals with 
ID have a lifelong need of care and it is known that they have significantly more 
physical and mental comorbidity.16-23 The costs of health care for people with ID 
amount to a total of 8.8-10% of the national health care budget.24 This underlines 
that ID is not only a frequent disorder, but has a major personal and social impact 
as well. 
1.3  The importance of a causal diagnosis
ID is one of the main reasons for referral to a clinical geneticist. Until recently, the 
cause of ID remained unexplained in at least 50% of the affected individuals. 
Previous cohort studies showed that in 50-70% of the affected individuals the cause 
is unknown.25-30 These percentages concern populations that have been evaluated 
by clinical geneticists. In practice, the number of people with unexplained ID may 
be even higher, because many individuals, especially adults, have never received a 
genetic diagnostic assessment.31 Likely, many individuals with mild ID have not 
received such an assessment as well, because a multifactorial cause is suspected. 
The importance of identification of the underlying cause in an individual with ID is 
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the diagnostic categories multifactorial syndromes and culturofamilial ID, which 
they considered to be partly genetic. If these are not taken into account the total of 
genetic diagnoses sums up to 21%. Adding 17% acquired diagnoses, the diagnostic 
yield of this study was 38%. Rauch et al.27 analysed the diagnostic yield of 
conventional karyotyping, subtelomeric Fluorescent in Situ Hybridization (FISH) 
screening, molecular karyotyping, and specific DNA diagnostic tests and targeted 
FISH analyses based on clinical evaluation in a cohort of patients who had mostly 
an age below six years. In 20 of the total group of 670 patients they also performed 
molecular karyotyping by 10K array analysis. They report in 39.5% a genetic 
diagnosis, including in 35.5% a pertinent, molecularly confirmed genetic diagnosis 
and in the remaining a ‘’clinically unambiguous known syndrome’’, and/or an 
unclassified disorder with evidence of Mendelian inheritance by means of pedigree 
or X-inactivation pattern (4%). Adding 1.3% acquired diagnoses, the total yield of 
their study amounts to a total of 40.8%.
Other studies reviewed the diagnostic yield of a number of previous studies. In 
2005, van Karnebeek et al.25 published a systematic review based on 126 previously 
published studies on the diagnostic yield of six major diagnostic investigations 
used in previous cohort studies, including cytogenetic studies, subtelomere FISH 
studies, cytogenetic and molecular fragile X investigations, metabolic investigations 
and neuroimaging. They also observed a wide range in diagnostic yield between 
the several studies. Recently, Michelson et al.33 published a systematic review of the 
diagnostic yield of genetic and metabolic evaluation in children with global 
developmental delay or ID. They assessed the yield of G-banded karyotyping (at 
least 4%), subtelomere FISH (3.5%), microarray analysis (7.8%-10.6%) and metabolic 
tests (0.2-4.6%). Testing of FMR1 was positive in at least 2% of patients with 
mild-moderate ID, and testing of MECP2 in females with moderate to severe ID had 
an average yield of 1.5% in the studies they reviewed. These numbers are average 
numbers, but the results of individual studies showed a much broader range.33
Several studies focused on the evaluation of the yield of one or more specific 
genetic diagnostic tests. Knight et al. (1999)34 showed that subtelomere FISH tests 
in children with unexplained ID had a high detection yield of subtle chromosomal 
aberrations of 7%. Using subtelomeric Multiplex Ligand Probe Amplification (MLPA), 
Koolen et al. (2004)35 identified in a cohort of 210 children with unexplained ID a 
clinical relevant aberration in 6.3%, 5.1%, and 1.7% of the children with severe, 
moderate and mild ID respectively. 
The majority of the aforementioned studies were performed before the era of the 
genome-wide array analysis technologies had started. After the introduction of 
these technologies, several studies on the diagnostic yield of genome-wide array 
analysis were reported. These studies have been reviewed by Hochstenbach et al. 
(2009)36, Sagoo et al. (2009)37 and Miller et al. (2010).38 These studies together 
In previous cohort studies on the aetiology of ID, the percentage of causal 
diagnoses and the proportion of different diagnostic categories is quite variable. 
These differences are related to factors as study methodology, characteristics of 
the study population (age and sex distribution and level of ID), definition and 
categorization of diagnoses, and availability and application of genetic and other 
diagnostic tests (such as metabolic screening and neuro-imaging).9, 25-30 These 
factors hinder the comparison of the diagnostic yield of previous cohort studies.29 
Table 1 gives an overview of previous cohort studies before the era of routine use 
of genome-wide array analysis in diagnostics of ID. These studies reported a 
diagnostic yield between approximately 30% and 50%.
In the Netherlands, Van Buggenhout et al. (2001)30 and van Karnebeek et al. (2005b)26 
performed systematic aetiologic surveys in Dutch populations of individuals with 
ID. Van Buggenhout et al. examined a cohort of 471, mainly male individuals with an 
age ranging from 3 to 75 years, living in residential settings of health care providers 
in the Netherlands. They performed cytogenetic studies, fragile X screening by 
analysis of CGG repeat expansion in FMR1, metabolic tests and in a small subset 
specific DNA diagnostic tests and brain imaging. They defined a diagnosis in about 
48.8%, comprising both genetic (34.2%) and acquired disorders (14.6%). In 1.7% a 
central nervous system malformation was established as the causal diagnosis. Not 
all monogenic diagnoses were molecularly confirmed and metabolic disorders 
(3.4%) were classified as autosomal recessive monogenic disorders. The study of 
van Karnebeek and others26 was performed among a group of about 281 male and 
female children who were referred to a paediatric/clinical genetics department for 
diagnostic evaluation of unexplained ID between 1998 and 2000. Diagnostic 
evaluations comprised cytogenetic, molecular and metabolic studies, neurologic 
examination, and in a minority evaluation by other medical specialists. In 30.6% 
(86/281) a diagnosis that was classified as ‘’certain’’ was established, comprising 
in 15.6% diagnoses confirmed by genetic and/or metabolic tests, in 13.9% clinical 
diagnoses, and in 1.1% acquired disorders. Compared to the study of van Buggenhout 
et al., it is remarkable that van Karnebeek et al.  established a significantly lower 
percentage of cytogenetic diagnoses. This is explained by the fact that they did not 
include cases of trisomy 21, which comprise a major part of this diagnostic category. 
In addition, van Buggenhout et al. defined substantially less acquired diagnoses. 
These differences explain part of the difference in diagnostic yield between these 
two studies. The important difference in study population, with an overrepresenta-
tion of males in the study of van Buggenhout et al. likely influences these numbers 
as well, as is reflected by the higher yield of Fragile X studies in the study of van 
Buggenhout et al.
Stevenson et al.28 reported a diagnostic survey amongst a cohort of almost 11,000 
individuals with ID. They report a genetic diagnosis in 28%. However, they included 
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Table 1   Yield of previous systematic cohort studies on the aetiology of ID  
before the genome-wide array analysis era
Study Van Buggenhout  et al., 200130 Stevenson et al., 200328 Van Karnebeek et al., 2005b26 Rauch et al., 200627
Patient cohort 471, mainly male patients, 
age range 3-75y,  
IQ<50 in >80%
10,997 patients, 59% males, 
57% >20 y,
IQ<50 ‘’overrepresented’’ 
281 patients, 52% male patients, 
all children, 
IQ<50 in 45%
670, mostly with an age<6 y, 
male:female ratio not mentioned; 
Cytogenetic diagnoses
Conventional karyotyping
•   Trisomy 21
•  Other    
(Subtelomere) FISH/MLPA
(Molecular cytogenetic)
21.2%
21.2%
•   18%
•   3%
-
-
11%
~11%
•   8.1%
•   2.9%  (in small subset 
 subtelomere anomalies)c
-c
-
11%
7.8%
•   -
•   7.8%
3.2%
-
30.7%
17.5%
•   9.2%
•   8.3%
6.6%
(6.6i)
Monogenic diagnoses
Fragile X
Other
13%
3.2%
9.8%a
8%d
1.7%
5.3%d
2.8%
0.4%
2.4%
4.8%
1.2%
3.6%
Metabolic diagnoses -a Not mentionede 1.8%g Not mentionedj
Clinical diagnosis, 
not molecularly confirmed
-a 2% 13.9% 4%
Total genetic cause 34.2% 21% 29.5 39.5
Total acquired cause 14.6% 17% 1.1% 1.3%
Total diagnosis
(genetic+acquired)
48.8%b 38%f 30.6%h 40.8%
a Metabolic diagnoses (3.4%) and clinical diagnoses were included in the group of monogenic diagnoses 
b excluding 1.7% diagnosed with a CNS malformation c In the paper of Stevenson et al.,  the percentages 
of the subgroups numerical, structural and subtelomere anomalies are not further quantified, together 
they amount to a total of 2.9% d It is not indicated whether all cases were molecularly confirmed. Therefore, 
this number may be lower and the percentage of clinical diagnoses higher. In addition microdeletions 
associated with Prader-Willi, Angelman, Williams an velocardiofacial syndrome were included in this 
category e Metabolic diagnoses are not mentioned separately, likely these were included in the category 
monogenic disorders f Stevenson et al., also included the diagnostic categories multifactorial, culturofa-
milial (together 8%). These were not taken into account here g Metabolic studies were performed in a 
subgroup of 216 patients h Van Karnebeek et al. divided the diagnostic categories into certain and 
probable. Only diagnoses from the category certain were taken into account here i Rauch et  al., performed 
a pilot with 10K SNP array analysis in 20 patients and extrapolated their results to the total group j Rauch 
et al. included a diagnostic category mendelian disorders. It might be that some metabolic disorders were 
included in this category or in the category monogenic disorders. The category Mendelian disorders was 
not taken into account here, because the diagnoses in this category were not molecularly confirmed.
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progress in genetic diagnostics has been made.39 In table 2 the most important 
historical hallmarks in genetic diagnostic technologies of ID are represented. (see 
also figure 1)
Especially during the recent years rapid progress has been made in the development 
of new genetic technologies that enabled the detection of genetic variants with 
increasing resolution. In diagnostics of ID, conventional cytogenetic studies have 
been replaced by genome-wide array analysis in a short period of time.38, 39 The 
introduction of genome-wide array technologies has led to the identification of 
numerous novel microdeletion and microduplication syndromes, which previously 
escaped detection by routine cytogenetic and molecular cytogenetic techniques.41-52 
The phenotypic characteristics of some microdeletion syndromes are caused by 
haploinsufficiency of single genes, such as EHMT1 in Kleefstra syndrome58 
showed an average diagnostic yield of 15-20%, which compared to conventional 
cytogenetic tests represents an additive yield of 8-12%.36-38 Patients suspected of 
Down syndrome were not included in these results.   
1.5  Historical hallmarks in genetic diagnostics of 
intellectual disability
The yield of cohort studies on the genetic aetiology of ID is apparently highly 
dependent on the selected patient cohort, the type and resolution of available 
genetic tests, and the contemporary genetic knowledge. Since the discovery of the 
first chromosomal disorder in 1959 by Lejeune (trisomy 21), major technological 
Table 2   Historical hallmarks in genetic diagnostic technologies of ID
Date Technique Detection/resolution Yield 
1950s Conventional karyotyping Numerical and gross structural chromosomal 
disorders. 1959: trisomy 21 identified as the 
cause of Down syndrome
Together ~4.5-6.5% (excluding trisomy 21)
In ~8% trisomy21, 26-28, 30, 33, 40
1970s Banding techniques + cell cycle  
synchronization
Chromosomal rearrangements (translocations, 
inversions, deletions-duplications 3-5 Mb)
1990s Sanger sequencing Single nucleotide change Highly dependent on recognition of clinical phenotype. Rubinstein-Taybi syndrome  
(OMIM 180894), Tuberous Sclerosis (OMIM 191100) and ATRX syndrome (OMIM 301040) 
were amongst the first syndromes in which the causative genes were identified.32
Mid 1990s Fluorescent In Situ Hybridization (FISH) Clinically recognizable microdeletion 
 syndromes
Subtelomere microdeletions (later replaced  
by MLPA)
~6-10% in total33-35, 40
Mid 2000s Genome-wide array analysis Increasing resolution, up to <1 kb
Small microdeletion and duplication  
syndromes41-52 Identification of causal genes  
in shortest regions of overlap47, 50, 53-58
~15-20% (including chromosomal aberrations that can be detected by conventional 
 cytogenetics as well33, 36-38
2009  
(research)
2011  
(diagnostics)
Next generation sequencing (NGS):
Targeted sequencing 
Whole exome sequencing
Near future: Whole genome sequencing
Single nucleotide change
Autosomal dominant de novo, autosomal 
recessive and X-linked monogenic disorders
Systematic studies evaluating the diagnostic yield of the various NGS approaches are not  
yet available. Several approaches have been evaluated in research setting:
-  Whole exome, family based trio sequencing approach (dominant de novo mutations): 
 Vissers et al. Identified in 6/10 individuals a causative mutation59
-  Whole X-exome: Kalscheuer et al. estimated that up to 70% of X-linked ID can be explained60
-  Targeted, 86 known X-linked genes: Hu et al.61 reported in 42% of X-linked families  
potentially disease-causing sequence variants 
-  Targeted, homozygous regions (autosomal recessive mutations): Najmabadi et al.62  
reported in 54% of included families potentially disease-causing sequence variants in  
known and novel candidate ID genes 
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de novo gene mutations in an increasing number of ID-associated syndromes, 
such as Kabuki syndrome66, Schinzel-Gidion syndrome67, Bohring-Opitz syndrome68 
and KBG syndrome.69 Furthermore, targeted NGS was successfully used in 
identification of ID related genes on the X-chromosome and genes involved in 
autosomal recessive ID in consanguineous families.61, 62 
Application of WES will increase the proportion of individuals in whom a genetic 
cause for their ID can be established. The rapid expansion of genes involved in ID 
by NGS approaches including WES will shed light on the spectrum of genetic 
causes of ID and corresponding phenotypes. Identification of novel genes and 
subsequent functional studies will provide new insight in underlying pathogenic 
mechanisms and involved molecular and biological pathways, which is the first 
important step towards development of treatment strategies. Moreover, it is 
expected that in the near future whole-exome sequencing will be followed-up by 
whole-genome sequencing in the application of gene identifying strategies in ID.70 
This technique will also be able to uncover disease causing variants in non-coding 
regulatory sequences, such as intronic variants which may lead to alteration of 
expression and splicing, and may elucidate novel epigenetic causes of ID. 
It is obvious that this rapid progress in genetic diagnostic technologies will have 
great implications and will provide new challenges in care and counselling of 
individuals with ID and their families.  
1.6  Scope and outline of this thesis 
The preceding reflections on the importance of a diagnosis, the large number of 
undiagnosed individuals with ID and the great new opportunities in genetic 
diagnostic technologies provided the motivation for the studies described in this 
thesis. For these studies we selected a large cohort of 253, mainly adult, individuals 
with unexplained ID (see chapter 2). This cohort is selected from a group of more 
than 2,000 persons with ID, receiving services from three large service providers in 
the East of the Netherlands. The 253 individuals represented in our study cohort 
had not received a present-day genetic diagnostic assessment before and might 
be considered as representatives of the large group of 50-70% individuals with ID 
that remained undiagnosed before the era of genome-wide array analysis.
The main objectives of this study were: 
 1)   to identify genetic causes of ID 
 2)   to study and describe the corresponding phenotypes in detail, including the 
evolution into adulthood
 3)   to assess the diagnostic yield of the currently available genetic diagnostic 
repertoire and present-day knowledge
(previously named 9q subtelomeric deletion syndrome), RAI1 in Smith-Magenis 
syndrome63, TCF4 in Pitt-Hopkins syndrome56 and KANSL1 in 17q21.31 microdeletion 
syndrome.55 Moreover, the application of genome-wide array technologies with 
increasing density of probes and the study of overlapping microdeletions has led 
to the identification of several genes associated with developmental disorders or 
abnormal brain development.64, 65 
 
The recent implementation of next generation sequencing (NGS) has marked a 
revolution in research and diagnostics of ID. Whole-exome sequencing (WES) 
offers the opportunity to identify disease causing variants throughout the whole 
human exome. Recently, several studies showed that WES is effective in the 
identification of genes involved in ID. A family based trio screening approach was 
successfully applied to identify de novo autosomal dominant causes of ID.59 In 
addition, WES in clinically recognizable syndromes has led to the identification of 
Figure 1   Hallmarks in genome-wide diagnostics of intellectual disability
This figure illustrates the major hallmarks in the development of genetic technologies for genome-wide 
screening in diagnostics of ID. 
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2.1  Organization
This study was embedded in the Dutch research consortium ‘’Sterker op Eigen 
Benen/Stronger on Your Own Feet’’, which is a collaboration between the Radboud 
University Medical Centre in Nijmegen, The Netherlands, and three service 
providers for people with intellectual disability (ID) in the eastern part of the 
Netherlands (Pluryn, Dichterbij and Siza). The consortium facilitates research on 
behalf of individuals with ID. This specific study was organized within the setting 
of the department of Human Genetics of the Radboud University Medical Centre. 
The study was approved by the local ethical committee (NL13636.091.07). 
2.2  Total pre-selection cohort
Individuals with unexplained ID who participated in this study were selected from a 
large cohort of 2,069 individuals living in residential settings of Pluryn, Dichterbij 
and Siza, or receiving ambulatory care of these service providers. The total number 
of all individuals receiving services of these service providers exceeded this 
number, but for a large number of individuals insufficient data was available 
regarding level of ID and/or whether a diagnosis was already known. These 
individuals were not considered for this study. Available data were derived from the 
records provided by the care services.
The characteristics of the cohort from which participating individuals were selected 
(pre-selection cohort) are summarized in Table 1. Data regarding age, gender, 
level of ID and diagnosis are indicated. Diagnostic categories included the 
categories unknown diagnosis, chromosomal cause, monogenic cause, metabolic 
cause, clinically recognizable syndrome and acquired cause. Acquired diagnoses 
for example included perinatal complications and congenital or postnatal infections. 
For the definition of an acquired diagnosis there had to be sufficient evidence that 
this diagnosis was the most likely diagnosis. For example, documentation of 
perinatal asphyxia without confirmation by objective medical data was not accepted 
as an acquired diagnosis, but was classified as unknown diagnosis. Clinically 
recognizable syndromes included clinically defined diagnoses without known 
underlying genetic cause, such as Goldenhar syndrome (OMIM 164210) and 
Sturge-Weber syndrome (OMIM 185300), or with a known genetic cause, though 
not molecularly confirmed in the affected individual, such as Borjeson-Forssman-
Lehmann syndrome (OMIM 301900), neurofibromatosis (OMIM 162200), Williams 
syndrome (OMIM 194050) and CHARGE syndrome (OMIM 214800). On average, in 
70.9% of the individuals the cause of ID was unknown. This is in agreement with 
previous studies on aetiology showing that 50-70% of ID is unexplained.1-6 
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found, since it was assumed that the likelihood of a genetic cause is higher in 
familial ID and in ID in combination with additional features.7, 8 
Table 2  Selection criteria
1. Presence of unexplained ID (IQ≤70 or a developmental age equivalent of  
≤ 12 years)
2.  Presence of ≥1 of the features below (HPO* terms)
 Short stature or overgrowth (height ≤ -2 SD or ≥ +2 SD)
 Microcephaly or macrocephaly (head circumference ≤ -2 SD or ≥ +2 SD)
 Facial dysmorphism 
 Congenital abnormality (non-CNS) (i.e. cardiac, renal, skeletal, gastro-intestinal, 
urogenital, craniofacial, skin/hair/nail anomalies)
 Abnormality of the CNS (i.e. disorders of the central and /or peripheral nervous system, 
extrapyramidal and /or cerebellar disorders, regression and/or neurodegenerative signs
 Familial ID or consanguinity
*HPO: Human Phenotype Ontology (http://www.human-phenotype-ontology.org/) 
Further selection of candidate participants was based on the data in the medical 
files of the service providers. Only individuals of whom sufficient data were available 
to determine whether they fulfilled the criteria for selection were taken into account. 
The parents or legal representatives of selected individuals were asked for their 
informed consent by a letter including information about participation in the study 
and an informed consent form. They had the possibility to indicate either permission 
or decline of participation. Some parents/legal representatives mentioned their reasons 
for decline. In a minority of the cases the parents/legal representatives were personally 
approached by a specialist ID physician of one of the participating care services. In 
total, the parents or legal representatives of 838 individuals were approached. 
Informed consent was obtained for 270 individuals (32.2%). Informed consent was 
declined for 280 individuals (33.4%). The parents or legal representatives of 288 
individuals (34.4%) did not reply (see Figure 1).
Hundred nineteen of 280 (42.5%) parents and/or legal representatives who declined 
participation, mentioned their motives. Most frequent reasons were:
1)  participation is too incriminating to the candidate participant (in 37%) 
2)  the causal diagnosis is already known according to the parents/legal representative 
(in 17.6%) 
3)  medical condition and/or behavioural problems of the candidate participant 
hinder participation (in 13.4%)
4)  practical reasons, i.e. transport problems, no guidance, no time (in 9.2%) 
Participants of the study were recruited among individuals in the group of 70.9% of 
individuals with an unknown cause of ID. 
Table 1  Overview of the characteristics of the total cohort (pre-selection)
Number (%)
Total number of individuals (%) 2069 (100)
Characteristics
Sex
Male
Female 
1190 (57.5)
  770 (42.5)
Age group (y)
0-18
18-40
>40
    81 (3.9)
  573 (27.7)
1415 (68.4)
Level of ID
Mild
Moderate
Severe
Unknowna
 461 (22.3/23.7d)
 711 (34.4/36.5d)
 777 (37.6/39.9d)
 120 (5.8)
Diagnosis 
Unknown
Chromosomal
Monogenic
Metabolicb
Clinical Syndromec
Acquired
1467 (70.9)
  331 (16)
    31 (1.5)
    32 (1.5) 
    68 (3.3)
  140 (7.1)
a The exact level of ID was not documented, but the IQ level was at least ≤70.
b  Metabolic causes often have an autosomal recessive inheritance, but in almost all individuals with a 
metabolic diagnosis, the diagnosis was based on metabolic examinations and not confirmed by molecular 
genetic tests. Therefore, these were classified in the metabolic category instead of the monogenic category.
c  Though the underlying genetic cause of several clinical syndromes has been elucidated, this was not yet 
molecularly confirmed in affected individuals assigned to this diagnostic category. 
d calculated % if people with unknown level of ID are not taken into account. 
2.3  Patient selection and recruitment
Selection of study participants from the total pre-selection cohort was based on the 
presence of unexplained ID (unknown diagnosis group) in combination with 
presence of one or more additional features as summarized in Table 2. The second 
criterion was used to increase the likelihood that a genetic diagnosis would be 
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2.4  Included subjects
In total 253 individuals from 234 families participated in the study. Detailed character-
istics regarding gender and age distribution, distribution of the level of ID, type and 
number of selection criteria and familial cases are represented in Table 3. The majority 
of the participants had an adult age above 40 years. Male to female ratio was 1.75:1, 
which corresponds with the overrepresentation of males in the total population of 
people with ID.9 
2.5  Genetic diagnostic assessment
The study was divided into two phases:
1) the diagnostic phase and 
2) the diagnostic related research phase
During the first, diagnostic phase we performed clinical investigations and used 
genetic diagnostic tests that are currently routinely used in clinical genetic practice. 
Clinical investigations
In collaboration with the department of primary care of the Radboud University 
Medical Centre, chair ‘’health care for people with ID’’, we have established a mul-
tidisciplinary outpatient clinic for the clinical evaluation of the participating patients. 
At this outpatient clinic, patients were simultaneously seen by a research physician, 
a clinical geneticist and a specialist ID physician. The evaluation included a 
thorough medical history taking and physical and dysmorphological examinations. 
If indicated, other medical specialists, such as a (paediatric) neurologist, (paediatric) 
specialist metabolic diseases, and a psychiatrist were consulted. During the visit, 
blood samples were taken from the patients and, if available, from their parents as 
well. DNA was obtained from peripheral blood cells and extracted according to 
standardized procedures. 
Molecular genetic analyses in the diagnostic phase (phase 1)
During the first, diagnostic phase, specific DNA diagnostic tests were requested based 
on the clinical suspicion of a recognizable syndrome in a subset of the patients. 
Genome-wide microarray analysis to detect (sub)microscopic chromosomal 
aberrations/copy number variations (CNVs), and a metabolic screen were performed 
as standard. In addition, DNA samples of patients and available parents were 
stored for possible future use in both diagnostics and research. 
In all patients genome wide SNP (Single Nucleotide Polymorphism) array analysis 
In the remaining 22.8% various other reasons were mentioned, including: genetic 
investigations have already been performed, the participant does not benefit from 
the investigations, the investigations have no use.
Seventeen of 270 participants dropped out after initial inclusion. One individual 
died and in eleven cases the parents or legal representatives decided to withdraw 
their permission, for example because of practical reasons. In one case, it turned 
out that a genetic diagnosis had already been established. Four individuals were 
excluded because, after initial inclusion, further evaluation turned out that they had 
an IQ level above 70 and thus did not fulfill the selection criteria (see Figure 1).  
In total 253 of the total cohort of 2,069 individuals (12.2%) were included in this study.
After obtaining written permission from the parents or legal representative for 
participation, patients were invited to visit the outpatient clinic of the department of 
Human Genetics of the Radboud University Medical Centre in Nijmegen for an 
extensive multidisciplinary clinical evaluation (see paragraph 2.5).
Figure 1   Flowchart of patient selection and recruitment
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was performed according to the standard Affymetrix GeneChip protocol (Affymetrix, 
Inc., Santa Clara, CA, USA). In the majority of the individuals the Affymetrix 250k 
NspI SNP array platform was used. More recently, the Affymetrix 2.7M array platform 
was used, due to its introduction as the standard array platform in the diagnostic 
services at our department later during the study. Copy number estimates were 
determined using the updated version 2.0 of the CNAG (Copy Number Analyzer for 
Affymetrix GeneChip mapping) software package (Affymetrix 250k SNP array) or 
the ChAS (Chromosome Analysis Suite for Affymetrix GeneChip mapping) software 
package (Affymetrix 2.7M array). The normalized ratios were subsequently analyzed 
for genomic imbalances by a standard Hidden Markov Model (HMM). Copy number 
variations (CNVs) were mapped according to the UCSC genome browser build 
May 2004 (http://genome.ucsc.edu/; NCBI35/Hg17) for the Affymetrix 250k array 
platform and to build March 2006 (NCBI36/Hg18) for the Affymetrix 2.7M array 
platform. Subsequently, Mb positions of CNV breakpoints were converted to the 
latest version of the UCSC genome browser (Hg19 assembly, February 2009).   
The Affymetrix 250k SNP array platform in addition allowed the detection of 
homozygous regions on the chromosomes, which are possible candidate regions 
for the localization of genes involved in autosomal recessive (AR) forms of ID.
In all patients a standard metabolic screen in serum and, if available urine, was 
performed. This included measurement of amino acids, carnitine and acylcarnitines, 
quantitative creatine biosynthesis, very long chain fatty acids, sialotransferrines 
and lactate in serum; and amino acids, organic acids, uric acid, creatinine, purines 
and pyrimidines, and mucopolysaccharides and oligosaccharides in urine. On clinical 
indication screening tests for lysosomal disorders were included as well.
In all patients, except for those with microcephaly, DNA analysis of the FMR1 gene 
was performed to exclude Fragile X syndrome. 
When possible, segregation of genetic/chromosomal variants was tested in the 
parents and/or other family members by SNP array, Multiplex Ligation-dependent 
Probe Amplification (MLPA), Fluorescence In Situ Hybridization (FISH) or DNA analysis 
of the specific gene mutation. 
Molecular genetic analysis in the diagnostic related research 
phase (phase 2)
About one quarter (24.6%) of the patients in whom a genetic diagnosis could not be 
established in the first phase of the study, were further analyzed by various next 
generation sequencing (NGS) approaches. These patients could be roughly divided 
into two groups 1) patients with sporadic ID and 2) patients with familial ID, further 
subdivided into patients from families with an X-linked (XL) pedigree and patients 
from families with an AR pedigree, with or without the presence of homozygous 
regions ≥3 Mb. 
Table 3   Characteristics of participants
Total Number of Indexa Participants (%) 234 (100)
Patient Characteristics N (%)
Gender                                               
Male
Female
149 (64)
  85 (36)
Age Group (y)
0-18
18-40
>40
  
40 (17.1)
  84 (35.9)
110 (487)
Level of ID 
Mild (IQ 50-70)
Moderate (IQ 35-50)
Severe (IQ<35)
  
60 (25.64)
  60 (25.64)
114 (48.70)
Selection Criteria (HPO terms) b
Short stature or overgrowthc
Microcephaly or macrocephalyd
Facial dysmorphism
Congenital abnormality (non-CNS)
Abnormality of the CNS
Familial ID or consanguinity
(Epilepsy)e 
  
70 (29.9)
  64 (27.4)
119 (50.9)
  74 (31.6)
  63 (26.9)
  99 (42.3)
  93 (39.7)
Number of Positive Selection Criteria
1
2-3
4-5
>5
 
 84 (35.9)
121 (51.7)
  27 (11.5)
    2  (0.9)
Familial Cases 
Sibpair
>2 siblings
Mother-child
  
13 (+13)
  2 (+5)
    1 (+1)
Total Number of Individualsf  253 (234+19)
CNS= central nervous system 
a excluding participating affected family members (see familial cases)
b several participants fulfilled more than 1 selection feature
c short stature: height ≤ -2 SD; overgrowth height ≥ +2 SD
d microcephaly: head circumference <-2 SD/<P2; macrocephaly: head circumference >+2 SD/>P98 
e epilepsy was not used as a selection criterion
f including participating affected family members
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Microdeletions and microduplications that can be considered as a strong risk 
factor for ID but have sporadically been reported in healthy controls or are inherited, 
such as  16p11.2 microdeletions14 and 15q13 microdeletions and duplications15, 
were either classified as (likely) pathogenic or as of unknown clinical significance 
depending on the phenotype of the respective patient. For example, if a CNV was 
detected in a patient with a very severe phenotype that did not resemble the 
phenotype in other patients with a similar CNV, it was assumed that other yet 
undetermined factors have contributed to the phenotype. In these cases, the 
particular CNV was classified as ‘’unknown clinical relevance’’, whereas in a patient 
with a mild phenotype that resembles the phenotype in other patients with a 
comparable CNV, the same CNV could have been classified as ‘’(likely) pathogenic’’. 
Isolated patients were considered for the involvement of de novo mutations with a 
dominant effect. Hence, these patients were potential candidates for family-based 
whole-exome sequencing (WES). Patients with an IQ<50, normal karyotype, 
negative family history and availability of DNA samples from both of the parents 
were selected for this approach, as previously described by Vissers et al.10 and 
described in chapter 5.2 of this thesis.11 The analysis also allows the identification 
of recessive mutations, though these patients were selected against AR inheritance 
patterns.
Index patients with familial ID were included in further NGS studies including WES 
or X-exome sequencing. In three AR families, homozygosity mapping as described 
by Schuurs-Hoeijmakers et al.,12 was performed initially, followed by direct Sanger 
sequencing of candidate genes in the overlapping homozygous regions. In index 
patients from families with a pedigree that could both fit an AR and XL inheritance 
pattern, WES was performed to search for causative homozygous, compound 
heterozygous and X-linked mutations. Index patients from families compatible with 
XL inheritance were candidates for X-exome sequencing in collaboration with the 
Max Planck Institute for Molecular Genetics in Berlin.13 
Validation and segregation analysis of putative causative variants were done by 
Sanger sequencing. 
Assessment of clinical relevance
Abnormal findings in both the diagnostic and diagnostic related research phase of 
the study, including chromosomal CNVs, intragenic variants and abnormalities in 
metabolic tests, were classified into three different categories reflecting the presumed 
clinical relevance. The classification categories include:
1)  (likely) pathogenic: in case of a pertinent or plausible causal relationship with 
the observed phenotype
2)   unknown clinical relevance: in case of limited or absent evidence for a direct 
causal relation. However, the clinical relevance of the respective variant cannot 
be excluded.
3)  (likely) non-pathogenic: in case a relation with the observed phenotype was 
pertinent absent or very unlikely
Table 4 shows a schematic overview of the general criteria that were considered to 
assess clinical relevance and to classify abnormal findings into these three 
categories. Classifications of findings in each individual patient in this cohort were 
based on careful consideration of the full picture of the criteria for assessment of 
clinical relevance as mentioned in Table 4. None of the criteria was absolute and 
each criterion was considered in perspective to the other criteria, the currently 
available information in literature and databases, and the phenotype of the patient. 
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Table 4   Criteria for assessment of clinical relevance, grouped by the three  
different classification categories
Criteria Classification
(Likely) pathogenic Unknown (Likely) non-pathogenic
Inheritance De novo occurrence or segregation with the phenotype in 
familial ID
Segregating with the phenotype, but other 
variants present as well
Presence in a non-affected family member 
or not segregating with the phenotype
Occurrence in patients 
and controls (databases: 
DGV, dbSNP, ECARUCA, 
DECIPHER, in house 
databases)
Similar genetic defects in patient(s) with overlapping 
phenotype
No reports in healthy controls
Low detection rate in apparently healthy 
controls, but higher frequency in individuals 
with ID 
Polymorphism in healthy controls
No segregation with the phenotype within 
the family
Size and gene content 
(CNVs)
Size (>1.5 Mb) and gene content (>20 genes) Small number of genes that have not been 
previously related to ID
No genes involved
Known association with ID 
of involved genes
CNV overlaps with known ID gene
Mutation in known ID gene
Role of involved gene(s) is not known Gene involved is not associated with ID 
phenotype
Function and expression of 
involved genes
Role in pathway involved in ID and/or brain development/
functioning
Brain specific expression of involved gene(s)
Unknown function and/or unknown or 
ubiquitous expression pattern of involved 
gene(s)
Involved gene does not play a role 
in pathway involved in ID or brain 
development/functioning Gene is not 
expressed in brain
Type of mutation,
Conservation, biochemical 
difference, prediction 
programmes
Nonsense, frameshift
Highly conserved missense (PhyloP>3), high Grantham 
score (>50)
Predicted to be deleterious by SIFT and POLYPHEN
Missense
Moderately conserved (PhyloP 1-3)
Moderate Grantham score (25-50)
Predicted to be deleterious by one of the 
prediction programs and tolerated by the 
other
Synonymous 
Poorly conserved (PhyloP<1)
Low Grantham score (<25)
Predicted to be tolerated by SIFT and 
POLYPHEN
Metabolic disorder Repeatedly abnormal values of metabolites in serum 
and/or urine that could fit with the phenotype and are not 
explained by medication or nutrition (i.e. anti-epileptic 
drugs)
Consistent aspecific abnormal values of 
metabolites in serum and/or urine with 
unknown association with the phenotype
Abnormal values of metabolites in serum 
and/or urine that have no association with 
the ID phenotype and/or have an iatrogenic 
source.
Mouse models Central nervous system or (neuro)developmental disorder 
and/or lethal phenotype
Unknown phenotype No phenotype
DGV: database of genomic variants (http://projects.tcag.ca/variation/); dbSNP: the single nucleotide poly - 
morphism databases (http://www.ncbi.nlm.nih.gov/projects/SNP/); ECARUCA: European Cytogeneticists 
Association Register of Unbalanced Chromosome Aberrations (http://umcecaruca01.extern.umcn.nl:8080/ 
ecaruca/ecaruca.jsp); DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using 
Ensembl Resources (http://decipher.sanger.ac.uk/) 
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Abstract
Deletions of the distal 3q22.3 region encompassing the gene forkhead transcription 
factor FOXL2 (FOXL2) usually result in intellectual disability (ID) and the highly 
recognizable blepharophimosis-ptosis-epicanthus inversus syndrome (BPES). We 
encountered three patients with molecularly defined interstitial deletions distal to 
the FOXL2 gene. They present with remarkably similar manifestations comprising 
variable ID, a coarse facial appearance, including prominent nose and eyebrows, 
hypogonadism and skin pigmentation abnormalities, and they share an approximately 
8.8 Mb overlapping 3q24q25 deletion. Interestingly, one of the present patients was 
described previously in a clinical report with emphasis on her clinical similarity to 
the Wisconsin syndrome, suggesting that Wisconsin syndrome might be caused by 
a (micro)deletion within the 3q24q25 region.
Introduction
Interstitial chromosomal aberrations of the distal long arm of chromosome 3 are 
quite rare.1-2 Most patients with a deletion in this region have  blepharophimosis-ptosis-
epicanthus inversus syndrome (BPES; OMIM#110100) due to deletion of the gene 
forkhead transcription factor FOXL2 (FOXL2; OMIM*605597) located in 3q22.3.3-5 
Patients with interstitial deletions of the long arm of chromosome 3 also have intellectual 
disability (ID), microcephaly, pre-and postnatal growth retardation, congenital heart 
defects and various skeletal anomalies.1, 6-19 
In 2003 a female patient with an interstitial deletion in chromosome region 3q23q25 
was reported as the second case of Wisconsin syndrome2, 20 after the first delineation 
of this syndrome  by John M. Opitz in 1976, who described a combination of cranio-
synostosis, ID, upslanted palpebral fissures, small ears and short fourth metatarsals 
with recessed fourth toes as Wisconsin syndrome.
Here we describe the clinical and molecular characteristics of 3 patients resembling 
Wisconsin syndrome with overlapping interstitial deletions in 3q24q25 that are 
located distally to the FOXL2 gene. We compared the clinical and molecular 
 characteristics of these 3 patients with 16 previously published patients with an 
interstitial deletion overlapping the deletion of one or more of the present patients, 
both with and without involvement of the BPES region. 
Patients and Methods
Patient 1
This patient was referred at the age of 60 years. No genetic evaluation had been 
performed prior to referral. She was the second of 13 children, born to non-consan-
guineous parents. There was no information available regarding pregnancy and 
birth. Psychomotor development was moderately to severely delayed. Formal 
developmental assessment at adult age had demonstrated a developmental level 
of a 3-year-old child. She had  primary amenorrhea, hypermetropia and a bilateral 
mixed hearing loss of 60 decibels. Behaviour problems included self mutilation and 
sometimes aggressive outbursts. She had a high pain threshold. At the age of 59 
years she received a total hip prosthesis because of arthrosis. At the age of 60 she 
had a masculine appearance. Her height was 152 cm (<3rd centile), weight 66 kg 
(75-90th centile) and head circumference 51 cm (<3rd centile). The skull was 
brachycephalic and she had coarse face with a broad nose with prominent alae 
nasi and nasal tip, arched eyebrows, midface hypoplasia, macrostomia with full 
everted lower lip, short philtrum, large protruding tongue and large ears. The neck 
was broad and short (Fig. 1 A-C). There was no breast development. Axillary and 
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Patient 2
This boy was referred for chromosome analysis at the age of 6 11/12 years because 
of developmental delay with moderate learning difficulties. He was conceived through 
assisted conception with Pergonol treatment. Birth was complicated by an emergency 
caesarian section at 40+6 weeks gestation due to fetal distress. Birth weight was 
3,200 g (just below 25th centile). Head circumference at birth was 34.5 cm (50th 
centile). The patient was born in good condition but was slow to feed. He was 
ascertained due to concerns about his development. At 6 months of age he was a 
quiet baby, with absence of typical babble. At 2 years he was not making any attempts 
at speech although he had some understanding. He had speech therapy and was 
initially diagnosed with isolated speech delay and verbal dyspraxia. Recent 
assessment of his speech at the age of 12 years showed a language level of 6 9/12 
years. There were no concerns regarding his early motor development, though he 
walked at age 2 years. He learned to ride a bicycle at 7 years and has reasonably fine 
motor skills. There have been no concerns about his hearing but he was diagnosed 
with myopia requiring glasses at age 12 years. He had concentration problems and 
preferred to be in a routine, but was generally a co-operative child with good 
behaviour. He was able to attend mainstream school for his primary education but 
thereafter attended a special school for children with learning disabilities. He was 
able to read and write simple sentences. The patient’s general health had been 
good without any hospital admissions. He progressed normally through puberty 
during his teenage years. On physical examination at the age of 13 years had a head 
circumference of 57.9 cm (91st centile) and  a broad nose and a large mouth. The eye- 
brows were unusually shaped and upsweeping (Fig.1 D-E). The skin was soft  with a 
small hypopigmented patch on the right knee. He had tapering fingers with very 
mobile joints in his hands. His large joints were hyperextensible and he had a Beigton 
score of 9. There were no joint contractures. He had some very small areas of alopecia 
within his scalp hair that had been present since birth. He had bilateral supernumerary 
nipples. Genitalia were normal with no signs of hypogonadism. Cardiovascular status 
was normal. Conventional high resolution cytogenetic analysis at the age of 7 years 
demonstrated a deletion of chromosome bands 3q25.1 to 3q25.33.  
Patient 3
This  patient was described previously by Ko et al.2 Summarized, the phenotype 
included moderate ID, epilepsy, primary hypogonadotrophic hypogonadism, short 
recessed fourth toes and facial dysmorphism (Fig.1 F-G). Conventional high 
resolution cytogenetic analysis showed a deletion of chromosome bands 3q23-q25. 
Genome-Wide Array Analysis
To further characterize the cytogenetically detected deletions, we performed genome- 
pubic hair-growth was normal. External genitalia appeared normal. She showed a 
mild clinodactyly of the 5th fingers and bilateral hockey stick-lines, and flat feet, 
hallux valgus and normal other toes. She had local hirsutism on the cheeks, toes 
and ears. The skin at the extensor sides of the wrists showed several hypopigmen-
tation spots. Routine cytogenetic analysis by G-banding showed an interstitial 
deletion encompassing chromosome bands 3q23 to 3q25.3. Evaluation of the 
hormonal profile documented hypogonadotropic hypogonadism (LH 0.15 E/l, FSH 
0.27 E/l, estradiol 69 pmol/l). Bone densitometry showed signs of osteoporosis, 
mainly in the lumbar spine. To prevent osteoporotic complications she is now on 
treatment with bisphosphonates and vitamin D.                        
Figure 1   Facial appearance of patient 1 at 60 years (b-c) and at younger  
adult age (a), of patient 2 at age 13 years (d-e) and of patient 3 at 
age 18 years (f-g) Note the coarse face, prominent nose, full lower 
lip, large mouth and unusually shaped, bushy eye brows.
a b
d
f
e
g
c
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available for segregation analysis. Further delineation of the deletion in patient 2 by 
array CGH showed a minimal deletion of 8.83 Mb and a maximum of 8.95 Mb. The 
proximal breakpoint was within the 121 kb between oligos A_14_P106909 at Mb 
position 150,951,254 and A_14_P121635 at Mb position 151,072,501 and the distal 
breakpoint was within the ~8 kb between oligos A_14_P133326 at 159,897,607 and 
A_14_P123284 at 159,905,167. Maternal chromosomes were normal but the paternal 
chromosomes have not been examined. The final karyotype was formulated as 
follows:  46,XY,del(3)(q25.1q25.33).arr cgh 3q25.1q25.32(151,072,501-159,897,607)
x1. The minimal deleted region contains 42 annotated genes. Genetic and clinical 
details of patients 1 and 2 have been submitted to the ECARUCA database (www.
ecaruca.net, case ids. 4312 and 4513 respectively). Genome wide 250k SNP array 
analysis in patient 3 demonstrated a 19.38-Mb loss in 3q24q26.1 (147,27-166,66 Mb 
(Figs. 2 and 3)). The final karyotype was formulated as follows: 46,XX,del(3)
(q24q26.1).arr snp 3q24q26.1(147,273,493-166,655,467)x1, with flanking normal 
probes SNP_A-1863440 and SNP_A-1929743 at respectively 147,267,706 and 
166,726,888 Mb of chromosome 3. This region comprises more than 50 genes. 
Discussion
We report on three patients with syndromic ID and an overlapping interstitial 
deletion in 3q24-q25. The manifestations of these patients are compared with those 
observed in 16 patients with a previously reported overlapping deletion (Table 1, 
Fig. 2). In most previously reported patients, except for patient 9,10 and 18, the 
deletions were identified by conventional cytogenetic studies and thus breakpoint 
delineations were not as precise as in patients 1, 2 and 3. This hampers exact 
genotypic comparison between the present and previously reported patients. 
Genome-wide array analysis in patients 1, 2, and 3 showed that the deletions in 
these patients did not comprise the 3q23 region, as initially was assumed by 
conventional cytogenetic examination in patients 1 and 3. The 5 previously reported 
patients (patients 4-8) with a deletion encompassing the distal boundary of the 
3q22.3 region where the FOXL2 gene is located, showed the highly recognizable 
BPES phenotype. Five other patients (patients 10-14) who were reported to have a 
deletion with a proximal delineation at chromosomal band 3q23 detected by 
conventional cytogenetics, also had BPES. So, most likely these deletions extend 
beyond the boundary between chromosomal bands 3q22.3 and 3q23. Remarkably, 
in patient 9 array CGH showed that the FOXL2 gene was not deleted, though this 
patient had the classical phenotype of BPES. It was suggested that this might be 
the result of disruption of regulatory elements regulating FOXL2 expression [Rea et 
al., 2010]. Patients 15-19 are the only five previously reported patients with an 
wide array analysis. In patient 1 and 3 genome-wide single-nucleotide polymorphism 
(SNP) array analysis was performed on DNA with the Affymetrix 250k SNP array 
platform according to the standard Affymetrix GeneChip protocol (Affymetrix, Inc., 
Santa Clara, CA, USA). In patient 2 an oligonucleotide array comparative genomic 
hybridisation (oaCGH) was carried out with patient and normal pooled sex matched 
control DNA using a customised Agilent 60-mer oligonucleotide array in a 4 x 44K 
format (NGRL (Wessex) Constitutional Array CGH v2). All deletions were mapped 
according to the March 2006 assembly of the UCSC genome browser (NCBI Build 
36.1/hg18; http://genome.ucsc.edu).
Results
Clinical manifestations
Clinical findings of the three patients are shown in Table 1 and compared with those 
observed in 16 patients with an overlapping deletion previously reported and cited 
in online databases, including the DatabasE of Chromosomal Imbalances and 
PHenotypes using Ensembl Resources (Decipher) and the European Cytogeneticists 
Association Register of Unbalanced Chromosome Aberrations (ECARUCA )(Table 1 
and Fig. 2). Corresponding traits in these 19 patients are ID (19/19), various skeletal 
(digital and joint) anomalies (14/19), external ear anomalies (13/19), microcephaly 
(10/19), pre- and postnatal growth retardation (respectively in 6/19 and 11/19), 
cardiac anomalies (8/19), ocular problems (8/19) and genital anomalies (4/19 (3/4 
males)). The digital anomalies include arachnodactyly, camptodactyly, clinodactyly, 
syndactyly and brachydactyly. Reported joint anomalies include club feet, hip 
dysplasia, hyperextensibility and limited/restricted movement or contractures. 
Cardiac anomalies in 4/8 of the patients were a ventricular septal defect. Reported 
ocular problems are mostly non specific and variable, including refraction errors and 
strabismus. More severe reported ocular problems are optic atrophy (in patients 12 
and 17) and microphthalmia (patient 9 and 13). Genital anomalies include hypospadias, 
cryptorchidism, and micropenis. 
Genome-Wide Array Analysis
Further characterization of the deletion in patient 1 by genome wide 250k SNP array 
analysis (Affymetrix inc, Santa Clara California) showed a 16.2 Mb loss in 3q24q25.33 
(Figs. 2 and 3). The final karyotype was formulated as follows: 46,XX,del(3)
(q24q25.33).arr snp 3q24q25.33(144,654,575-160,842,543)x1 with flanking normal 
probes SNP_A-4209748 and SNP_A-2244366 at, respectively, 144,621,072 and 
160,873,241 Mb on chromosome 3. At present, there are at least 70 known genes 
in this deleted region of 3q24q25.33. Unfortunately, the patient’s parents were not 
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(ZIC1; OMIM*600470) and Zinc finger protein of cerebellum, 4 (ZIC4; OMIM 
*608948) (Fig. 3). Patient 10 was too young age to assess the severity of her 
developmental delay. Interestingly, in patients with a deletion of 3q24, heterozygous 
loss of ZIC1 and ZIC4 has been reported to be the cause of Dandy-Walker 
malformation, which often is accompanied by  developmental delay.21 Moreover, 
the Zic family of zinc-finger proteins is thought to play a crucial role in neural 
development.22 In most patients results of brain imaging were not reported, therefore 
structural brain anomalies in these patients, including patients 1, 3 and 18, are not 
excluded. In one of the previously reported patients with an overlapping deletion 
(patient 19) a Dandy-Walker malformation was reported. However, since this 
deletion is not molecularly defined, it is unclear whether it encompasses ZIC1 and/
overlapping deletion who do not show the clinical phenotype of BPES and thus, are 
the most suitable candidates for phenotype-genotype comparison with the present 
3 patients, though comparison of the phenotypes is also hampered due to limited 
description of clinical features of patients 15-19. These 8 patients (1-3 and 15-19) 
with deletions located distally from the BPES region in 3q22.3 share several traits, 
including ID,  prominent nose, genital anomalies and/or hypogonadism and digital 
anomalies. Genotype-phenotype comparison of the patients with a more precise 
determination of the breakpoints by genome wide array analysis or FISH and 
marker analysis (patients 1, 2, 3, 9, 10 and 18) documented that the overlapping 
deleted region of patients 1, 3 and 18, who have  more severe developmental delay 
than patients 2 and 9, comprises the genes Zinc finger protein of cerebellum, 1 
Figure 2   Schematic overview of the deletions of patients 1-3 and overlapping 
deletions in 16 previously reported patients 
Figure 3   Schematic overview of the four deletions identified and delineated  
by genome-wide array analysis and one deletion that was further 
delineated with FISH techniques and DNA marker analysis 
Light grey bars indicate deletions detected by conventional cytogenetics. The grey bar indicates a 
deletion delineated by FISH and marker analysis (patient 10). The dark grey bars indicate deletions 
delineated by genome wide array analysis (patients 1-3, 9 and 18). The relative positions of the genes 
FOXL2, ZIC1 and ZIC4 are indicated.
Regions that might be associated with a more severe developmental delay and hypogonadism are 
indicated by vertical lines. The relative positions of the genes ZIC1 and ZIC4 are indicated. SRO: shortest 
region of overlap.
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with recessed fourth toes. Karyotyping in 1976 showed normal results. However, at 
that time resolution was limited, so the presence of a small interstitial deletion could 
not be excluded. If, however, we assume that patient 3 is indeed a second patient 
with Wisconsin syndrome the other patients with an interstitial 3q deletion distal to 
FOXL2 might also be considered as Wisconsin syndrome patients. These patients 
lack the short fourth metatarsals with recessed fourth toes and also the presence 
of craniosynostosis cannot be established, though patient 1 has an abnormal 
shape of her skull which is likely the result of abnormal closure of sutures. Further 
cases should provide evidence that Wisconsin syndrome is indeed caused by 
interstitial 3q deletions.
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or ZIC4. Though this is speculative, molecular delineation might show involvement 
of ZIC 1 and/or ZIC4 in the deletion of this patient. 
The region of overlap of the molecularly defined deletions of patients 1, 2, 3, 9 and 
18 contains approximately 20 genes. None of these genes has previously been 
associated with ID. This region comprises one OMIM disease related gene, solute 
carrier family 33, member A (SCL33A1; OMIM*603690), involved in autosomal 
dominant spastic paraplegia 42. In a single family with autosomal dominant 
inherited spastic paraplegia haploinsufficiency of SCL33A1 was reported to be the 
cause of spastic paraplegia with a variable presentation in onset and severity, and 
incomplete penetrance.23 Clinical signs of spastic paraplegia were not noticed in 
patients 1,2, 3, 9 and 18, neither in the 10 patients (patient 4, 11-19) with overlapping 
deletions. This might be explained by variable expression of the phenotype and/or 
incomplete penetrance as seen in the family reported by Lin et al. 
Hypogonadism was exclusively observed in patients 1 and 3 and not reported in 
patients with overlapping deletions. Only taking into account the molecularly 
defined deletions, the unique region of overlap in patients 1 and 3 (159,897,607-
160,842,543 Mb)  comprises four known genes: retinoic acid receptor responder 1 
(RARRES1; OMIM*605090), major facilitator superfamily domain containing 1 
(MFSD1), the IQ motif containing J  (IQCJ), and the Schwannomin interacting protein 
1 gene (SCHIP1; OMIM*611622) (Fig. 3). None of these genes is likely to be directly 
involved in hypogonadism. However, MFSD1, IQCJ and SCHIP1 fusion genes are 
expressed in the hypothalamus and haploinsufficiency of these genes therefore 
might hypothetically influence thalamic hormonal regulation, including the gonado-
tropin-releasing pathway. Underreporting of hypogonadism in patients with an 
overlapping deletion cannot be excluded, because it can easily be missed, 
especially before puberty. In males hypogonadism can present or be associated 
with micropenis and/or hypospadia, as seen in patient 16, but both traits can also 
have another origin. 
Non penetrance of hypogonadism in patients with overlapping deletions and/or a 
coincidental occurrence of hypogonadism in patients 1 and 3 might be other 
explanations for the exclusive presentation of hypogonadism in patients 1 and 3. 
Patient 1 illustrates that it is important to search for signs of hypogonadism and to 
subsequently perform hormonal evaluation when indicated. Adequate treatment 
can prevent secondary complications like osteoporosis and cardiovascular 
diseases. 
Patient 3 was previously reported as the second patient with Wisconsin syndrome 
on account of clinical similarity to a patient with Wisconsin syndrome, discovered in 
1976 by John M. Opitz and later described by Cohen.2,20 The Opitz patient reported 
by Cohen had craniosynostosis, ID, upslanting palpebral fissures, unusual shaped 
eyebrows, a prominent and coarse nose, microtia, and short fourth metatarsals 
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Abstract
Clinical and molecular characteristics of two patients with a 6.75 Mb overlapping 
interstitial deletion in the 8p12p21 region are described and compared with 
previously reported cases with an overlapping deletion. The most common charac-
teristics of interstitial deletions of proximal 8p are developmental delay, postnatal 
microcephaly and growth retardation. Other frequently reported findings are 
hypogonadism associated with haploinsufficiency of GNRH1 and ocular problems. 
Congenital heart anomalies are also common and might at least to some extent be 
due to haploinsufficiency of NKX2-6 or NRG1. The aforementioned clinical charac-
teristics should be considered in the care of patients with a proximal interstitial 
8p12p21 deletion.
Introduction
Since the eighties of the last century the terminal 8p- syndrome was proposed as a 
new clinical entity with pre- and postnatal growth retardation, intellectual disability 
(ID), microcephaly, epicanthal folds, low-set and malformed ears, thin lips, 
micrognathia, short neck, wide-set nipples and congenital heart defect as reviewed 
by Tsukahara et al. in 1995.1 Since then, the number of patients with a deletion of 
the short arm of chromosome 8 has increased progressively along with the 
improved ability of molecular techniques to identify small chromosomal 
aberrations.2, 3 Although most cases are terminal deletions encompassing the 8p23 
region, several 8p syndromes associated with deletions in different regions on 8p 
have been reported.1, 3-6 It has been proven difficult to link the separate clinical 
features to specific chromosomal locations since  the various different regions were 
just partly overlapping and not highly specific.2, 3, 7, 8 Moreover, so far only one 
reported case has been studied by molecular cytogenetic techniques which 
provided more accurate boundaries of the deletion.8 The critical deleted region 
responsible for the clinical features observed in patients with a terminal deletion in 
8p was initially assigned to the region between 8p21.3 and 8p23, because of 
absence of clinical features such as growth retardation, microcephaly and 
congenital heart defect in patients with a very distal 8p deletion (8p23-8pter).1, 6 
However, several phenotypic features of this so called terminal 8p- syndrome were 
also described in patients with a proximal interstitial deletion not encompassing 
this ‘critical region’, for example in a patient with a deletion in 8p11.21p11.23.1 More 
recently, the chromosome 8p23 deletion syndrome was outlined as a distinct 
syndrome including mild to severe ID, microcephaly, growth retardation, congenital 
heart defect and facial anomalies including micrognathia and low-set ears, the 
same major features as were previously attributed to the clinical entity terminal 8p- 
syndrome.3, 4, 7 Other reported findings are behavioural disturbance, genitourinary 
anomalies and congenital diaphragmatic hernia.3, 4, 9-11 Critical regions for some 
features have been delineated, such as heart defects assigned to 8p23.1, 
encompassing the GATA4 gene3, 6, 7, 9, 12 and GNRH1 in 8p21.2 as a candidate gene 
for hypogonadism.8
To further delineate the phenotypic spectrum of interstitial deletions proximal to 
8p23, we studied the clinical and molecular characteristics of two additional 
patients with overlapping interstitial 8p12p21 deletions and compared these with 19 
previously published cases with an 8p deletion. 
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head circumference to below the 0.6th centile (42 cm). She had mild facial dysmorphic 
features, including long eye lashes, narrow palpebral fissures, full hooked nose, broad 
dental gums and thin upper lip (Figs. 1 C-F). She also had broad thumbs and halluces, 
similar to her father.
Cytogenetic and FISH analysis
Cytogenetic analysis and Fluorescence In Situ Hybridisation (FISH) analysis was 
performed on cultured peripheral blood lymphocytes according to routine procedures. 
Patients and methods
 
Patient 1
This male was born at 40 weeks of gestation with a birth weight of 3,050 g (10th-25th 
centile). He was the first child of non-consanguineous parents. On the sixth day he 
was referred to the paediatrician because of feeding difficulties. An echocardiogra-
phy, performed because of a heart murmur, showed a perimembranous ventricle 
septum defect (VSD) which was surgically corrected at the age of one month. 
Magnetic Resonance Imaging (MRI) of the brain at the age of 11 weeks showed 
hypoplasia of the corpus callosum and hypomyelinisation. At nine months of age 
he was referred to the clinical geneticist because of  the aforementioned congenital 
malformations. By that time his length was 70 cm (25th centile), his weight was 7,200 g 
(2nd centile) and his head circumference was 43 cm (5th-10th centile). He had a 
prominent metopic suture, but craniosynostosis was excluded with a computer 
tomography (CT) -scan of the skull. He had a hypospadia. Facial dysmorphic features 
included upward slanting palpebral fissures, long eye lashes, small arched 
eyebrows, inverted epicanthal folds, bilateral malformation of the upper helices, a 
small right auricular pit, a long and smooth philtrum, thin lips and down turned 
corners of the mouth (Figs. 1 A-B). At 18 months of age head circumference had 
declined to the 2nd centile (45.5 cm) and length to the 0.6th centile (74 cm). A neuro-
psychological test showed a developmental delay of 2-5 months. An ophthalmologic 
examination revealed astigmatism. A hearing test showed bilateral sensorineural 
hearing loss of 70 decibel. Renal ultrasound did not show any abnormalities.
Patient 2
This female was born at 42 weeks of gestation with a birth weight of 3,530 g 
(25th-50th centile). She was the second child of healthy non-consanguineous 
parents and had a healthy older sister. The amniotic fluid was meconium stained 
and she had a difficult start (Apgarscores 3 and 6 after 1 and 5 minutes respectively), 
but she quickly recovered. In the neonatal period she was hypotonic and had a 
gastroesophageal reflux. After four months very little eye contact and a high 
hypermetropia without structural eye abnormalities was noticed. At that moment 
length was 60.5 cm (25th centile), weight was 6,345 g (2nd centile) and head 
circumference was 39 cm (0.6th centile). At the age of one year further genetic 
diagnostic evaluation was performed because of developmental delay. Basic 
metabolic examination showed no abnormalities and a cerebral MRI did not reveal 
any structural brain malformations. At the age of 22 months she was referred to 
the clinical geneticist. The psychomotor development was delayed with standing 
independently at 21 months and she was speaking seven to eight words at that 
time. Upon physical examination height had declined to the 2nd centile (75 cm) and 
Figure 1   Photographs of two patients with a 8p12p21 deletion.  
A-B Patient 1 at 9 months of age, showing long dark eye lashes, 
arched eyebrows, inverted epicanthal folds, a long and smooth 
philtrum, thin lips, downturned corners of the mouth and over folded 
upper helices of the ears. C-F Patient 2 at age of 12 months  
(C), 20 months (D) and 33 months (E-F), showing mild facial 
dysmorphic features, including thin upper lip, a full hooked nose  
and narrow palpebral fissures.
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in retrospect cytogenetically visible. In patient 2, an interstitial 6.75 Mb loss in 
8p21.2p12 was identified (24.5-31.3 Mb; USCS genome browser build March 2006): 
46,XX.arr snp 8p21.2p12(SNP_A-2078711SNP_A-2226461)x1 dn. The distal and 
proximal (centromeric) array targets with normal ratios being SNP_A-1936044 
and  SNP_A-1885633, respectively. Region specific FISH analysis in the patients 
confirmed these losses and subsequent analysis in both parental couples gave 
normal results, suggesting a de novo origin of the deletion in both patients. The 
deleted region of patient 1 completely overlaps the deleted region of patient 2. In this 
overlapping region of 6.75 Mb more than 40 genes are localized. The distal, non-
overlapping deleted region of patient 1 harbours six known genes, including NKX2-6. 
In the proximal non-overlapping region 15 genes including NRG1 are localized.
Discussion
Here two patients with an interstitial deletion of 8p12p21 are reported and compared 
with 19 previously reported cases with an overlapping deletion. Noteworthy, in the 
previously reported cases, except for the patient reported by Klopocki et al.8 the 
deletions were identified by conventional cytogenetic studies and thus breakpoint 
delineations were not as precise as in patients 1 and 2 in whom the deletions and 
the breakpoints were delineated by genome wide SNP array analysis. This hampers 
exact genotypic comparison between the present and previously reported patients. 
Corresponding clinical features in the total number of 21 patients were psychomotor 
retardation (21/21), pre- and postnatal growth retardation (respectively in 12/21 and 
17/21) and microcephaly (14/21) (Table 1). Patients 1 and 2 did not show evident 
facial resemblance (Figs. 1 A-B and 1 C-F). Facial features commonly described in 
patients with overlapping deleted regions were external ear anomalies (14/21), 
hypertelorism (7/21), epicanthal folds (11/21), micrognathia (9/21), short nose (5/21), 
small mouth (5/21) and thin lips (5/21). Some of these features were also noted in 
patient 1. Patient 2 showed remarkable facial resemblance to patient 138 with 
narrow palpebral fissures and thin upper lip. Cardiac anomalies, genital anomalies 
and ocular problems are frequently reported features, respectively present in 8, 14 
and 9 out of the total number of 21 cases. Reported cardiac anomalies comprise 
pulmonary valve stenosis, atrio-ventricular septal defects, persistent left superior 
vena cava, hypoplastic right ventricle, subaortic stenosis and mitral valve 
insufficiency. In patients with an overlapping deletion encompassing the 8p23 
region, a higher prevalence of congenital heart malformation was seen (5/7 versus 
3/14). This is in agreement with previous studies that localized the critical region for 
heart defects, in a region encompassing the GATA binding protein 4 (GATA4) (MIM 
600576), on 8p23.1. 3, 7, 12 However, congenital heart defects were also reported in 
For confirmation of the deletions detected by genome wide array analysis and for 
segregation analysis in their parents, region specific FISH analyses were performed 
using BAC-probes RP11-531L22 (8p21.2), RP11-615F9 and RP11-14D16 (8p21.1), 
RP11-139G09, RP11-317 J08 and RP11-724C15 (8p12).
 
MLPA analysis
The subtelomeric regions were screened for imbalances by Multiplex ligation-de-
pendent Probe Amplification (MLPA) analysis using commercially available kits 
(P036D and P070, MRC-Holland, the Netherlands) to test the patients’ DNA 
samples. DNA was isolated from blood samples according to standard procedures.
 
SNP array analysis
Genome wide Single Nucleotide Polymorphism (SNP) array analysis performed on 
DNA with the Affymetrix 250k SNP array platform according to the standard Affymetrix 
GeneChip protocol  (Affymetrix, Inc., Santa Clara, CA, USA). Copy number estimates 
were determined using the updated version 2.0 of the CNAG (Copy Number 
Analyzer for Affymetrix GeneChip mapping) software package.13 The normalized 
rations were subsequently analyzed for genomic imbalances by a standard Hidden 
Marker Model (HMM), essentially as described before.6
Results
Clinical features
Clinical features of the two patients are shown in Table 1 and compared with those 
observed in 19 patients with an overlapping deletion previously reported in literature. 
 
Routine cytogenetic and molecular findings
Patient 1 had a normal male karyotype and 22q11.2 FISH analysis revealed a 
normal pattern. Patient 2 had a normal female karyotype, she did not have a 22q11.2 
deletion upon FISH analysis and fragile X syndrome as well as Angelman syndrome 
were excluded by the respective molecular tests. Subtelomeric MLPA analysis did 
not reveal any imbalances in either patient one or patient two.
Genome wide SNP array analysis
SNP array analysis revealed a significant deletion in 8p in both patients (schematically 
depicted in Figure 2). In patient 1, an interstitial 14.1 Mb loss was found in 8p21.3p12 
(23.3-37.4 Mb; USCS genome browser build March 2006): 46 XY.arr snp 8p21.3p12 
(SNP_A-1870401SNP_A-2132186)x1 dn. The flanking normal SNP probes being 
SNP_A-1860990 (distal) and SNP_A-1937102 (proximal; centromeric). This loss was 
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cardiac outflow tract.14, 15 The involvement of NKX2-6 in the heart defects of patients 
with a deletion of 8p21 seems less likely, because of a heterozygous loss of this 
gene. However in the original report, only partial loss of activity of NKX2-6 was 
shown by studying functional properties of the missense mutation.15 So based on 
this, it is not ruled out that haploinsufficiency might contribute to the origin of heart 
defects. Another candidate gene for congenital cardiac malformations is the gene 
Neuregulin-1 (NRG1) (MIM 142445) in 8p12. NRG1 is involved in two different 
aspects of cardiac development, namely trabeculation (development of  the 
finger-like extensions of the heart’s wall) and valvuloseptal formation. Nrg1 null 
mutations in mice were shown to result in an embryonic-lethal cardiac defect.16, 17 
NRG1 was also deleted in patient 138, though she did not have a heart defect. This 
might be explained by non-penentrance or a multifactorial cause of congenital 
heart defects. Furthermore, NRG1 is shown to have many functions during neural 
development, including stimulation of neuronal migration and differentiation.16, 17 
Haploinsufficieny of NRG1 could therefore also play a role in the occurrence of 
peripheral neuropathy that was reported in patient 13.8 However, our patient 1 did 
not show signs of neuropathy at 18 months of age. Interestingly, neuropathy was 
also reported in patients 418, 6 and 719 and 1120, in whom the proximal cytogenetic 
breakpoints of the deletion are in 8p11, suggesting that NRG1 is deleted. 
Genital anomalies in the patients with proximal 8p deletions include hypospadias, 
cryptorchidism, micropenis and more generally, hypogonadism. Genital anomalies 
were only noted in patient 1. However, in females hypogonadism might not present 
before puberty as seen in patients 4 and 11 when hypogonadism manifested in 
puberty by primary failure of sexual development and primary amenorrhea.18, 21 
Almost all patients with genital anomalies had a deletion of 8p21.2 which harbours 
gonadotropin-releasing hormone 1(GNRH1) (MIM 152760), the gene that is suggested 
to be associated with genital anomalies.8 
Mild ocular abnormalities were seen in both of our patients. Patient 1 had astigmatism 
and patient 2 had hypermetropia. Reported ocular problems in literature are very 
heterogeneous and vary from aspecific or mild (for example strabismus, hyper -
metropia and myopia) to more severe disorders like retinal dysplasia and iris 
coloboma in patient 1120, and hypoplastic papillae in patient 13.8 It seems that 
ocular problems occurred more often in the more proximal deletions encompassing 
8p11p12, whereas ocular problems were not reported in deletions distally from 
8p21. This suggests that genes located in the more proximal deleted region could 
be implicated in (severe) ocular problems, although we were not able to identify a 
candidate gene in this region. In 2006 Klopocki et al.8 suggested EXTL3 (MIM 
605744),which is located on region 8p21.1, as a candidate gene for the ocular 
abnormalities in their patient (corresponding to patient 13) and in the case reported 
by Okamoto et al. (corresponding to patient 11). EXTL3 is thought to be involved in 
patient 1 and two other patients with more proximal deletions (patient 11 and 12), 
suggesting other, more proximally located loci for heart defects as well. The deletion 
of patient 1 contains the gene NK2 transcription factor related, locus 6 (NKX2-6) 
(MIM 611770) in 8p21.2. NKX2-6 is one of several genes that are co-expressed with 
the gene T Box-1 (TBX1) (MIM 602054) in the second heart field. TBX1 is associated 
with velo-cardio-facial syndrome and is required for the development of the cardiac 
outflow tract, right ventricle and part of the atria. Tbx1 knockout mice embryos have 
major cardiac outflow tract defects. NKX2-6 is significantly down regulated in the 
second heart field of tbx1 knockout mice embryos.14 This suggests that TBX1 
enhances the expression of NKX2-6. The role of NKX2-6 in cardiac outflow tract 
development is further supported by the finding that a homozygous missense 
mutation in NKX2-6 was found in one large consanguineous family with persistent 
truncus arteriosus in six family members, which is due to failure of septation of the 
Figure 2   Schematic overview of deleted regions on chromosome 8p in  
patients 1 and 2 and previously reported patients. The relative 
positions of  NKX2-6, GNRH1 and NRG1 as well as the BAC array 
clones are indicated for clarity 
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axonal guidance in the optic tract. Disruption of this gene could possibly result in 
ophthalmological problems related to distortion of the optical nerve and related 
structures (i.e. retinal dysplasia and papillar hypoplasia, respectively reported in 
patient 11 and 13).8 However a causal relation between disruption of this gene and 
the occurrence of other reported, more aspecific, ocular abnormalities such as 
strabismus and hypermetropia seems very unlikely. 
Structural brain malformations are rare. In patient 1, however, hypoplasia of the 
corpus callosum and hypomyelinisation were noted. Similar abnormalities were 
also reported in patients 138 and 1412. Since cerebral imaging was not reported in 
every patient,  brain abnormalities might have gone unnoticed. Seizures are also 
rarely reported in patients with 8p deletions and were not present in our patients 
either. Sensorineural hearing loss is present in patient 1. Hearing loss is rarely 
reported in the published cases. One previously reported patient had a conductive 
hearing loss due to congenital stapedial fixation.
In summary, we conclude that interstitial deletions of the proximal short arm of 
chromosome 8 are characterized by psychomotor retardation, postnatal micro cephaly 
and growth retardation. The facial features vary considerably which hamper the 
recognition of patients on a characteristic facial appearance. Frequently reported 
features are hypogonadism, probably associated with haploinsufficieny of GNRH1, 
cardiac anomalies, which might be associated with haploinsufficiency of NKX2-6 
and NRG1, and ocular anomalies. Therefore, these features should be considered 
in clinical management of patients with proximal 8p deletions. 
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Abstract
The clinical utilization of array comparative genomic hybridization in the evaluation 
of patients with multiple congenital anomalies and/or intellectual disability has 
recently led to the discovery of a number of novel microdeletion and microduplica-
tion syndromes. We present four male patients with overlapping molecularly defined 
de novo microdeletions of 16q24.3. Clinical features observed in these patients 
include facial dysmorphisms comprising prominent forehead, large ears, smooth 
philtrum, pointed chin and wide mouth, variable cognitive impairment, autism 
spectrum disorder, structural anomalies of the brain, seizures, and neonatal throm-
bocytopenia. While deletions vary in size, the common region of overlap is only 90 
kb and comprises two known genes, Ankyrin Repeat Domain 11 (ANKRD11) (MIM 
611192) and Zinc Finger 778 (ZNF778), and is located approximately 10kb distally 
to Cadherin 15 (CDH15) (MIM 114019). This region is not found as a copy number 
variation in controls. We propose that these patients represent a novel and 
distinctive  microdeletion syndrome, characterized by autism spectrum disorder, 
variable cognitive impairment, facial dysmorphisms and brain abnormalities. We 
suggest that haploinsufficiency of ANKRD11 and/or ZNF778 contribute to this 
phenotype and speculate that further investigation of non-deletion patients who 
have features suggestive of this 16q24.3 microdeletion syndrome might uncover 
other mutations in one or both of these genes.  
Introduction
Whole-genome scanning technologies such as array comparative genomic 
hybridization (array CGH) and single nucleotide polymorphism oligonucleotide arrays 
(SNP array) have enabled the detection of submicroscopic chromosomal 
aberrations, which previously escaped detection by routine cytogenetic and 
molecular cytogenetic techniques.1-3 These methods have proven invaluable in the 
elucidation of genomic regions associated with intellectual disability (ID) and/or 
congenital anomalies.4-8 Several clinically distinct microdeletion and microduplica-
tion syndromes have been reported based on data derived from these techniques 
such as the 17q21.31 microdeletion syndrome5  and the 1q41-1q42 microdeletion 
syndrome9, as well as microduplication syndromes involving 7q11.2310, 11 and 17p11.2.12 
The phenotypic characteristics of microdeletion syndromes can be caused by 
 haploinsufficiency of single genes, for example TCF4 (MIM 602272) in Pitt-Hopkins 
syndrome,13 EHMT1 (MIM 607001) in 9q34.3 subtelomeric deletion syndrome14 
and  either CREBBP (MIM 600140) or EP300 (MIM 602700) in Rubinstein Taybi 
syndrome.15, 16 The application of genome-wide array technologies with increasing 
density of probes has led to the identification and localization of several genes 
associated with developmental disorders or abnormal brain development8  including 
CHD7 (MIM 608892) in CHARGE syndrome17 and FOXG1 (MIM 164874) in congenital 
Rett syndrome.18 Aberrations of chromosome 16q with clinical relevance have rarely 
been reported. Previous to the present report, interstitial deletions restricted to 
band 16q24.3 have not been described. There are only a few reports in the medical 
literature of patients with larger, cytogenetically visible deletions comprising this 
region, mostly due to an unbalanced complex chromosomal rearrangement.19-29 
In this study we aimed to characterize the clinical and molecular features of four 
patients with submicroscopic interstitial 16q24.3 microdeletions ascertained by 
genome-wide array analysis and to determine the shortest region of overlap (SRO) 
to identify candidate genes responsible for their overlapping phenotype.
 
Patients and Methods
Patient 1 
Patient 1 was ascertained at age 22 years when SNP array was performed because 
of ID, autism spectrum disorder, dysmorphic features and congenital anomalies. 
He was born after an uncomplicated pregnancy, induced at 36 weeks gestation 
because of maternal preeclampsia. Growth parameters were appropriate for 
gestational age with a birth weight between the P50 and P75. Head circumference 
was not measured at birth. He was diagnosed with congenital hip dysplasia, but 
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nonverbal IQ of 100, Preschool Language Scale 4 (PLS-4) showed that auditory 
comprehension was severely delayed (1st centile) and that expressive communication 
was moderately delayed (P4). On physical examination, he had a height of 94 cm 
(10th-25th centile) and weight of 13.5 kg (10th-25th centile) and a head circumference 
of 49.5 cm (50th centile). Facial dysmorphic features included frontal bossing, long 
palpebral fissures, wide mouth with full lips, long and smooth philtrum, anteverted 
nares, pointed chin and large ears (ears originally outstanding/cupped and 
asymmetric, now post surgical correction) (figure 1E). Diagnostic studies, including 
routine G-banded chromosome analysis, FISH for the Williams syndrome 
microdeletion, and molecular analysis for fragile X syndrome were negative. 
CT-scan of the brain was normal and examination by the ophthalmologist did not 
show any abnormalities. 
 
Patient 3
Patient 3 was ascertained at age 6 years 3 months when array CGH analysis was 
performed because of ID, dysmorphic features, and congenital anomalies. He was 
born at term by vaginal delivery after an uncomplicated pregnancy and his size was 
appropriate for gestational age. At delivery he was noted to have a skin rash and 
hepatosplenomegaly with thrombocytopenia. TORCH (toxoplasmosis, rubella, cyto-
megalovirus, herpes) infection was excluded and the organomegaly and thrombo-
cytopenia resolved. He suffered a mild intracranial hemorrhage secondary to the 
thrombocytopenia, and was diagnosed with a ventricular septal defect (VSD), 
patent foramen ovale (PFO), cleft mitral valve and left cryptorchidism in the new - 
born period. VSD and PFO were repaired at age 3 months. Routine G-banded 
chromosome analysis was normal. At the time of the genetics consultation at age 6 
years and 3 months he had been admitted to hospital for an acute parvovirus 
myocarditis and dilated cardiomyopathy with severely depressed biventricular 
function. Further evaluation revealed a history of developmental delay (he walked 
at age 3 years, and spoke his first words at 18-20 months), ID and febrile seizures. 
On physical examination he had a height on the 5th -12th centile and a head 
circumference on the 10th centile. Dysmorphic features that were observed included 
a triangular face with a high forehead and frontal bossing, arched eyebrows, large 
ears, smooth philtrum, wide mouth, pointed chin and high palate (figure 1 F-G). MRI 
of the brain revealed a posterior fossa arachnoid cyst, thinned corpus callosum, 
periventricular heterotopias, optic nerve hypoplasia, and evidence for an old left 
hemorrhagic parietal infarct. The heterotopias were unilaterally localized along the 
lateral margin of the trigone of the right lateral ventricle extending along the temporal 
horn of the right lateral ventricle. Ophthalmic examination revealed high myopia, 
intermittent exotropia, horizontal nystagmus, and possible right amblyopia. Audiogram 
revealed moderate to severe bilateral mixed sensorineural and conductive hearing 
had no other difficulties in the neonatal period. His psychomotor development was 
delayed. He walked independently  at the age of 2,5 years and began using single 
words after age four years. At the age of three years he was referred to a pediatric 
neurologist, because of his developmental delay and epilepsy (absence and 
generalized epilepsy). Cerebral imaging with a computer tomography-scan 
(CT-scan) showed colpocephaly, hypoplasia of the corpus callosum and 
heterotopia. Vision and audiological evaluations were normal. Routine chromosome 
analysis showed a normal male karyotype. At the age of 22 years he was referred 
for reevaluation. He had a moderate ID and showed behavior consistent with autism 
spectrum disorder. A Dutch formal test for autism spectrum disorders (AVZ-R 
(‘’Autisme- en Verwante stoornissenschaal-Z-Revisie’’, 1999) showed borderline 
results for the diagnosis of an autism spectrum disorder. His epilepsy was under 
good control and medical treatment was gradually stopped. On physical 
examination he exhibited dysmorphic features, with high forehead, bitemporal 
narrowing, long palpebral fissures, large ears, smooth philtrum, wide mouth and 
micrognathia (figure 1 C-D). He had a kyphoscoliosis and strabismus. His height 
was 175 cm (3rd-10th centile), his weight was 64 kg (50th centile) and his head 
circumference was 59.5 cm (90th centile). Cardiac ultrasound revealed no 
abnormalities. Bone densitometry showed normal bone density. Genetic diagnostic 
evaluation with subtelomeric multiplex ligation-dependent probe amplification 
(MLPA, SALSA MLPA Kit P036, MRC Holland, Amsterdam, The Netherlands) was 
normal.
 
Patient 2 
A cursory analysis of patient 2 has been included in a large Canadian autism cohort 
study,30 and here we provide a more detailed clinical and molecular description. 
Patient 2 was ascertained at age 3 years and 3 months when SNP array analysis 
was performed because of developmental delay, autism spectrum disorder and 
dysmorphic features. He was born at term after an uncomplicated pregnancy and 
delivered by Caesarean section on maternal indication. He was born with strikingly 
outstanding and asymmetric ears. On day three he developed low platelets. It was 
documented as caused by alloimmune idiopathic thrombocytopenic purpura (ITP) 
due to his mother’s ITP. After treatment his platelets remained within the normal 
range. Psychomotor development was delayed. At 21 months of age he was not 
able to walk independently and used 3 single words with meaning. He was 
diagnosed with autism by formal tests, at age 2 years by ADOS-1 (Autism Diagnostic 
Observation Schedule) and at age 3 years and 4 months by ADI-R (Autism 
Diagnostic Interview Revised). Psychometric testing at age 6 years and 5 months 
showed average results for nonverbal intelligence; Naglieri Nonverbal Ability test 
(NNAT) score was at the P50 and Test of nonverbal intelligence (TONI-3) gave a 
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available upon request) to measure relative copy number in the patient and parents 
and controls between this chromosome 16q24.3 and a control region (FOXP2). The 
same approach was used to validate a de novo 500 kb CNV gain at 3p14.2 near the 
common fragile site FRA3B in patient 2. Subsequently, patient 2 was also tested on 
the Affymetrix 6.0 array.
In patient 3 and his parents a 244K oligo array analysis, according to the Agilent 
protocol (Agilent Technologies Inc., Santa Clara, CA, USA) was performed. 
In patient 4 and his parents a 105K oligo array according to the Agilent protocol was 
performed (design ID 019015, Agilent Technologies Inc.).
 
 
Results
Clinical features
A summary of the clinical features of the four patients with a chromosome 16q24.3 
microdeletion is shown in Table 1. All patients show a prominent forehead and large 
ears. Moreover, patients 1-3 share distinct other features (Figure 1A-G) including 
long smooth philtrum, broad mouth and pointed chin. These were  not seen in 
patient 4 (Figure 1H-I). In addition to variable cognitive impairment, ranging from 
moderate ID to normal nonverbal IQ with moderate-severe speech delay, all four 
patients have either autistic features (patient 1) or met the diagnostic criteria for an 
Autistic Spectrum Disorder (ASD) (patients 2-4). Interestingly, brain abnormalities, 
including structural anomalies and neuronal migration disorders, were noticed in 
two of the three patients who underwent brain imaging (patient 1 and 3). Epilepsy 
and (transient) thrombocytopenia were each noticed in two out of the four patients. 
Nonspecific ocular problems were seen in three of the four patients. One patient, 
patient 3, with the largest deleted region, had a ventricular septal defect and cleft 
mitral valve.  
Molecular findings 
The de novo CNV results observed in the four patients are summarized in Table 1 
and the overlapping deletions at chromosome 16q24.3 are schematically shown in 
Figure 2. All deletions were mapped according to the USCS genome browser build 
May 2004.
In patient 1 an interstitial 378 kb loss was identified (87,65-88,03Mb): 46, XY.arr snp 
16q24.3 (SNP_A-1895824SNP_A-2058988)x1 dn.   
In patient 2 an interstitial loss of 265 kb (87,80-88,06 Mb): 46,XY, 16q24.3 
(SNP_A-2223520  SNP_A-4274603)x1 dn was identified. Detailed analysis of the 
qPCR data in patient 2 revealed that the deletion does not extent to the last exon of 
CDH15. According to the assays the coordinates 87,788,807-87,788,909 (Build 36) 
impairment. Complete blood count showed mild macrocytosis (MCV 92.4 FL; 
normal 76-90), with normal homocysteine and folate values. The cardiomyopathy 
and macrocytosis resolved, yet he developed complex partial seizures at age 7 ½ 
years with EEG showing a seizure focus of the left temporal region.  He continued 
to make progress in school. He meets criteria for autism under the ADOS.
Patient 4
Patient 4 was ascertained at age 8 years and 10 months when array CGH analysis 
was performed because of psychomotor retardation, features of autism spectrum 
disorder and dysmorphic features. He was born at term after an uneventful 
pregnancy by a Caesarean section because of breech presentation. Birth weight 
was 3,850 grams (50th-90th centile). Birth length and head circumference are 
unknown. In the first weeks there were feeding problems, probably caused by poor 
sucking. There was no hypotonia. Psychomotor development was slightly delayed 
with independently sitting at 12 months of age and independently walking at the 
age of 18 months. Language development was delayed. Throughout childhood 
there were periods of obstipation. There were frequent ear infections. Hearing was 
tested normal. There is severe bilateral astigmatism. At the age of 7 years and 2 
months verbal IQ was 81 and performal IQ was 67 as assessed by the WISC III 
intelligence test. He was diagnosed with an Autism Spectrum Disorder (ASD)/ 
Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) by a child 
psychologist and psychiatrist. There are no signs of epilepsy. On physical 
examination he showed dysmorphic features with a high and broad forehead, 
mildly upslanting palpebral fissures, a double hair whorl, large ears, a preauricular 
tag and bilateral fusion of the central and lateral incicors (figure 1 H-I). His height 
was 126.3 cm (10th-25th centile), his weight was 23.7 kg (5th-25th centile) and his head 
circumference was 52.2 cm (50th-75th centile). Cardiac examination was normal. The 
left hand showed a single transverse palmar crease. Thumbs were slightly 
proximally placed. X-rays of the hands showed pseudo-epiphyses of the second 
metacarpals. Routine G-banded chromosome analysis showed a normal male 
karyotype. Molecular analysis for fragile X syndrome was negative. Complete blood 
count showed no abnormalities at the age of 8 years. 
 
Methods
DNA was obtained from peripheral blood leucocytes and isolated according to 
standard procedures. In patient 1 and 2 and both parental couples a 500k SNP 
array analysis with the combined two-chip Affymetrix NspI and StyI GeneChip 
Human Mapping Commercial was performed according to the standard Affymetrix 
GeneChip protocol (Affymetrix inc, Santa Clara, California, USA). For CNV validation 
in patient 2, multiple SYBR Green-based qPCR assays were used (primer sequences 
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Table 1   Clinical features of the four presented patients with a 16q24.3microdeletion 
Patient Patient 1 Patient 2 Patient 3 Patient 4 Total
Size of 16q24 deletion 378 kb 265 kb 2.07 Mb 1.1 Mb 90 kb overlap
Mb positions 87,65-88,03 87,80-88,06 86,06-88,13 86,79-87,89 Mb SRO: 87,80-87,89 Mb 
Age at examination 22y 3y, 3m 6y, 3m 8y, 10m mean age 10y
Cognitive impairment moderate
ID
normal nonverbal IQ with 
moderate-severe speech delay
Moderate
ID
borderline-normal verbal IQ
mildly impaired nonverbal IQ
4/4
Autism Spectrum Disorder borderline + + + 4/4
Height 3-10th percentile 10-25th percentile 5th-12th percentile 10-25th percentile all (low) normal
Head circumference 90th percentile 50th percentile 10th percentile 50-75th percentile all normal
Facial characteristics
High forehead
Frontal bossing
Bitemporal narrowing
Long oval face
Long palpebral fissures
Arched eyebrows
Large ears
Smooth philtrum
Broad mouth
Pointed chin
Micrognathia
High palate
+
-
+
+
+
-
+
+
+
+
+
+
-
+
-
-
+
-
+
+
+
+
+
-
+
+
-
-
-
+
+
+
+
+
-
+
+
-
-
-
-
-
+
-
-
-
-
-
3/4
2/4
1/4
1/4
2/4
1/4
4/4
3/4
3/4
3/4
2/4
2/4
Congenital heart defect - - VSD, PFO and cleft mitral valve with  
severe mitral regurgitation
NT 1/2
Structural brain 
malformation
corpus callosum 
hypoplasia
colpocephaly  
- corpus callosum hypoplasia  
dilated ventricles
optic nerve hypoplasia
NT 2/3
Neuronal migration 
disorder
heterotopias normal unenhanced  
CT cerebrum
perventricular heterotopias (unilateral) NT 2/3
Seizures absences and 
generalized
- partial complex - 2/4
Ocular problems strabismus - high myopia astigmatism  
horizontal nystagmus
severe bilateral astigmatism 3/4
Hearing loss - - mixed sensorineural and conductive  
hearing loss
- 1/4
Skeletal anomalies kyphoscoliosis - - - 1/4
Genital anomalies - - unilateral cryptorchidism - 1/4
Hematologic disorder - neonatal thrombopenia 
(resolved)
thrombopenia, macrocytosis
(resolved)
- 2/4
NT= not tested
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are not deleted (results not shown). Patient 2 also carried a 500 kb de novo gain at 
3p14.2. An interstitial loss of 2.07 Mb in chromosome band 16q24.2q24.3 was 
identified in patient 3 (86,06-88,13 Mb) (probe A_16_P40717088  probe A_16_
P20559418). In patient 4, an interstitial loss of 1,1 Mb in chromosome band 16q24.2q24.3 
was detected  (86,79-87,89 Mb) (probe A_14_P119277  A_14_P111955).
In all four cases analysis of both parents showed normal copy numbers for the 
deleted regions, suggesting a de novo origin of the deletions. These four chromosome 
16q24.3 deletion cases are the only cases that have been detected in a total cohort 
of more than 3000 patients with developmental delay and/or autism or congenital 
anomalies. The same region was interrogated over 1000 population controls31 and 
found not to be copy number variable. The Database of Genomics Variants32 shows 
Figure 1   Facial profiles of patients 1-4. A-C: Patient 1 at several ages from  
6 years (A) to 22 years (B-C). D-F: Patient 2 at the age of 3 years  
(D) and at the age of 8 years (E-F). G-H: Patient 3 at the age of  
7 years. I-J: Patient 4 at the age of 8 years and 10 months.   
Facial features comprise high forehead/frontal bossing and large 
ears (all patients), broad mouth, long smooth philtrum and pointed 
chin (patient 1-3). Note the change in facial phenotype in patient 1  
at adult age, showing a long and oval face with full upturned nose, 
retrognathia and pronounced groove in the chin.
Figure 2   Schematic overview of deleted regions on chromosome 16q24.3  
in the presented patients.
All deletions were mapped according to the USCS genome browser build May 2004. The relative positions 
of the genes of interest are indicated. The region of 90kb overlap is demarcated with a grey zone. The 
deletions of patient 3 and 4 extend beyond the figure (Mb positions of proximal delineations: 86,06 and 
86,79 respectively). The arrows indicate the direction in which the genes are transcribed.
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appears not to be involved in the deletion of patient 2. It is not excluded that a 
position effect or disruption of gene regulatory elements could create a functional 
null allele for CDH15 also in this patient. The potential involvement of CDH15 is of 
particular interest since nonsynonymous variants of this gene have been identified 
in a cohort of mentally disabled patients.34 However the group of non-affected 
controls in this study was relatively small and segregation of the variants in 
unaffected family members has not been tested consistently or was not in 
agreement with the presumed pathogenicity of the detected variant. Of interest, a 
recently published genome wide association study among cases with ASD 
identified common genetic variants on 5p14.1 that are associated with susceptibility 
to ASD. The nearby genes CDH9 (MIM 609974) and CDH10 (MIM 604555) are also 
members of the Cadherin gene family involved in neuronal cell adhesion. This 
implicates a role of CDH9 and CDH10 and possibly other members of the Cadherin 
family in the pathogenesis of ASD by affecting the neuronal cell adhesion.35 
Haploinsufficiency for either or both ANKRD11 and ZNF778  is an attractive explanation 
for the syndromic autism phenotype with variable cognitive impairment observed in 
the four patients. ANKRD11 encodes a member of the family of ankyrin repeat 
containing cofactors that interacts with p160 nuclear receptor coactivators and 
histone deacetylases corepressors, and inhibits ligand-dependent transcriptional 
activation of target genes by nuclear receptors.36 Therefore, haploinsufficiency of 
ANKRD11 may disrupt transcription regulation. Disruption of epigenetic processes 
has been shown to play a role in the cause of ID. Examples are disruption of a 
methyl-CpG-binding protein caused by mutations in MECP2 (MIM 30005) in Rett 
syndrome, mutations in EMHT1 in the 9q subtelomere deletion syndrome and 
mutations in either CREBBP or EP300 in Rubinstein-Taybi syndrome. In these cases 
ID might be caused by epigenetic effects on the expression of genes that are not 
themselves mutated.37 
Interestingly, Barberic et al.38 described a mouse mutant, named Yoda, with a 
missense mutation in the Ankrd11 gene. Homozygous knock out Yoda mice are not 
viable and die during embryogenesis. This suggests that the gene has a crucial 
function in embryonic development. A major feature of heterozygous mutant mice 
is reduced bone mineral density. They also show cranio-facial abnormalities, like 
shortened snouts, wider skulls, deformed nasal bones and failure of the interfrontal 
suture to close. Body size is reduced and with ageing many Yoda mice developed 
kyphosis.38  Mild kyphoscoliosis was seen only in the oldest patient (patient 1), 
however examination of bone density in this patient showed normal results. Based 
on in silico data ANKRD11 is widely expressed, including in several brain regions 
(amygdala, parietal lobe, occipital lobe and cerebellum) and the heart (UCSC 
Genome Browser, Microarray Expression Data, Unigene). 
The other gene localized in the SRO, ZNF778, encodes a member of the extensive 
one CNV (Variation_4018) at this site33, involving the first two exons of ANKRD11 but 
not ZNF778, but it is not found in other studies.
 
Discussion 
We present detailed clinical and molecular features of four patients with micro-
deletions within the chromosomal band 16q24.3. The four patients have autistic 
features or a diagnosis of ASD, variable cognitive impairment and facial dysmorphism, 
and share a 90kb overlapping region comprising two annotated genes, Ankyrin 
Repeat Domain 11 (ANKRD11) and zinc finger 778 (ZNF778) (Figure 2). The level of 
cognitive impairment that was observed in these four patients is considerably 
variable, ranging from moderate ID in patient 1 and 3 to a normal nonverbal IQ 
with moderate-severe speech delay in patient 2. Patient 2 showed a remarkable 
discrepancy between his verbal and nonverbal capacities in disadvantage of speech/
auditory development. An opposite discrepancy in IQ levels, however less extreme, 
was reported in patient 4 who had a borderline-normal verbal IQ of 81 and a mildly 
impairment nonverbal IQ of 67. 
Remarkably, both patients 1 and 3 have structural brain abnormalities, including 
hypoplasia of corpus callosum, colpocephaly/dilated ventricles, as well as periven-
tricular heterotopias that might be causative for the epilepsy these two patients 
experienced. They share a deletion interval comprising ANKRD11, ZNF778 and 
CDH15, suggesting that haploinsufficiency for one or more of these genes is 
involved in neuronal migration and causes the gray matter heterotopias in patient 1 
and 3. The localization of the heterotopias in patient 1 was likely bilaterally, but no 
further details were available by cerebral imaging for this patient. The heterotopias 
in patient 3, however, were unilaterally localized which  raises the possibility that 
this migrational defect was caused by an (in utero) acquired event rather than a 
genetic defect. Both patient 2 and 3 had temporary thrombocytopenia, although 
the neonatal thrombocytopenia in patient 2 was attributed to his  mother’s ITP. 
Nonspecific ocular problems were noted in three of the four patients. Features that 
were only observed in patient 3 (with the largest deleted region) were a congenital 
heart defect, unilateral cryptorchidism and sensorineural hearing impairment. 
Patient 2 also carried a 500 kb de novo gain at 3p14.2 at the FRA3B (MIM 601153) 
locus, which may also contribute to his phenotype, however patient 2 had no specific 
other features.
By molecular characterization of these four overlapping deletions in 16q24.3, two 
likely candidate genes for the observed autism phenotype with cognitive impairment 
were present in the SRO. A third gene, Cadherin 15 (CDH15), is located just proximal 
to the SRO and is involved in the deletion of patients 1, 3 and 4 (Figure 2). CDH15 
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ZNF385B (MIM 612344) with the 2q31.2 deletion syndrome.41 Therefore, haploinsuf-
ficiency of ZNF778 might also, or exclusively, be involved in the phenotype observed 
in the reported patients. 
Table 2 provides an overview of these and other interesting genes that are involved 
in the non-overlapping deleted regions. Proposed functions, phenotype in knockout 
mice (if available), previously reported cases and the possible clinical correlation of 
haploinsufficiency of these genes with the observed phenotype in our patients are 
family of KRAB-domain zinc finger proteins. Based on the available in silico data, 
this gene is also expressed in several tissues, including the brain and the heart 
(Unigene). KRAB-domain zinc finger proteins are found in transcription regulatory 
complexes, which are directed to the regulatory elements of target genes through 
the C2H2 zinc finger domains that recognize specific DNA binding sites. Moreover, 
several human zinc finger genes have been associated with MR: ZNF41 (MIM 
314995), ZNF81 (MIM 314998) and ZNF674 (MIM 300573) with X-linked MR39-41 and 
Table 2   Clinical features of patients 1 and 2 and  previously reported patients  
with an overlapping chromosome 8p deletion 
Gene   
(Mb positions)
Function Mouse null Mouse heterozygous Previously reported cases Possible clinical correlate
ANKRD11 
(87,86-88,08)
nuclear receptor mediated transcriptional 
regulation (inhibitory) 36, 38
lethal 38 reduced bone mineral 
density
craniofacial abnormalies
reduced body size38
Marshall et al. identified 
a 16q24.3 deletion 
encompassing ANKRD11 in  
an ASD case30
kyphoscoliosis in patient 1, 
however he has a normal bone 
density
syndromic autism phenotype  
with variable cognitive 
impairment in patients 1, 2, 3 
and 4
ZNF778 
(87,81-87, 82)
encodes a member of the  KRAB domain 
containing zinc finger protein family, suggesting 
involvement in transcription regulation 39-42
no data available no data available Several other human zinc  
finger genes have been 
associated with ID39-42
syndromic autism phenotype 
with variable cognitive 
impairment in patients 1, 2, 3 
and 4
CDH15 
(87,77-87,79)
cell-cell adhesion in skeletal muscle and  
human brain34, 43
no data available no data available Bhalla et al. identified 4  
nonsynonymous variants of 
CDH15  in a cohort of patients 
with ID34
cognitive impairment in patient 
1, 3 and 4 
ZFPM1 (FOG1) 
(87,05-87,13)
co-regulator of the transcriptional
activator GATA1, which regulates the expression 
of certain genes during erythroid and 
megakaryocytic differentiation44 
GATA-1 knockout mice are not viable. 
Mice with selective loss of GATA-1 
expression in megakaryocytes have 
thrombopenia. 
no data available Freson et al. demonstrated a 
disturbed interaction between  
mutants of GATA1 and
FOG1 in patients with 
macrothrombocytopenia and 
dyserythropoiesis.44
neonatal thrombocytopenia in 
patient 2 and 3
unexplained macrocytosis in 
patient 3
CBFA2T3  
(MIM 603870)
(87,47-87,57)
regulates the proliferation and the differentiation 
of erythroid progenitors
no data available no data available - unexplained macrocytosis and 
neonatal thrombocytopenia in 
patient 3
CDT1 
(87,39-87,40)
transcriptional regulator (initiation)45 no data available no data available - ?
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Abstract
MicroRNAs (miRNAs) are non-coding gene transcripts involved in post-transcrip-
tional regulation of genes. Recent studies identified miRNAs as important regulators 
of learning and memory in model organisms. So far, no mutations in specific miRNA 
genes have been associated with impaired cognitive functions. 
In three sibs and two unrelated patients with intellectual disability (ID), we detected 
overlapping 1p21.3 deletions by genome-wide array analysis. The shortest region 
of overlap included dihydropyrimidine dehydrogenase (DPYD) and microRNA 137 
(MIR137). DPYD is involved in autosomal recessive dihydropyrimidine dehydrogenase 
deficiency. Hemizygous DPYD deletions were previously suggested to contribute to 
a phenotype with autism spectrum disorder and speech delay. Interestingly, the 
mature microRNA transcript microRNA-137 (miR-137) was recently shown to be 
involved in modulating neurogenesis in adult murine neuronal stem cells. Therefore, 
we investigated the possible involvement of MIR137 in the 1p21.3-deletion 
phenotype. Our patients displayed a significantly decreased expression of both 
precursor and mature miR-137 levels, as well as significantly increased expression 
of the validated downstream targets microphthalmia-associated transcription factor 
(MITF) and Enhancer of Zeste, Drosophila, Homologue 2 (EZH2), and the newly 
identified target Kruppel-like factor 4 (KLF4). We also demonstrated significant 
enrichment of miR-137 at the synapses of cortical and hippocampal neurons, 
suggesting a role of miR-137 in regulating local synaptic protein synthesis machinery. 
This study showed that dosage effects of MIR137 are associated with 1p21.3 
microdeletions and may therefore contribute to the ID phenotype in patients with 
deletions harbouring this miRNA. A local effect at the synapse might be responsible.
Introduction
microRNAs (miRNAs) are small RNAs that are highly conserved and involved in 
several biological processes like developmental timing, cell proliferation, apoptosis, 
metabolism, cell differentiation, and morphogenesis.1 They regulate gene 
expression by binding to the 3’-untranslated region (UTR) of target mRNAs and 
inhibiting protein synthesis or causing mRNA degradation.2,3 Each miRNA can act 
on many mRNAs, and conversely, individual mRNAs can be targeted by a number 
of miRNAs. Recent estimate puts the number of human miRNAs at 1100 or more, 
influencing the expression of as many as a two-third of all genes.4,5 A few miRNAs, 
for example miR-124, miR-134 and miR-338 are specifically expressed in brain, 
suggesting unique regulatory roles in neuronal development and function.5,6 The 
large number of miRNAs imposes a formidable challenge for studying miRNAs, 
their target mRNAs, and their functions in learning and memory, brain development 
and brain plasticity.7 Multiple lines of evidence suggest that altered neuronal 
plasticity and morphology as seen in neurodevelopmental disorders may result 
from disruption of a common post-translational process that is under tight regulation 
by miRNAs.5,7 Several intellectual disability (ID) syndromes, such as Fragile X 
syndrome, Rett syndrome, and Down syndrome, have been associated to miRNA 
pathways.8-12 Little is known, however, about the pattern of expression of these 
small non-coding RNA molecules in the brains of normally developing individuals 
or patients with disorders of the nervous system. Moreover, no previous reports 
linked the disruption of specific microRNAs to ID.
While interstitial deletions of the short arm of chromosome 1 are rarely reported, a 
recently published study identified hemizygous microdeletions restricted to the 
chromosomal region 1p21.3.13 The individuals described had autism spectrum 
disorder and severe speech delay. The authors of this study suggested that 
hemizygous deletions of the DPYD locus are contributing to these phenotypes. 
Though, absence of reports of abnormal cognitive functioning in the many 
heterozygous carriers of DPYD loss-of-function mutations opposes against an 
exclusive role for DPYD in the observed cognitive impairment.14 DPYD is involved in 
autosomal recessive dihydropyrimidine dehydrogenase (DPD) deficiency. The 
phenotype is variable, but frequently comprises developmental delay and 
convulsions.15 
In the present study, we have collected five individuals with ID who have overlapping 
1p21.3 microdeletions that included DPYD but also the miRNA gene microRNA 137 
(MIR137). Expression studies revealed reduced levels of precursor and mature 
microRNA-137 (miR-137) and increased levels of downstream targets of miR-137 in 
the patients compared to controls. Our studies indicate that alteration in miR-137 
expression levels is a likely explanation for their ID phenotype. To our knowledge, 
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RNA isolation
1 to 5 micrograms of total RNA were isolated from cell suspensions of approximately 
1x106 EBV-transformed B cells from individual cell lines using the NucleoSpin RNA 
II RNA isolation kit form Machery-Nagel (Düren, Germany). The concentration and 
quantity of RNA were measured by UV absorbance at 260 and 280 nm (A260/280 
ratio) and checked by gel electrophoresis. 
Quantitative reverse transcription-PCR (qRT-PCR) of precursor 
and mature miRNA-137 and its downstream targets
qRT-PCR quantification of precursor and mature miR-137 levels and its validated 
and newly identified downstream targets was performed on RNA from 
lymphoblastoid cell lines (LCL) of patients and controls, as well as on RNA from 
several human brain regions and mouse cortical synaptosomal preparations, 
according to previously described protocols.17, 18 Precursor miR-137 primers were 
designed to anneal within the hairpin sequence of the miRNA-137 precursors. 
Precursor miRNA-137 cDNA was synthesized from total RNA by using gene-specific 
miR-137 reverse PCR primers. The forward primers for qPCR analyses for mature 
miR-137 were designed using the entire mature miRNA sequence (primer 
sequences are shown in Table 1). 
Mature miR-137 cDNA was synthesized from total RNA (1μg) using the NCode 
miRNA First Strand cDNA synthesis kit (Invitrogen) according to the manufacturer’s 
protocol. Using first-strand cDNA as a template, triplicate qPCR reactions were 
performed from samples derived from 3 different experiments for mature miRNA 
using miR-137-specific forward primers and the NCode Universal qPCR reverse 
primer. Minus template and minus forward primer controls were included to ensure 
lack of signal in the assay background. U6 snRNA levels were used as a loading 
control. All Ct values used for analyses were averaged from three to six replicates 
and those with high standard deviation (>1) were not included in the analyses. 
Melting curve analysis was performed to test for the specificity and quality of the 
qPCR amplifications. Relative expression was calculated using the comparative CT 
method18 normalized to the expression of U6 snRNA. To assess the levels of 
this is the first study that demonstrates that a reduced copy number of a specific 
miRNA might be associated with ID.  
Patients and Methods
Patients
Patients 1,2 and 4 were ascertained by genome-wide array analysis during a 
pending cohort study in patients with unexplained ID at the department of Human 
Genetics in Nijmegen, The Netherlands. Patient 5 was ascertained by genome-wide 
array analysis during routine diagnostic evaluation of her ID at the departments of 
clinical genetics and neuropediatrics in Lille, France. Patients 1-3 were siblings. 
From patient 3 we obtained a blood sample for genetic testing and concise 
information on her developmental level, but it was not possible to perform a clinical 
examination. Chromosomal analysis in the parents of the three affected sibs was 
not possible, because they were deceased. They were known with low cognitive 
abilities and had not been able to take care for their children, who were placed in 
foster homes. Patients 4 and 5 were single unrelated patients. Fragile X syndrome 
and Prader Willi syndrome were excluded in patients 1 and 2 from family 1 and in 
patients 4 and 5. 
 
SNP array analysis
DNA was obtained from peripheral blood leucocytes and isolated according to 
standard procedures. In patients 1-4, as well as in the parents of patient 4, 
genome-wide Single Nucleotide Polymorphism (SNP) array analysis was performed 
by the Affymetrix 250k SNP array platform according to the standard Affymetrix 
GeneChip protocol (Affymetrix, Inc., Santa Clara, CA, USA). In patient 5 and her 
parents genome-wide array analysis was performed by the Agilent 44k array 
platform. Copy number estimates were determined using the updated version 2.0 
of the CNAG (Copy Number Analyzer for Affymetrix GeneChip mapping) software 
package.16 The normalized rations were subsequently analyzed for genomic 
imbalances by a standard Hidden Marker Model (HMM). CNVs were mapped 
according to the USCS genome browser build March 2006. To confirm the deletions 
detected by 250k SNP array analysis, quantitative Polymerase Chain Reaction 
(qPCR) analysis on DNA extracted from blood lymphocytes was performed. 
 
Metabolic tests
In patients 1 and 2 (siblings) and in patient 4 measurements of serum and urine 
levels of purines and pyrimidines were performed to rule out DPD deficiency.
 
Table 1   Primers used for qRT-PCR of precursor and mature miR-137
Gene Forward primer (5’ → 3’) Reverse primer (5’ → 3’)
U6 snRNA CTCGCTTCGGCAGCACA AACGCTTCACGAATTTGCGT
rno-miR-137 GTGACGGGTATTCTTGGGT GACTACGCGTATTCTTAAGCAA
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and quality was determined with a NanodropTM ND-1000 spectrophotometer 
(Thermo Fisher Scientific) and 1% agarose gel electrophoresis, respectively. The 
samples were kept at -80 °C until further analysis. 
 
miRNA computational predictions
To assess the potential regulatory impact of miR-137 at the synapse, we searched 
the TargetScan miRNA target database for conserved, putative rodent targets of 
miR-137.21, 22 
 
Neuronal cell cultures and transfections
Primary cultures of cortical neurons were prepared from embryonic day 18 rats as 
described23 and maintained in a neurobasal medium supplemented with B27 
(Invitrogen, Carlsbad, CA, USA) and 2 mmol/L glutamine. For miR-137 expression 
experiments, the miRNASelect™ pEGP-mmu-mir-137 Expression Vector (Cell 
Biolabs, Inc., San Diego, CA) constructs expressing mouse miR-137 precursor and 
GFP, or the negative control pEGP-null vector (expressing GFP) were purchased. 
Locked nucleic acid miR inhibitor, anti-miR-137, as well as nontargeting control 
anti-miR-NT were obtained from Exiqon (Denmark). Small RNAs and Constructs 
were introduced into primary neurons using Lipofectamine 2000 (Invitrogen).
Statistical Analysis
Student’s t test was used to determine significant differences in transcript levels 
between the patients and the controls.
One-way ANOVA was used to analyze significant differences among multiple 
groups; p<0.05 was considered significant.
 
Results
Clinical results 
A summary of the clinical features is shown in Table 2. Photographs of patients 1, 2, 
4 and 5 are shown in Figure 1. Though the patients have no distinct dysmorphic 
facial features, they showed similarities in facial appearance, including long ears, 
deeply set eyes, broad nasal tip and thick lower lip. The level of ID ranged from 
borderline-mild (patient 1) to mild-moderate (patient 2 and 3). Remarkably, patients 
1, 2 and 4 showed a similar discrepancy between verbal and performal IQ with a 
relatively low score on verbal capacities. Such a discrepancy was not reported in 
patient 5. Patient 2 of family 1 and patient 4 also showed similar speech deficits 
including poor intelligibility and specific pronunciation deficits (in patients 1, 3 and 
5 speech tests were not performed). Similar behaviour characteristics included a 
miR-137 downstream target mRNAs, Two μg of DNAse-treated, total RNA from 
each sample was used for cDNA synthesis, using the RevertAidTM H Minus First 
Strand cDNA Synthesis kit (Fermentas Inc., USA). Prior to qPCR analysis, each 
cDNA sample was diluted 1:10 with MilliQ water. qPCR was performed according to 
previously described protocols17, 18, using standard cycling conditions, and 
performing a melting protocol to control for product specificity. The MaximaTM SYBR 
Green qPCR Master Mix Kit (Fermentas Inc., USA) was used in the qPCR reactions. 
Primers were designed using NCBI Primer-Blast (www.ncbi.nlm.nih.gov/tools/
primer-blast/) and synthesized at Biolegio BV (The Netherlands). Primer sequences 
for MITF, EZH2, and KLF4 are available upon request. The relative levels of the 
transcripts of the downstream targets were normalized to beta-glucuronidase 
(GUSB) and beta-actin (ACTB) mRNAs to provide an internal control for reverse 
transcription. These messages were used as reference genes, because of their 
stable expression in lymphocytes.19 All other human RNAs investigated were 
purchased from Stratagene (La Jolla, CA, USA).
 
Synaptosomal preparation
Synaptosomes were isolated based on the method of Gray and Whittaker (1962).20 
All the procedures were performed at 4 ˚C, and under RNase-free conditions. 
Briefly, mouse cortical tissue was homogenated using a Dounce Homogenizer 
(B. Braun Biotech International) in 5mM HEPES buffer containing 0.32 M sucrose, 
protease inhibitor cocktail (Roche) and 1U/mL RNase inhibitor (Fermentas). The 
homogenate was centrifuged at 1000x g for 10 min, obtaining supernatant S1 and 
pellet P1. Pellet P1 was resuspended with homogenization buffer and centrifuged 
at 1000x g for 10 min, obtaining supernatant S2 and pellet P2 (containing the 
nuclear fraction). Supernatants S1 and S2 were pooled together and centrifuged at 
20,000x g for 10 min, obtaining supernatant S3 (contaning the cytoplasmic fraction) 
and pellet P3. Pellet P3 was resuspended in homogenization buffer, loaded on a 
discontinuous sucrose density gradient (0.85 M and 1.2 M sucrose layers), and 
centrifuged at 30,000x g for 2h. The interface between the two sucrose layers was 
collected and centrifuged at 25,000x g for 30 min, obtaining a pellet containing the 
synaptosomal fraction. The purity of the synaptosomal fraction was determined by 
Western blot assay using the synaptic marker (PSD95, 1:5000; NeuroMab) and 
markers known not to be enriched at the synapse (tubulin, 1:500; in-house 
antibody). GADPH (1:1000; Cell Signaling) was used as a housekeeping marker. 
The nuclear, cytoplasmic and synaptosomal fractions were kept at -80 °C until 
further analysis. RNA from nuclear, cytoplasmic and synaptosomal fractions was 
isolated with TRIzol® Reagent (Invitrogen), according to the manufacturers 
protocol. The procedure was modified for small amounts of tissue by using 800 μl 
of TRIzol® Reagent and adding 1 μl of glycogen (Fermentas). RNA concentration 
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Genome-wide array analysis
Figure 2 provides a schematic representation of the overlapping deletions in 1p21.3 
in our patients and in the patients reported by Carter and others.13 In patients 1-3 an 
identical interstitial 1.75 Mb loss was identified (97,50-99,25 Mb, according to Hg 18 
UCSC genome browser): 46, XY/XX.arr snp 1p21.3 (SNP_A-2211294­SNP_A-2131140)x1. 
remarkable shy and friendly behaviour, (tendency) to overeating and features of 
autism spectrum disorder (ASD). Patients 1, 2, 4 and 5 were obese or had a 
tendency to obesity. Patients 1, 2 and 4 had a-specific ocular problems.
Serum and urine measurements of purine and pyrimidine levels in patients 1, 2 and 
4 revealed no abnormalities indicative for DPD deficiency.
Table 2   Clinical and molecular features of overlapping 1p21.3 microdeletions  
in patients 1-5 
Patient 1* 2* 3* 4 5 Overlapping region
Size of deletion 1.75 Mb 1.75 Mb 1.75 Mb 1.41 Mb 2.45 Mb 1.22 Mb
Mb positions (Hg 18) 97.50-99.25 97.50-99.25 97.50-99.25 97.32-98.73 96.27-98.72 97.50-98.72
Involved genes DPYD, SNX7, LPPR5, 
MIR137
DPYD, SNX7, LPPR5, 
MIR137
DPYD, SNX7, LPPR5, 
MIR137
DPYD, MIR137 PTBP2, DPYD, MIR137 DPYD, MIR137
Gender male male Female Male female
Age at clinical examination 42 years 38 years - 33 years 18 years
Total
Intellectual disability borderline-mild
(TIQ 73, verbal IQ  65,  
performal IQ 90)
mild-moderate
(TIQ 52, verbal IQ  
< performal IQ (70)
mild-moderate mild
(TIQ 62, verbal IQ 59, 
performal IQ 71)
mild 
(TIQ 66)
5/5
Behaviour characteristics
Features of ASD
(Tendency) to overeating
Self mutilation
Aggressive outbursts
Remarkable shy and friendly
Specific speech deficits
+
+
-
-
+
NT
+
+
+
+
+
+
unknown
NT
+
+
-
-
+
+
-
-
-
+
+
NT
3/4
3/4
1/4
2/4
4/4
2/2
Weight 90th centile >98th centile unknown 98th centile >98th centile 4/4 (tendency)
to overweight
Facial characteristics
Deeply set eyes
Full cheeks
Micrognathia
Broad nasal tip
Long ears
Macrostomia
Thick lower lip
+
-
-
+
+
-
+
-
-
-
+
+
+
+
unknown
+
+
+
+
+
-
+
-
+
-
-
+
-
+
2/4
2/4
1/4
3/4
4/4
1/4
4/4
Ocular problems myopia astigmatism unknown astigmatism, myopia - 3/4
*patients 1-3 are sibs. ASD= autism spectrum disorder. NT= not tested. TIQ: total intelligence quotient
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Differential miR-137 expression in LCL from the patients
To study the effect of loss of one copy of MIR137, we performed qRT-PCR on 
precursor and mature miR-137 in patient 2 (one of the siblings) and patient 4. LCL 
from patient 5 were not available. As controls we used RNA extracted from the LCL 
of 3 healthy male controls. Decreased precursor and mature miR-137 levels were 
found in the LCL from patient 2 as well as the LCL from patient 4, as compared to 
healthy controls and normalized to snoRNA U6 (one-way ANOVA, p<0.001) (Figure 3). 
The results demonstrate a great degree of reduction of miR-137 levels in the 
patients.
 
Increased levels of MITF and EZH2 in patient cell lines
While the major effect of miRNA’s has been proven to be on the translation of target 
mRNAs, recent studies indicate that miRNAs also have a specific impact on the 
mRNA levels.3, 24 We therefore investigated whether reduced levels of miR-137 in our 
patients corresponded to an increased level of the previously validated miR-137 
targets EZH225, and MITF.26 To assess miR-137-mediated modulation of EZH2 and 
In patient 4 an interstitial loss of 1.41 Mb was identified (97,32-98,73 Mb, according 
to Hg 18 UCSC genome browser ): 46,XY, 1p21.3 (SNP_A-1881473 SNP_A-1789641)
x1. In patient 5 an interstitial loss of 2.45 Mb was identified (96,27-98,72 Mb, 
according to Hg 18 UCSC genome browser): 46, XX, 1p21.3 (probe A_14_P100140 
 probe A_14_P113179). The deletion of patients 1-3 comprised 3 annotated 
Refseq genes, including DPYD, SNX7 and LPPR5, and the microRNA gene MIR137. 
The deletion of patient 4 comprised the annotated gene DPYD and MIR137 and the 
deletion of patient 5 comprised the annotated genes PTBP2 and DPYD and MIR137. 
The shortest region of overlap is 1.22 Mb in size and included DPYD and MIR137.
Genome-wide array analysis in the parents of patient 4 and 5 showed that the 
deletions in these patients had occurred de novo. DNA samples from the parents of 
patients 1-3 were not available for segregation analysis, because they were 
deceased. 
 
Figure 1   Facial appearance of patients 1, 2, 4 and 5. 
Figures A-B show patient 1 at age 42 years, figures C-D patient 2  
at age 38 years, figures E-F patient 4 at 34 years and  
figures G-H patient 5 at age 18 years. Note the minor facial 
dysmorphic features, including long ears, deeply set eyes, full tip  
of the nose and thick lower lip.
Figure 2   Schematic representation of the overlapping deleted regions in 
chromosome 1p21.3 identified by genome-wide array analysis
The box indicates the chromosomal location that is schematically depicted below. The relative positions 
of the deleted regions in patients 1-3, 4 and 5 are indicated by black bars. The deletions in the patients 
reported by carter and others13 are indicated in gray. The relative positions of the genes PTBP2, DPYD, 
SNX7, LPPR5 and MIR137 are indicated. The deletion of patient 5 extends distally beyond the figure. SRO: 
shortest region of overlap (in the present patients).
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Using commercially available RNA isolated from a subset of human brain 
compartments, we showed that miR-137 is most abundant in the hippocampus. 
Similarly, high miR-137 levels can be detected in the occipital, frontal, as well as the 
parietal cortical regions, while the lowest miR-137 levels were detected in the brain 
stem and cerebellum (Figure 5A). 
Recent findings indicate that miRNAs can be enriched in synaptic compartments of 
neurons.29 This notion suggests that miRNAs may be ideally positioned to quickly 
regulate local translation in response to synaptic activity.30 A recent study revealed 
that the neuron-enriched miR-137 has a prominent role in the synapse maturation 
and morphogenesis of young neurons.31 We therefore hypothesized that miRNA-137 
might reside near the synapse, where it could act as local regulator of the translation 
of synaptically enriched target mRNAs. Recent studies employed biochemically 
isolated synaptosomes from young rat brains to demonstrate that these small 
vesicular structures preserve components of local protein synthesis, including 
polyribosomes, mRNAs and regulatory RNAs, including microRNAs.32, 33 We used 
differential fractionation to isolate mouse synaptosomal compartments, and the 
preparations were assessed by Western blotting using PSD95, GAPDH, and tubulin 
antibodies (Figure 5B), as well as by  real-time RT-PCR measurements of CAMK2a, 
MITF mRNA levels, we monitored transcript levels in LCL of our patients and healthy 
controls by qRT-PCR. This investigation revealed significantly increased MITF and 
EZH2 levels in the patients as compared to two healthy controls (Figure 4).
 
miR-137 is enriched in the hippocampus and cortical  
brain regions, and highly abundant at the synaptodendritic 
compartments of neurons
Many miRNAs have been isolated from mammalian embryonic neurons and mature 
brains and some of them are neuronal-specific.27 Although miR-137 is specifically 
expressed in neuronal tissue28, little is known about its abundance and function 
during neuronal maturation. To analyze the miR-137 level expression patterns in 
embryonic and mature brain, qRT-PCR was performed on total RNA isolated from 
fetal and adult (post-mortem) human brain. As shown in Figure 5A, miR-137 levels 
are approximately 100 times higher in the adult as compared to embryonic brain, 
suggesting that the expression of miR-137 is increasing during brain development 
and during neuronal differentiation indicating that it might have an important role in 
human brain development and functioning. 
Figure 3   Precursor and mature miR-137 levels are decreased in the patients. 
The quantitative RT-PCR assay was used to assess levels of 
precursor and mature miR-137 isolated from either the LCL of 
patients 2 and 4 and 3 healthy controls (HC). Levels of precursor  
(A) and mature (B) miR-137 levels are expressed relative to U6 
snRNA which was used as an internal control.
Figure 4   Validated miR-137 targets MITF and EZH2 mRNA levels are 
increased in the patients. The qRT-PCR assay was used to assess 
mRNA levels of MITF (A) and EZH2 (B) isolated from either the LCL 
of patients 2 and 4, and 2 healthy controls. mRNA levels are 
expressed relative to β-actin and GusB which were used as an 
internal controls. 
Error bars represent the Standard Error of the Mean (SEM) for triplicate PCR reactions from n=3 
independent experiments; one-way ANOVA, *** p < 0.0001. 
Error bars represent the SEM for triplicate PCR reactions from n=3 independent experiments; one-way 
ANOVA, * p < 0.05. 
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to verify that these components were enriched relative to total forebrain homogenate. 
This experiment revealed significant enrichment of miR-137 in RNA preparations 
from mouse synaptosomes compared to the cytosolic fractions, as assessed by 
qRT-PCR (Figure 5C). The outcome of this experiment suggests that miR-137 may 
have a local role in translation-dependent synaptic morphology. 
 
Regulation of neuronal levels of KLF4 mRNA by miR-137
To further assess the potential regulatory impact of miR-137, we searched the 
TargetScan database for additional mRNAs that contained a putative miR-137 
binding site.34 This revealed a large number putative miR-137 target mRNAs (data 
not shown). Among these mRNAs are three members of the kruppel-like factor 
genes - KLF4, KLF11, and KLF12- which contained highly conserved binding sites 
for miR-137 in their 3’UTRs. Kruppel-like factor proteins (KLFs) are a family of tran-
scriptional repressors associated with axon growth in central nervous system 
(CNS) neurons35, and previous studies identified coordinated activities of different 
KLFs to enhance the regenerative capacity of CNS neurons. The predicted miR-137 
target site (MTS) in KLF4 3’UTR (Figure 6A) had a high aggregate PCT score with the 
cognate miR (0.77), suggesting a conserved targeting of the MTS for miR-137.36
To explore whether miR-137 regulates Klf4 mRNA levels in neurons, we monitored 
Klf4  mRNA levels after transfecting rat cortical neurons (DIV 10) with a miR-137 
precursor vector. miR-137 transfection with an expression vector resulted in a 
1000-fold increase in mature miR-137 levels compared with the endogenous 
miR-137 levels in null vector-transfected cortical neurons (not shown). Klf4 mRNA 
levels decreased 20% in miR-137 overexpressing cortical neurons when compared 
with the null-vector transfected neurons (Figure 6B). Conversely, transfection of 
neurons with a locked nucleic acid inhibitor of miR-137 resulted in a three-fold 
increase in Klf4 mRNA as early as 72 hrs after transfection (Figure 6C), when 
compared with the non-targeting anti-miR control. 
The results from the miR-137 overexpression or inhibition experiments in rat cortical 
neurons prompted us to investigate KLF4 levels in LCL from our patients. This 
revealed significantly increased KLF4 mRNA levels in the patients as compared to 
the healthy controls (Figure 6D).
 
Discussion
We present evidence for likely involvement of MIR137 in the ID phenotype of patients 
with 1p21.3 microdeletions. The shortest region of overlap included DPYD and 
MIR137. DPYD is involved in autosomal recessive DPD deficiency, which is 
characterized by developmental delay and convulsions.15 Several arguments 
Figure 5   miR-137 is overexpressed in the hippocampus and cortical brain 
regions, and enriched at synaptic compartments. (A) Differential 
brain regional distribution of miR-137. The qRT-PCR miRNA assay 
was used to quantify precursor mir-137 across different human brain 
regions. (B) Differential fractionation was used to isolate mouse 
synaptosomal compartments, and the preparations were assessed 
by western blotting using PSD95, GAPDH and tubulin antibodies.  
(C) qRT-PCR based quantification of precursor mir-137 isolated from 
the synaptosomal and the cytosolic fractions of mouse brain. Levels 
of precursor mir-137 are expressed relative to U6 which was used as 
an internal control.
Error bars represent the SEM for triplicate PCR reactions from n=3 independent experiments; t-test *** 
p<0.0001.
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heterozygous carriers. In a recent report, four patients from three families with 
overlapping microdeletions in the same region were described.13 It was suggested 
that the associated phenotype, consisting of speech delay and autism, was due to 
hemizygous deletion of DPYD. However, one of the deletions in this report also 
comprised MIR137 and the identical deletion reported in two siblings was located 
only 40 kb proximally from MIR137 and might affect expression of MIR137. Finally, 
the fourth patient had an intragenic DPYD deletion which was inherited from a 
healthy mother and thus likely representing an inherited variant similar to many 
heterozygous carriers that are known. It is likely that one of the parents of sibs 1-3 
from the present report also had the deletion, but both parents had impaired 
cognitive abilities and were not able to raise their children who, consequently, had 
been placed in foster care. Therefore, we conclude that at least for the patients with 
a heterozygous deletion encompassing MIR137, the phenotype is more likely 
associated with haploinsufficiency of MIR137, although a role for DPYD is not fully 
excluded. Indeed, previous reports of miR-137 studies showed that its expression 
is epigenetically regulated by Methyl-CpG-binding protein 2 (MeCP2) during 
different aspects of neurogenesis in mice.25, 31 Therefore, MIR137 represents a good 
candidate for the observed ID phenotype in our patients.
There is one other example of the involvement of microRNA mutations in a human 
genetic disorder: mutations in MIR96 cause autosomal dominant hearing 
impairment.37 In addition some reports have shown that disruption of the recognition 
sites in target genes for specic miRNAs might be associated with a genetic trait in 
humans. In this regard, some evidence was provided that a mutation in the binding 
domain for miR-189 in the SLITRK1 is associated with Tourette syndrome and other 
neuropsychiatric features.38 Other studies have highlighted the importance of 
miRNA pathways in neuronal processes. A recent study39 showed increased 
cognition of adult Dicer1 mutant mice, lacking miRNAs (such as miR-137) in mature 
neurons in adult brain compared to controls, thereby providing evidence for a role 
of miRNAs as key players in learning and memory processes of mammals. In 
addition, recent findings indicate that miRNAs may be involved in modulating 
short-term synaptic plasticity.40 Furthermore, synaptic activity can influence miRNA 
expression: recent reports indicated that miRNA levels are altered in hippocampal 
neurons that are induced to display long-term depression (LTD) or long-term 
potentiation (LTP).41, 42 This finding suggests that different levels or variation in 
miRNA expression levels will affect translation of synaptic proteins and consequently 
synaptic plasticity. Expression studies of precursor and mature miR-137 in our 
patients and controls demonstrated significantly reduced expression levels in the 
patients. We performed these studies in LCL of the patients. A number of previous 
investigations assessed the relevance of using LCL as probes to study the genetics 
of neurodevelopmental disorders.43, 44 Baron and others43 assessed the feasibility of 
oppose an (exclusively) causative role of deletion of DPYD in the ID phenotype of 
the presented patients. First, none of the present patients in whom metabolic tests 
were performed (patients 1, 2 and 4) showed the typical thymine-uraciluria 
associated with DPD deficiency. Second, although heterozygous mutations in 
DPYD, including loss-of-function mutations, occur frequently and contribute to 
toxicity for the anti-cancer drug 5-fluoroacil (5-FU)14, ID has not been reported in 
Figure 6   miR-137 target KLF4. (A) Putative miR-137 binding site in the rat  
Klf4 3’ UTR. The 6 nt seed sequence is marked by vertical lines.  
(B) miR-137 overexpression reduces Klf4 levels in rat primary  
cortical neurons. (C) Quantification of Klf4 mRNA levels in rat cortical 
neurons transfected with anti-miR-137, or non-targeting short 
 oligonucleotides (anti-miR-NT), as determined by qRT-PCR 72 hrs 
after  oligonucleotide transfection. (D) KLF4 mRNA levels are 
increased in patients 2 and 4. mRNA levels are expressed relative  
to β-actin which was used as an internal control.
Error bars represent the SEM for triplicate PCR reactions from n=3 independent experiments; one-way 
ANOVA, * p < 0.05.
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using LCL for genome-wide expression profiling and showed the usefulness of this 
tool for identifying genes associated with neurodevelopmental disorders. As shown 
in Figure 3, the expression of miR-137 is even more than 2-fold reduced. This might 
be explained by the short half life of miR-137 in mammalian cells45 in combination 
with an elevated synthesis of proteins involved in RNA turnover processes which 
are targeted by miR-137 (caused by a reduced inhibition of these proteins due to a 
reduced level of miR-137). This could further accelerate RNA turnover in the 
patients, which would result in lower miR-137 levels.
Our studies in mice also suggested an enrichment of miR-137 in RNA preparations 
of mouse synaptosomes, corresponding with the results of a recent study that 
revealed a significant role of the neuron-enriched miR-137 in the synapse maturation 
and morphogenesis of young neurons.31 This suggests that miR-137 may have a 
local role in translation-dependent synaptic morphology and that defects in miR-137 
could interfere with proper synaptic signal transduction, thereby affecting cognitive 
brain function. We also showed a significantly increased expression of the previously 
validated downstream targets MITF and EZH2 and the newly identified downstream 
target KLF4. MITF encodes a transcription factor that is involved in the regulation of 
differentiation and development of melanocytes in the retinal pigment epithelium. 
Heterozygous loss-of-function mutations in MITF are involved in Waardenburg 
syndrome type 2A [MIM 193510] and Tietz syndrome [MIM 193510]. As expected, 
our patients, who have an opposite dosage effect of MITF, did not show the classic 
features of these syndromes (hypopigmentation and deafness). 
The downstream target EZH2 is a histone H3 lysine 27 methyltransferase and a 
member of the Polycomb protein family. It functions as a transcriptional repressor. 
The protein regulates CpG methylation by direct interaction with DNA methyltrans-
ferases.46 Histone methylation plays an important role in modulating chromatin 
structure and function. It was previously shown that the EZH2 protein interacts with 
the ATR-X gene which is involved in alpha-thalassemia/mental retardation syndrome 
(ATRX-syndrome) [MIM 301040].47 Furthermore, several other genes that are 
associated with ID phenotypes, such as MECP248 and EHMT149 are involved in 
chromatin modulation. Therefore, an association between altered expression of the 
downstream target EZH2 with the ID phenotype in our patients might very well be 
possible. In addition, the here newly identified downstream target KLF4 might 
contribute to the ID phenotype as well, since it was shown to act as a transcrip-
tional repressor of axon growth in central nervous system.35 The reduced expression 
of miR-137 likely results in significantly altered expression of other putative miR-137 
targets as well. Moreover, the identification of additional aberrations in MIR137 in 
other patients with ID and normal genome-wide array results would provide further 
evidence for the role of MIR137. In our in house database, comprising the results of 
genome wide array analysis in more than 4,000 ID patients and controls, no 
additional  deletions restricted to 1p21.3 have been registered. In addition we 
screened a large cohort of approximately 1000 ID patients who had been previously 
tested negative for Fragile X and/or Prader Willi syndrome and had normal 
karyotypes, for MIR137 aberrations. We selected this cohort of patients because no 
designated phenotypic features were present except ID and overweight. We have 
not found additional MIR137 aberrations (results not shown), suggesting that 
disruption of MIR137 would be at any rate a rare cause of ID. 
To further unravel the underlying mechanism, additional expression studies of other 
known downstream targets that are expressed in the dendrites are warranted. 
Furthermore, future studies are needed to further determine the synaptic role of 
miR-137 as a regulator of local translation in dendrites which is known to be a 
pivotal mechanism of synaptic maturation and plasticity.
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Abstract
Genome-wide array studies are now routinely being used in the evaluation of 
patients with cognitive disorders (CD) and/or congenital anomalies (CA). Therefore, 
inevitably each clinician is confronted with the challenging task of the interpretation 
of copy number variations detected by genome-wide array platforms in a diagnostic 
setting. Clinical interpretation of autosomal copy number variations is already 
challenging, but assessment of the clinical relevance of copy number variations of 
the X-chromosome is even more complex. This study provides an overview of the 
X-Chromosome copy number variations that we have identified by genome-wide 
array analysis in a large cohort of 4,407 male and female patients. We have made 
an interpretation of the clinical relevance of each of these copy number variations 
based on well-defined criteria and previous reports in literature and databases. The 
prevalence of X-chromosome copy number variations in this cohort was 57/4,407 
(~1.3%), of which 15 (0.3%) were interpreted as (likely) pathogenic.
Introduction
Both intellectual disability (ID) and autism spectrum disorders (ASD) are relatively 
frequent  in the population, with an estimated prevalence of 2-3% and 1% 
respectively.1, 2 The prevalence of both disorders is higher in males than in females.2, 
3, 4 ID and ASD are clinically and genetically heterogeneous. Genetic factors are 
expected to play a causal role in a substantial part of the cases.5-10 A large proportion 
of patients with ID have ASD as well, suggesting that shared underlying genetic and 
biological defects may be involved.11 
In the recent years genome wide array technologies including array comparative 
genomic hybridization (array-CGH) and single nucleotide polymorphism oligonu-
cleotide arrays (SNP array) have become routine tools in the clinical evaluation of 
patients with ID and/or congenital anomalies (CA) and are increasingly used in the 
evaluation of other neuropsychiatric disorders as ASD, ADHD and schizophrenia as 
well. This has led to the identification of several causative submicroscopic 
chromosomal aberrations/copy number variations (CNVs), including X chromosomal 
aberrations, that are too small in size to be detected by routine cytogenetic and 
molecular cytogenetic techniques. Among previously reported genome-wide array 
studies in unselected cohorts of patients with ID, CA and/or dysmorphic features, 
the reported detection rate of X-chromosome CNVs (X-CNVs) varied from 0% to 
about 40%, but in the majority of the studies prevalence ranged from 0-5%. These 
figures are influenced by the low total number of patients in some studies, 
differences in patient selection, the use of different array platforms with variable 
probe coverage on the X-chromosome and different detection limits. Some studies 
only reported pathogenic X-CNVs.12-33 Studies using X-chromosome specific 
array-CGH reported a higher detection rate of X-CNVs which is also partly explained 
by the selection of a cohort of predominantly male patients with the suspicion of an 
X-linked mode of inheritance.34-40 Studying the X-chromosome aberrations detected 
by X chromosome specific arrays has led to the identification of novel X-linked ID 
genes, like ZNF674 in non-syndromic X-linked ID.41 Such studies have also identified 
deletions and duplications of chromosomal regions that contain known X- linked ID 
genes, with duplications of the Xq28 region encompassing the MECP2 gene being 
the most frequently identified causative X-CNV.42 
Genome-wide array studies in cohorts of patients with ASD revealed several 
associated CNVs in this group of patients as well, including X-CNVs. Clinical 
relevant CNVs are detected in about 5-8% of ASD patients.10, 43 Interestingly, several 
of these CNVs are present both in cohorts of patients with ID, and in cohorts of 
patients with ASD. In addition, such aberrations have also been identified in patients 
with other neuropsychiatric disorders like Attention Deficit Hyperactivity Disorder 
(ADHD) and schizophrenia. Well-known examples are 15q11q13 duplications, 
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Methods
Genome-wide copy number profiling
Genome-wide copy number profiling was either performed by the Agilent 32 k BAC 
array (669 patients) or the Affymetrix 250k SNP array (3,738 patients) analysis 
platform. Since 2009, genome-wide 250k SNP array analysis has replaced routine 
cytogenetic chromosome studies as the first line diagnostic test for patients with 
CD and/or CA in our laboratory. 
Genome-wide 32k BAC array analysis was performed as previously described.14 
Samples for genome-wide 250k SNP array analysis were processed in accordance 
with the standard Affymetrix GeneChip protocol (Affymetrix inc, Santa Clara, 
California, USA) and analyzed using the Copy Number Analyzer for GeneChip 
(CNAG) v2.0 software package.48 CNVs were mapped according to the USCS 
genome browser build March 2006. 
Segregation analysis
Segregation of the detected CNVs was tested in the parents if available. In case of 
affected family members, segregation of the CNV with the disease was further 
examined. Segregation was tested by Multiplex Ligation-dependent Probe Amplification 
(MLPA), Fluorescent In Situ Hybridization (FISH), quantitative Polymerase Chain 
Reaction (qPCR) experiments or 250k SNP array analysis. 
X- chromosome inactivation (XCI) analysis
XCI analysis was performed whenever an X-CNV inherited from a healthy (or 
obviously milder affected) mother was identified. XCI patterns were determined 
using a widely used method based on the presence of a polymorphic repeat within 
the 5’ end of the Androgen Receptor (AR) gene, as described by Allen et al.49 
A sample was considered to have skewed X-inactivation if the same X chromosome 
was inactivated in at least 90% of the cells.50 
Assessment of clinical relevance
X-CNVs were classified into three different categories reflecting their presumed 
clinical relevance. The classification categories include:
1)  (likely) pathogenic CNVs
2)  CNVs with unknown clinical relevance
3)  (likely) non-pathogenic CNVs
Table 1 shows a schematic overview of the criteria that were considered to assess 
clinical relevance and to categorize the X-CNVs into these three classification 
categories. Classifications of X-CNVs in each individual patient in this cohort were 
22q11.21 deletions and 16p11.2 deletions and duplications.43 The study of CNVs in 
ASD revealed a number of ASD related genes as well, such as NRXN1, CNTN4, 
NLGN1 and ASTN2.44 Most of these genes are associated with ID as well. This is 
another indication for involvement of similar underlying molecular and biological 
pathways in the etiology of variable cognitive disorders (CD), as ID/developmental 
delay (DD), ASD and other neuropsychiatric disorders. 
Whole-genome scanning technologies have also identified a large number of 
submicroscopic CNVs that could not be directly associated with CD and/or CA. 
Furthermore, many CNVs, either on the autosomes or the X-chromosome, are also 
present in the general population, giving rise to difficulties in the interpretation of 
these CNVs.45-47 X-CNVs form a special group, because dosage effects likely differ 
in males and females and causative CNVs in a male patient can be inherited from 
a healthy mother. 
In total, various studies reported over 100 X-CNVs in control individuals, which are 
collected in databases37 (Database of Genomic Variants: http://projects.tcag.ca/
variation).
In the present study we provide an overview of X-CNVs identified by genome wide 
array analysis in a cohort of 4,407 individuals with various clinical presentations of 
CD, and/or CA, including an interpretation of the clinical relevance. Our aim was to 
provide a resource for clinicians and laboratory specialist for the interpretation of 
X-CNVs that are picked up by genome wide array platforms in a routine diagnostic 
setting. 
Patient Data
Ascertainment of patients
Our data are derived from genome wide copy number profiling performed among 
a cohort of 4,407 individuals. All individuals had been referred between January 
2003 and August 2010 to our diagnostic center for the evaluation of cognitive 
disorders (CD) -including unexplained ID/DD, neuropsychiatric disorders- and/or 
CA. Neuropsychiatric disorders included mainly autism spectrum disorders (ASD) 
and Attention Deficit Hyperactivity Disorder (ADHD). In the majority the indication 
for genome-wide array analysis was DD/ID (with or without other neuropsychiatric 
disorders and/or CA). In a minority of the patients genome-wide array analysis was 
performed because of CA or behavior problems without presence of DD/ID. Two 
third of the total cohort had an age between 1 and 18 years. The male to female 
ratio was 1.2:1. 
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Twenty-six percent of these (15/57, 7 gains, 8 losses) were classified as pathogenic, 
and 42% (24/57) were classified as non-pathogenic (16 gains, 8 losses). In 18 cases we 
could not make a decision about the pathogenicity (12 gains, 6 losses). This gives a 
detection rate of approximately 0.3% pathogenic X-CNVs in our cohort, that 
noteworthy consists of patients not preselected on the suspicion of an X-linked 
disorder. ID was reported in 93% (14/15) of the patients with a pathogenic CNV. 
The male to female ratio of patients with an X-CNV in this cohort is 1.5:1, compared 
to a 1.2:1 male to female ratio in the total of our cohort. The male to female ratio of 
patients with a pathogenic X-CNV is with a ratio of 6.5:1 significantly higher (13 males 
and 2 females). 
The inheritance of 40 (70%) X-CNVs was tested. Four out of 40 (10%) had occurred 
de novo (all pathogenic X-CNVs). Thirty-four of 36 inherited X-CNVs were maternally 
inherited (94%). Nine out of 15 pathogenic CNVs (60%) were maternally inherited. 
In two cases segregation in the grandparents was tested (patients 22 and 51). 
X-inactivation analysis was performed in 21 out of 34 (62%) carrier mothers. 
X- inactivation was significantly skewed (at least 90:10) in four of these 21 carrier 
mothers (19%) (three analyses were uninformative). 
based on careful consideration of the total combination of the criteria for assessment 
of clinical relevance as mentioned in Table 1. None of the criteria was absolute and 
each criterion was considered in perspective to the other criteria, the currently 
available information in literature and databases, and the phenotype of the patient.
 
Results
General overview
In total 57 X-CNVs were analyzed. Tables 2-4 summarize (likely) pathogenic 
X-CNVs, CNVs with unknown clinical relevance and (likely) non-pathogenic CNVs, 
respectively. Concise information about the phenotype is included as well. X-CNVs 
that had initially been identified by conventional karyotyping and were further 
delineated by SNP array analysis, microscopically visible X-CNVs, and X-CNV 
gains of the pseudo-autosomal region (PAR) indicating an XXY or XYY karyotype, 
were excluded from the analysis. The total number of X-CNVs comprised 57 in 
4,407 (1.3%), including 22 losses and 35 gains. CNV size ranged from 10 kb to 8.5 Mb. 
Table 1   Criteria for assessment of clinical relevance, grouped by the three different  
classification categories. 
Criteria Classification
(Likely) pathogenic Unknown (Likely) non-pathogenic
Inheritance De novo occurence Inherited X-CNV in a male Paternally inherited X-CNV in female
X-inactivation Skewed X-inactivation of the affected allele in a healthy 
carrier mother
Random or unknown X-inactivation pattern  
in carrier mother
Skewed X-inactivation of the non-affected 
allele in a healthy carrier mother
Occurrence in patients  
and controls
Similar CNV in patient(s) with overlapping phenotype
No reports in healthy controls
Low detection rate in apparently healthy 
controls, but higher frequency in individuals 
with CD and/or CA 
Polymorphism in healthy controls 
No segregation with the phenotype within 
the family
CNV size and gene content Size (>1.5 Mb) and gene content (>20 genes) 17 Small number of genes that have not been 
previously related to CD and/or CA 
No genes involved
Known association with CD  
and/or CA of involved genes
Overlap with known CD/CA associated gene No overlap with known CD/CA associated 
gene
Expression and function of  
involved genes
Role in brain development and/or functioning 
Brain specific expression of involved gene(s)
Unknown function and/or expression pattern 
of the gene
Non CD and/or CA related gene function 
Not expressed in brain
Mouse models Signs of central nervous system disorder and/or lethal 
phenotype in knockout mouse
Unknown phenotype in mouse No phenotype in knock out mouse
CD= cognitive disorders CA=congenital anomalies
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Table 2   X-CNVs that are (likely) pathogenic (N=15). 
Number Sex Phenotype CNV Chromosomal 
region
Start-End 
Mb positions 
(Hg18)
Size/Gene content Inheritance XCI Genes of 
interest
Disease association References 
 previously reported 
overlapping CNVs
1 M ID, 
 Chondroplasia 
punctata
Loss Xp22.33 0.20-3.21 3 Mb /20 genes Mat NT 1) SHOX
2) ARSE
1)  Leri-Weill dyschondrosteosis 
(OMIM id 127300); Langer 
mesomelic dysplasia (OMIM 
id 249700); short stature, 
idiopathic, X-linked (OMIM id 
300582);
2)  Chondroplasia punctata 
(OMIM id 302950)
Decipher id 978, 2207
23, 43, 53-55, 72
2 M MCA (skeletal) Loss Xp22.33 0.14-1.98 2.1 Mb/12 genes NT NT 1) SHOX 1) see point 1) above See above
3 M Moderate-severe 
ID, short stature, 
 hydrocephaly
Loss Xp22.31p22.33 0.14-6.41 6.4 Mb/20 genes Mat
(Mat learning 
difficulties)
UI in mother 
Random 
in affected 
sister (4572)
1) SHOX
2) ARSE
3) NLGN4
1) see point 1) above
2) see point 2) case 1506
3)  Autism, X-linked,  susceptibility 
to, 2, mental retardation 
 X-linked included (OMIM id 
300495) 
See above
4 M ID, Kallman 
syndrome, 
 ichthyosis
Loss Xp22.31p22.33 0.14-8.67 8.5 Mb/37 genes NT NT 1) SHOX
2) ARSE
3) NLGN4
4) STS
5) KAL1
1-3) see above
4)  X-linked ichthyosis (OMIM id 
308100)
5)  Kallman syndrome (OMIM id 
308700)
See above
5 M DD, ASD, 
 micropenis, 
ichthyosis
Loss Xp22.31p22.32 5.20-7.91 2,7 Mb/6 genes Mat NT NLGN4 Autism, X-linked, susceptibility 
to, 2, mental retardation X-linked 
included (OMIM id 300495)
43, 68-70
6 M Muscular 
 dystrophy, mild 
ID
Gain Xp21.1 32.47-32.71 240 kb /1 gene Mat NT DMD muscular dystrophy Duchenne 
type (OMIM id 310200)
60% of patients with 
Duchenne muscular 
dystrophy carry a large 
deletion in DMD 73
7 F ID, microcephaly Loss Xp11.4p11.3 41.86-45.31 3.5 Mb/9 genes De novo Slightly 
skewed 
(70:30)*
1)NDP
2)MAOA
1) Norrie disease (OMIM id 
310600)
2)  Brunner syndrome (OMIM id 
300615)
33, 35, 40
8 M ID, autism, 
 myopathy 
Gain Xq11.2q13.1 62.80-70.52 7.7 Mb/14 genes Mat  
(mother mild 
ID)
Skewed 
 pattern in 
mother 
(100:0)*
1) OPHN1
2) EFNB1
3) DLG3
4) MED12
5) ARGHEF9
1)  Mental retardation,  X-linked, 
with cerebellar hypoplasia and 
distinctive facial appearance 
(OMIM id 300486)
2)  Craniofrontonasal dysplasia 
(OMIM id 304110)
3)  Mental retardation, X-linked-90 
(OMIM id 300850)
4)  Lujan-Fryns syndrome (OMIM 
id 309520)
5)  Epileptic encephalopathy, early 
infantile, 8 (OMIM id 300607)
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Table 2   Continued. 
Number Sex Phenotype CNV Chromosomal 
region
Start-End 
Mb positions 
(Hg18)
Size/Gene content Inheritance XCI Genes of 
interest
Disease association References 
 previously reported 
overlapping CNVs
9 M Severe ID, 
 relatively 
large head 
 circumference, 
autism
Gain Xq13.1 69.54-70.11 575 kb/ 6 genes (G)Mat; 
 cosegregation 
with disease 
in male  family 
members
Skewed 
 pattern in 
mother 
(80:20)**, 
 random in GM
DLG3 Mental retardation, X-linked 90, 
MRX90
Tucker et al. reported  
a larger (2Mb) 
 overlapping gain31
10 F ID,  microcephaly, 
cerebellar  vermis 
hypoplasia
Gain Xq13.1q13.2 72.15-72.92 500 kb/5 genes De novo In  patient: not 
 informative
- Partly overlapping gain in patient 
with phenotypic overlap, reported 
by Mc Mullan  et al. [22]
Distally overlapping 
gain in Deciper,  
id 251339  
(ID, microcephaly)
11  
(previously 
reported by 
Lugtenberg 
et al. [78] 
M Severe ID, minor 
facial and genital 
anomalies, short 
stature, broad 
thorax
Gain Xq13.2q21.1 72.39-79.35 7 Mb/28 genes De novo - 1) ATRX
2) MAGT1   
3) SLC16A2
1)  Alpha thalassaemia mental 
 retardation  syndrome(#301040) 
2)  mental retardation, X-linked 95 
(#300716)
3)  MCT8 deficiency (#300523)
40
Decipher id 250180, 
251333, 251339, 
251751
12 M Severe ID and 
neurological 
problems
Gain Xq22.1q22.3 99.78-105.33 5.5 Mb/60 genes Mat (Mat bor-
derline ID)
Skewed 
 pattern in 
mother 
(100:0)*
PLP1 Pelizaes Merzbacher disease 
(#312080)
Decipher id 320, 4480, 
249139, 249995, 
250543
13
(previously 
reported by 
de Leeuw  
et al., [74]
M Moderate-severe 
ID, microcephaly, 
VSD, genital, 
skeletal, intestinal 
and immuno-
logical problems, 
seizures
Loss Xq24 118.40-118.60 200 kb/4 genes Mat NT UBE2A Mental retardation, X-linked, 
 syndromic (OMIM id 312180) 
UBE2A deficiency syndrome 
74-76
14 M Severe ID,  
short stature, 
microcephaly
Gain Xq25q26.2 128.53-133.23 4.68 Mb/28 genes Mat Skewed 
 pattern in 
 mother 
(100:0)*
1) MBNL3
2) GPC3 
3) ZDHHC9
4) PDCD8
1)  Co-localization of the protein 
with repeat foci in DM1 and DM2 
(Duchenne muscular dystrophy)
2)  Simpson-Golabi-Behmel (OMIM 
id 312870)
3)  X-linked syndromic mental 
 retardation (OMIM id 300799)
4)  combined oxidative 
 phosphorylation deficiency-6 
(OMIM id 300816)
Decipher id 253888
Two overlapping  
cases with similar 
phentypes in personal 
communication (TK)
15 M ID, bilateral 
i nguinal hernia, 
ataxia
Loss Xq28 147,21-148,54 1.3 Mb/ kb/10 
 genes
De novo - 1) FMR2
2) IDS
1)  Mental retardation, X-linked, 
FRAXE type 1 (OMIM id 309548)
2)  Hunter syndrome/  
 Mucopolysaccha ridosis II 
(OMIM id 309900)
Decipher id 250246.
XCI: X-chromosome inactivation UI: uninformative. NT=not tested. NR: not relevant. VSD: ventricular septal 
defect. P: paternal. Mat: maternal. GP: grandpaternal. GM: grandmaternal. BP: brotherpair. 
* preferential activation of the normal allele ** preferential activation of the allele with the CNV.
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Table 3   X-CNVs with unknown clinical relevance (N=18). 
Number Sex Phenotype CNV Chromosomal 
region
Start-End 
positions 
(Hg18)
Size/Gene count Inheritance XCI Genes of 
interest
Disease assocation References 
 previously reported 
overlapping CNVs
16 (sib  
of case 3)
F Moderate-severe 
ID, hyperactivity, 
height -2 to -1 
SD)
Loss Xp22.31p22.33 0.14-6.41 6.4 Mb/20 genes Mat 
(Mat learning 
difficulties)
UI in mother
Random in 
patient  
1) SHOX
2) ARSE
3) NLGN4
1)  Leri-Weill dyschondrosteosis 
(OMIM id127300); Langer 
mesomelic dysplasia (OMIM 
id 249700); short stature, 
idiopathic, X-linked (OMIM id 
300582);
2)  Chondroplasia punctata 
(OMIM id 302950)
3)  Autism, X-linked,  susceptibility 
to, 2, mental retardation 
 X-linked included (OMIM id 
300495)
Decipher id 978, 2207
23, 43, 53-55, 72, 77
17 M X-linked 
 ichtyosis, 
 concentration 
and emotional 
problems
Loss Xp22.31 6.51-7.66 1.15 Mb/ 2 genes NT NT STS 
VCX3A
X-linked ichtyosis (OMIM id 
308100). The CNV explains 
part of the phenotype, but an 
 association with the psychological 
problems is uncertain
32, 64-66 Also many cases 
reported in Decipher. 
Reported associations 
with ID are conflicting
18 M ID, MCA Gain Xp22.31 7,04-7,23 190 kb/2 genes NT NT STS See case 17 See case 17
19 M X-linked 
 ichthyosis, 
 spastic 
 quadriplegia, ID
Loss Xp22.31 6.83-7.84 1 Mb/4 genes NT NT STS
VCX3A
See case 17
The CNV explains the X-linked 
ichthyosis, and might contribute 
to the ID, but an association 
with the spastic quadriplegia is 
unlikely
See case 17
20 M X-linked 
 ichthysosis, 
 skeletal 
 dysplasia, 
 epilepsy, ID
Loss Xp22.31 6.51-8.12 1.6 Mb/5 genes Mat Random 
 pattern in 
mother
STS
VCX3A
See case 17
The CNV explains the X-linked 
ichthyosis, and might contribute 
to the ID, but is likely not related 
to the other symptoms in this 
patient
See case 17
21 M Autism, DD, 
 X-linked ichtyosis
Loss Xp22.31 6.41-8.05 1.6 Mb/6 genes Mat NT STS 
VCX3A
See case 17. 
The CNV explains the X-linked 
ichthyosis, and might epxplain 
the DD and autism
See case 17
22 M ID, hypotonia, 
nasal lacrimal 
duct anomaly
Gain Xp22.31p22.32 5,89-6,41 520 kb/1 gene Mat+ GP NT NLGN4 Autism, X-linked, susceptibility 
to, 2, mental retardation X-linked 
included (OMIM id 300495)
43, 68-70
23 M ADHD Gain Xp22.2p22.32 9.04-10.02 600 kb/4 genes Mat Random pat-
tern in mother
GPR143 Albinism, ocular, type 1(OMIM id 
300500)
-
24 M ID, 
 extrapyramidal 
disorder, 
 dysmorphism
Gain Xp22.2 15.81-16.26 400 kb/1 gene Mat Random pat-
tern in mother
GRPR - Ishikawa-Brush et al. 
56 reported a female 
patient with 27-year-
old female patient 
manifesting multiple 
exostoses and autism 
accompanied by ID  
and epilepsy and a 
balanced translocation 
through GRPR
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Table 3   Continued. 
Number Sex Phenotype CNV Chromosomal 
region
Start-End 
positions 
(Hg18)
Size/Gene count Inheritance XCI Genes of 
interest
Disease assocation References 
 previously reported 
overlapping CNVs
25 M ID, MCA Gain Xp22.2p22.13 17,00-17,47 470 kb/2 genes Mat NT NHS Nance Horan Syndrome  
(OMIM id 302350)
Hayashi et al.33 
 reported  a slightly 
larger gain in a male 
patient
26 M DD, 
 trichonocephalyI 
UGR, ASD, 
hypermetropia, 
asthma
Gain Xp22.11 22.01-22.11 10 kb/1 gene Mat Skewed 
 pattern in 
mother 
(80:20)*
PHEX Hypophosphatemic rickets,  
X-linked dominant  
(OMIM id 307800)
In Jaillard et al.18 
2 brothers with 
larger overlapping 
mat  inherited gain 
are reported . Their 
 phenotype includes ID 
and microcephaly
27 M IUD Loss Xp21.3 25.75-26.55 800 kb/3 genen Mat Skewed 
pattern in 
the mother 
(85:15)*
- - -
28 M DD Gain Xp11.4p21.1 37.49-38.26 770 kb/6 genes Mat Random 
 pattern in 
mother
OTC Involved in ornithine transcar-
bamylase deficiency (OMIM id 
300461).  No corresponding 
metabolic defect in this patient
-
29 M ID Gain Xq22.1 99.41-99.65 250 kb/1 gene NT NT PCDH19 Epilepsy, female-restricted, with 
mental retardation (OMIM  id 
300088) Scheffer et al78. reported 
obsessive, rigid personalities in 
5 males
-
30 M Clinical 
 diagnosis 
of Noonan 
 syndrome
Gain Xq24 117.5 - 117.7 200kb/
1 gene
Mat Random 
 pattern in 
mother
- - -
31 M ID, MCA Gain Xq28 148.00-148.50 500kb/6 genes Mat Slightly 
skewed 
 pattern  
(80-20%)**
1) IDS
2) MAGEA9
1)  Hunter syndrome/ 
 Mucopolysaccha 
ridosis II (OMIM id +309900)
2)  may be implicated in 
 dyskeratotis congenita 
( Refseq, July 2008)
-
32 M hypotonia Gain Xq28 148.33-148.53 200 kb/5 genes Mat Random 
 pattern in 
mother
1) IDS
2) MAGEA9
See above -
33 M ID,MCA Gain Xq28 149.16-149.63 480 kb/3 genes Mat UI in mother MTM1 X-linked myotubular myopathy 
(OMIM id 310400)
-
XCI: X-chromosome inactivation UI: uninformative. NT=not tested NR: not relevant. IUD: intra-uterine 
death. P: paternal; Mat: maternal; GP: grandpaternal. * preferential activation of the normal allele ** 
preferential activation of the allele with the CNV.
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Table 4   (Likely) non pathogenic X-CNVs (N=24). 
Number Sex Phenotype CNV Chromosomal 
region
Start-End 
positions 
(Hg18)
Size/Gene count Inheritance XCI Genes of 
interest
Disease association References 
 previously reported 
overlapping CNVs 
34 F ID Gain Xp22.32p22.33
In addition:
a de novo 8 Mb 
loss in 1qter
0.14-5.83 5.7 Mb/>10 genes NT NT 1) SHOX
2) ARSE
3) NLGN4
1)  Leri-Weill dyschondrosteosis 
(OMIM id127300); Langer 
mesomelic dysplasia (OMIM 
id 249700); short stature, 
idiopathic, X-linked (OMIM id 
300582);
2)  Chondroplasia punctata 
(OMIM id 302950)
3)  Autism, X-linked,  susceptibility 
to, 2, mental retardation 
 X-linked included (OMIM id 
300495)
Decipher id 978, 2207
23, 43, 53-55, 72
35 F ID, acoustic 
canal atresia, 
MCA
Gain Xp22.33
In addition:
5.1 Mb de novo 
loss in 18q22.3
0.16-2.41 2.3 Mb/12 genes NT NT SHOX See above See above
36 F ID Gain Xp22.33 1.74-3.35 1.5 Mb/8 genes Mat In the  patient 
70:30 
 X-inactivation 
pattern** 
In mother 
random 
 X-inactivation.
ARSE See above See above
Overlapping gains are 
reported in healthy 
controls
37 M MCA Gain Xp22.33 1.98-3.18 1.1 Mb/9 genes NT NT ARSE See above See above
38 F Severe ID, 
 microcephaly, 
growth 
 retardation, 
 neuronal 
 migration 
 disorder
Gain Xp22.31 6.03-6.68 600 kb/ 2 genes P NT NLGN4 See point 3 case 34 43, 68-70
39 F ID, Costeff 
 syndrome 
 (genetically 
confirmed)
Gain Xp22.31 6.5-8.1 1.55 Mb/6 genes NT NT 1) STS
2) VCX3A
1) X-linked ichtyosis (OMIM id 
308100).
32, 64-66 Also many cases 
reported in Decipher. 
Reported associations 
with ID are conflicting
2) Deletion of VCX3A 
was thought to be 
related to ID because 
of the gene’s absence 
in XLI patients with ID 
and its presence in XLI 
patients without ID.64
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Table 4   Continued. 
Number Sex Phenotype CNV Chromosomal 
region
Start-End 
positions 
(Hg18)
Size/Gene count Inheritance XCI Genes of 
interest
Disease association References 
 previously reported 
overlapping CNVs 
40 F Severe  
speech delay
Gain Xp22.31 6.5-8.1 1.55 Mb/6 genes NT NT STS, VCX3A See above See case 39
41 F DD Gain Xp22.31 6.5-8.1 1.55 Mb/6 genes Mat NT STS, VCX3A See above See case 39
42 F ID, progressive 
cerebellar ataxia, 
hypotonia
Gain Xp22.31 7.05-8.1 1 .05 Mb/4 genes Mat Skewed 
inactivation 
(90:10) in the 
mother*; non 
informative 
analysis in 
patient
STS, VCX3A See above See case 39
43 F ID, epilepsy, 
alopecia, hearing 
loss
Loss Xp22.31 6.5-8.1 1.55 Mb/6 genes Mat In patient: UI STS, VCX3A See above See case 39
44 F Severe ID Loss Xp22.31 6.5-8.1 1.55 Mb/6 genes Mat NT STS, VCX3A See above See case 39 
45 F Cerebellar ataxia 
(rombencepha-
losynapsis), 
attention and 
concentration 
deficits
Loss Xp22.31 6.5-8.1 1.55 Mb/6 genes NT NT STS, VCX3A See above See case 39
46 F ID, mitochondrial 
disease
Loss Xp22.31 6.5-8.1 1.55 Mb/6 genes NT NT STS, VCX3A See above See case 39
47 F ID Loss Xp22.31 6.5-8.1 1.55 Mb/ 6 genes Mat NT STS, VCX3A See above See case 39 
48 F Abnormal hair, 
scoliosis
Loss Xp22.31 6.5-8.1 1.55/6 genes NT NT STS, VCX3A See above See case 39
49 F ID/MCA Loss Xp22.31
In addition: 
5.3 Mb de 
novo loss in 
7q32.3q33
6.5-8.1 1.55 Mb/6 genes NT NT STS, VCX3A See above See case 39
 
50 F ID Loss Xp22.31 6.5-8.1 1.55 Mb/6 genes NT NT STS, VCX3A See above See case 39
51 F Growth retarda-
tion, congenital 
heart and kidney 
defects 
Gain Xp21.2 30.30-31.34 1.04 Mb/5 genes Mat +GP Uninformative 
(in patient)
1) DMD
2) GK 
1)Duchenne muscular dystrophy
2)Glycerol kinase deficiency 
(#307030)
-
52 M ID Gain Xp11.4 38.39-38.44 50 kb /1 gene Mat NT TSPAN7 Mental retardation, X-linked 58 
(OMIM id 300210)
58-63
53 M ID Gain Xp11.4 38.39-38.44 50 kb /1 gene Mat Random 
pattern  in the 
mother
TSPAN7 See above See above
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including NDP (Norrie disease, OMIM ID: 310600) and MAOA (Brunner syndrome, 
OMIM ID: 300615). The phenotype of this patient is not specific for neither of these 
syndromes, nevertheless, these genes might have contributed to the phenotype as 
well as the other involved genes. Overlapping deletions are more often reported in 
patients with ID, including one female case.33, 35, 40
575 kb Maternally inherited gain in Xq13.1 (case 9)
This gain comprises Discs, Large Homolog 3 (DLG3). This gene has previously 
been associated with ID.51-52 Though these cases comprise loss-of-function 
mutations, we classified this gain as pathogenic, since we demonstrated 
cosegregation with the ID phenotype in the affected males from this family. The 
mother of the index male had a slightly skewed inactivation of the X-chromosome 
that was not inherited by her son, which may be explained by the detection of a loss 
comprising seven exons of the Dystrophin (DMD) gene on her other X-chromosome. 
A larger (2 Mb) gain was reported by Tucker et al.31
In one carrier mother we observed preferential inactivation of the normal allele. 
In all four carrier mothers with significant skewed X-inactivation, the allele with the 
X-CNV was preferentially inactivated. In one carrier mother we noticed a slightly 
skewed pattern with preferential activation of the allele carrying the X-CNV inherited 
by her son (patient 25). In eight female patients X-inactivation was performed. None 
of them had a skewed X-inactivation (five analyses were uninformative). 
Twenty-six X-CNVs (46%) comprised together 31 genes which have been related to 
X-linked CD and/or CA in previous reports, or are known X-linked genes associated 
with CD and/or CA, including ZNF41, ZNF81, SYN1, TSPAN7, OTC, GK, DMD, GRPR, 
NHS, NLGN4, OPHN1, DLG3, ATRX, SLC16A2 (MCT8), MAGT1, ATP7A, PCDH19, 
PLP1, IDS, ARSE, SHOX, FMR2, UBE2A, GPC3, ZDHHC9, PDCD8, NDP, MAOA, 
EFNB1,MED12 and ARGHEF9.
(Likely) pathogenic CNVs
De novo 3.5 Mb loss in Xp11.4p11.3 (case 7)
This X-CNV was detected in a 2-year old female with DD, microcephaly and facial 
dysmorphic features. The CNV comprises 2 genes that are implicated in ID syndromes, 
Table 4   Continued. 
Number Sex Phenotype CNV Chromosomal 
region
Start-End 
positions 
(Hg18)
Size/Gene count Inheritance XCI Genes of 
interest
Disease association References 
 previously reported 
overlapping CNVs 
54 F ID, renal dys-
genesis, optical 
coloboma 
Gain Xq21.1 76.44-77.37 600 kb/ 7 genes Mat UI in patient 1) ATRX, 
2) ATP7A
1)  Alpha thalassaemia mental re-
tardation  syndrome(#301040)
2) Menkes disease (#309400)
40
Decipher id 250180, 
251333, 251339, 
251751
55 M Death at 3 
months of age, 
hypertrophic 
cardiomyopathy
Gain Xq26.2 130.44-130.80 360 kb/2 genes Mat NT - - -
56 M MCA (hand 
anomalies)
Gain Xq26.2 130.44-130.80 360 kb/2 genes NT NT - - -
57 F Severe ID, ASD Gain Xq27.1q27.2
In addition:
1 Mb de novo 
gain in 18q21.2 
(TCF4)
140.05-140.38 330 kb/2 genes P NT - - -
XCI: X-chromosome inactivation UI: uninformative. NT=not tested NR: not relevant. P: paternal. Mat: maternal; 
GP: grandpaternal. * preferential activation of the normal allele ** preferential activation of the allele with 
the CNV.
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X-inactivation pattern and that the mild phenotype in the mother might be due to a 
skewed X-inactivation pattern. X-inactivation analysis in the mother was uninformative, 
so we were not able to confirm this. We cannot exclude that in the severely affected 
sister other factors contribute to her phenotype as well. 
400 kb Maternally inherited gain Xp22.2 (case 24) 
This gain comprises the gene gastrin-releasing peptide receptor (GRPR).GRPR is 
only once reported in relation to ID and ASD. A translocation disrupting this gene 
was identified in a single female with ID and autism56, but additional evidence for 
involvement of GRPR in ID and/or ASD is lacking. Though, we cannot exclude an 
association of the duplication of this gene with the observed phenotype in this male 
patient.
470 kb Maternally inherited gain in Xp22.13p22.2 (case 25)
In patient 25 a maternally inherited duplication comprising the Nance Horan 
Syndrome gene (NHS) was detected. This syndrome is associated with a syndromic 
ID phenotype. However, a causal relation with the ID observed in this patient is 
uncertain since he does not show the other typical manifestations of Nance-Horan-
Syndrome (OMIM ID: 302350). Moreover, this CNV includes a duplication of the 
region where NHS is located, while Nance-Horan syndrome causing mutations are 
loss-of-function mutations.  
10 kb Maternally inherited gain in Xp22.11 (case 26)
The breakpoints of this gain disrupt the phosphate-regulating endopeptidase gene 
(PHEX), which is involved in X-linked dominant hypophosphatemic rickets (OMIM 
ID: 307800). This disease is not associated with ID and patient 26 does not show 
signs of the disease. We still classified this CNV as unknown, because Jaillard et 
al.18 described two brothers who had an overlapping gain and overlap in phenotype. 
The authors concluded that dosage effects of PHEX may be involved in their 
phenotype. This was based on the observed phenotype in mice with PHEX 
duplications, including behavior and craniofacial abnormalities.57 The gain in the 
brothers reported by Jaillard et al.18 comprised in addition the gene ZNF645. An 
effect of duplication of this gene in the phenotype of those brothers cannot be 
excluded.
250 kb Gain in Xq22.1 (case 29)
This gain comprises the gene Protocadherin 19 (PCDH19). Loss-of function 
mutations in PCDH19 are involved in a female restricted phenotype, Epilepsy and 
mental retardation limited to females (EFMR) (OMIM ID: 300088). This gain was 
detected in a male patient with ID, but without epilepsy. It cannot be excluded that 
500 kb De novo gain in Xq13.1q13.2 (case 10)
This gain was detected in a 5-year old female patient with severe ID, microcephaly 
and structural anomalies of the cerebellum on brain MRI. The region does not 
comprise genes known to be involved in CD and/or CA, nevertheless, the de novo 
occurrence suggests that an association with the ID phenotype is likely. Furthermore, 
two overlapping cases have been reported. McMullan et al.22 reported a slightly 
smaller overlapping gain in a female patient with severe ID, microcephaly, hypotonia 
and cerebral atrophy. In Decipher a distally overlapping gain in a male patient with 
ID and microcephaly is reported (DECIPHER ID: 251339).  
4.7 Mb maternally inherited gain in Xq25q26.2 (case 14)
We classified this gain identified in a male patient with ID as pathogenic. Arguments 
were the relatively large CNV size, involvement of several genes that are implicated 
in ID phenotypes and a 100% skewed X-inactivation pattern in the mother, with 
preferential inactivation of the allele with the duplication. The mother had a normal 
intellect, but a relatively short stature and head circumference.  
Furthermore, we know of two families with overlapping X-CNVs in this region. The 
male cases have similar phenotypes including severe ID, growth retardation and 
microcephaly. Female carriers had a variable and milder phenotype including 
normal to mild ID and short stature (personal communication TK). 
1.3 Mb de novo loss in Xq28 (case 15)
In the Decipher database several, mostly larger overlapping cases are reported. 
Decipher case number 250246 comprises a 3.5 Mb de novo deletion in a male 
patient with ID, microcephaly and hypotonia. Both the present deletion and the 
deletion reported in the Decipher database involve the Fragile X Mental Retardation 
2 gene (FMR2), which is a likely explanation for the observed ID phenotype.
CNVs with unknown clinical relevance
6.4 Mb familial deletion in Xp22.31p22.33 
In a brother (case 3) and a sister (case 16) both with moderate-severe ID we identified 
a maternally inherited Xpter deletion. The mother had mild learning disabilities. FISH 
studies on blood lymphocytes excluded a mosaic in this tissue. The phenotype of 
the brother is likely explained by this deletion, but his sister has a relatively severe 
level of ID for a female and compared to her mother who has an identical deletion. 
Previously reported females had normal mental performance or mild learning 
difficulties, a Turner syndrome neurocognitive profile (selective non-verbal deficits) 
and short to low normal stature. Female carriers might be protected from a severe 
phenotype by a favorable skewed X-inactivation pattern.53, 54, 55 It might be 
speculated that the severe phenotype in the sister is explained by her random 
144 145
chapter 3 identification and characterization of chromosomal disorders with id
3
features and/or MCA, compared to a frequency of 0.15% in a healthy control 
population. These data suggest a potential causal relationship of the duplication 
with the abnormal phenotype, possibly an additive effect.66 Nevertheless, we 
classified several CNVs in this region in female patients as non-pathogenic, 
because of a severe and/or syndromic phenotype that is likely not explained by this 
X-CNV. In the male cases we classified these CNVs as CNVs with unknown clinical 
relevance.
Chromosomal region Xp22.31p22.32 (cases 5, 22 and 38)
Six X-CNVs comprised the region where NLGN4  is localized. Three of these were 
larger deletions comprising several genes and corresponding phenotypes are 
likely the result of contiguous deletion of these genes. Three of these X-CNVs 
(cases 5, 22 and 38) were smaller and included NLGN4 as the only candidate gene 
for the phenotype. In patient 5, a 10-year-old male with ASD as the main presenting 
feature, a 2.7 Mb deletion involving NLGN4 was found. The phenotype included 
mild DD, and ichthyosis as well. Loss-of-function mutations in this gene were 
previously associated with ASD.67 Deletions comprising NLGN4 are more often 
described and are associated with a variable phenotype comprising both ID, and 
ASD. Some patients have a normal cognitive performance.43, 68-70  
In two patients (cases 22 and 38) copy number gains involving NLGN4 were 
detected. Most previous reports concern deletions and loss-of-function mutations. 
Though, Daoud et al.71 reported the detection of de novo mutations in the promoter 
region of the gene leading to increased expression in patients with ID and autism. 
The gains in our patients segregated in unaffected males, but we still classified the 
gain of patient 22 as unknown, because a variable phenotypic spectrum including 
normal intellectual function has been reported for the deletions54, so we cannot 
exclude that gains may lead to a similar broad spectrum as well. The gain of patient 
38 was classified as (likely) non-pathogenic, because this concerns a very severe 
phenotype in a female with a healthy father who carries an identical gain.
Discussion
In a large cohort of patients with CD and/or CA examined by genome-wide array 
analysis in a diagnostic setting, we demonstrated a 1.3% detection rate of X-CNVs. 
Genome-wide array platforms are now widely being used in the clinical diagnostic 
setting. As a result, X-CNVs are frequently being detected in routine diagnostics. A 
careful interpretation of these X-CNVs is essential for adequate counseling of 
patients and their families. The interpretation of the clinical relevance of X-CNVs is 
challenging and complicated by many factors. We classified the X-CNVs in our 
an opposite dosage effect of PDCH19  is the explanation for the phenotype in this 
male patient. Unfortunately segregation analysis in the mother was not possible. 
(Likely) non pathogenic X-CNVs
50 kb Maternally inherited gain in Xp11.4 (cases 52-53)
This gain comprises the gene Tetraspanin 7 (TSPAN7). In several reports aberrations 
of TSPAN7 have been associated with ID.58-62 Though, Froyen et al.35 reported an ID 
family with a duplication involving TSPAN7, in which the duplication did not 
cosegregate with the ID phenotype. Furthermore, Cai and colleagues63 identified 
two TSPAN7 duplications in 174 healthy male controls. Therefore, we classified the 
gains of Xp11.4 comprising TSPAN7 as non-pathogenic.
600 kb Maternally inherited gain in Xq21.1 (case 54)
This gain was detected in a female patient and comprises two disease associated 
genes, including ATRX  (Alpha thalassaemia mental retardation syndrome, OMIM 
ID: 301040) and ATP7A (Menkes disease, OMIM ID: 309400). Because involved 
genes are involved in X-linked recessive diseases with a different phenotype, and 
the gain was inherited from a healthy mother we assigned this gain to the (likely) 
non pathogenic group.
 
Patients with additional autosomal CNVs that explain the phenotype
Patients 34, 35, 49 and 57 had an additional autosomal CNV being the most likely 
explanation for their phenotypes. 
Recurrent gains and losses 
Chromosomal region Xp22.31 (cases 17-21 and 39-50)
This Xp region has a high frequency of interstitial CNVs due to non allelic 
homologous recombination (NAHR). In this cohort we detected as many as 17 
CNVs  in this region (12 losses and 6 gains), suggesting that CNVs in this region are 
extremely frequent. Five of the CNVs in this region occurred in male patients. 
The region comprises several genes, including Steroid Sulfatase isozyme S (STS) 
and VCX3A. Haploinsufficiency of STS causes X-linked recessive ichthysosis (XLI) 
(OMIM id 308100). Deletion of VCX3A was thought to be related to ID because of the 
gene’s absence in XLI patients with ID and its presence in XLI patients without ID.64 
However, a subsequent study detected deletions encompassing VCX3A in 62 XLI 
patients without ID, which is in conflict with a causative relation of deletion of VCX3A 
with ID.65 Furthermore, the Database of Genomic Variants includes many genomic 
variants, comprising small copy number variants (mainly gains) in which VCX3A is 
involved. A recent study reported a frequency of 0.37% of the Xp22.31 duplication 
in a cohort of patients, both males and females, with DD, ID, autism, dysmorphic 
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being implemented in both research and diagnostics, may contribute to further 
deciphering of the X-linked genetic base of these disorders. 
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cohort in three categories of clinical relevance, thereby making use of our own 
well-defined criteria, previous literature and database reports and the current 
insights and knowledge. Our report could serve as a resource for clinicians and 
laboratory specialist in the interpretation of X-CNVs that are detected by genome 
wide array platforms in a routine diagnostic setting. However, it is obvious that in 
individual patients the assessment of the clinical relevance of a certain X-CNV 
should always be made on solid grounds, taking into account the individual 
situation of the patient -with respect to specific information on phenotype and 
family history for example- and up-to-date insights and knowledge.
Based on our classification the detection rate of pathogenic X-CNVs in our cohort 
was 0.3%. The detection rates of X-CNVs with potential/ unknown clinical relevance 
and non-pathogenic clinical relevance were 0.4% (18/4,407) and 0.5% (24/4,407) 
respectively. Our results are likely influenced by the relatively poor probe coverage 
of the X-chromosome on the 250 k SNP array platform, through which we might 
have missed small X-CNVs in relatively poor covered regions. For example, MECP2 
duplications, which are frequently found in males with ID and progressive 
neurological symptoms, are not being detected by the array platforms we used, 
which is of course a serious limitation of these specific platforms.  
Interpretation of clinical relevance was mainly based on involvement of known CD 
and/or CA associated genes in combination with the clinical phenotype. Some 
gains comprising known ID genes, we did not classify as pathogenic, because 
previous reports regarding these genes in relation to ID concerned loss-of-function 
mutations and/or deletions, rather than a gain-of-function. However, it was shown 
that duplications and loss-of function mutations involving the same gene can each 
lead to different ID phenotypes, for example loss-of function mutations in MECP2 
give rise to Rett syndrome and duplications involving this gene give rise to a 
different ID phenotype without the classical features of Rett syndrome.42, 47 
Therefore, we cannot excluded that the gene dosage independently of whether this 
is an increase or decrease, may be critical. 
In selected cases we performed XCI analysis. These analyses mostly confirmed the 
initially proposed clinical relevance rather than having a significant contributive 
impact on the final classification in one of the categories. Moreover, results of XCI 
analysis were not always informative, due to homozygosity for the (CAG)n repeat 
within the 5’ end of the Androgen Receptor (AR) gene.
The identification of additional identical or overlapping X-CNVs in patients and/or 
controls, may shed light on X-CNVs that we classified as unknown or ambiguous 
variants and may in addition reveal additional X-CNVs associated with CA and/or 
CA. Moreover, the combination of these data together with data generated by 
exome and genome sequencing of the X-chromosome, which is now increasingly 
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Abstract
Kleefstra syndrome is characterized by the core phenotype of developmental 
delay/ intellectual disability, (childhood) hypotonia and distinct facial features. The 
syndrome can be either caused by a microdeletion in chromosomal region 9q34.3 
or by a mutation in the euchromatin histone methyltransferase 1 (EHMT1) gene. 
Since the early 1990s, 85 patients have been described, of which the majority had 
a 9q34.3 microdeletion (>85%). So far, no clear genotype-phenotype correlation 
could be observed by studying the clinical and molecular features of both 9q34.3 
microdeletion patients and patients with an intragenic EHMT1 mutation. Thus, to 
further expand the genotypic and phenotypic knowledge about the syndrome, we 
here report 29 newly diagnosed patients, including 16 patients with a 9q34.3 
microdeletion and 13 patients with an EHMT1 mutation, and review previous 
literature. The present findings are comparable to previous reports. In addition to 
our previous findings and recommendations, we suggest cardiac screening during 
follow-up, because of the possible occurrence of cardiac arrhythmias. In addition, 
clinicians and caretakers should be aware of the regressive behavioral phenotype 
that might develop at adolescent/adult age and seems to have no clear neurological 
substrate, but is rather a so far unexplained neuropsychiatric feature.
Introduction
Kleefstra syndrome (KS) (OMIM 610253), previously named 9q subtelomeric 
deletion syndrome (9qSTDS), is characterized by the core clinical phenotype of 
mostly moderate to severe developmental delay (DD)/intellectual disability (ID), 
(childhood) hypotonia and distinct facial features, comprising brachy(micro)
cephaly, synophrys, unusual shape of the eyebrows, midface hypoplasia, full 
everted lower lip, cupid bowed upper lip, protruding tongue and prognathism. 
Additional clinical features include congenital heart and urogenital defects, 
epilepsy, behavioral and psychiatric disorders and overweight. The syndrome is 
either caused by a submicroscopic deletion in the chromosomal region 9q34.3 or 
an intragenic mutation of the euchromatin histone methyltransferase 1 (EHMT1) 
gene causing haploinsufficiency of EHMT1 . So far 85 patients, including 75 patients 
with a 9q34.3 deletion and 10 patients with an EHMT1 mutation have been reported.1 16 
EHMT1 encodes a histone H3 Lys 9 methyltransferase and is thereby involved in 
chromatin remodeling.17 Among the genetically confirmed cases the majority of the 
patients have a deletion and the remaining a mutation in EHMT1.11, 18 Almost all 
cases are sporadic, but recently we described 3 familial cases due to a subtelomeric 
9q deletion present in mosaic pattern in the mothers.16 Since the identification of 
EHMT1 as the major gene13, an increasing number of mutations in this gene is 
being detected in patients with the core phenotype of KS. Genotype-phenotype 
studies in patients collected so far indicated that patients with an EHMT1 mutation 
and those with a 9q34.3 deletion smaller than 3 Mb have highly comparable clinical 
findings.10, 19 Here we report 29 additional diagnosed patients with KS that have not 
been published before. Sixteen cases were caused by a submicroscopic 9q34.3 
deletion and 13 cases by an intragenic EHMT1 mutation. We describe the clinical 
and molecular characteristics of this additional cohort, provide an overview of 
previous patients and compare present and previous findings. 
Patients and Methods
A subset of the patients included in this study was diagnosed at our diagnostic 
center after referral from our outpatient clinic or from clinical geneticists from 
national/international collaborating centers. Others were referred to our diagnostic 
center for follow-up (studies) after the diagnosis had been established elsewhere. 
The cohort included 16 patients with a 9q34.3 deletion and 13 patients with an 
intragenic EHMT1 mutation. 
DNA was obtained from peripheral blood cells and extracted according to standardized 
procedures. Deletions were detected by routine subtelomeric multiplex ligation-
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2 mutations (the recurrent p.Arg620X) occurred in the C3HC4 type zinc-finger 
(RING finger) (C3HC4) domain (patient 17 and patient 29 without available clinical 
data) and 1 mutation was localized outside the characterized domains (patient 23). 
The intragenic deletion of patient 24 comprised all characterized domains.
Clinical Data
The clinical features of the patients in this study are summarized in table 2 (9q34.3 
deletions) and table 3 (EHMT1 mutations). Information on the clinical features of the 
patient with the p.Gln1043fs mutation (patient 28) and one of the patients with the 
dependent probe amplification (MLPA) (P070, MRC Holland)/FISH (probes from 
Vysis ) or whole genome array analysis with different platforms (Agilent Technologies 
and Affymetrix Inc., Santa Clara, Calif., USA). In patients without a deletion in 
9q34.3, subsequent gene-specific extensive MLPA analysis and direct sequencing 
of the coding region of EHMT1 was performed as described previously.13 In addition, 
2 novel coding exons were sequenced, since the recent identification of an 
elongated EHMT1 transcript (NM_024757.4).20
Results
 
Molecular Data
Figure 1 shows a schematic overview of the deleted regions in patients 1--8 and 
11--16 diagnosed with a 9q34.3 deletion. Five deletions were initially identified by 
routine subtelomeric MLPA analysis (patients 1–3, 9 and 10). The deletions of 
patients 1--3 were fine mapped by additional region-specific MLPA experiments 
with probes in EHMT1 and flanking genes, with the most proximal probe in the gene 
RAPGEF1, which is located approximately 6 Mb distant from EHMT1 and the most 
distal probe in CACNA1B. The deletion of patient 1 was shown to have a minimum 
size of 200 kb and a maximum size of 6 Mb and thus poorly mapped (no probes 
could be tested in between RAPGEF1 exon 2 (present) and MRPL41 exon 1 
(deleted)). Deletions of patients 9 and 10 are not shown, because these could not 
be further fine-mapped either. The deletions of patients 4--8 and 11--16 were 
identified and delineated by different genome wide array platforms, including the 
Affymetrix 250K SNP array (patients 5 and 16), 2.7M array (patient 4) and 6.0 SNP 
array platforms (patients 13, 14 and –15), and the Agilent 60K (patient 7), 105K 
(patients 11 and 12) and 180K oligoarray (patients 6 and 8) platforms. Mb-positions 
were converted to UCSC genome browser build February 2009 (Hg 19). Present 
deletions vary in size from 270 kb (patient 15) to 3.85 Mb (patient 4).
EHMT1 mutations of the present and previously reported patients are shown in 
figure 2. Present mutations found in the present group are summarized in table 1 as 
well. The mutations in the present group and include 6 frameshift mutations, 3 
nonsense mutations (2 identical: p.Arg620X), 2 exon deletions, 1 missense mutation 
and 1 mutation in a donor splice site. In 5 patients de novo occurrence of the 
mutation was confirmed by segregation analysis in the parents (patients 21, 22, 24, 
25 and 27). In the remaining cases, DNA of one or both parents was not available. 
Two mutations occurred in the Su(var)3--9, Enhancer-of-zetste, Trithorax (SET) 
domain (patients 22 and 26), 4 in the preSET domain (patients 19, 25, 27 and 
patient 28 for whom clinical data was not available), 2 in the ankyrin repeats (ANK) 
domain 7 (patients 18 and 21), 1 affected the donor splice site in exon 22 (patient 20), 
Figure 1   Schematic overview of deleted regions in 9q34.3 in patients 1--8  
and 11--16.
The relative positions of involved genes and the P070 MPLA probe are indicated (UCSC genome browser 
build February 2009, Hg 19). Deletions of patients 1--3 were identified by MLPA. Deletions of patients 4--8 
and 11--16 were detected by genome-wide array analysis. The deletion of patient 4 was identified by 2.7M 
array, the deletion of patients 5 and 16 by 250K SNP array, the deletions of patients 6 and 8 by 180K 
oligoarray, the deletion of patient 7 by 60K oligoarray and the deletions of patients 11 and 12 by 105K 
oligoarray. In patients 13--15 the Affymetrix 6.0 SNP array platform was used. Deletions of patients 9 and 
10 are not depicted, because these were poorly delineated.
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remarkably mild phenotype and was even able to read and write (patient 13). In the 
cohort of patients with an intragenic EHMT1 mutation cognitive performance varied 
from mild ID with speaking in full sentences and ability to read and write (patient 24) 
to moderate ID with regression at adult age (patients 20 and 25). Speech ability 
ranged from a few single words to long sentences with a vocabulary of more than 
100 words (patients 23 and 24). All were able to walk.
Microcephaly was present in 8 out of 14 patients with a microdeletion and in 2 out 
of 11 patients with an intragenic EHMT1 mutation. Overweight (body mass index 
(BMI) >25) was reported among 3 of 15 patients with a deletion and was more 
frequent among patients with a mutation (4 of 10). Reported heart anomalies were 
mainly structural defects, including atrial septal defects, ventricular septal defects, 
valve anomalies comprising pulmonal valve stenosis and bicuspid aortic valve, 
persistent open foramen ovale and ductus arteriosus anomalies. One patient 
(patient 20) was diagnosed with atrial flutter and 1 patient had an aberrant muscle 
bundle in the left ventricle (patient 14). Genital defects were only observed in males 
and included cryptorchidism, hypospadia and micropenis (in 5 of 8 males with a 
microdeletion and in 1 out of 3 males with a mutation, respectively). Musculoskeletal 
anomalies were reported in 4 of 16 patients with a microdeletion and in 3 of 11 
patients with a mutation, respectively, and comprised joint hypermobility, scoliosis 
p.Arg620X mutation (patient 29) was not available and therefore not included in 
tables 3 and 4. Clinical features were systematically obtained by a standardized 
clinical data sheet. The age of patients with a microdeletion ranged from 1 to 25 
years (average age 9.5 years/median age 5.5 years, including 3 adults and 13 
children) and from 1 to 41 years among patients with an EHMT1 mutation (average 
age 11.8 years/median age 7.5 years, including 2 adults and 9 children). All patients 
had the core KS phenotype, including DD/ID, childhood hypotonia and distinct 
facial features. Clinical photographs of patients with a submicroscopic 9q34.3 
deletion are shown in figure 3. Patients with EHMT1 mutations are shown in figure 4. 
Patient 20 with an EHMT1 mutation is described in more detail by Willemsen et al.21
Among the patients with a deletion, the degree of ID ranged from mild to severe, but 
the majority of the patients had severe ID. Five patients were not yet able to walk 
(patients 1, 3, 4, 7 and 9 at 5 years, 33 months, 5 years, 12 months and 16 months 
of age, respectively). Most patients, except for patients 4, 5, 8, 10 and 16, developed 
some speech, though mostly very primitive (single words). One patient had a 
Figure 2   Schematic diagram of the EHMT1 gene structure (including  
27 exons) and the protein domain structure of the EHMT1 protein.
The conserved domains include the C3HC4 type zinc-finger (RING finger) (C3HC4) domain, 7 ankyrin 
repeat (ANK) domains, the Su(var)3--9, Enhancer-of-zetste, trithorax (SET) domain and the PreSET 
domain (N-terminal to the SET domain).The relative positions of in total 22 mutations are displayed, 
including the 13 mutations of the present patient cohort (1 recurrent mutation (p.Arg620X), present in 2 
patients) and 9 previously reported mutations. The first identified intragenic EHMT1 aberration due to a 
translocation X;9 is not shown. Del, deletion; SS, splice site mutation
Table 1   Intragenic EHMT1 mutations identified in patients 17–29
Patient Mutation NM_024757.4 Alteration NP_079033.4
17 c.1858C>T p.Arg620X
18 c.2863_2864del p.Val955fsX221
19 c.3229C>T p.Gln1077X
20 c.3180+1G>T (donor splice site)
21 c.2878_2881 p.Ser960GlyfsX7
22 c.3375–?_3541+?del (exon 24+25 deletion)
23 c.2029insG p.Pro677fs
24 exon 12–27 deletion
25 c.3181-80_3233del p.Tyr1061fs
26 c.3589C>T p.Arg1197Trp
27 c.3072_3073del p.Val1026fs
28 c.3126_3127del p.Gln1043fs
29 c.1858C>T p.Arg620X
162 163
chapter 4 further phenotypic delineation of well known id syndromes
4
Table 2   Clinical features of present and previous patients with a 9q34.3 deletion. 
Clinical features Present patients (corresponding photographs in figure 3) Total Previous 
1
(A, B)
2
(C–E)
3
(no)
4
(F, G)
5
(H, I)
6
(J, K)
7
(L)
8
(M–O)
9
(no)
10
(P, Q)
11
(R–U)
12
(V)
13
(no) 
14
(no)
15
(no)
16
(no)
n = 16 (%) n = 75 (%)
Deletion size (Mb) 0.2–6 ~0.6 0.27–0.41 3.85 1.2 0.6 0.7 3.1 STD STD 0.4 0.6 0.5 0.7 0.27 056–1.32 0.2–6 0.04–CV
Age (years, mo) 5 6 2 9/12 5 11 2 1 10 1 4/12 25 5 5 14 15 25 18 1–25 0–59
Gender M M F F F F F M M F M F M M F M 8 M, 8 F M = F 
Growth parameters
High birth weight – + – – NR – – – – – – – – + – – 02/15 (13) 04/51 (8)
Microcephaly + – + NR + NR + – + + + + – – – – 08/14 (57) 24/50 (48)
Short stature + – – NR – – – – – + – – – – – – 02/15 (13) 16/41 (39)
Overweight (BMI >25) – – – NR – – – + – – – – + + – 03/15 (20) 15/49 (31)
DD/ID sev. mild sev. sev. sev. mild yes sev. mild sev. mod. yes mild sev. mod. sev. 16/16 (100) 75/75 (100)
Heart defect – – – + + – – – + – – – – + + – 05/16 (31) 22/50 (44)
Genital anomaly – + – – – – – – + – + – + – – + 05/8 (63) 12/45 (27) 
Renal anomaly (including VUR) – – – – – – – – – – – – – – – – 00/16 (0) 07/43 (16)
Recurrent infections – – – + – – + + – – – – – – – + 04/16 (25) 05/19 (26)
Hearing deficit – +/– – – – – – – + + + – + – – – 05/16 (31) 07/36 (19)
Gastro-esophageal reflux – + – – + – + + – – – – – + – + 06/16 (38) 04/36 (11)
Epilepsy – – – +/– – – – – – – + + + + + + 07/16 (44) 14/43 (33)
Behavioral/psychiatric – + + + + – – + – + + + – – + + 10/16 (63) 22/43 (51)
Anomalies on brain imaging NR NR – + + NR NR – NR NR – + + + – – 05/10 (50) 20/33 (61)
Tracheomalacia – – – – – – – – – – – – – – – – 00/16 (0) 06/37 (16)
Umbilical/inguinal hernia – – – – – – – + + – – – – – – + 03/16 (19) 06/38 (16)
Anal atresia – – – – – – – – – – – – – – – – 00/16 (0) 02/51 (4)
Musculoskeletal anomaly – – – + + – – – – – + – – – – + 04/16 (25) 09/35 (26)
Respiratory complications* – – – + – – + – – + – – – – – – 03/16 (19) 05/42 (12)
Other – – – – T – – E – – – – – – – E
CV, cytogenetically visible; DD/ID, developmental delay/intellectual disability; mild, mild ID; mod., moderate ID; 
sev., severe ID; yes, ID present (level not known); E, eye anomalies: coloboma in patient 8, severe hyperme-
tropia in patient 16, congenital cataract in patient 23; F, female; M, male; NR, not reported; STD, subtelomeric 
deletion; T, teeth anomalies;. VUR, vesicoureteral reflux. *Including cardiorespiratory failure, apneas; +, yes; –, 
no; +/– uncertain
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Table 3   Clinical features of present and previous patients with an intragenic  
EHMT1 mutation. 
Clinical features Present patients (corresponding photographs in figure 4) Total Previous
17
(A, B)
18
(C–E)
19
(F, G)
20
(H, I)
21 
(J, K)
22
(no)
23
(no)
24
(L–N)
25
(O–R)
26 
(S–U)
27
(V, W)
n = 11 (%) n = 10 (%)
Mutation (NM_024757.4) p.Arg
620X
p.Val
955fs
p.Gln
1077X
SS 
exon 22
p.Ser929
GlyfsX
del. exon 
24–25
p.Pro
677fs 
del. exon 
12–27 
p.Tyr
1061fs
p.Arg
1197Trp
p.Val
1026fs
Age (years, mo) 2 2/12 6 2/12 2 9/12 41 5 5/12 7 5/12 2 5/12 9 2/12 32 10 11 5/12 2 9/12-41 2,6–16
Gender M F M F M F F F F F F 3 M, 8 F 4 M, 6 F
Growth parameters
High birth weight – – – – – NR – – + – – 01/10 (10) 03/9 (33)
Microcephaly + – – – – – + – – – – 02/11 (18) 02/10 (20)
Short stature – – – – – NR – – + – – 01/10 (10) 02/8 (25)
Overweight (BMI >25) – – + + – + – – NR + – 04/10 (40) 04/9 (44)
DD/ID yes mod. yes mod. yes mild mild mild mod. yes mod. 11/11 (100) 10/10 (100)
Heart defect + – + + – – + + – – – 05/11 (45) 04/10 (40)
Genital anomaly + – – – – – – – – – – 01/3 M (33) 02/4 M (50)
Renal anomaly (including VUR) – – + – – – – + – – – 02/11 (18) 01/10 (10)
Recurrent infections – + + + + – + – + – + 07/11 (64) NR
Hearing deficit – – – – + – – – + + + 04/11 (36) 01/10 (10)
Gastro-esophageal reflux – – + – + – – – – – + 03/11 (27) 00/10 (0)
Epilepsy + – – – + – – – – – – 02/11 (18) 03/10 (30)
Behavioral/psychiatric problems – + – + + – + + + + + 08/11 (73) 07/9 (78)
Anomalies on brain imaging – – + + + + NR + + + – 07/10 (70) 05/9 (56)
Tracheomalacia – – – – – – – – – – – 00/11 (0) 01/10 (10)
Umbilical/inguinal hernia – – – – – – + – – – – 01/11 (9) 01/10 (10)
Anal atresia – – – – – – – + – – – 01/11 (9) 00/10 (0)
Musculoskeletal anomaly – – – – – – + + + – – 03/11 (27) 01/10 (10)
Respiratory complications – – – – – – + – – – – 01/11 (9) 00/10 (0)
Other – – T – – – S E H – –
DD/ID, developmental delay/intellectual disability: mild, mild ID; mod., moderate ID; yes, ID present, level not 
known; E, eye anomalies: coloboma in patient 8, severe hypermetropia in patient 16, congenital cataract in pa-
tient 23; F, female; H, hormonal: central pubertas praecox; M, male; NR, not reported; S, hyperelastic skin;  SS, 
splice site; T, teeth anomalies; VUR, vesicoureteral reflux. +, yes; –, no.
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crises and severe sleep disturbance. In 2 of the 5 patients who had reached adult 
age at the time of the examination, a behavioral change at adult age was reported. 
They showed alternating periods with apathy and catatonia-like behaviors with a 
general decline in functioning (patient 20 and 25). These neuropsychiatric conditions 
were recently described in detail by Verhoeven et al.22
In 10 of the 16 patients with a microdeletion and in 10 of the 11 patients with an 
intragenic EHMT1 aberration, cerebral imaging by MRI had been performed. 
Variable anomalies were reported in 5 and 7 patients, respectively, and included dilated 
ventricles, white matter anomalies, corpus callosum hypoplasia and cerebellar hypoplasia. 
and club feet. Renal anomalies were only twice reported in this cohort. Both patients 
had an EHMT1 mutation. One was diagnosed with vesicoureteral reflux (patient 19) 
and the other was shown to have a hydronephrosis (patient 24). Epilepsy was 
present in 7 of 16 patients with a microdeletion and in 2 of 11 patients with a mutation. 
Behavioral problems were often reported (in 10 of 16 microdeletion patients and in 
8 of 11 patients with an intragenic EHMT1 mutation) and comprised autistic features, 
attention deficit problems, self mutilation, aggressive and emotional outbursts/
Figure 3   A–V Facial profiles of patients with a 9q34.3 deletion, including 
patient 1 at age 2 years (A) and 5 years (B), patient 2 at age 9 
months (C), 2 years (D) and 6 years (E), patient 4 at age 5 years  
(F, G), patient 5 at age 11 years (H, I), patient 6 at age 1 year (J) and 
2 years (K), patient 7 at age 9 months (L), patient 8 at different 
childhood ages (M–O), patient 10 at young childhood age (P, Q), 
patient 11 at age 3 years (R, S) and 5 years (T, U) and patient 12 at 
age 5 years (V). The highly recognizable facial features comprise 
hypertelorism, midface hypoplasia, prognathism, prominent 
eyebrows, cupid bow or tented upper lip and everted lower lip.
Figure 4   A–W Facial appearance of patients with an EHMT1 mutation, 
including patient 17 at age 2 years (A, B), patient 18 at age 1 year 
(C) and 6 years (D, E), patient 19 at age 3 years (F, G), patient 20 at 
age 41 years (H, I), patient 21 at age 5 years (J, K), patient 24 at age 
2 years (L, M) and 10 years (N), patient 25 at childhood age (O), 
during teenage (P), and age 32 years (Q, R), patient 26 at age 2 
years (S) and age 10 years (T, U), patient 27 at age 11 years (V, W). 
Facial characteristics are similar to Kleefstra syndrome patients with 
a 9q34.3 deletion.
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Discussion
In this study 29 novel identified patients with KS are described (clinical data were 
not available for patients 28 and 29) and compared to 85 previously reported 
patients. The majority of the deletions described here (11/16) were identified by 
genome-wide array analysis. A large number of previous deletions were reported 
before genome-wide array platforms became common use in routine diagnostic 
settings, and were either detected by routine FISH or MLPA.3-5, 7, 9 Some studies 
reported fine-mapping of deletions with additional specific 9q probes.6, 8 Only 2 
previously reported deletions were cytogenetically visible, indicating that large 
 cytogenetically visible deletions are a relatively rare cause of KS.1, 2 More recent 
reports also included 9q34.3 deletions identified and delineated by genome-wide 
array analysis.11, 19 Genome-wide array analysis generally enables a more precise 
delineation of the breakpoints, though many array platforms have poor coverage of 
the 9q subtelomeric region. The use of different methods for molecular character-
ization in previous and present studies makes exact genotype-phenotype 
comparison more difficult. In agreement with the more recent reports, the sizes and 
breakpoints of the present deletions are heterogeneous.11, 19 Previously, it was 
indicated that patients with microdeletions smaller than 3 Mb in size show highly 
similar clinical findings. In the present study we observed a tendency to a more 
severe ID in patients with deletions of >1 Mb in size. Three to seven patients had a 
deletion of more than 1 Mb (patients 4, 5 and 8; in patients 1, 9, 10 and 16 deletion 
size was not well defined, but possibly more than 1 Mb). In 6 of these 7 patients a 
severe level of ID was documented. In 9 patients a deletion smaller than 1 Mb was 
identified. Three of them had mild ID and in 2 patients severe ID was reported. 
However, the reported level of ID has to be considered with caution, because we 
noticed more often that at very young age the severity of the delay is sometimes 
underestimated and tends to become more obvious at school age when a higher 
level of performance is expected. In this cohort 5 out of 16 patients with a 9q34.3 
microdeletion were diagnosed with a structural heart defect. Two of them had a 
deletion of more than 1 Mb in size. The deletion of patient 9 with a heart defect was 
delineated poorly and is possibly more than 1 Mb in size. The deletion of patient 15 
was relatively small (270 kb). She had a perimembraneous ventricle septal defect 
for which an operation was not necessary. These numbers are too low to conclude 
that the more severe structural cardiac defects are more common in deletions sized 
>1 Mb. Furthermore, structural heart defects are equally present in patients with 
intragenic EHMT1 mutations. Of note, in patient 4 the deletion encompasses both 
COL5A1, associated with Ehlers-Danlos type I [OMIM 130000], and NOTCH1, 
shown to be associated with aortic valve anomalies [OMIM 109730].23 Therefore, 
the heterozygous deletion of both COL5A1 and NOTCH1 likely has contributed to 
Tables 2 and 3 also include a summary of the clinical features reported in previous 
reports. Table 4 summarizes the frequency of clinical features in the total (present 
and previously reported patients) cohort of patients with KS, including 91 patients 
with a 9q34.3 deletion and 21 patients with an EHMT1 mutation. 
Table 4   Frequency of features in presently and previously reported patients 
with KS 
Clinical features of total number of 
KS cases
Mutation
9q34 deletions
n (%)
EHMT1 mutations
n (%)
Age range, years (y, mo) 0–59 2.5–41
High birth weight (>P90) 06/66 (9) 04/19 (21)
Microcephaly 32/64 (50) 04/21 (19)
Short stature 18/56 (32) 3/18 (17)
Overweight (BMI >25) 18/64 (28) 08/19 (42)
DD/ID 91/91 (100) 21/21 (100)
Heart defect 27/66 (41) 09/21 (43)
Genital anomaly (in males) 17/53 M (32) 03/7 M (43)
Renal anomaly 07/59 (12) 03/21 (14)
Recurrent infections 09/35 (26) 07/11 (64)
Hearing deficit 12/52 (23) 05/21 (24)
Gastro-esophageal reflux 10/52 (19) 03/21 (14)
Epilepsy 21/59 (36) 05/21 (24)
Behavioral/psychiatric problems 32/59 (54) 15/20 (75)
Anomalies on brain imaging 25/43 (58) 12/19 (63)
Tracheomalacia 06/53 (11) 01/21 (5)
Umbilical/inguinal hernia 09/54 (17) 02/21 (10)
Anal atresia 02/67 (3) 01/21 (5)
Musculoskeletal anomaly 13/51 (25) 04/21 (19)
Respiratory complications 08/58 (14) 01/21 (5)
Study group included 91 patients with a 9q34.3 deletion (75 previous and 16 present) and 21 patients with 
an EHMT1 mutation (10 previous and 11 present). Two patients with an EHMT1 mutation are not included, 
because clinical data were not available.
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and presence of other major medical problems, and the respective domain 
localizations and type of the mutations. 
Comparison of observed clinical features between the total (including present and 
previous patients) 9q34.3 deletion group and the total intragenic EHMT1 mutation 
group revealed only a few remarkable differences between both groups (table 4). 
This is in agreement with previous observations that EHMT1 is responsible for the 
core phenotype of KS and most of other associated features. EHMT1 is an 
epigenetic regulator that affects gene transcription by histon modification. It is one 
of a rapidly growing list of ID genes that are implicated in chromatin remodeling.14, 
26, 27 It is likely that other associated features besides ID can be explained by the 
effect of EHMT1 mutations on the expression of a variety of target genes. 
In the present mutation group the mean age is higher than in the deletion group. 
There are no indications that patients with a deletion die at a younger adult age than 
patients with a mutation. There is only 1 death (cause unknown) at adult age 
reported. This concerns a 21-year-old male patient with a deletion.19 The increased 
average age in the present mutation group compared to the present deletion group 
might be due to an older age of diagnosis in the mutation group, because deletions 
can be detected by standard genome-wide array analysis and thus are more easily 
recognized than mutations for which analysis has to be specifically requested on 
the base of the clinical phenotype. 
Microcephaly and short stature were more frequent in the 9q34.3 deletion group 
(50% vs. 19% and 32% vs. 17%, respectively). Respiratory complications and 
tracheomalacia were also more frequently observed in the 9q34.3 deletion group 
(14% vs. 5% and 11% vs. 5%, respectively). Features that were observed more often 
in the EHMT1 mutation group included high birth weight (9% in the deletion group 
vs. 21% in the mutation group) and overweight (28% and 42%, respectively). 
Recurrent infections and behavioral problems were also more often reported in 
patients with an EHMT1 mutation (in 26% vs. 64% and in 54% vs. 75%, respectively). 
These observations are highly consistent with our report in 2009.19 The explanation 
for the observed differences in frequency of certain features is unclear, but might 
be partly explained by inconsistent report of some features in previous studies 
among 9q34.3 microdeletion patients and relatively low numbers of patients with 
an EHMT1 mutation which influences the figures. The distinct pattern of behavior 
problems observed in several teenage and adult patients with KS has recently 
gained more attention15, 19, 22 and thus behavior problems are likely more consistently 
reported in recent reports. 
The present report confirms to a large extent the phenotypic spectrum described in 
earlier reports. Most frequently observed clinical features in KS apart from the core 
phenotype included behavioral problems (~50--75%), various brain anomalies 
(~60%), heart defects (~40--45%), male genital defects (~30--40%), microcephaly 
the cardiac valve phenotype in this patient presenting with aortic and pulmonary 
valve defects in addition to cardiac septal defects. Deletion of COL5A1 likely 
contributed to the generalized joint hypermobility that was observed in patient 4. 
However, in patient 8, who also has a deletion comprising these genes, neither a 
heart defect nor signs of connective tissue disease were observed, so penetrance 
seems incomplete. Of note, 13 of the 16 identified deletions comprised the gene 
CACNA1B as well. We did not observe differences in phenotype between patients 
with a deletion comprising CACNA1B (patients 2--12, 14 and 16) and patients with a 
deletion excluding CACNA1B (patients 1, 13 and 15). CACNA1B is a voltage-depen-
dent calcium channel and despite the demonstrated importance of the a1B subunit 
for neurotransmission in most neuronal cells during embryogenesis and after birth, 
the null-mutant mice showed no gross abnormalities and normal motor coordination. 
These data suggest that the a1B gene is not essential for synaptogenesis and 
neuronal differentiation during embryonic and postnatal development.24 This might 
underscore why a heterozygous loss of this gene does not contribute significantly 
to the observed phenotype in 9q34.3 deletions. Moreover, Yatsenko et al.11 
described a familial case with a heterozygous loss of CACNA1B but not EHMT1. 
Affected family members had a normal development and did not have the KS 
phenotype. Previous reports suggested a higher prevalence of respiratory 
complications in patients with deletions ≥3 Mb.18 In the present study respiratory 
complications were present in patient 4 with a large deletion of 3.85 Mb, in patient 
10 with a poorly defined deletion, but possibly larger than 1 Mb in size, and in 
patient 7 with a 700 kb deletion. However, the respiratory problems in these patients 
were of different origin. Patient 4 suffered from central apneas and patient 7 and 10 
had respiratory problems secondary to a viral bronchiolitis and aspiration, 
respectively. Central apneas have been reported in 1 previously published patient 
who had a cytogenetically visible deletion.9 From a personal communication we 
know an additional patient with central apneas who has a 9q subtelomeric deletion 
of more than 3 Mb as well. So, it might be that central apneas are associated with 
deletions over 3 Mb.
Since the identification of EHMT1 in 2005 as the gene responsible for the 
phenotype13, 25, mutations in EHMT1 are increasingly being detected. So far, 23 
intragenic EHMT1 defects have been reported (including this report). Except for one 
(c.1858C>T), all present mutations were unique and not reported before. Presence 
of distinct clinical features is comparable between the present and previously 
reported cohorts. Mutations are scattered throughout the gene, but are more 
frequent on the 3¢ end of the gene and occur mostly in the PreSET domain (fig. 2). 
All mutations in this cohort, except for 1 missense mutation and 1 splice donor site 
mutation, are truncating mutations suggesting loss-of-function. We did not observe 
a correlation between the severity of the phenotype, indicated by the degree of ID 
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(~20--50%) and overweight (~30--40%). Interestingly, cardiac defects that we 
observed in this cohort included structural anomalies but also other defects. In 
patient 14 an aberrant muscle bundle in the left ventricle was observed. Patient 20 
and 1 of the previously reported patients with an intragenic EHMT1 mutation were 
both diagnosed with cardiac arrhythmias, including atrial flutter (personal 
communication). Epilepsy (~25--35%), musculoskeletal anomalies (~20--25%), 
recurrent infections (>25%), hearing problems (20--25%) and constipation (personal 
observation) are quite common as well. Features that are observed more rarely are 
renal anomalies and other congenital anomalies, gastro-esophageal reflux and 
respiratory complications (table  4). As concluded previously, only minor indications 
for phenotype-genotype correlations could be observed within the group of 
deletion patients (between larger (>1 Mb) and smaller deletions), as well as between 
the 9q34 deletion and EHMT1 mutation group. Based on the phenotypic data 
presented here, we recommend cardiac screening during follow-up of KS patients, 
because of the possible occurrence of cardiac arrhythmias, even if no structural 
heart defect is present. In addition, clinicians and caretakers should be aware of the 
regressive behavioral phenotype that might develop at adolescent/adult age and 
seems to have no clear neurological substrate, but is rather a so far unexplained 
neuropsychiatric feature. 
Identification of increasing numbers of patients with (smaller) deletions and EHMT1 
mutations will probably further increase our knowledge of the phenotypic and 
genotypic spectrum of KS. Furthermore, application of novel sequence technologies 
might lead to the identification of other genes involved in phenotypes compatible 
with KS. Interestingly, our group recently published that the learning and memory 
defects in EHMT mutant Drosophila melanogaster could be rescued when EHMT 
expression was restored.26 These studies indicate that learning and memory are 
dynamic processes that might be rescued at least to some extent even when 
caused by genetic defects such as mutated EHMT. This opens the window in 
understanding the mechanisms of ID and strongly emphasizes the need for further 
investigations on possible intervention strategies that might become available in 
future for some aspects of cognitive processes. 
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Abstract
The Kleefstra syndrome (Online Mendelian Inheritance in Man 607001) is caused 
by a submicroscopic 9q34.3 deletion or by intragenic euchromatin histone methyl 
transferase 1 (EHMT1) mutations. So far only de novo occurrence of mutations has 
been reported, whereas 9q34.3 deletions can be either de novo or caused by 
complex chromosomal rearrangements or translocations. Here we give the first 
descriptions of affected parent-to-child transmission of Kleefstra syndrome caused 
by small interstitial deletions, approximately 200 kb,  involving part of the EHMT1 
gene. Additional genome wide array studies in the parents showed the presence of 
similar deletions in both mothers who only had mild learning difficulties and minor 
facial characteristics suggesting either variable clinical expression or somatic 
mosaicism for these deletions. Further studies showed only one of the maternal 
deletions resulted in significantly quantitative differences in signal intensity on the 
array between the mother and her child. But by investigating different tissues with 
additional FISH and MLPA analyses, we confirmed somatic mosaicism in both mothers. 
Careful clinical and cytogenetic assessments of parents of an affected proband 
with an (interstitial) 9q34.3 microdeletion are merited for accurate estimation of 
recurrence risk.
Introduction 
The Kleefstra syndrome, previously known as the 9q Subtelomeric Deletion 
Syndrome (9qSTDS), is one of the first clinically recognizable subtelomeric deletion 
syndromes.1, 2 Affected individuals have severe hypotonia with speech and gross 
motor delay. The facial features comprise micro- or brachycephaly, hypertelorism, 
synophrys, arched eyebrows, midface hypoplasia, a short nose with upturned 
nares, a protruding tongue, everted lower lip and down-turned corners of the 
mouth. Approximately half of affected individuals have congenital heart defects 
and 10-20% have a combination of epilepsy, behaviour and sleep disturbances. 
A variety of other major and minor anomalies have been reported.1-6 We previously 
demonstrated that the syndrome is caused by haploinsufficiency of euchromatin 
histone methyl transferase 1 (EHMT1), a gene involved in histone methylation.3, 7, 8 
We and others found no evidence for phenotype-genotype correlations.3, 4 
All individuals with Kleefstra syndrome identified so far have been single cases or 
sib pairs, the latter affected as a consequence of a balanced chromosomal 
rearrangement involving the 9q34.3 region in one parent.
Here, we report the clinical and molecular cytogenetic findings in two unrelated 
families where a small interstitial 9q34.3 deletion is segregating. This new observation 
is relevant for accurate genetic counseling in families with a proband who carries a 
9q34.3 deletion.
Case reports
 
Family 1
The family is shown in Figure 1. The proband was born at term to a gravida 1 para 
0 mother who had had one early miscarriage. He weighed 3,520 grams (50th 
centile). Glandular hypospadias was noted at birth but he was otherwise thought to 
be well. By the age of 7 weeks reduced muscle tone and persistent head lag were 
evident. At 16 weeks of age delayed motor development and lack of visual interest 
in surroundings were noted. By 6 months of age, axial tone had improved with 
better head control, but the occipito-frontal circumference (OFC) had fallen from 
the 25th centile at age 6 weeks to the 2nd centile by age 30 weeks. Right inguinal 
hernia was noted in addition to the hypospadias and  both were repaired by surgery. 
Bilateral forefoot adduction deformities were treated with splints. By age one year, 
unusual short absences with hypotonia and atypical spasms were noted but EEG 
examination was normal as were blood tests including full blood count, urea and 
electrolytes, liver function tests, creatine kinase and uric acid.  Cerebrospinal fluid 
biochemistry including protein, glucose and lactate levels, was also normal. Global 
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considered (HbH inclusions indicative of ATRX syndrome were sought but not 
found). The parents were advised that in the absence of a definite diagnosis, there 
was a moderate chance of recurrence of unexplained learning difficulties in a 
second child. 
     
Some years later, after a second early miscarriage, the parents’ second son 
presented to the paediatric service at the age of 9 weeks following concerns about 
his neurodevelopmental process. He had been born by emergency caesarean 
section at 37 weeks following an uneventful pregnancy, his birth weight was close 
to the 50th centile (3,400 grams) and his OFC was on the 10th centile. There were no 
perinatal problems, but axial hypotonia and post axial polydactyly affecting one 
foot were noted in the newborn period. These observations caused concern that 
the baby had the same undiagnosed, neurodevelopmental condition as his older 
brother. At the age of 9 weeks he attended the paediatric service with axial hypotonia 
and marked head lag, visual inattention and he was not smiling. He had increased 
tone of the upper limbs with fisting and brisk peripheral reflexes. He was reported 
to be feeding poorly. His weight was 4,800 grams (25th centile) and his OFC had 
fallen to the 2nd centile. He had unusual morphology of the ear lobes. Subsequent 
neurodevelopmental progress was similar to the proband and was abnormal in all 
domains. In particular, he had difficulties with feeding, partly caused by tongue 
protrusion. He had abnormal speech and language development with babble but 
no single words and no symbolic play at the age of 2 years. At this age he was, 
however, sitting independently and would pull to stand and attempt to cruise around 
the furniture. Like his brother, he had had problems with vomiting and poor weight 
gain as well as a poor sleep pattern. Also similar to his brother, his parents reported 
short or generalised clonic events consistent with epileptic seizures but associated 
with normal EEG examinations. His OFC continued to grow along the 2nd centile.
Family 2 
This family is shown in figure 2. The proband is the second child of consanguineous 
parents. She was born at a gestational age of 36 weeks and 6 days and had a birth 
weight of 3,030 grams (50th centile). The pregnancy had been uneventful. She had 
a perinatal infection from which she recovered after antibiotic treatment. During the 
first months of life she was a very quiet, hypotonic baby and she showed very little 
development. At the age of 2 months she had pneumonia which was attributed to 
swallowing difficulties and gastro esophageal reflux. At that time a heart murmur 
was noticed but there was no evidence of a congenital heart defect at ultrasound 
and electrocardiography. She had mild dysmorphic features, including  hypertelorism, 
depressed nasal bridge and an upturned nose (Fig. 1 A). Routine karyotyping showed 
a normal female chromosomal pattern (46,XX). 
delays in development became more evident, with sitting at 1 year, walking at 2.5 
years and emergence of single words at 3 years. A Giemsa banded karyotype 
revealed a balanced, reciprocal translocation (46,XY,t(2;13)(q31;q34). This balanced 
reciprocal translocation was inherited from the proband’s healthy father and was 
judged not to be of any significance in relation to the proband’s condition. There 
was no evidence of a fragile X syndrome triplet repeat expansion or a chromosome 
15 DNA methylation abnormality that is associated with Angelman syndrome.    
At the age of  21 months, a cerebral MRI was performed which showed white matter 
abnormalities that were interpreted as T2 hyperintensities in the peritrigonal regions, 
suggestive of periventricular leucomalacia. 
In estimating the chance of recurrence in a sibling of what was then an undiagnosed 
disorder in the proband, the family history was considered pertinent because 
mother had had some learning difficulties and had required additional help at 
school. No other health problems were admitted. Mother’s OFC was just under the 
50th centile. The possibility that the proband had a sex-linked disorder was 
Figure 1   Photograph of family 1. The proband (left) with his younger brother 
and his mother. Note the characteristic facial appearance of 
Kleefstra syndrome in the proband and the mild facial features in  
the mother. The younger brother shows marked hypotonia.
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depressed nasal bridge and a short nose with anteverted nares, a mildly hypoplastic 
midface, a wide mouth with thick lips, small teeth and a dry skin (Fig. 2 B). DNA 
analysis of the MECP2 gene, MLPA MR deletion and duplication syndromes 
(including the 17p11.2 region for Smith Magenis syndrome)(MLPA-kit: P064, 
MRC-Holland), MLPA of the subtelomeric regions (MLPA-kit: P036C and P070, 
MRC-Holland) and analysis of the methylation pattern of the Prader-Willi Angelman 
region (15q12) did not show any abnormalities.
At 5 years of age, when she was reevaluated, she spoke two-word sentences, had 
a steadier gait and showed less tantrums. She seemed to have a high pain 
threshold. There were no signs of epilepsy, hearing problems or visual problems. 
Physical examination revealed dysmorphic features in conformity with those 
observed at the age of 3 years, except for an asymmetry of the palpebral fissures, 
with mild ptosis on the left side (Fig. 2 E).
The family history revealed that the proband’s older sister, who has had normal 
psychomotor development, had a combined immune deficiency of unknown cause 
, for which she had a bone marrow transplantation. The girls’ mother experienced 
learning difficulties and she did not finish high school. She suffered from a 
depression and was quite shy. Physical examination revealed obesity and minor 
dysmorphic features, including a hypoplastic midface, small upslanting palpebral 
fissures, depressed nasal root and anteverted nares (Fig. 2 F-G).
Methods
MLPA
Routine MLPA studies to search for subtelomeric abnormalities were performed 
using the P070 kit of MRC-Holland as previously described.9
Fluorescent in situ hybridization (FISH)
FISH analysis on slides prepared from buccal swabs was performed using directly 
labeled BAC probes RP11-417A4 (Chr9: 139,523,178 – 139,716,008 Mb (hg18)) and 
RP11-467E5 (Chr9: 139,633,667 - 139,799,808 Mb (hg18)) (BlueGnome Ltd, 
Cambridge, UK) in combination with the centromere probe for chromosome 9 
(Vysis Inc., Downers Grove, IL, USA). FISH was performed according to the 
manufacturer’s instructions and our established laboratory protocol.
Genome wide array analysis
In family 1 the Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, 
USA) was used to screen for CNVs. Genome-wide SNP-array hybridization was 
performed following the manufacturer’s instructions. Genome wide copy number 
A brain MRI at the age of 18 months did not show any abnormalities. Hearing was 
not impaired and X-rays of femur and calcaneus revealed no stippling indicative of 
peroxisomal disorders  and metabolic screening of plasma and urine did not show 
any abnormalities. 
Upon evaluation at the age of 3 years she did not speak  and all her motor milestones 
were delayed. She had started rolling at the age of 11 months, had been able to sit 
without support since the age of 12 months and had started walking at the age of 
2,5 years, but she had a very unstable gait. The parents reported her being very 
cheerful in general, but she did have tantrums and occasionally self-harm. Physical 
examination revealed a length of 94 cm (2nd centile), a weight of 15 kg (70th centile) 
and a head circumference of 48 cm (16th centile). She was hypotonic and had 
hypermobile joints. She showed stereotypic hand movements and had an unsteady 
gait. She had coarse facial features, hypertelorism, blue sclerae, a broad and a 
Figure 2   Photographs of family 2. The proband at the age of 2 months (a),  
3 years (b), 4 years and 6 months (c, d) and 5 years (e), and her 
mother (f, g). Note the hypertelorism, broad and depressed bridge  
of the nose, flared nostrils (a, b, d, e), mild midface hypoplasia  
(c) and broad mouth with full lips in the proband (b, d, e).  
The mother has marked obesity and minor dysmorphic features, 
including a hypoplastic midface, small palpebral fissures, a 
depressed nasal bridge and anteverted nares (f, g).
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browser, March 2006, NCBI Build 36.1/hg18; http://genome.ucsc.edu). The deletion 
was confirmed with FISH using BAC probes RP11-417A4 and RP11- 467E5. Array 
CGH testing of the parents showed that the patient’s deletion was inherited from 
her mother, with the mother showing a less pronounced loss as determined by the 
log ratio (not shown here), suggestive of mosaicism. 
Mosaic pattern detection
To further investigate whether the milder phenotypes in the mothers might be explained 
by presence of the 9q deletion in a mosaic pattern, we performed additional FISH 
and MLPA experiments in different cell types. 
In family 1 MLPA analysis using probes in exons 1, 2, 5, 8, 10, 13, 16, 19, 21, 24 and 
26 of the EHMT1 gene was performed in blood lymphocytes and fibroblasts, each 
on two different samples. This revealed in both cell types a mosaic pattern in the 
mother, showing a lower percentage of cells with the 9q deletion  in the fibroblasts 
than in the lymphocytes. (Fig.4 A and B)
analysis was performed using the Affymetrix Genotyping Console version 4.0 and 
the Affymetrix Genotyping Console Browser version 1.10.12, and a reference set of 
47 in-house control DNA samples. 
In family 2 the Agilent 105k array (Agilent Technologies, Palo Alto, CA) has been 
used to screen for CNVs and to determine the 9q subtelomeric deletion. Labeling 
and hybridization procedures were performed according to the manufacturer’s 
instructions. Images of the arrays were obtained using a microarray scanner 
G2505B (Agilent technologies) and image analysis was performed using feature 
extraction software (version 9.1; Agilent Technologies). The Agilent CGH-v4_91 
protocol was applied using default settings. Data analysis was performed with 
Agilent analysis software (DNA analytics, Agilent Technologies, Inc.). The predicted 
copy numbers of each CNV were determined using the Hidden Markov Model 
(HMM) incorporated in each data analysis software package.
Results
Family 1
Routine subtelomeric MLPA studies in the proband revealed a decreased intensity 
of the 9q probe located in EHMT1, indicative for a deletion of this region. Further 
segregation studies by MLPA in the younger brother and the mother, revealed a 
similarly decreased signal of the EHMT1 probe in both. The maternal grandparents 
of the proband were not available to be examined.
We confirmed the findings by analyzing DNA material of the proband and his 
mother on the 6.0 SNP array showing an identical loss of 233 kb in chromosomal 
band 9q34.3 (Fig. 3) between markers SNP_A-2178662 (139,747,286) and 
CN_1303976 (139,979,603) (UCSC browser, March 2006, NCBI Build 36.1/hg18; 
http://genome.ucsc.edu), with a proximal breakpoint between exons 4 and 5 of the 
EHMT1 and a distal breakpoint between exons 10 and 11 of the CACNA1B gene. 
Similar signal intensities were observed in the proband and his mother, so our 6.0 
SNP array gave no indications for a mosaic pattern in the mother.
No additional CNVs were detected, neither in the proband, nor in his mother.
Family 2
Genome wide array-CGH in the proband revealed an approximately 200 kb deletion 
in chromosome band 9q34.3 (fig 3). The start of the deletion is between base pairs 
139,567,629 (probe A_14_P101384) and 139,578,983 (probe A_14_P127304) and 
the end is between base pairs 139,757,789 (probe A_16_P02195928) and 139,777,287 
(probe A_14_P124669), indicating a minimal deletion of 179 and a maximal deletion 
of 210 kb which at least contains the first five exons of the EHMT1 gene. (UCSC 
Figure 3   Schematic overview of the deleted regions in chromosome band 
9q34.3 in probands and mothers of family 1 (139,747,286-
139,979,603 Mb) and 2 (139,757,789-139,777,287 Mb) delineated by 
genome wide array analysis.
Relative positions of EHMT1, flanking genes, the MLPA probe of MLPA kit P070 (MRC-Holland) and the 
FISH probes in this region are indicated. Both deletions involve EHMT1.
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In family 2, interphase FISH analysis on a buccal swab sample from the mother 
showed the deletion in 80% of her cells (50 cells analyzed) indicating that she is a 
mosaic carrier of the 9q34.3 deletion (Fig. 4 D-E). This argues for a de novo event 
in the mother. 
Discussion
This is the first report of familial Kleefstra syndrome. In two different families three 
cases of Kleefstra syndrome were identified and explained by mosaicism in their 
mothers for a 9q.34.3 deletion encompassing part of the EHMT1 gene. Importantly, 
both mothers showed a significantly milder phenotype. Thus, in family 1 a sex-linked, 
Angelman-like disorder was first suspected and in Family 2 the MECP2 (Rett 
syndrome) gene was analysed before Kleefstra syndrome was correctly diagnosed 
in the proband.
Familial transmission of autosome imbalances with milder phenotypes that display 
variable expression, such as deletions in 22q11.2 and duplications in 15q11q13, are 
reported10-23 and Barber has listed 200 families with a directly transmitted, cytoge-
netically visible, autosomal anomaly.24 Most familial cases are explained by either a 
parental balanced chromosomal rearrangement or parental mosaicism. Mosaicism 
can either be germline or somatic. Carriers of a somatic mosaic imbalance can be 
similarly affected, less affected, or unaffected (with preservation of reproductive 
fitness).There are literature reports of somatic mosaicism for both the severe and 
less severe autosome imbalance syndromes including mosaic 17p11.2 del 
(Smith-Magenis syndrome), mosaic 22q11.2 del (DiGeorge/VCF syndrome), 
mosaic 3q29 del, mosaic 22q13 del, mosaic 20p del (Alagille syndrome), mosaic 
8q24 del (Langer Giedion syndrome), mosaic 5pdel (Cri-du-Chat syndrome) and 
mosaic 4qter del.25-32 But in both families with Kleefstra syndrome whom we report, 
it was a surprise to discover the proband’s condition was transmitted by a mildly 
affected, mosaic mother. 
Somatic mosaicism for chromosomal imbalances may be more frequent than 
appreciated due to inability of diagnostic tests to detect low level mosaicism that 
causes mild or even no clinical signs. In conventional cytogenetic analysis, low 
level mosaicism may be missed unless large numbers of cells are tested and even 
then, the cell culture process may complicate detection due to selective 
disadvantage of cells with the chromosomal imbalance.33 Genome-wide array 
analysis was shown to be capable of consistently detecting mosaicism with a level 
as low as 20%.33 Consequently, the introduction of genome wide array technologies 
in routine diagnostic settings is likely to increase the detection rate of mosaic 
Figure 4   Mosaic pattern detection in family 1 and 2. The results for 4 control 
probes and exons 1, 2, 5, 8, 10, 13, 16, 19, 21, 24 and 26 of the EHMT1 
gene are indicated. (a) and (b) indicate the results of the MLPA analysis 
in the proband and the mother of family 1, showing mosaicism for the 
9q34.3 deletion in both blood lymphocytes (a) and fibroblasts (b) of the 
mother. Note that a lower percentage of the fibroblasts carries the 9q 
deletion as compared to the lymphocytes. (c)-(e) show the results of the 
FISH analysis on cells derived from buccal swabs in the proband and 
the mother of family 2. (c) shows only one red signal, indicating the 
deletion of probe RP11-417A4 (red color) in chromosome region 9q34.3 
in the proband. (d) and (e) show mosaicism in the mother with a normal 
signal pattern for probe RP11-417A4 in (d) (two red signals) and only 
one red signal in (e), indicative for a loss in 9q34.4 in this cell. The 
centromere 9 probe is labeled green and shows a normal FISH pattern 
(two signals) in (c)-(e).
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chromosomal imbalances . Noteworthy, in family 2 array analyses suggested the 
presence of a mosaicism in the mother based on a less pronounced decrease in 
signal intensity for the 9q34.3 region as compared to the proband, whereas in 
family 1, the signal intensities were similar in mother and her affected child. MLPA 
proved a reliable and efficient method to identify mosaicism in this latter family 
showing reproducible, quantitative differences in signal intensity between the 
mother and her child. Moreover, these analyses permitted detection of different 
percentages of mosaicism in peripheral blood cells compared to fibroblasts (Fig. 4 
A and B).
Chromosomal imbalances can arise both meiotically and somatically.34 Most 
recurrent interstitial chromosomal imbalances result from meiotic non allelic 
homologous recombination (NAHR) within recombination hotspots. Examples are 
the 1.4 Mb type 1 deletion in neurofibromatosis 1 and the 3.7 Mb deletion in 17p11.2 
causing Smith-Magenis syndrome.35,36 In these specific deletions, the chance of 
parental somatic mosaicism might be considered  very low because of the 
presumed meiotic origin of the imbalance. Interestingly, NAHR was also shown to 
play a significant role in non-recurring chromosomal rearrangements and can 
comprise either inter-or intrachromosomal unequal crossing over events.36,37 It 
appeares that somatic NAHR is mediated by intrachromosomal exchange during 
mitosis and germline NAHR by interchromosomal non-homologous pairing during 
meiosis.35 Furthermore, NAHR is frequently involved in the generation of  genomic 
rearrangements in somatic cells.34,38 This suggests that somatic NAHR might be 
one explanation for the occurrence of mosaic chromosomal imbalances. 
In conclusion, this report emphasizes that parental somatic mosaicism can occur 
in a parent of a child with a severe chromosomal imbalance syndrome such as 
Kleefstra syndrome and mild learning disabilities may be the only clue. Detailed 
chromosome studies that may extend to array CGH, FISH or MLPA experiments in 
different tissues are required to demonstrate somatic mosaicism and alert the 
parents to the high risk of syndrome recurrence. 
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Abstract
Angelman- and Rett-like syndromes share a range of clinical characteristics, 
including intellectual disability (ID) with or without regression, epilepsy, infantile 
encephalopathy, postnatal microcephaly, features of autism spectrum disorder and 
variable other neurological symptoms. The phenotypic spectrum generally has 
been well studied in children, however evolution of the phenotypic spectrum into 
adulthood has been documented less extensively. To obtain more insight in natural 
course and prognosis of these syndromes with respect to developmental, medical 
and socio-behavioural outcomes, we studied the phenotypes of 9 adult patients 
who were recently diagnosed with 6 different Angelman- and Rett-like syndromes. 
All these patients were ascertained during an ongoing cohort study involving a 
systematic clinical genetic diagnostic evaluation of 250 mainly adult patients with 
ID of unknown etiology. We describe the evolution of the phenotype in adults with 
EHMT1, TCF4, MECP2, CDKL5 and SCN1A mutations, and 22qter deletions, and 
also provide an overview of previously published adult cases with similar diagnoses. 
These data are highly valuable in adequate management and follow-up of patients 
with Angelman- and Rett-like syndromes and accurate counseling of their family 
members. Furthermore they will contribute to recognition of these syndromes in 
previously undiagnosed adult patients. 
Introduction
Clinical characteristics of known syndromes including associated health and behaviour 
issues and recognizable facial features are generally well studied and described in 
patients at childhood. Often little is known about evolution of the phenotype across life 
span. Information on health and social outcomes is necessary for an adequate 
management and follow-up of patients with specific intellectual disability (ID) syndromes 
and enables careful counseling of family members regarding prognosis, natural course 
of the disease and life expectancy. Delineation of phenotypes at adult age will also 
contribute to recognition and diagnosis of ID syndromes at adult age. 
In the past decade improvements in diagnostic and research technologies have led to 
the identification of several novel chromosomal microdeletions and -duplications as well 
as single genes that are associated with known and novel ID syndromes, referred to as 
‘’Angelman- and Rett-like syndromes.’’1-11 After the initial identification of the gene methyl 
CpG binding protein 2 (MECP2) as the cause of Rett syndrome2, additional genes 
associated with a Rett-like/ aspecific Rett syndrome phenotype have been subsequently 
identified. These include forkhead box G1 (FOXG1), cyclin-dependent kinase-like 5 
(CDKL5) and myocyte enhancer factor 2C  (MEF2C).1, 6-7, 11 Furthermore, in several 
patients with a clinical diagnosis of Angelman-like syndrome, mutations in MECP2 and 
CDKL5 have been identified.12-15 In addition several mutations in the gene transcription 
factor 4 (TCF4, Pitt Hopkins syndrome) have been identified in patients with Angelman-like 
phenotypes as well.16 So, Angelman- and Rett-like syndromes have an overlapping 
phenotypic spectrum with heterogeneous underlying genetic defects which can mimic 
each other. The phenotypic spectrum comprises (severe) ID with or without regression, 
epilepsy, infantile encephalopathy, features of autism spectrum disorder, stereotypies 
and hand apraxia, postnatal microcephaly, autonomic dysfunction (including breathing 
anomalies, vasomotor disturbance and gastro-intestinal symptoms), and other 
neurological symptoms, including ataxia and spasticity. Furthermore, various underlying 
genetic defects are thought to act in similar and/or interacting pathways. For example, 
MECP2 is thought to be involved in the epigenetic regulation of UBE3A (associated with 
Angelman syndrome).17-18 Also, MECP2, CDKL5 and MEF2C were shown to interact 
directly which suggest involvement in a common pathway.11, 19  
During an ongoing cohort study among mainly adult patients with so far unexplained 
ID, we identified in 9 adult patients with Angelman- and Rett-like phenotypes an 
associated genetic defect. We found mutations in the genes TCF4, CDKL5, euchromatic 
histone-lysine N-methyltransferase 1 (EHMT1), MECP2 and sodium channel, voltage- 
gated, type I, alpha subunit (SCN1A), and small terminal deletions in chromosomal 
region 22q13.3, associated with Phelan- McDermid syndrome. Here we describe the 
evolution of their phenotypes up to different adult ages and give an overview of 
previously reported adult cases. 
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Results
Patient 1: Kleefstra syndrome (EHMT1)
This female patient was ascertained at age 41 years. She was born at term after an 
uncomplicated pregnancy and delivery in breech position. Birth weight was more 
than 3 kg (>10th centile). At the age of six weeks she was admitted to the hospital 
because of persistent excessive regurgitation and weight loss, probably due to 
severe gastro-esophageal reflux. Her motor development was mildly delayed with 
walking independently at age 18 months. Speech development was more severely 
delayed and she was not able to speak single words until the age of 3 years. 
Contact making was diminished and she had mood swings. An intravenous 
pyelogram at age 10 years, because of recurrent urinary tract infections, showed no 
abnormalities. Ophthalmological evaluation revealed substantial strabismus. At 
age 38 years her developmental age as assessed by the WISC-RN scale was 5.5 
years with a discrepancy between verbal capacities (age equivalent 4.3 years) and 
performal capacities (age equivalent 6.6 years). She was able to walk, to talk in 
short simple sentences and needed some help in self care. Around age 38 years 
she presented with a remarkable change in her behaviour pattern, including periods 
of apathy, decreased emotional responsiveness, staring, low motor activity, stupor 
and sleep disturbance, characterized by frequent awakenings during the night and 
daytime sleepiness. Detailed behavioral characteristics have been published elsewhere 
[Verhoeven et al., 2011: patient 1].Furthermore, impulsivity and aggressive outbursts 
were reported. She also showed focal myoclonic twitches of the right shoulder. 
Electro-encephalography was repeatedly normal. Brain MRI showed multifocal 
poorly defined abnormal white matter signal intensities, mainly localized deeply in 
the parietal lobe. In addition, bilaterally abnormal signal intensity in the globus 
pallidus was noticed. These abnormalities were not indicative for perinatal asphyxia. 
Cardiologic evaluation revealed hypertrophy of the left ventricle and paroxysmal 
atrial fibrillation. Upon physical examination at age 41 years her height was 176 cm 
(75th centile), weight 103 kg (>98th centile) and head circumference 53.5 cm (10th 
centile). Facial dysmorphic features comprised a flat midface, slight upslant of the 
palpebral fissures, short philtrum, prognathism, and full everted lower lip (fig. 1A-B). 
Chromosomal analysis by 250k SNP array analysis was normal and screening 
metabolic tests revealed no abnormalities. Because of the clinical suspicion of 
Kleefstra syndrome without a deletion in chromosomal region 9q34.3, mutation 
analysis of EHMT1 was performed and revealed a pathogenic mutation in the splice 
site of intron 20 of the EHMT1 gene (c.3087+1G>T). Segregation analysis in the 
parents was not possible. 
Patients and methods 
All patients were ascertained during an ongoing cohort study among patients with 
ID of unknown etiology. This study was approved by the local ethical committee. 
Patients were selected from a large population of approximately 4000 people living 
in residential settings associated with three service providers for the care of people 
with ID in the eastern part of the Netherlands. Patients were selected on the base of 
an IQ level ≤ 70 in combination with presence of one or more of the following 
features: micro-or macrocephaly; growth retardation or overgrowth; neurological 
features (for example ataxia, spasticity, neurodegenerative signs), congenital 
anomalies (i.e. congenital heart/renal/skin/genital defects); consanguinity and/or 
positive family history for ID; and/or dysmorphic features. More than 80% of the 
patients in the total cohort were adult patients. After obtaining written permission 
from the parents or legal representative for participation in this study, patients were 
invited to visit the department of human genetics at the Radboud University 
Nijmegen Medical Centre for an extensive multidisciplinary clinical evaluation. 
Specific DNA diagnostic tests were requested when indicated. In all patients 
genome wide SNP (Single Nucleotide Polymorphism) array analysis was performed 
according to the standard Affymetrix GeneChip protocol  (Affymetrix, Inc., Santa 
Clara, CA, USA). In eight patients the Affymetrix 250k array platform was used and 
in one patient (patient 7) the Affymetrix 2.7 M array platform. Copy number estimates 
were determined using the updated version 2.0 of the CNAG (Copy Number 
Analyzer for Affymetrix GeneChip mapping) software package (Affymetrix 250k 
SNP array) or the ChAS (Chromosome Analysis Suite for Affymetrix GeneChip 
mapping) software package (Affymetrix 2.7M array). The normalized ratios were 
subsequently analyzed for genomic imbalances by a standard Hidden Marker 
Model (HMM). CNVs were mapped according to the UCSC genome browser build 
May 2004 (NCBI35/Hg17) for the Affymetrix 250k array platform and to build March 
2006 (NCBI36/Hg18) for the Affymetrix 2.7M array platform. 
All patients underwent screening metabolic tests in urine and serum as well, 
including quantification of lactate, amino acids, creatine biosynthesis, carnitines, 
organic acids, purines and pyrimidines, and transferrin subfractions.
Segregation analysis
When possible, segregation of genetic/chromosomal variants was tested in the 
parents and/or other family members by SNP array, Multiplex Ligation-dependent 
Probe Amplification (MLPA), Fluorescence In Situ Hybridization (FISH) or sequencing 
of the involved gene. 
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speech. His behaviour  was characterized by severe pica behavior, including the 
drift to ingest soft objectives such as socks. Several times he underwent a 
gastroscopy to remove socks from his stomach. To prevent further ingestion 
incidents, he was prescribed to wear a helmet with face mask. In addition he 
showed hyperactive and self mutilation behaviours and he had a high threshold of 
pain. During puberty he frequently had outbursts of crying, but later on he was 
generally in a happy mood. Apart from an atopic constitution presenting with 
allergy, asthma and eczema, his general health was quite good. After a fall at the 
age of 36 years, in addition to a fresh compression fracture of the twelfth thoracic 
vertebra, multiple old fractures, including metacarpal, humeral and femoral 
fractures, were detected and he was diagnosed with  osteoporosis. Ophthalmo-
logical evaluation revealed myopia. Upon physical examination at the age of 40 
years his height was 173 cm (>2nd centile), weight 56 kg (16th centile) and head 
circumference 53.5 cm (0.6th centile). He showed evident facial dysmorphism 
including remarkable prognathism, a broad nose with full tip, hyperplastic alae 
nasi, broad mouth with downturned corners and widely spaced teeth (fig. 1C-D). 
The chest was asymmetric with a mild pectus excavatum and he had a mild left 
convex scoliosis. His feet were flat and both hands showed short fifth fingers and 
tapering of the fingers with concave nails (fig. 2A-B). On the right hand a single 
palmar crease was present. He preferred to sit on the ground with his legs sideward 
rotated to the left. He had difficulties to stand up from this position and showed a 
mildly increased muscular tone. Chromosomal analysis by 250k SNP array analysis 
was normal and screening metabolic tests revealed no abnormalities. Because of 
some facial characteristics of Pitt Hopkins syndrome, mutation analysis of TCF4 
was requested and revealed a known pathogenic mutation (c. 1739G>A (p.
Arg580Gln)). Segregation analysis in the parents showed that the mutation had 
occurred de novo.
Patient 3: familial MECP2 mutation
This male patient was ascertained at the age of 27 years. Pregnancy and birth were 
uncomplicated. Birth weight was 3750 grams (50th-75th centile). After the age of 24 
months his parents noticed a delay in his psychomotor development. He was able 
to walk independently between age 2 and 2.5 years and could speak a few single 
words. At the age of about 12 years he had developed tonic clonic seizures. 
Seizures persisted on anti-epileptic drug treatment with a frequency of 1-2 times a 
day. Cerebral imaging by a CT scan at that time and later at adult age by MRI 
revealed no abnormalities. At adult age his total IQ level as assessed by the WISC 
was 33. His behaviour was characterized by lack of initiative and he was very calm, 
introverted and friendly. He had features of autism spectrum disorder and periodic 
tics. Since his early twenties he showed a progressive decline in general functioning, 
Patient 2: Pitt-Hopkins syndrome (TCF4) 
This male patient was ascertained at the age of 40 years. He was born at term after 
an uneventful pregnancy and delivery. Birth weight was 3200 grams (>20th centile). 
His psychomotor development was severely delayed. He was able to sit independently 
since the age of 4 years and able to walk at 8 years of age. He did not develop 
Figure 1   Clinical pictures, A and B show the typical facial features of  
Kleefstra syndrome in patient 1. Note the midface hypoplasia, 
arched eyebrows and prognathism. C and D show the typical facial 
appearance of Pitt Hopkins syndrome in patient 2. Note the coarse 
face with prognathism, broad mouth with down turned corners and 
large nose. E-H show patient 3 with a mutation in MECP2 (E-F) and 
his carrier sister (G-H). I-J show patient 4 in whom we identified a 
mutation in CDKL5. Note her coarse face. K-N show patient 5 (K-L) 
and 6 (M-N) with Dravet syndrome. O-P show patient 7 with 
 Phelan-McDermid syndrome. Note the long face and full lips.  
Q-T show the brother pair with Phelan-McDermid syndrome.  
Note the long face, prominent chin and large ears in both brothers.
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The family history mentioned learning disabilities in the mother and his 3 years 
younger sister. The mother was admitted to a psychiatric hospital because of severe 
psychiatric problems. His sister had followed special education. At the age of 24 
years she was employed as a packer at a distribution office and lived independently 
together with her husband. On physicial examination she had a height of 167 cm (25th 
centile), a weight of 76 kg (90th centile) and a head circumference of 54.3 cm (20th 
centile). She had no evident dysmorphic features (fig. 1G-H). 
Chromosomal analysis by 250k SNP array analysis and screening metabolic tests 
revealed no abnormalities. Because of the deterioration in functioning, neurological 
symptoms and a family history suggestive for an X-linked inheritance pattern, mutation 
analysis of both ARX and MECP2 was performed. This revealed a pathogenic 
hemizygous late truncating mutation in MECP2 (c.1233_1243del (p.Ser411fs)). 
Segregation analysis showed an identical heterozygous mutation in the sister. 
Mother was not available for testing. 
Patient 4: Rett syndrome variant with infantile spasms (CDKL5)
This female patient was diagnosed at age 47 years. Pregnancy and birth were 
uncomplicated. The first six months of her life she was doing well. At the age of six 
months she developed seizures and since then she had a delay in psychomotor 
development. Her motor development was only mildly delayed, however, she never 
learnt to speak. At adult age her ID was profound. The seizures persisted during her 
life span and despite treatment with multiple anti-epileptic drugs she suffered from 
frequent (atonic) seizures. In addition she developed a mild spasticity. She had a 
friendly personality and her behaviour was characterized by hyperactivity, self 
mutilation and no sense of fear. At the age of 40 years a cerebral CT-scan -which 
was made because of a fall from a horse- showed signs of hypoplasia of the corpus 
callosum. The family history documented ID due to rhesusantagonism in two sons 
from two different brothers from the father. Upon physical examination at the age of 
47 years she had a height of 162.5 cm (<16th centile), a weight of 45 kg (2nd centile) 
and a head circumference of 53 cm (< 16th centile). She had prominent cheekbones, 
a mild prognathism, deep-set eyes and blepharochalasis. The ears seemed to be 
slightly high positioned and she had a full upturned nose with hypertrophic alae 
nasi. The lips were full and she missed several teeth due to caries (fig. 1I-J). She 
had thin limbs and small hands. Her feet showed slight clino-and syndactyly of the 
second and third toes. Chromosomal analysis by 250k SNP array analysis was 
normal and screening metabolic tests revealed no abnormalities. Because of the 
severe ID combined with persistent therapy resistant seizures and the Rett 
syndrome-like phenotype, mutation analysis of MECP2, CDKL5, FOXG1 and SCN1A 
was performed and a pathogenic splice site mutation in intron 7 of CDKL5 was 
found (c.464-1G>A). Segregation analysis in de parents was not performed.
including loss of speech (before he was able to talk in 2-3 word sentences), 
progressive neurological symptoms including walking difficulties with frequent 
falling, tremors of both arms, and apathy (showing significantly less initiative than 
before). He needed more help in self care as well. During the nights he frequently 
awakened and wandered around. After the start of anti-depressive drug treatment 
he seemed to improve a little, but did not regain his former level of functioning. On 
physical examination at the age of 27 years he had a height of 176 cm (16th centile), 
a weight of 51.5 kg (2nd centile) and a head circumference of 57 cm (25th-50th centile). 
He had a mild brachycephaly and a long face with a pronounced chin. Other 
dysmorphic features included a full upturned tip of the nose and a broad mouth 
with full lips and everted lower lip (fig.1E-F). He had narrow feet and hands with 
slender digits. His muscular tone was generally slightly increased and the reflexes 
were symmetrically brisk. There was a generalized muscular atrophy and a tremor 
of the arms. 
Figure 2   Clinical pictures, A and B show clubbing of toe and finger nails in 
patient 2 with a mutation in TCF4. Figures C and D show 2-3 toe 
syndactyly in patient 7 who was diagnosed with Phelan-McDermid 
syndrome.
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delay. At the age of 36 years conventional karyotyping and tests for Fragile X 
syndrome and Angelman syndrome were all normal. Upon physical examination at 
age 49 years his height was 175 cm (10th centile), weight was 72.5 kg (84th centile) 
and head circumference was 57.4 cm (<50th centile). He had minor facial 
dysmorphism including a high forehead, large lop ears, a prominent philtrum and a 
full lower lip. His teeth had been removed because of caries (fig. 1M-N). On the feet 
he had a clinodactyly of the second toe and a cutaneous syndactyly of the second 
and third toes. His motor function was clumsy and he had mild spasticity. 
Chromosomal analysis by 250k SNP array analysis and screening metabolic tests 
revealed no abnormalities. Because of his severe ID and intractable seizures 
mutation analysis of SCN1A was performed and revealed a frameshift mutation in 
exon 7 leading to a premature stop codon (c.3526delG (p.Glu1176fs)). Parents were 
not available for segregation analysis.
Patients 7, 8 and 9: Phelan-McDermid syndrome (22qter deletion)
Patient 7
This male patient was ascertained at the age of 48 years. He was born as the fifth 
child of his parents. Pregnancy, delivery and perinatal period were not remarkable. 
During his second year parents had noticed a delay in his psychomotor development. 
He learnt to walk significantly later than his siblings. His speech did not develop. At 
adult age his ID was severe. His behaviour was not remarkable and he had good 
social interactions. An abnormal breathing pattern, including intermittent irregular 
and rapid breathing was observed. At the age of 27 years he was diagnosed with 
hyperthyroidism and treatment with Strumazol and Thyrax was started, but otherwise 
his general health was good. His vision was reported to be mildly impaired due to 
mild myopia and a slightly limited visual field of unknown cause. Since the age of 
45 years his general functioning had declined remarkably after an hospital 
admission because of severe pneumonia complicated by respiratory insufficiency. 
He was no longer able to walk, had feeding problems due to swallowing difficulties 
and became dependent on tube feeding. Contact making and social interaction 
diminished and he also developed seizures. Cerebral imaging by both CT scan and 
MRI scan showed normal brain anatomy apart from mild enlargement of the cisterna 
magna and central atrophy. The family history reported mild learning and behaviour 
problems in an older sister and severe intellectual and physical disability in a son of 
a brother of father.
Upon physical examination at age 48 years height was on the 50th centile. Head 
circumference and weight were on the 80th centile. Facial appearance was coarse 
with bushy eyebrows, a short philtrum, a broad mouth with very full lips and widely 
placed dentition and he had large ears (fig. 1O-P). He had evident syndactyly of the 
second and third toes, with on the right side nearly complete fusion of these toes 
Patients 5 and 6: Dravet syndrome (SCN1A)
Patient 5
This male patient was diagnosed at age 34 years. He was born at term after an 
uncomplicated pregnancy and birth. Birth weight was 4000 grams (<90th centile). 
The first 5 months of his life he was doing well. At age 5 months he developed 
seizures after vaccination. Since then he had regularly absences but developed 
normally according to his parents. At the age of two years seizure frequency 
increased and his speech gradually declined. At three years of age he had a status 
epilepticus followed by a coma state of several days. After awakening he had a 
severely retarded psychomotor function and furthermore a right hemiplegia and 
was no longer able to sit or walk. Gradually the hemiplegia partially recovered and 
he learnt to walk again, though he did not regain the ability to speak. The epilepsy 
persisted throughout his life and he suffered from intractable seizures (for which he 
wore a helmet), despite treatment with multiple anti-epileptic drugs. At adult age he 
had a profound ID (age equivalent 10-18 months). His behaviour was very friendly 
and characterized by little initiative, obsessive traits and a self mutilation (pulling 
out his nails). He had a very high threshold of pain. He recurrently had upper and 
lower airway infections. Upon physical examination at age 34 years his height was 
193 cm (90th centile), his weight 84 kg (>50th centile) and his head circumference 59 
cm (80th centile). He had a slight micrognathia and several scars on his face due to 
recurrent epileptic falls. The ears were large and the lips full, but his appearance 
was not quite dysmorphic (fig. 1K-L). He was able to walk but he was somewhat 
hindered in his motor function by a mild right-sided hemiplegia. Chromosomal 
analysis by 250k SNP array analysis was normal and screening metabolic tests 
revealed no abnormalities. Because of the severe ID and intractable seizures 
mutation analysis of SCN1A was performed and revealed a pathogenic mutation in 
exon 26 (c.5304T>G (p.Ser1768Arg)). Segregation analysis in the parents showed 
that the mutation had occurred de novo.
Patient 6
This patient was ascertained at age 49 years. Pregnancy and birth were uneventful. 
He developed seizures after vaccination at about six months of age. His psychomotor 
development was delayed. Motor milestones were only  mildly delayed according 
to his brother. Speech development was more severely delayed and he only learnt 
to speak a single word. At adult age he had a severe ID, but had a good mobility. 
The epilepsy (mixed seizures) persisted throughout his life despite  treatment with 
multiple anti-epileptic drugs. Seizures were provoked by psychological stress 
and constipation. He had a friendly personality and loved to get attention. Ophthal-
mological evaluation revealed a high hypermetropia and a substantial astigmatism. 
The family history of the mother was positive for epilepsy without developmental 
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outbursts as well as periods with apathy. Now and then he had sleeping difficulties 
with awakening and wandering during the night. He was diagnosed with a bipolar 
mood disorder as well. At young age he underwent an operation because of 
cryptorchidism and phimosis. His general health condition was good. Upon 
physical examination he had a normal height (185 cm, 50th centile) and weight 
(50th-75th centile), and a small head circumference on the 2nd centile (54 cm). He had 
a brachycephaly. Just as his brother he had a prominent chin and large ears. In 
addition he had a left sided epicanthal fold, a subtle bifid point of the nose and 
horizontal ear lobe creases (fig.1S-T). He had a similar posture like his brother, 
including an increased lordosis of the lumbar spine. 
Brain MRI showed in both brothers hypoplasia of the cerebellar vermis, an enlarged 
cisterna magna, and mild enlargement of the lateral ventricles.
Chromosomal analysis by 250k SNP array analysis identified an identical terminal 
loss of 2.12 Mb in chromosomal region 22q13.32q13.33 (47,35-49,47 Mb) in both 
brothers. Chromosomal analysis in blood lymphocytes from the parents both by 
SNP array analysis and FISH analysis with probes localized on chromosomal 
regions 22q11 and 22q13, gave normal results. To further investigate the probability 
of presence of the 22qter deletion in a mosaic pattern in one of the parents, we 
performed additional FISH experiments in buccal cells of the parents as well. 
Indications for a mosaic pattern in the parents were not found.
Evolution of phenotypes in present and previous cases
Kleefstra syndrome
Adult patients with Kleefstra syndrome have rarely been reported before.8, 20-22 Table 1 
summarizes the phenotypic features of the present and 8 previously reported adult 
patients diagnosed with Kleefstra syndrome. Developmental outcome varied from 
moderate to severe ID. Most patients have little speech ability, though mostly very 
primitive. Five out of seven patients (in two patients presence of regression was not 
reported) showed some kind of regression during adolescence or adulthood, 
which was in three patients reported to be associated with a concurrent striking 
behavioural change including periods of diminished responsiveness, hypoactivity, 
passivity and catatonic phenomena. Five out of nine had (a history of) seizures, 
though in general not very severe. All adult patients had the typical facial features 
of Kleefstra syndrome. In the present patient the facial features were the major clue 
to the diagnosis in addition to the characteristic regressive behavioural pattern with 
onset at adult age. Microcephaly was present in four out of nine patients, three out 
of six had a short adult height and three out of seven patients presented with 
obesity. In conclusion, most important diagnostic clues at adult age seem to be the 
typical facial features and behaviour pattern which might be associated with 
regression of general functioning. 
(fig. 2C-D). He was wheelchair dependent and showed hypertonia with spastic 
posture of the hands and feet. Genetic tests included chromosomal analysis by 
2.7M SNP array analysis and mutation analysis of TCF4, because of clinical 
similarities with Pitt Hopkins syndrome. 2.7 M SNP array analysis identified a 1.8 Mb 
loss in chromosomal region 22q13.32q13.33 (47,782,571-49,543,031 Mb). Parents 
were not available for chromosomal analysis. Mutation analysis of TCF4 revealed 
no abnormalities. 
Patients 8 and 9 
This brother pair was ascertained at the age of 31 and the age of 29 years 
respectively. Both were born after an uneventful pregnancy and delivery and had 
normal birth parameters. During the neonatal period the older brother (patient 8) 
was treated with phototherapy because of hyperbilirubinaemia. He was a very quiet 
baby. Since birth he had a mild spasticity of his right leg. He was treated with splints 
because of inverted position of his ankles. His psychomotor development was 
delayed. He was able to sit and walk independently respectively at the age of 12 
months and 24 months. Speech development was delayed, but he learnt to speak 
simple sentences. Since childhood he had intermittently high levels of bilirubin and 
was diagnosed with Gilbert syndrome. At child age he underwent an unilateral 
orchidopexy because of torsio testis and his phimosis was corrected.  At adult age 
he had a moderate to severe ID. He was diagnosed with a bipolar mood disorder. 
During depressive episodes he suffered from sleeping disorders and refused to 
eat. In general his behaviour was friendly, but regularly he showed aggressive 
behaviour. Social interaction was good. Upon physical examination at the age of 31 
years he had a high normal height (190 cm, 75th centile), and a normal weight 
(50th centile) and head circumference (20th centile). Hands and feet were large- 
ormal. Facial characteristics included a long face with prominent chin and large 
ears (fig. 1Q-R). He had an increased lordosis of the lumbar spine which was 
suggestive for muscular hypotonia of the trunk. The feet were slightly inverted.   
In contrast to his brother the younger brother (patient 9) was an hyperactive baby 
with poor contact making. Since he was two months of age his parents noticed that 
he developed abnormally. The motor development was mildly delayed with sitting 
independently at age 13 months and walking independently at 20 months of age. 
Speech development was more severely delayed with the first single words at age 
4 years. With age his social interaction improved and he had good contact with his 
parents, brother and care-takers, however contact with housemates was limited. 
He showed mild features of autism spectrum disorder, including obsessive 
behaviours. His developmental level was somewhat lower than his brother’s and 
corresponding with a developmental level of a two to three year old child. His mood 
and behaviour were changeable, including periods with hyperactivity and aggressive 
206 207
chapter 4 further phenotypic delineation of well known id syndromes
4
Table 1   Clinical features in present and previously reported patients with  
(genetically confirmed) Kleefstra syndrome. 
Present patient References previous reports
 
Total
8 20-21 22, 41 22
Number of adults 1 1 6 4 (excl. present patient 1) 1 (other 2 adults are included in 41)  13
Genetic defect EHMT1 mutation: c.3087 
+1 G >T
Microdeletion 6/6 microdeletion 3/4 microdeletion
1/4 EHMT mutation
Microdeletion 11/13 microdeletion
2/13EHMT1 mutation
Age, years 41 36 20–59 18-32 19 18–59
Gender f F 4 m, 2 f 3 f, 1 m f 5 m, 8 f
Developmental 
 outcome
moderate ID, some 
speech
severe ID 6/6 variable ID Moderate--severe ID Moderate ID 13/13 moderate--severe ID
Motor symptoms Focal myclonic twitches 
shoulder, fixed flexure 
arms and hands 
NR 1/2 progressively immobile
1/2 frequent myoclonic twitches, slight 
hypertonia
fixed flexure arms and hands in 2/2
1/4 rigid flexure of the arms and 
hands
Slow, perseverative and clumsy 
motor functioning at adult age
In two patients myoclonic 
twitches
In 1 patient immobility
In 4 fixed flexure extremities
Regression (of psycho-
motor function)
+ NR 3/5 1/4 + 6/11
Behavior/psychiatric Impulsivity and aggressive 
outbursts. Around age 
38 remarkable behavior 
change: periods of apathy, 
decreased emotional 
responsiveness, staring, 
low motor activity, stupor, 
and sleep disturbance
+, not further 
specified
2/5 aggression
2/5 sleep disturbance
3/5 passive periods
2/5 mood disorder
2/2 stereotypic orofacial movements
3/5 increase of behavior problems/
temporary regression during teenage 
years
2/2 during midlife occurrence of  bizarre 
and distinct posture,  hypoactivity, 
minimal emotional response, lack of 
initiative, and staring
1/4 sleep disturbance 1/4 
 stereotypies
2/4 mood disorder
1/4 hyperactivity
1/4 increase of behavior 
 problems during teenage years 
with progressive inactivity and 
catatonic features
Sleep disturbance
Increase of behavior problems in 
adolescence with later on general 
inactivity and irritability 
Stereotypies
Variable behavior problems 
in all; temporary  (behavioral) 
 regression/increase of 
 behavioral problems during 
adolescence; onset of typical 
behavior pattern at middle age 
including periods with passivity, 
decreased responsiveness and 
hypoactivity in a subset. 
Seizures – + 4/6 2/4 - 7/13
Recognizable facial 
features
+ + + + + present in all
Medical problems,  
age of onset  
(when documented)
Hypertrophy of the left 
ventricle and paroxysmal 
atrial fibrillation, diagnosed 
around age 40 years
NR 1/6 scoliosis
1/6 severe GOR with weight loss
1/6 pyloric stenosis
1/6 death with unknown cause at  
age 21
2/4 frequent respiratory infec-
tions/aspiration,
1/4 mild pulmonic regurgitation 
as an adult
1/4 scoliosis
Ventricular septum defect 3/12 cardiac
2/12 scoliosis
2/12 gastro-intestinal
1/12 early death
2/12 recurrent respiratory 
 problems
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MECP mutations in males
MECP2 mutations are involved in Rett syndrome. Initially it was thought that Rett 
syndrome occurs exclusively in females due to lethality of hemizygous mutations in 
males. Though, after the identification of the MECP2 gene in 1999, several MECP2 
mutations have been detected in males as well. The phenotypic variability in males 
with MECP2 mutations is wide and roughly three groups of phenotypes can be 
observed: 1) classical/atypical Rett syndrome occurring in males with a classical 
Rett syndrome mutation in mosaic pattern or in males with an XXY karyotype 2) 
severe congenital encephalopathy, mostly associated with a mutation that causes 
Rett syndrome in females and 3) a broad group with wide phenotypic spectrum 
including variable levels of ID and variable occurrence of other neurological and/or 
psychiatric disorders.23-25 The phenotypes caused by MECP2 duplications are not 
considered here. Mutations that cause the classical Rett syndrome phenotype in 
females are considered to be either prenatally lethal in males or leading to severe 
congenital encephalopathy and early death.26 The present patient can be assigned 
to the third group. Several males from X-linked ID families and single male patients 
with a phenotype fitting in the third group have been reported before.27-30 Frameshift/
truncating mutations, as observed in the present patient infrequently have been 
reported in males before (2 previous reports).23 31 Adult phenotypes of present and 
Pitt Hopkins syndrome
The present patient is the oldest reported patient with Pitt Hopkins syndrome (PHS). 
As far as we know, 7 adult patients with genetically confirmed PHS have been 
reported in previous studies (Table 2). All adults with PHS had a severely impaired 
developmental outcome. A minority suffered from seizures that presented at 
childhood age. Late-onset seizures were not reported, suggesting that if seizures 
develop, they present at young age. Medical problems were relatively mild, 
including mainly constipation, scoliosis and aspecific ocular problems, though one 
patient died prematurely from pneumonia. Motor functioning was mildly impaired in 
some cases. Reported behavioural problems are diverse, but most patients have a 
happy disposition. Among this small group of adults with PHS there are no 
indications for significant regression at adult age. The typical facial characteristics 
persist during adult age. In the present patient his facial gestalt was the clue to the 
diagnosis. In general, the combination of the typical facial characteristics, severe 
ID, the breathing pattern with periods of hyperventilation followed by apnoea, and 
the clubbing of finger and toe nails might suggest the diagnosis PHS in adults.  
 
 
Table 1   Continued.
Present patient References previous reports
 
Total
8 20-21 22, 41 22
Adult growth 
 parameters
head circumference normal Normal 3/6 microcephaly 1/3 microcephaly microcephaly 5/13 microcephaly
height normal NR 2/4 short stature 2/4 short stature Short stature 5/10 short stature 
weight obesity Obesity 1/5 obesity 1/4 obesity obesity 5/12 obesity
Other brain MRI: poorly defined 
abnormal white matter 
signal intensities, manly 
localized deep in the 
parietal lobe, bilaterally 
abnormal signal intensity 
in the globus pallidus
Brachydactyly 1/6 hearing loss
2/6 cryptorchidism
1/6 VUR
3/5 minor anomalies on brain MRI: 1/5 
small pons, 1/5 prominent Virchow-
Robin spaces, 1/5 asymmetry of ante-
rior horns
1/4 Hearing loss
1/4 brachydactyly
1/4 hyperopia
1/4 cryptorchidism
1/3 white matter lesions, corpus 
callosum hypoplasia
- 5/10 variable anomalies on 
brain MRI
NR = not reported; GOR = gastro-oesophageal reflux; VUR = vesicoureteral reflux
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Table 2   Clinical features in present and previously reported patients with  
(genetically confirmed) Pitt Hopkins syndrome. 
Present patient References previous reports Total
9 42 43
Number of adults 1 2 3 1 7
Genetic defect TCF4 mutation: c.1739G>A TCF4 mutations: c.1153 C>T and 
IVS9–1G>C
TCF4 mutations: c.1699A>T, 
c.469C>T, c.1073G>T 
64-kb microdeletion 18q21.2 6 TCF4 mutations, 1 small 
microdeletion
Age, years 40 29 18--20 19 18--40
Developmental outcome severe ID severe ID severe ID severe ID severe ID
Motor symptoms mild hypertonia 1/2 ataxia 
1/2 wide based walking pattern 
1/3 ataxia walks with assistance 2/7 ataxia, 1/7 hypertonia
Regression
(of psychomotor function)
– NR NR NR never reported
Behavior/psychiatric happy disposition, pica 1/2 very anxious, self mutilation 2/3 happy disposition
1/3 violent outburst, stereo-
typies
happy disposition, bangs on 
objects, sleeping problems
mostly happy disposition, but 
diverse behavior problems do 
also occur
Seizures – – 1/3, since 9 months of age – 2/7, onset during childhood
Recognizable facial 
 features
+ + 2/3 +
1/3 +/–
+ 7/7
Medical problems, age of 
onset (when documented)
myopia, scoliosis, osteoporosis 
and atopic constitution, onset in 
childhood
1/2 severe constipation, and 
 strabismus in, onset NR
1/2 lymphoma and dislocated hip, 
onset NR
2/3 constipation, scoliosis
1/3 myopia, strabismus
strabismus, myopia constipation, scoliosis, and 
aspecific ocular problems in 
several patients
Adult growth parameters
head circumference P0.6 2/2 <P3 2/3 <P3, 1/3 normal P50 5/7 microcephaly
height  >P2 2/2 <P3 NR P10–25 3/4 short stature
weight P16 2/2 <P3 NR P60 2/4 underweight
Abnormal breathing  
patterna
– 2/2 2/3 +, breath holding 5/7
Other finger and toe nail clubbing finger and toe nail clubbing in 1/2 NR NR 2/3 nail clubbing
NR = not reported.
P = Percentile.
a Comprising periods with hyperventilation followed by apnoea.
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problems were secondary to neurological problems. Behaviour symptoms included 
Rett-like behaviours, such as (hand)stereotypies.
Dravet syndrome 
In contrast to the other reported syndromes in the present study, follow-up of Dravet 
syndrome patients into adulthood has more often been documented before.39-40 
The phenotype of 37 adult patients, including the present two patients, is 
summarized in table 5. Age ranged from 18 to 49 years. The majority had a poor 
developmental outcome with severe ID in more than 80%. Seventy-five percent had 
motor symptoms (including pyramidal, cerebellar and extrapyramidal symptoms), 
varying from clumsiness to bedridden. Regression was uncommon. In 86% 
intractable seizures with a history of early onset in the first year of life, persisted into 
adulthood. Behaviour characteristics were not systematically reported, though the 
present two patients both had a friendly and cooperative personality. Medical 
problems were not systematically reported. 
Poor developmental and seizure outcome in combination with motor symptoms, 
but lack of other specific features might be indicative of Dravet syndrome in adult 
male and female patients.
Phelan-McDermid syndrome
Clinical features of the present patients and 15 previously reported adult patients 
are summarized in Table VI. Age ranged from 19 to 48 years. The present patient 7 
is the oldest patient reported. Developmental outcome varied from mild to severe 
ID. Most patients did have some speech ability. We observed a tendency to 
deterioration in  motor functioning above the age of 40 years, including presence of 
pyramidal signs. The present patient 7 showed a severe decline in motor functioning, 
as well as in cognitive and health performance.
About half of the patients did at least have one seizure during lifetime, but severe 
seizure disorders were not reported. The majority of the adult patients had variable 
behaviour problems, including autistic behavioural features, though in some 
patients these seemed to improve with age. Other features that were more frequently 
reported included a long face and large ears, large and/or slender hands/feet and 
hypotonia with/without lumbar lordosis. 
In four patients, including the present patients 8 and 9, results of cerebral imaging 
by MRI were reported. Interestingly, in three of these patients similar anomalies, 
comprising cerebellar vermis hypoplasia, enlargement of the cisterna magna and 
dilatation of ventricles were observed.
23 previous cases are summarized in Table 3. Age ranged from 21 to 56 years. All 
have an impaired developmental outcome, though varying from mild to profound 
ID. From these data a significant phenotype-genotype correlation with respect to 
the degree of ID cannot be observed. In two of the families reported, identical 
mutations lead to a developmental level varying from mild to severe disability.29, 32-33 
Almost all patients showed evident motor/neurological symptoms, as tremors 
(46%), pyramidal signs (58%) and in two patients ataxic signs were observed. 
Interestingly, in one family tremors were reported in the carrier females as well.29, 33 
Almost 30% of the males showed regression in functioning at adult age. One third 
of the patients had seizures, with the exception of one, onset was reported at 
childhood age. A majority (64%) had microcephaly and short stature (67%). One 
out of six developed kyphosis/scoliosis with age. Many were reported to have a 
friendly and cooperative behaviour, though a few patients showed aggressive 
outburst. Mood/depression and anxiety disorders were frequently observed. A 
subset of the patients had a passive, inactive personality and some were shy/
introverted in social interaction. In conclusion, clue features that might indicate 
presence of a MECP2 mutation in adult males are: variable ID in combination with 
neurological symptoms, including pyramidal signs and tremors, mood and anxiety 
disorders and possibly regression at adult age. Facial features are not remarkable 
and do not contribute to the diagnosis.
Rett syndrome variant with infantile spasms (CDKL5 mutations)
The present patient is the oldest patient with a mutation in CDKL5 reported. Table 4 
summarizes the clinical features of the present and 9 other adult female patients.7 
34-38 The developmental outcome is very poor. Remarkably, in one patient (twin 
sister of severely affected patient) the developmental level was reported to be only 
mildly impaired.38 Six out of ten patients were not able to speak. All patients showed 
motor symptoms, including mostly pyramidal signs, but also cerebellar symptoms 
were reported. Secondary locomotor tract deformities including scoliosis and/or 
contractures were present in six out of eight patients. Five out of nine patients 
had signs of autonomic dysregulation (intestinal symptoms, breathing anomalies 
and vasomotor disturbance). Regression was reported in 4 out of 10 patients. 
Seizure outcome was very poor. Nine patients suffered from persistent intractable 
seizures into adulthood. Behaviour characteristics that were frequently present 
included (hand) stereotypies and poor social interaction. Sleeping problems were 
documented in four patients. Small hands and/or feet were also more often reported 
(in 4/7). 
In conclusion, the consistent clinical features at adult age included a very poor 
developmental and seizure outcome in combination with other neurological signs 
including pyramidal tract and cerebellar signs and autonomic signs. Major health 
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Table 3   Clinical features of present and previously reported male patients with ‘mild’  
MECP2 mutations that do not cause classical Rett syndrome in female patients  
or severe neonatal encephalopathy/prenatal death in males. 
Present patient References previous reports Total 
29, 32-33  (MRX16) 30, 33  (T44) 29, 33  (T36) 28   (X307, MR48, MR50, 
X308)
44-45 27, 46
Number of adults 1 7 3 4 4 4 1 24
Mutation/domain frameshift: 
c.1233_1243del 
(p.Ser411fs)/ 
C-terminus
missense: 
c.410A>G 
(p.Glu137Gly)/MBD
in frame deletion 
c.1161_1400del/ 
C-terminus
missense: 
c.499C>T 
(p.Arg167Trp)/ 
Co-repressor 
 interacting region
missense: c.493 C>T 
(p. Ala140Val)/MBD
missense: c. 493 C>T 
(p.Ala140Val)/MBD
nonsense: c.1216 
C>T (p.Glu406X)/C-
terminus
19/24 missense
1/24 nonsense,
1/24 frameshift,
3/24 in frame deletion
5/24 in MBD 
5/24 in C-terminus
4/24 in co-repressor interacting 
region
Age, years 27 21--56 24—55 25--50 27--40 25—41 39 21--56
Developmental 
 outcome
severe ID 6/7 mild/ 
moderate ID
1/7 profound ID
1/3 mild ID
1/3 moderate ID
1/3 severe ID
4/4 mild ID 4/4 severe ID 4/4 moderate ID severe ID 24/24 variable ID
Motor symptoms mild spasticity, 
hypertonia, brisk 
reflexes, generalized 
muscular atrophy; 
frequent falling; 
 resting tremor.
5/6 hyperreflexia 
(1 NR)
1/3 hypertonia 3/4 resting tremor
3/4 hyperreflexia
1/4 ataxia
4/4 resting tremor 3/4 resting tremor
3/4 hyperreflexia
2/4 hypertonia
spasticity, hyperre-
flexia, choreoathetotic 
movemements, ataxic 
gait
11/24 tremor
14/24 pyramidal signs
2/24 ataxia
Regression (of 
 psychomotor function)
+, global decline 
since early twenties
4/6 language 
 egression 
– 1/4 deterioration of 
articulation
– – +, around age 30 mo-
tor decline/progressive 
spasticity
7/24
Behavior/psychiatric passiv-
ity, lack of  initiative, 
 cooperative, calm, 
shy and friendly; 
depression, sleep 
disturbance
4/7 introvert/ 
timid/ shy
3/7 anxiety
2/7 passivity/ 
slowness
1/3 irritabil-
ity,  depression, 
 emotional 
 disturbance
1/3 poor contact 
and violence
1/3 shy, quiet, 
 anxious, and 
 attention problems
3/4 pleasant
1/4 aggression
1/4 anxiety
slow, friendly 3/4 depression
2/4 aggression
NR 6/23 shy/timid
10/23 mood/anxiety disorder
4/23 aggression
4/23 passivity/hypoactivity
Seizures +, grand mal, onset 
age 12
1/7, single seizure 1/3 2/4 NR 1/4 +, grand mal onset 
age 27
7/20
Recognizable facial 
features
– – – NR NR – – Not present
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Table 3   Continued.
Present patient References previous reports Total 
29, 32-33  (MRX16) 30, 33  (T44) 29, 33  (T36) 28   (X307, MR48, MR50, 
X308)
44-45 27, 46
Medical problems, 
age of onset (when 
documented)
– 1/7 severe  
myopia
3/7 kyphosis/ 
scoliosis
NR NR NR 1/4 congestive heart 
failure, onset age 39
1/4 kyphoscoliosis 
bilateral cataract 
age 30, episodes of 
 unexplained diarrhea; 
death at  age 39 from 
pneumonia
variable, 
4/24 kyphosis/scoliosis
Adult growth  
parameters
head circumference P25–P50 3/7 <P3 1/3 normal, 2/3 NR 2/4 <P3 4/4 normal 4/4 normal Normal 5/22 <P3
height P16 6/7 <P3 2/3 normal, 1/3 NR 4/4 <P3 NR 2/4 short stature NR 12/18 short stature
weight P2 >P98 in 2/5 NR 3/4 obesity NR 1/4 obesity NR 6/14 obesity
Other – – – – – macro-orchidism, 
pyramidal signs
siallorhoe no consistent other features
Family history learning disabilities 
in mother and sister, 
mother has severe 
psychiatric prob-
lems
patients are from the 
same family,  carrier 
females all normal ]
intelligent
4 affected males in 
one family, no infor-
mation about carrier 
females
progressive tremor 
in 2 carrier females, 
normal intelligence 
in carrier females
mother and carrier 
sister have mild ID
mother low intelligence borderline intelli-
gence in 1 of 2 carrier 
 females; severe ID in 
nephew
all familial cases; 
in 4/6 families carrier females 
have mild ID/learning difficulties 
(NR in 1 family)
MBD = methyl binding domain; P = Percentile; MRX/T/X/MR numbers refer to the family identification numbers in 
the original papers
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Table 4   Clinical features in present and previously reported patients with  
CDKL5 mutations.
Present patient References previous reports Total
38 38 7 34 35-36 37
Number of adults 1 2 1 2 1 2 1 10
Mutation c.464-1G>A c.183delT IVS13-1G>A 525A>T (R175S) c.del2362_2366 C1892.1893dupTA/
c.229delGAAG
Del exon 1a–3
Age, years 47 19 (twins) 28 41 (twins) 18 19, 26 20 18--47
Sex f f F f f f f 10 f
Developmental  
outcome
severe ID, no 
speech
Severe ID, no 
speech in twin 1, 
mild ID in twin 2
severe ID, 
no speech
severe ID in both, no 
speech
severe ID, speech in 
phrases
severe ID, first patient 
able to speak 3 word 
sentences, second 
patient no speech
severe ID, no speech 9/10 severe ID
1/10 mild ID (speech is rare)
Motor signs spastic tetraplegia, 
unable to walk with-
out support, ataxia 
wheel chair bound, 
generalized spastic-
ity, hyperreflexia 
(twin 1)
unsteady gait one is wheel chair 
bound, twin sister is 
able to walk since 
age 8 with support. 
In both mild ataxia
motor dyspraxia, 
limited hand skills, 
hypotonia,  but walks 
and swims
unable to walk, limited 
hand skills
wheelchair bound, 
hyporeflexia
10/10, comprising pyramidal 
and sometimes cerebellar 
components
Regression (of 
 psychomotor function)
+, decline motor 
functioning
twin 1: + normal 
development until 
10 mo, then loss of 
skills
+, between age 2--5 
years loss of skills
not significant – – +, between ages 4-7 
years
4/10
Behavior/psychiatric self mutilation, ste-
reotypic movements 
(hand biting), hy-
peractivity, no sense 
of fear
twin 1: poor eye 
contact, hand ste-
reotypies
hand stereotypies, 
dystonia, sleep 
disturbances
hand stereotypies, 
mood swings, little 
eye contact and 
interaction with 
 environment in both
hand stereotypies, 
autism, bruxism, mood 
lability, sleep distur-
bance
hand stereotypies, 
autistic features, sleep 
disturbances (both). 
Bruxism (2)
NR 8/9 hand stereotypies 
6/9 poor social interaction/
autism
4/9 sleep disturbance
Seizures 
onset 6 months 1/2: 9 weeks 6 weeks 10 weeks 2 months 6--12 weeks first 2 weeks of life,
type and severity, 
therapy resistance
atonic, intractable; 
persistent seizures 
despite of multiple 
medication
1/2 infantile spasms, 
later mixeda seizure 
disorder
1/2: no seizures
severe infantile 
spasms, later mixed 
intractable seizures
infantile spasms un-
til 6 months in both, 
later absences (in 
one of the twins)
West syndrome, sub-
sequent severe mixed 
seizure disorder
no infantile spasms
1/2 refractory seizures
1/2 seizure arrest at 2 
weeks
+, mixed, intractable 
and therapy resistent
9/10
9/9 early onset
8/9 persistent severe seizure 
disorder into adulthood
Facial features coarseness NR no dysmorphism NR NR NR coarseness , bilateral 
exotropia
2/3 coarseness (possibly due  
to anti-epileptic medication)
Medical problems, 
age of onset
Pes equin-
ovarus  (related 
to  spasticity), 
 gastrostomy tube
thoracolumbal 
scoliosis
scoliosis progressive 
 dorso-lumbal 
 scoliois in and flexion 
contractures in both
– NR gastrostomy tube 6/8 locomotor tract problems 
secondary to spasticity
2 patients with gastrostomy 
because of feeding difficulties
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Table 4   Continued.
Adult growth 
 parameters
head circumference <P16 1/2 normal NR 2/2 P5--P15 normal 2/2 microcephaly normal 2/9 microcephaly
height <P16 1/2 <P3
1/2 P3–P10
NR NR normal NR normal 1/8 short stature
weight P2 1/2 <P3
1/2 P10–P25
NR NR NR NR normal 2/6 cachexia
Autonomic features constipation 1/2:  breathing 
 abnormalities, 
 peripheral 
 vasomotor 
 disturbance; severe 
constipation
+ episodes of  
hyperventilation, 
abdominal  
distention in both
– 1/2 NR 5/9
Other small hands, corpus 
callosum agenesis
small hand and feet; 
male brother also 
affected, died at 
age 16 of respiratory 
failure
small feet, hirsutism NR NR NR acne, hirsutism 4/7 small hands and/or feet
P = Percentile; a Mixed: tonic-clonic, myoclonic, absences.
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Table 5   Clinical features of present and previously reported male patients with  
genetically confirmed Dravet syndrome.
Present patient 5 Present patient 6 References previous report Total
39 40
Number of patients 1 1 10 25 37
Mutation c.5304T>G (p.Ser1768Arg) c.3526delG (p.Glu1176fs) NR 14/25 missense
5/25 nonsense
6/25 frameshift
Missense > frameshift> 
 nonsense
Age, years 34 49 mean 26 (range 18--47) 18--43 18--49
Gender M m NR 9 males, 16 females 11 males, 16 females, 10 NR
Developmental outcome severe ID, no speech severe ID, very little speech 1/10 normal
4/10 moderate ID
5/10 severe ID
24/25 severe ID
06/25 no speech 
08/25 very limited speech
06/25 single words
04/25 simple speech
01/25 mild ID
31/37 severe ID
04/37 moderate ID
01/37 mild ID
01/37 no ID
Motor symptoms mild right-sided hemiplegia, after 
epileptic state, able to walk
clumsiness, spasticity 5/10 pyramidal 
3/10 cerebellar  
4/10 extrapyramidal
2/10 no motor signs
2/25 bedridden
11/25 clumsy
7/25 ataxia
5/25 no motor signs
30/37 motor signs, comprising 
pyramidal, cerebellar and extra-
pyramidal signs 
Regression +, onset at age 2 years – uncommon 5/25 6/27
Behavior/psychiatric very friendly, little initiative, 
 obsessive traits, self mutilation, 
very high threshold of pain
friendly personality, loves to get 
attention
NR NR 2/2 cooperative and friendly 
personality
Seizures
age at onset 5 months 6 months 3--8 months <first year of life 37/37 onset within first year  
of life
seizure types absences, tonic-clonic mixed at onset: 1/10 myclonic ,4/10 
generalized tonic-clonic, 5/10 
febrile; later: mixed seizures in 
8/10 (tonic-clonic, absences, 
mycoclonic, partial)
generalized at adult age, only in 
6 mixed seizures
variable types of seizures
severity once epileptic state, intractable 
seizures despite of multiple anti-
epileptic drugs 
intractable seizures despite of 
multiple anti-epileptic drugs
intractable seizures in 10/10 intractable in 20/25.  
In 5 seizures suppressed for 
1--3 years
32/37 intractable seizures 
 persisting throughout adulthood
Recognizable facial 
 features
– – NR NR not present
Medical problems upper and lower airway infections high hypermetropia and a 
 substantial astigmatism
NR 1 patient described as case 
report: pneumonia
2/3 airway infection (not 
 systematically reported)
Growth parameters Normal normal NR NR 12/12 normal growth 
 parameters
NR = not reported.
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Table 6   Clinical features of present and previously reported patients with  
Phelan-Mc Dermid syndrome.
Present  
patient 7
Present 
 patients 8, 9
References previous reports Total
47 48 49 50 51 52 53 54
Number of 
adults
1 2 1 1 1 1 (from broth-
er pair)
2 1 7 1 18
Genetic defect 1.8-Mb deletion 2.12-Mb  
deletion 
130-kb terminal 
deletion
submicroscopic 
deletion
100-kb terminal 
22q13.3  
deletion
3.5-Mb 
 deletion
5.65-Mb  
and 5.79-Mb 
deletions
intragenic 
SHANK3  
deletion  
due to 
translocation 
Xq21.33 and 
22q13.33
6 with r(22),  
1 with t(22)
46,XX,  
der(22)t(14;22)
q32.31;q13.33
9/18 22q13.3
1 intragenic SHANK3 
deletion
6/18 ring chromosome 
22
2/18 balanced 
 translocation
Age, years 48 31, 29 22 26 33 24 19, 31 20 20--36 46 19--48
Gender m m f f F m m, f f 3 m, 4 f f 8 m, 10 f
Developmental 
outcome
severe ID, no 
speech
moderate-
severe ID
severe ID, no 
speech
learning 
 difficulties
mild ID severe ID,  
limited speech
significant 
speech delay
moderate 
ID, simple 
speech, 
 difficult to 
understand
7/7, in 2/7 
severe  
(all r(22)). 
+ 18/18, variable, most 
have some speech
Motor signs hypertonia, 
progressive 
spasticity and 
wheelchair 
bound after age 
45; swallowing 
difficulties after 
age 45
1/2 mild 
 spasticity right 
leg
2/2 truncal 
hypotonia 
fully mobile NR ataxic gait hypotonia NR oral: poor 
articulation 
5/7 hypotonia hyper reflexia 
and  clonus, 
ataxia, 
 decreased 
ambulation
tendency to 
 deterioration in  motor 
functioning above 
age 40, with onset of 
 pyramidal signs
Regression +, general 
decline in func-
tioning
no NR NR +, at adult 
age, decline in 
speech, motor 
function, daily 
living functions, 
incontinence
NR NR NR NR +? limited 
early history
2--3/18 (at age >35 
years)
Behavior/
psychiatric
not remarkable bipolar mood 
disorder, sleep 
disturbance and 
high threshold  
of pain in both.
Mild features of 
autism spectrum 
disorder,  
improving with 
age (pat. 9)
NR NR autistic features: 
lack in contact, 
stereotypic 
movements
quiet and  
loving, but 
stubborn; 
peculiar 
catatonic like 
episodes, 
high threshold 
of pain
+, not further 
specified
hand stereo-
typies,  
sometimes 
irritated and 
aggressive; 
more social 
and less 
ritualistic than 
in childhood
7/7 very se-
vere
NR 14/15 variable, 
 tendency to 
 improvement of social 
interactions with age?
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Table 6   Continued.
Present  
patient 7
Present 
 patients 8, 9
References previous reports Total
47 48 49 50 51 52 53 54
Seizures +, onset at age 
45 y
no NR NR + +, febrile, 
incidental
1: no 2: yes NR 2/7 +, focal and 
petit mal
7/15
Facial 
 dysmorphic 
features
coarse, bushy 
eyebrows, short 
philtrum, broad 
mouth, full lips, 
widely placed 
dentition, large 
ears
1/2 long face 
2/2 prominent 
chin, large ears
microgna-thia, 
simple ears, 
prominent nose, 
gap between 
incisors
wide broad 
 forehead, 
bulbous nose 
tip, prominent 
columella, high 
palate
long face, high 
nasal bridge, 
broad nose
asymmetry 
of the face, 
midface 
 hypoplasia, 
square  
forehead, 
prominent 
supraorbital 
ridges,  
bulbous tip 
of the nose, 
short philtrum, 
large ears, 
prominent 
lower lip, high 
arched palate, 
gap between 
incisors
NR  periorbital 
puffiness, 
broad nasal 
bridge, slightly 
low-set and 
outwardly 
rotated ears, 
high and 
narrow palate, 
narrow  
bitemporal  
 diameter, 
micro-
retrognathia, 
low hairline 
neck
5/7 dysplastic 
ears
narrowed 
bitemporal 
diameter,  
epicanthal 
folds,  
periorbital 
fullness, flat 
midface
long face, large ears; 
midface hypoplasia, 
periorbital fullness are 
more often reported
Medical  
problems, age 
of onset (when 
documented)
hyper-
thyreodism 
since age 27 
years
Gilbert 
 syndrome  
(pat. 8) since 
childhood
– mitral valve 
prolaps,  
diagnosed at 
age 18 years
– right convex  
scoliosis, 
diagnosed at 
age 22 years; 
constipation, 
since first 
years of life
 recurrent 
 upper 
 respiratory 
tract infections 
in 1/2
– NR NR variable
Growth 
 parametersa
height P50 P75 (pat. 8); 
P50 (pat. 9)
NR P75-90 slender build P25 1: accelerated, 
2: normal
P75 6/7 normal 1/6 
short stature
NR normal-increased in 
majority
weight P80 P50 (pat. 8); 
P50–75 (pat. 9)
NR NR NR >P97 NR P90 NR NR normal-increased in 
majority
head circum-
ference
P80 P20 (pat. 8);  
P2 (pat. 9)
NR >P97 NR >>P98 NR P10 NR NR normal-increased in 
majority
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Table 6   Continued.
Present  
patient 7
Present 
 patients 8, 9
References previous reports Total
47 48 49 50 51 52 53 54
Other intermittent 
irregular and 
rapid breathing.
2/3 syndactyly  
of the toes
1/2 endorotation 
ankles, normal-
large hands and 
feet 
2/2 genital 
anomalies
2/2 on brain 
MRI hypoplasia 
of the cerebellar 
vermis, en-
larged cisterna 
magna, mild 
dilatation lateral 
ventricles
2/3 long, thin 
fingers, 2/3 
syndactyly of 
the toes, club 
feet deformity
long thin 
 fingers,  nasal 
speech, 
 unusual 
hair  texture, 
 recurrent 
 miscarriages.
long fingers and 
toes, normal 
brain MRI
large hands 
and feet, 
persistence 
of fetal finger 
pads. 2/3 
syndactyly of 
the toes
brain MRI: 
cortical atro-
phy, pachy-
gyria, cer-
ebellar vermis 
hypoplasia, 
enlarged 
cisterna and 
ventricles
NR prominent 
lumbar l 
ordosis;  
slender hands 
with mild  
webbing  
between 
fingers,  
webbing 
between 2/3 
toes
NR NR lumbar lordosis,  
probably related to  
truncal hypotonia
2/3 syndactyly toes, 
large and/or slender 
hands.
3/4 similar anomalies 
on brain MRI 
NR = not reported; P = percentile.
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of the phenotype and outcome, could be observed, though conclusions are 
hampered by the small numbers (Table 7). Patients with Kleefstra syndrome, males 
with MECP2 mutations and females with CDKL5 mutations, showed a further 
decline in functioning/regression at adult age, whereas patients with Pitt Hopkins 
syndrome, Phelan-McDermid syndrome and Dravet syndrome seemed to have a 
relatively stable performance. The prognosis with regard to the outcome of epilepsy 
showed also significant differences, with the poorest outcome in Dravet syndrome 
patients and patients with CDKL5 mutations. Motor symptoms were clearly present 
in some syndromes, including male Rett syndrome, Kleefstra syndrome (catatonic 
phenomena) and in patients with CDKL5 mutations, but absent or minor in other 
syndromes. Distinctive behaviour patterns could be observed as well, for example 
Discussion
The adult phenotype of most of the presented syndromes has not been systematically 
reviewed and described in previous reports, except for SCN1A mutations, involved 
in Dravet syndrome.39-40
We described the phenotype of 9 adults with 6 different Angelman- and Rett-like 
syndromes and reviewed previously reported adult cases in literature. As in 
childhood patients, adult patients with the reported Angelman- and Rett-like 
syndromes showed an overlapping phenotypic spectrum as well. Despite the 
relatively low numbers of patients in each group that have been reported thus far, a 
tendency to specific phenotypic differences at adult age, with respect to evolution 
Table 7   Distinguishing features in adult patients with different Angelman-  
and Rett-like syndromes.
Kleefstra syndrome Pitt Hopkins syndrome MECP2 mutations  
in males
CDKL5 mutations Dravet syndrome Phelan-McDermid syndrome
Facial appearance recognizable recognizable non-recognizable non-recognizable non-recognizable subtle, including long face, 
large ears
Epilepsy +/–, mild +/–, mild +/–, mild +, intractable +, intractable +/–, mild
Motor symptoms +/–, catatonic phe-
nomena
+/– mild +, pyramidal, tremors, 
cerebellar
+, pyramidal, cerebellar +, pyramidal, cerebellar –
Degree of ID moderate–severe Severe mild–profound mostly severe severe mild–severe
Regression + (6/11), at adult age – + (1/3) at adult age + (4/10) – –
Typical behavior / 
psychiatric features
adult age onset  
periods with passivity, 
decreased responsive-
ness and hypoactivity; 
sleep disturbance
mostly happy 
 disposition, but diverse 
behavior problems 
including pica and self 
mutilation
mood/depression and 
anxiety disorders;  
shyness and passivity
(hand)stereotypies and poor 
social interaction
friendly and cooperative in 
general
autistic features, mood 
 disorders
Signs of autonomic 
dysfunction
– abnormal breathing  
pattern, constipation
– breathing anomalies, cold and 
purple feet/vasomotor distur-
bance, severe constipation
– +/– abnormal breathing 
 pattern in present patient 7
Growth parameters Microcephaly, short 
stature and obesity in 
about 40-50% 
microcephaly and short 
stature in majority
microcephaly and short 
stature in majority
normal–decreased normal normal–increased
Medical problems and/
or other distinctive 
features
no consistently 
 occurring medical 
 problems 
typical clubbing of 
finger and toe nails
spinal column deformity spinal column deformity, 
scoliosis; small hands and/
or feet; feeding problems/
gastrostomy
airway infections more often 
reported
long and/or slender fingers/
toes, 2/3 syndactyly toes
Life expectancy (oldest 
reported patient, years)
59 40 56 47 49 48
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adult onset of periods with passivity, decreased responsiveness and hypoactivity 
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facial features at adult age, and thus, in these patients their facial appearance is an 
important clue to the diagnosis. 
In conclusion, the combination of different key clinical features at adult age might 
be helpful to distinguish specific Angelman- and Rett-like syndromes from each 
other. These  key features comprise the degree of ID, seizure characteristics, motor 
symptoms, occurrence of regression and characteristic facial appearance (Pitt 
Hopkins syndrome and Kleefstra syndrome). Knowledge about and insight in 
syndrome specific adult clinical characteristics facilitates adequate management 
and follow-up of patients with Angelman- and Rett-like syndromes, and enables 
careful counseling of family members regarding prognosis, natural course of the 
disease and life expectancy. 
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Abstract
DYNC1H1 encodes the heavy chain protein of the cytoplasmic dynein 1 motor 
protein complex that plays a key role in retrograde axonal transport in neurons. 
Furthermore, it interacts with the LIS1 gene of which haploinsufficiency causes a 
severe neuronal migration disorder in humans, known as classical lissencephaly or 
Miller-Dieker syndrome. We identified de novo missense mutations in DYNC1H1 
(p.Glu1518Lys and p.His3822Pro) in two patients with severe intellectual disability 
and variable neuronal migration defects. An autosomal dominant mutation in 
DYNC1H1 was previously identified in a family with the axonal (type 2) form of 
Charcot- Marie-Tooth (CMT2) disease. Mutations in Dync1h1 in mice also cause 
impaired neuronal migration in addition to neuropathy. Our data suggest that 
mutations in DYNC1H1 can lead to a broad phenotypic spectrum and confirm the 
importance of DYNC1H1 in both central and peripheral neuronal functions. 
Neuronal migration disorders are an heterogeneous group of neurodevelopmental 
disorders that represent an important cause of intellectual disability (ID) and 
epilepsy in humans. Lissencephaly is  due to failure of migration of neuronal 
precursors from the paraventricular zone to the cerebral cortex during early brain 
development.1-3 Lissencephaly is classified in several subtypes, one of which is 
classical lissencephaly.1 Classical lissencephaly can be present as an 
endophenotype in contiguous gene syndromes, such as Miller Dieker syndrome 
(deletion chromosome 17p13) (MDLS (MIM 247200)), but can also be present in an 
isolated form. The vast majority of classical lissencephaly is caused by haploinsuf-
ficiency of the Lissencephaly 1(LIS1)/Platelet-activating factor acetylhydrolase, 
isoform 1B, alpha subunit (PAFAH1B) [MIM 601545] gene or mutations in the gene 
doublecortin (DCX (MIM 300121)) on the X-chromosome.1, 4 Patients with classical 
lissencephaly have severe ID and develop intractable epilepsy. In addition they may 
present with early hypotonia which evolves in spasticity.1-3
The LIS1 protein plays a key role in cell migration of neuronal progenitors during 
brain development. LIS1 interacts with platelet-activating factor acetylhydrolase 
and cytoplasmic dynein. By binding to cytoplasmic dynein LIS1 regulates 
microtubule dependent cell motility. This process is disrupted in lissencephaly.2, 3, 5 
Neuronal cell migration is processed by nucleokinesis, which involves an extension 
of the neuron into which the nucleus is translocated via microtubule transport. It 
was shown that the cytoplasmic dynein 1 motor protein complex is the driving 
motor force of this process. Thus, LIS1 stimulates cytoplasmic dynein functions 
that involve neuronal migration and axon growth.2, 3, 5
Recently, we reported a de novo missense mutation in dynein, cytoplasmic 1, heavy 
chain 1 (DYNC1H1 (MIM 600112)), a cytoplasmic dynein 1 motor complex gene, in 
a patient with ID as part of a larger study using a family-based exome sequencing 
approach.6 Here we report the identification of a second de novo mutation in this 
gene in another patient with a distinct phenotype which overlaps with the patient of 
the previous study. These data together suggest that de novo mutations in DYNC1H1 
cause variable phenotypes including severe ID with variable neuronal migration 
defects, and peripheral neuropathy.
Patient 1 was previously reported by Vissers et al.6 In brief, this boy was the first 
child born at term after an uneventful pregnancy with a weight of 3850g (60th centile) 
to healthy parents. At 6 months hypotonia was noted and physical therapy was 
started. Development was delayed. He could sit at 18 months and walk at 3 years. 
At the age of 4 years his developmental level was tested which showed a 2 years 
delay, consistent with moderately severe intellectual disability. At the age of 6 years 
and 6 months he could only speak several single words. On physical examination 
at the age of 2 years he had a normal height of 85.2 cm (15th centile) and head 
circumference of 47.5 cm (15th centile). He had mild (facial) dysmorphism consisting 
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of prominent forehead, plagiocephalic skull, a hypotonic face with downslanted 
palpebral fissures and short broad hands and feet. On further physical examination 
at the age of 6 years and 6 months he had a normal height (122 cm (25-50th centile)) 
and head circumference (53.5 cm (84th centile)), and similar dysmorphism as on 
previous examinations. Abnormal neurologic findings included hypotonia, general 
reduced tendon reflexes and broad-based waddling gait with toe walking. 
Re-evaluation of the brain MRI that was performed at the age of 5 years and 6 
months showed, despite its suboptimal quality, signs of bilateral cortical 
malformation with deficient gyration of the frontal lobes (without clear abnormalities 
of cortical thickness) and an area suggestive of focal cortical dysplasia (Figure 1 
A-C). A family-based exome sequencing approach revealed a de novo c.11465A>C 
mutation in DYNC1H1 (NM_001376.4), predicting a p.(His3822Pro) substitution 
(Figure 2 A).6 Although the Grantham score at 77 indicates a moderate physico-
chemical difference, the PhyloP score at 5.12 suggests a very high conservation of 
Figure 1   Cerebral imaging in patient 1 (A-C) en patient 2 (D-E)
Figure 2   Schematic representation of human DYNC1H1 and mutations  
in patient 1, 2 and the axonal (type 2) form of Charcot-Marie-Tooth 
(CMT2) disease family reported in Weedon et al.22 together with  
the mutations of known mouse models.
Panels A-C show axial, T2 weighted (A and B) and sagittal, T1-weigthed (C) MR images with deficient 
gyration of the frontal lobes and an area suspected for cortical dysplasia in patient 1 (circles in panels 
B and C). Figures D and E show CT images of patient 2, with enlarged ventricles, wide opercular 
regions, and clear signs of frontal lobe cortical malformation with an abnormal flat cortex with only a 
few, simple and shallow sulci.
Schematic representation of the mapped exome sequencing reads visualized using the Integrative 
Genomics Viewer (IGV) browser for patient 1 (panel A) and patient 2 (panel B), respectively. The upper 
part shows the per-base coverage, with coverage represented in gray indicating the wild-type base, 
whereas colored bases indicate the detection of variants. Also, a representation (part of) of exon 61 and 
exon 22 are provided for orientation. Individual sequence reads for patient 1 and patient 2 both show a 
heterozygous variant, which was followed up by Sanger sequencing, confirming the de novo occurrence 
in both patients. In panel (C), the DYNC1H1 protein is visualized according to Weedon et al. with the 
N-terminal region indicated by a gray horizontal bar, and the stem domain shown on above (amino acids 
53-1867). The residues involving DYNC1H1 dimerisation (300-1140) are shown by a pink bar. The 
C-terminal motor domain (amino acids 1868-4646) is shown in purple colour, with the seven ATPase 
domains represented by circles and the stalk region by a horizontal bar. The equivalent positions of 
mutations in three mouse models, Loa, Swl, and Cra1, are shown below the representation. Note that the 
human protein contains two additional glycine residues at position 7 relative to mouse Dync1h1, that is 
numbering of equivalent residues in human DYNC1H1 is 2 higher than in mouse models. The three 
mutations reported in patients, including p.(His3822Pro) in patient 1, p.(Glu1518Lys) in patient 2, and p.
(His306Arg) reported by Weedon et al. are  indicated with arrows according to their relative positions of 
the functional domains of the DYNC1H1 protein. 
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comparison of the patients 250k Affymetrix SNP profiles to their exome data 
(concordance >95%), and by the consistent segregation of uniquely inherited 
variants detected in the trios by exome sequencing. Thus, both changes represent 
bona fide de novo mutations in DYNC1H1. Combined with the fact that an average 
newborn is expected to have 0-2 nonsynonymous de novo mutations in his or her 
exome, the detection of nonsynonymous de novo events in DYNC1H1 in two patients 
with similar phenotypes strongly suggests that the mutations are causal for the 
phenotype.    
Dynein, cytoplasmic 1, heavy chain 1( DYNC1H1) has 78 exons and encodes the 
heavy chain protein (DYNC1H1) of the cytoplasmic dynein 1 motor protein complex.8 
The cytoplasmic dynein 1 motor protein complex is composed of a homodimer of 
two heavy chains, encoded by DYNC1H1, and associated intermediate, light 
intermediate and light chains. This complex is involved in several cellular functions, 
including spindle pole organization and nuclear migration during mitosis, the minus 
end transport of cell organelles along microtubules, and retrograde axonal transport 
in neurons.8-11 The C-terminal region of DYNC1H1 is the motor domain of the dynein 
complex and is arranged as a ring with six AAA (ATPases associated with cellular 
activities) domains, localizing ATP binding, required for energy generation, and a 
seventh uncharacterized domain, whereas the N-terminal region confines the stem 
domain, the region for homodimerization, and binding sites for the intermediate 
and light intermediate chains.8 The cytoplasmic dynein 1 complex was formerly 
shown to play a key regulatory role in retrograde axonal transport in neurons, in 
which the heavy chains are responsible for movement along the microtubule.8-11 
Furthermore, several studies in model organisms provided evidence that the 
cytoplasmic dynein 1 complex directly interacts and coprecipitates with the LIS1/
PAFAH1B protein.2, 3, 5, 12-15 The dynein heavy chain protein and the intermediate 
chains biochemically interact with the WD-40 repeat region of LIS1. WD-40 repeats, 
also known as WD or beta-transducin repeats, are short ~40 amino acid motifs 
often terminating in a Trp-Asp (W-D) dipeptide, which act as a site for protein-pro-
tein interaction. Within the heavy chain, interactions with LIS1 are with the first AAA 
repeat, and the N-terminal cargo-binding region.2, 8, 12
The Legs at odd angles (Loa/+), Cramping I (CraI/+) and Sprawling (Swl/+) mouse 
models, each harbour  different missense mutations in the stem domain of Dync1h1. 
Their phenotypes include abnormal neuronal migration and axon growth, as well as 
neurodegeneration, caused by defective retrograde transport.11, 16-19 Studies in 
these three mouse models in addition showed that heterozygous missense 
mutations in Dync1h1 are associated with neurologic phenotypes including gait 
abnormalities, reduced muscle strength, reduced reflexes and abnormal 
propriocepsis and nocicepsis in association with loss of motor and sensory 
the affected nucleotide among 46 vertebrate species. A prediction of the effect of 
this amino acid substitution at protein level by SIFT indicates that this mutation is 
deleterious to normal protein function.7
Patient 2 was a 51-year-old woman with severe ID. She had never been able to walk 
or speak. She was born after an uncomplicated pregnancy with a low-normal birth 
weight (5th centile). She had congenital clubfeet. At the age of 3 years she developed 
generalized epileptic seizures. At the age of 51 years she had a height of 135 cm 
(<0.6th centile) and a head circumference of 52 cm (2nd centile). She had small 
hands and feet (<3rd centile) and the toes were short and malpositioned. Craniofacial 
features included brachycephaly, prominent forehead, hypertelorism, deeply set 
eyes, wide mouth with everted lower lip and downturned corners of the mouth. She 
had secondary cataract as a result of automutilation, a kyphoscoliosis, spastic 
tetraplegia and was wheelchair dependent. At the age of 50 years she had 
developed progressive swallowing difficulties for which a gastrostomy tube was 
needed. A cerebral CT-scan at the age of 46 years, performed because of persistent 
seizures, showed wide lateral and third ventricles, and clear signs of cortical 
malformation with wide opercular regions and an abnormal flat cortex with only a 
few, simple and shallow sulci (especially in the frontal lobes) (Figure 1 D-E). It was 
not possible to obtain a cerebral MRI scan. Additional investigations comprising a 
routine screen in urine and blood for metabolic disorders including a screen for 
peroxisomal disorders and detailed chromosomal studies (250k SNP array), 
revealed no abnormalities. Also for this patient, a family-based exome sequencing 
approach was used and revealed a de novo c.4552G>A mutation in DYNC1H1, 
predicting a p.(Glu1518Lys) substitution (Figure 2 B). Similar to the mutation 
observed in patient 1 the Grantham score of 56 indicates a small physicochemical 
difference, whereas the PhyloP score at 6.03 indicates again a strong evolutionary 
conservation and SIFT predicts the mutation also to have a deleterious effect for 
protein function. 
Examination of 445 exomes previously sequenced in our unit for unrelated medical 
conditions did not show either of the changes in DYNC1H1 reported in patients 1 
and 2. Moreover, in this entire cohort only 10 changes were seen in DYNC1H1 that 
are not present in dbSNPv132. Of these, 9 variants are predicted to be synonymous 
changes, not affecting gene function, whereas the remaining variant predicts a 
missense p.Ser4603Ile substitution, which was detected in a single individual and 
involves a weakly conserved nucleotide (PhyloP -0.12). From this analysis, we 
conclude that nonsynonymous changes in DYNC1H1 are very rare. Of note, 
retrospective analysis of genes known to cause neuronal migration disorders, 
including LIS1, DCX, RELN, NDE1 and TUBA1A, did not reveal any pathogenic 
mutations whereas exon coverage for these genes was sufficient to detect such 
variants if present. Additionally, non-paternity and sample mix-up were excluded by 
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In summary, we conclude that de novo missense mutations in DYNC1H1 are a novel 
cause of severe ID associated with variable neuronal migration defects. The 
phenotype may include peripheral neuropathy as well. 
Acknowledgements
We thank the participating patients and their parents. We also thank all technicians 
from the genomic disorders group for excellent technical assistance.
Competing interests
No competing interest reported.
Funding
This work was supported by grants from the Consortium ‘’Stronger on your own 
feet’’ to T.K. and M.H.W., The Netherlands Organization for Health Research and 
Development (ZonMw grants 916-86-016 to L.E.L.M.V., 917-66-363 and 911-08-025 
to J.A.V., 917-86-319 to B.B.A.d.V., and 907-00-365 to T.K.), the EU-funded 
neurons.16-19 Loa and CraI homozygous mice show a more severe phenotype and 
die within 24 hours after birth due to inability to feed and move.17 Homozygous loss- 
of- function of Dync1h1 is embryonically lethal, indicating an important role of 
DYNC1H1 in human embryonic development.20 Interestingly, Loa mice not only 
exhibit defects in retrograde axonal transport, but also show clear central migration 
defects in hippocampus and cortex that are similar to defects observed in reduced 
LIS1 expression.21 The clinical findings in patients 1 and 2 strongly overlap with the 
phenotype observed in the Loa mouse model and strengthen the previous 
functional links between LIS1 and DYNC1H1. 
Recently, a missense mutation c.917A>G, predicting a p.(His306Arg), was reported 
in a large pedigree with dominant axonal (type 2) Charcot-Marie-Tooth Disease 
(CMT2).22 After comparison of the clinical presentation of our patients to those 
reported by Weedon et al.,22 we noted  some phenotypic overlap between patients 
1 and 2 and the affected members of the CMT2 family (Table 1), though the overall 
presentation is importantly different. 
The motor abnormalities and reduced tendon reflexes that were observed in patient 
1, and the congenital clubfeet in patient 2, might indicate the presence of peripheral 
neuropathy similar to that reported in the CMT2 family. This remains speculative 
however, since neither formal neurophysiologic investigations nor peripheral nerve 
biopsy were performed in our patients. 
Of note, in the CMT2 family, four of the 13 family members with a DYNC1H1mutation 
presented with global delay, speech delay and/or learning difficulties in addition to 
their motor problems. Whereas the delay in motor development may be explained 
by the peripheral neuropathy, the speech delay and/or learning difficulties obviously 
suggest additional involvement of the central nervous system. Brain imaging was 
not reported in the CMT2 family.
The important differences in phenotype between the two patients reported here 
and the dominant CMT2 family may indicate that heterozygous missense mutations 
in DYNCH1 represent a broad phenotypic spectrum. Possibly, the presentation with 
severe ID and neuronal migration defects depends on the location and nature of 
the mutation (Figure 2 C). The mutation in the CMT2 family is located in the stem 
domain at the N- terminal end of the homodimerization region.22 In patient 1 the 
mutation is located in the motor domain, where no previous mutations have been 
documented. The mutation of patient 2 is localized in the C-terminal end of the 
stem domain, but outside the homodimerization region (Figure 2 C). Further 
conclusions about genotype-phenotype correlations require that more patients 
with mutations in DYNC1H1 are identified and carefully characterized at the clinical 
level.
Table 1   Comparison of clinical features in patients 1 and 2 and the family 
reported by Weedon et al. with the axonal (type 2) form of Charcot- 
Marie-Tooth (CMT2) disease.22 
Patient 1 (age 5 
years) 
Patient 2 (age 51 
years)
CMT2 family22
Clinical features
ID/DD/LD Severe ID Severe ID 4/13 DD or LD
Neuronal migration 
defect
Mild Severe Not documented
Delayed motor 
milestones
Yes Yes, never learnt to 
walk
9/13 
Epilepsy No Yes Not reported
Gait abnormalities 
(waddling and/or broad-
based, frequent falls)
Yes Cannot walk 5/13
Reduced reflexes Yes Not tested 7/13
Hypotonia and/or 
lordosis
Yes No, hypertonia 13/13
Clubfeet No Yes 7/13
DD=  global developmental delay; LD=learning difficulties and/or language delay
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Abstract
Intellectual disability (ID) carries lifelong personal and social impact, but its causes 
remain largely unknown due to extensive clinical and genetic heterogeneity. We 
used family-based exome sequencing to detect causative mutations in a series of 
100 patients with unexplained severe ID (IQ <50). Patients were previously clinically 
evaluated to exclude known causes of ID. After informed consent was obtained, the 
coding regions of >21,000 genes were sequenced in 100 patients and their 
unaffected parents. A data analysis pipeline was developed to identify and classify 
de novo, autosomal recessive and X-linked mutations. In addition, a high-through-
put re-sequencing strategy was used to confirm new candidate ID genes in >750 
ID patients. All mutations were evaluated by molecular genetic scientists and 
clinicians in the context of the patients’ clinical presentation. Seventy-nine de novo 
mutations were identified in 53 of 100 patients. Predicted damaging de novo (n=10) 
and X-linked maternally-inherited (n=3) mutations in known ID genes yielded a 
diagnosis in 13 patients. Potentially causative de novo mutations in novel candidate 
ID genes were detected in 22 patients. For three of these candidate genes, 
additional de novo mutations were identified in patients with similar phenotypes, 
confirming that they are true ID genes. No causative autosomal recessive mutations 
were detected in this series. Thus, the total diagnostic yield was 16%, mostly 
comprising de novo mutations. De novo mutations represent an important cause of 
ID and exome sequencing is an effective diagnostic strategy for their detection.
Introduction
Severe intellectual disability (ID), also referred to as cognitive impairment or mental 
retardation, affects approximately 0.5% of the population in Western countries1, 2 
and represents an important health burden. A clinical diagnosis of severe ID is 
generally based on an IQ below 50 and significant limitations in daily life functions. 
In early childhood, the diagnosis is based on significant developmental delays, 
including motor, cognitive and speech delays. Non-syndromic forms of ID are 
clinically indistinguishable due to absence of specific associated abnormalities. ID 
can be caused by non-genetic factors such as infections and perinatal asphyxia. In 
the developed world, however, most severe forms of ID are thought to have a 
genetic cause.2 Genetic defects that cause ID range from large cytogenetically 
visible chromosomal abnormalities to point mutations in genes, but in spite of many 
years of genetic research and technological advances, the aetiology remains 
elusive in 55-60% of patients.3, 4 Understanding the genetic cause of ID is of great 
benefit for patients and their families, as a diagnosis provides information on the 
progress and prognosis of the condition, precludes further unnecessary (invasive) 
tests, and may lead to appropriate therapy. Moreover, a conclusive diagnosis often 
facilitates access to appropriate medical and social supportive care.5-8 Family 
members may benefit from knowledge on recurrence risk, availability of reproductive 
counselling and possible prenatal diagnosis. 
Previously, we9 and others10 provided evidence for the hypothesis that rare de novo 
point mutations can be a major cause of severe ID. Recent studies have indicated 
that there are more de novo mutations than in healthy controls, highlighting the 
clinical importance of these mutations.11-15 Additional support for the de novo 
hypothesis is found in the frequent sporadic occurrence of ID, without obvious 
environmental or familial factors. It has been estimated that mutations in well over 
1,000 different genes may cause ID.16 Because of this large mutational target, rare 
de novo mutations in these genes may collectively account for a considerable 
proportion of ID, thereby compensating for the severely reduced reproduction of 
patients with ID, and keeping its incidence in the general population stable.15 In the 
absence of diagnostic clues from the clinical phenotype, unbiased whole genome 
or whole exome sequencing approaches are required to diagnose these genetic 
mutations causing ID.9, 17, 18
Here, we evaluate the role of de novo as well as X-linked and autosomal recessive 
inherited mutations in a series of 100 patients with unexplained ID (IQ <50) using a 
family-based exome sequencing approach in a clinical diagnostic setting. Previous 
extensive clinical and genetic evaluation of these patients had not led to an 
aetiologic diagnosis. This series of patients therefore represents the end point of 
current diagnostic strategies where all conventional genetic resources have been 
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exhausted. It has been shown that this situation is the final conclusion for most 
patients with severe ID.19 Exome sequencing revealed 79 de novo mutations in 53 
patients, together with a limited number of X-linked and autosomal recessive 
inherited mutations. Careful analysis allowed us to provide a conclusive genetic 
diagnosis for 16% of ID patients. We conclude that exome sequencing offers an 
attractive diagnostic strategy for patients with severe ID of unknown cause.
Methods
Participants
We studied 100 patients (53 females, 47 males) with unexplained severe ID (IQ<50) 
and their unaffected parents (trios) (Table 1). This series is broadly representative 
for patients with severe ID referred to our tertiary clinic. All patients were clinically 
evaluated by a clinical geneticist (MHW, BWMvB, TKl, DAK, HGB, BBAdV). Prior to 
inclusion, patients had received an extensive diagnostic work-up including a 
genomic profile (250K Affymetrix SNP array), targeted gene tests and metabolic 
screening whenever indicated, but these had not led to a diagnosis. The study was 
approved by the Medical Ethics Committee of the Radboud University Medical 
Centre in Nijmegen, The Netherlands (NL13636.091.07; NL36191.091.11; NL19921.091.07), 
and we obtained written informed consent from the parents of all participants in the 
study. All experiments were performed at a diagnostic laboratory accredited to the 
CCKL Code of Practice, which is based on the EN/ISO 15189 (2003; Registration 
numbers R114/R115, Accreditation numbers 095/103). 
Detection of mutations
Genomic DNA was isolated from blood with the use of a QIAgen DNA mini kit 
(QIAgen). Exomes were enriched using a SOLiD-optimized SureSelect human 
exome kit (Agilent v2, 50Mb), followed by SOLiDTM4 sequencing (Life Technologies). 
After sequencing the trio, candidate de novo mutations were selected by excluding 
variants inherited from either parent, whereas recessive and X-linked mutations 
were identified by segregation analysis (Figure 1). Candidate de novo mutations 
were validated by conventional Sanger sequencing methods in DNAs of the patient 
and parents. 
Testing for additional mutations in candidate ID genes
Five candidate ID genes (DYNC1H1, KIF5C, ASH1L, GATAD2B and CTNNB1) were 
re-sequenced using array-based enrichment on pooled DNAs from a second 
series of 765 ID patients (Table 2) selected from our in-house collection of 5,621 
patients with undiagnosed ID. Written informed consent was previously obtained. 
Table 1   Overview clinical details 100 ID patients.
Level of ID Number of patients
IQ  <30 62
IQ  30-50 38
IQ  50-70 0
Gender
Male 47
Female 53
Age groups
<10 yrs 37
10-20 yrs 41
>20 yrs 22
Sibship size
1 12
2 47
3 36
4 1
≥5 2
unknown 2
Number of major congenital anomalies 
0 62
1 31
2 7
3 0
Short stature 
Yes 24
No 76
Microcephaly 
Yes 30
No 70
Macrocephaly 
Yes 4
No 96
Epilepsy
Yes 52
No 48
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All patients were clinically evaluated by a clinical geneticist to exclude known 
causes of ID and genomic array analysis had not revealed causal copy number 
variants. Detected variants were annotated and prioritized according to their 
presumed relevance to disease. Variants fulfilling prioritization criteria were validated 
using conventional Sanger sequencing. 
Table 1   Continued.
Abnormalities on brain imaging
Yes 30
No 40
Not assessed 30
Cardiac malformation 
Yes 2
No 98
Abnormality of the urogenitary system
Yes 13
No 87
Table 2   Clinical characteristics of ID patients selected to test for recurrent 
mutations in candidate ID genes.
Gender  
   Male 511 (59.2%)
   Female 352 (40.8%)
Age group
   <10 yrs 415 (48.1%)
   10-20 yrs 191 (22.1%)
   >20 yrs 257 (29.8%)
Age (years)
   Median age of series 11
   Range 0-89
   Interquartile Range 5-27.5
Level of ID
   IQ<30 207 (24.0%)
   IQ 30-50 145 (16.8%)
   IQ 50-70 264 (30.6%)
   not assessed* 247 (28.6%)
Clinical features
Short stature 185 (21.4%)
Microcephaly 136 (15.8%)
Macrocephaly 30 (3.5%)
Epilepsy 154 (17.8%)
Structural CNS abnormalities 68 (7.9%)
Cardiac malformations 43 (5.0%)
Urogenital abnormalities 94 (10.9%)
*due to young age of patient
Figure 1   Workflow Exome sequencing.
Experimental workflow for detecting and prioritizing sequence variants
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Results
Family-based exome sequencing of 100 patients with ID to 
identify de novo mutations
The power of family-based exome sequencing to provide a genetic diagnosis was 
evaluated for 100 patients with unexplained ID (IQ <50). An average of 24,324 
genetic variants was detected per patient. An automated prioritization scheme was 
applied to systematically identify candidate de novo mutations (Figure 1), resulting 
in a total of 690 candidate de novo mutations (average of 7 per patient; range 2-20). 
Sanger sequencing confirmed the presence of 79 de novo mutations in 53 patients 
(range 1-4 per patient). 
Description of de novo mutations and genes affected
Of 79 de novo mutations (affecting 77 genes), 16 mutations are predicted to lead to 
a synonymous change (Figure 2) of which none is predicted to alter splicing. 
Therefore, these mutations were classified as not causative for ID. The remaining 
63 changes were non-synonymous and included 15 severely disruptive mutations 
(4 nonsense, 2 canonical splice site and 9 insertion-deletions) and 48 missense 
mutations. Based on random mutation modeling22, our observation of 4 nonsense 
mutations (6.1%) exceeded expectation (3.3%) suggestive for an elevated level of 
such mutations in ID. Moreover, PolyPhen-2 prediction of all 48 missense mutations 
showed a significant increase of probably damaging mutations. 
Twelve de novo mutations were detected in known ID genes, including six severely 
disruptive mutations and six missense mutations (Table 3). Three de novo mutations 
were detected in genes known to cause a recessive form of ID. These mutations 
would only be considered causal for ID if a second, inherited, predicted pathogenic 
mutations was identified. For ARFGEF2 and TUSC3 no second mutation was 
identified. For LRP2 (patient 81), however, a rare paternally-inherited, predicted 
pathogenic variant was identified (c.6160G>A; p.(Asp2054Asn)). Analyses to show 
that the de novo event occurred on the maternal haplotype were inconclusive. 
Recessive LRP2 mutations cause Donnai-Barrow syndrome and clinical 
re-evaluation of patient 81 confirmed this diagnosis.
The remaining 51 de novo mutations were systematically analyzed for by gene 
function and predicted mutation impact for involvement in ID. This analysis identified 
25 mutations in 24 candidate ID genes (Table 3). Interestingly for DYNC1H1, the 
patient enrolled in this study represented the second patient with a de novo mutation 
in this gene (for first patient see ref. 9). Phenotypic comparison of both patients 
showed overlap for severe ID and a variable neuronal migration defect.23 (see 
Chapter 5.1).
Interpretation of confirmed mutations and diagnostic reporting
Mutations were classified based on the existing guidelines for evaluation of variant 
pathogenicity20, 21, which included an evaluation of seven parameters including 
1) gene function, 2) in silico prediction of mutation severity, 3) prediction of the functional 
effect at amino acid level, 4) evolutionary conservation, 5) brain expression patterns, 
6) GO-term analysis, and 7) animal models, if available. 
Using a classification scheme (Figure 2), predicted pathogenic mutations in known 
and/or novel ID genes were reported as a highly likely cause of ID, if the patients 
showed matching phenotypes. Predicted pathogenic mutations in candidate ID 
genes were reported as a possible cause of ID. For patients without causal de novo 
or bi-allelic inherited mutations, the diagnostic report stated that the genetic cause 
of ID was not identified.
Figure 2   Flow diagram for the classification of variants detected in patients 
with  severe ID.
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patients for de novo mutations
To provide further evidence for pathogenicity of de novo mutations in candidate ID 
genes, we re-analyzed previously generated exome data of undiagnosed patients 
with severe ID9 and performed a targeted high-throughput sequencing study for 
five genes (DYNC1H1, GATAD2B, ASH1L, KIF5C and CTNNB1) to identify additional 
mutations in a second series of 765 ID patients (Table 4).
One additional de novo mutation was identified in the transcriptional repressor 
GATAD2B. Both de novo mutations observed in this gene, p.(Gln470*) and 
p.(Asn195Lysfs*30), are severely disruptive and predicted to lead to a loss-of- 
function (Figure 3). Both patients presented with severe cognitive and motor delays, 
limited speech and similar facial features. One additional severely disruptive de 
novo mutation was detected in CTNNB1 (Figure 4). Both mutations, p.(Arg515*) and 
Table 3   Genes affected by de novo mutations with link to ID.
Type of 
mutation
Known
ID genes
Novel
ID genes#
Candidate
ID genes
Missense GRIN2A¥ DYNC1H1 GRIA1 PROX2
 GRIN2B CAMKIIG TANC2
 TCF4 KIF5C TNPO2
 TUSC3§ COL4A3BP PPP2R5D
 ARFGEF2§ RAPGEF1 ASH1L
 PHACTR1 LRP1
 PSMA7 MIB1
 EEF1A2 TRIO¥
Nonsense SCN2A GATAD2B PHIP WAC
Frameshift LRP2* CTNNB1 ZMYM6
 PDHA1 MTF1
 TUBA1A
 SLC6A8
Splice site SYNGAP1 MYT1L
¥: De novo mutations in two independent patients; §: Autosomal recessive ID gene where no second mutation 
was detected; *: Autosomal recessive ID gene where a second rare-inherited mutation was detected; #: Based 
on additional de novo mutations in patients with phenotypic overlap.
Table 4   Variants validated in recurrence test.
 Total variants selected for Sanger validation Confirmed
 KIF5C 2 1
 GATAD2B 4 2
 DYNC1H1 32 8
 CTNNB1 4 2
 ASH1L 11 6
 Total # 53 19 (36%)
Figure 3   Schematic overview of GATAD2B mutations.
Schematic representation of GATAD2B, with its domain structure based on Alamut2.0. In addition, the 
mutations identified in this gene are indicated with their respective location at protein level. aa denotes 
amino acid number.
Clinical comparison of patients with mutations in GATAD2B – Two patients were shown to have a de 
novo mutation, p.(Gln470*) and p.(Asn195Lysfs*30) respectively, in the transcriptional repressor 
GATAD2B. Phenotypic comparison of these two patients was highly suggestive for a related genetic 
cause. They both had severe developmental delay with delayed motor milestones, only limited speech 
and overlapping facial features.
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Identification of inherited mutations in autosomal recessive and 
X-linked genes
In 12 male patients, 14 X-linked inherited mutations were detected. Three of these 
mutations were located in known X-linked ID genes (PDHA1 and ARHGEF9 (n=2)). 
These were predicted to be pathogenic and the phenotypes observed in the 
patients matched that of those reported previously. In addition, 11 X-linked inherited 
mutations were identified in genes not previously associated with ID, of which one, 
TRPC5, was classified possibly causal. The analysis for autosomal recessive 
causes of ID revealed bi-allelic inherited mutations in nine genes, including two 
genes previously associated with an autosomal recessive form of ID  (PCNT and 
VPS13B). None of these mutations were classified as possible cause for ID.
Diagnostic implication of family-based exome sequencing in  
ID patients 
Conclusive genetic diagnoses were obtained for ten patients with de novo 
mutations in known autosomal ID genes and for three male patients with severely 
disruptive maternally-inherited mutations in known X-linked ID genes (Table 5). 
Importantly, the phenotypes of these patients fit well with the phenotypes known 
for patients with mutations in these genes. No diagnostically relevant autosomal 
recessive mutations were identified. Thus, a diagnostic yield of 13% was obtained 
by mutations in known ID genes (Table 5). 
p.(Ser425Thrfs*11), are predicted to result in loss-of-function. A third patient carried 
a p.(Gln309*) mutation in CTNNB1. This mutation was not present in maternal DNA, 
but paternal DNA was unavailable. All three patients presented with severe ID, 
absent or very limited speech, microcephaly and spasticity with severely impaired 
ability to walk . 
Patients 4 and 15 showed de novo missense mutations in TRIO, p.(Asp1368Val) and 
p.(Thr2563Met) respectively. TRIO plays a role in several signaling pathways that 
control cell proliferation.24 Phenotypic comparison revealed no similarities other than 
ID. Importantly, both patients also carried a de novo mutation in a known ID gene, 
ARHGEF9 and TCF4, respectively. Their phenotypes overlapped markedly with other 
patients showing mutations in ARHGEF9 and TCF4, indicating that these mutations 
are the most likely cause of ID, although the mutations in TRIO may still contribute. 
Figure 4   Schematic overview of CTNNB1 mutations.
Schematic representation of CTNNB1, with its domain structure based on Alamut2.0. In addition, the 
mutations identified in this gene are indicated with their respective location at protein level. aa denotes 
amino acid number
Clinical comparison of patients with mutations in CTNNB1 – Two patients were shown to have a de 
novo loss-of-function mutation in CTNNB1, including a p.(Arg515*) nonsense mutation and a p.
(Ser425Thrfs*11) frameshift mutation. For a third patient, carrying a p.(Gln309*) nonsense mutation, only 
maternal DNA was available for testing its segregation and was found to be absent. All patients presented 
with similar features comprising severe ID with absent or very limited speech, microcephaly and spasticity 
due to which the ability to walk was severely impaired.
Table 5   Diagnostic yield of exome sequencing in patients with ID of unknown 
cause.
Positive diagnosis Number of patients
De novo mutations 13
   Autosomal dominant 10¥
   X-chromosomal 2
   Autosomal recessive 1†
Inherited mutations 3
   X-chromosomal 3
   Autosomal recessive 0
Total diagnostic yield 16 
¥: Seven mutations in previously known autosomal dominant ID genes, three in novel autosomal dominant 
ID genes; †: one de novo mutation and a second, inherited, predicted pathogenic mutation.
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Table 6   Summary of diagnostic reports.
Patient Number of  
de novo 
mutations
Molecular 
diagnosis   for ID
Based on [gene] (inheritance)
1 0 NO  
2 1 Possible GRIA1 (de novo)
3 0 NO  
4 1 Highly likely PDHA1 (X-linked maternally inherited)
5 1 Possible PHIP (de novo)
6 1 Possible PSMA7 (de novo)
7 1 Highly likely TUBA1A (de novo)
8 2 NO  
9 0 NO  
10 2 NO  
11 0 NO  
12 0 NO  
13 1 Highly likely SLC6A8 (de novo)
14 0 NO  
15 4 Highly likely TCF4 (de novo)
16 2 Highly likely SYNGAP1 (de novo)
17 0 NO  
18 2 Highly likely ARHGEF9 (X-linked maternally inherited)
19 0 NO  
20 0 NO  
21 1 NO  
22 2 Highly likely SCN2A (de novo)
23 0 NO  
24 0 NO  
25 2 Highly likely GRIN2B (de novo)
26 1 NO  
27 0 NO  
28 0 NO  
29 0 NO  
30 0 NO  
31 1 Possible PROX2 (de novo)
32 2 Possible CAMKIIG (de novo)
33 0 NO  
34 0 NO  
Table 6   Continued.
Patient Number of  
de novo 
mutations
Molecular 
diagnosis   for ID
Based on [gene] (inheritance)
35 0 NO  
36 0 NO  
37 2 NO  
38 1 NO  
39 2 Possible LRP1 (de novo)
40 2 Possible WAC / MIB1 (de novo)
41 2 Highly likely ARHGEF9 (X-linked maternally inherited)
42 1 Possible TANC2 (de novo)
43 2 Possible TNPO2 (de novo)
44 1 NO  
45 0 NO  
46 0 NO  
47 0 NO  
48 0 NO  
49 0 NO  
50 0 NO  
51 1 NO  
52 2 Highly likely GRIN2A (de novo)
53 1 NO  
54 1 Highly likely DYNC1H1 (de novo)
55 0 NO  
56 0 NO  
57 0 NO  
58 1 Highly likely GRIN2A (de novo)
59 3 Highly likely PDHA1 (de novo)
60 1 NO  
61 1 NO  
62 0 NO  
63 0 NO  
64 0 NO  
65 0 NO  
66 2 Possible ASH1L (de novo)
67 0 NO  
68 1 NO  
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Our study identified 24 novel candidate ID genes affected by de novo mutations. A 
pathogenic role for three of these genes was substantiated by the identification of 
additional ID patients with severely disruptive mutations. In each case, there was 
striking phenotypic overlap observed between the patients with mutations in the 
same gene. We therefore conclude that DYNC1H1, GATAD2B and CTNNB1 are 
novel ID genes (Tables 3 and 5), raising the diagnostic yield to 16%. 
Discussion
Mutations in over 400 genes have been linked to ID, but most of these mutations 
have a very low prevalence and their phenotypes are often indistinguishable. This 
argues for an unbiased diagnostic approach, especially since these 400 genes 
may still represent less than half of all ID genes. We implemented family-based 
diagnostic exome sequencing for patients with severe unexplained ID. Exome 
sequencing is a procedure that is highly amenable to automation. Variants with 
potential clinical consequences can easily be validated by Sanger sequencing as 
an independent method. No major hurdles were identified in the laboratory workflow 
in this study, allowing smooth integration of this process into diagnostics. De novo 
mutations were present in 53% of the patients and provided a conclusive genetic 
diagnosis in at least 13%, with an additional 3% of X-linked inherited mutations in 
known ID genes. This diagnostic yield is similar in magnitude but complementary 
to current genetic diagnostic chromosome analyses by genomic arrays.4, 25-27 We 
expect that the diagnostic rate will increase further as additional patients with 
mutations in the novel candidate genes reported here will be identified.
Identifying causal mutations in known ID genes in 16 of 100 patients provides 
clinically useful information for clinicians and families involved, as much is known 
about their prognosis and recurrence. The identification of the underlying genetic 
cause may also lead to specific treatment options or dietary advice. As an example, 
a ketogenic diet was advised for our patients with a PDHA1 mutation.28 In addition, 
a specific anti-epileptic treatment strategy, including the avoidance of sodium 
channel blockers, may be suggested for our patient with a de novo SCN2A mutation, 
as this leads to better seizure control and improvement of cognitive functioning and 
quality of life in patients with SCN1A mutations.29 
Our studies indicate that several of the new candidate ID genes that we identified 
will be confirmed as recurrently mutated in ID. We already identified additional de 
novo mutations in three of five genes tested (DYNC1H1, GATAD2B and CTNNB1) 
and detailed clinical analysis of these patients provided definitive evidence that 
these are novel ID genes. For DYNC1H1 we identified a de novo mutation by exome 
sequencing both in our pilot study9, as well as in this series, and recently reported 
Table 6   Continued.
Patient Number of  
de novo 
mutations
Molecular 
diagnosis   for ID
Based on [gene] (inheritance)
69 1 Highly likely GATAD2B (de novo)
70 3 Highly likely CTNNB1 (de novo)
71 0 NO  
72 2 Possible PPP2R5D (de novo)
73 0 NO  
74 1 Possible KIF5C (de novo)
75 1 NO  
76 1 NO  
77 1 NO  
78 0 NO  
79 2 Possible COL4A3BP (de novo)
80 0 NO  
81 2 Highly likely LRP2 (de novo + rare inherited)
82 1 NO  
83 0 NO  
84 0 NO  
85 0 NO  
86 1 NO  
87 2 Possible RAPGEF1 (de novo)
88 1 Possible ZMYM6 (de novo)
89 0 NO  
90 1 Possible PHACTR1 (de novo)
91 2 Possible EEF1A2 (de novo)
92 1 Possible MYT1L (de novo)
93 1 Possible MTF1 (de novo), TRPC5 (X-linked 
maternally inherited)
94 0 NO  
95 0 NO  
96 0 NO  
97 1 NO  
98 0 NO  
99 0 NO  
100 0 NO  
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the clinical overlap for these two cases.23 The identification of recurrently mutated 
genes in combination with detailed clinical phenotyping is likely to rapidly reveal 
novel ID genes and identify specific clinical subtypes of ID that may require specific 
clinical management. No additional diagnoses were found when analyzing 
autosomal recessive inherited mutations, apart from LRP2 which contained a de 
novo and a rare inherited mutation. The apparent absence of pathogenic mutations 
in autosomal recessive ID genes in our series indicates that this form of ID is rare in 
patients with isolated ID from non-consanguineous parents. Analysis of referrals for 
ID to our tertiary center shows that approximately 90% of patients with ID are from 
non-consanguineous parent and sporadic, 6% represent familial cases and 2% are 
sporadic cases born to consanguineous parents. X-linked forms of ID were 
diagnosed in five of the 100 patients, two of which occurred de novo. Mutations 
outside the coding regions as well as mosaic, digenic and/or oligogenic causes of 
ID remain to be defined.
Unbiased diagnostic approaches such as exome sequencing may also reveal 
clinically relevant mutations not related to the disease under investigation. An 
independent expert panel determined the clinical relevance of such incidental 
findings. Prior to enrolment in this study, all families were counselled about this 
possibility and consented to being informed if findings were deemed relevant by 
this panel. We note that not a single family objected to being informed about 
incidental findings. In this study, we encountered one incidental finding, a de novo 
c.517C>T  (p.(Tyr173His)) change in RB1. Mutations in this gene are associated with 
retinoblastoma (RB; OMIM#180200), an embryonic malignant neoplasm of retinal 
origin, and associated with a low risk of developing osteosarcoma.30 The expert 
panel considered the RB risk negligible for this patient as he already reached the 
age of 8 years, but decided that it was important to inform the parents of the small 
chance that a sudden painful swelling of the extremities could be caused by an 
osteosarcoma and they should consult an oncologist at the first symptoms. No 
further incidental findings were encountered.
In conclusion, our study establishes exome sequencing as a relevant diagnostic 
procedure for patients with severe ID of unknown cause. The current diagnostic 
yield in this series is 16% and this may well increase as methods further improve 
and more ID genes are identified. 
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Abstract
Kinesin superfamily (KIF) genes encode various motor proteins that are supposed 
to have fundamental roles in brain functioning, development, survival and plasticity, 
by regulating the transport of cargoes along microtubules within the axons, 
dendrites and synapses of neurons. Studies in mouse models support the important 
functions of KIF genes in the nervous system. Reports that relate KIF genes to 
intellectual disability (ID) are rare. 
Of interest, previous studies suggested that many ID genes impinge on synaptic 
function, in particular on the balance between excitatory and inhibitory synaptic 
input, and as such contribute to the pathophysiology of ID. 
By applying next generation sequencing (NGS) we identified likely pathogenic 
mutations in the X-linked KIF4A gene and the autosomal KIF5C gene and suggest 
that these genes are novel players in ID. Four males from one family with a mutation 
in KIF4A (c.1489-8_1490delins10; p.?- exon skipping) showed mild to moderate ID 
and epilepsy. A female patient with a de novo missense mutation in KIF5C 
(c.11465A>C; p.(Glu237Lys)) presented with severe ID, epilepsy and microcephaly. 
Furthermore, we found supporting evidence for the causality of the mutations by 
showing that knock-down of KIF4A and KIF5C in rat primary neurons altered the 
balance between excitatory and inhibitory synaptic efficacy leading to altered 
neuronal excitability. Our results let us suggest that mutations in KIF4A and KIF5C 
cause ID by tipping the balance between excitatory and inhibitory excitability at the 
synapse.
Kinesin superfamily proteins (KIFs) are motor proteins involved in the movement of 
various cargoes, including vesicles, organelles, protein complexes, mRNAs and 
chromosomes, along the microtubules.1-4 KIF proteins act together with motor 
proteins from the dynein and myosin superfamilies. These molecular motors are 
supposed to have fundamental roles in several processes in the brain, including 
neuronal functioning, development, survival and plasticity, by regulating the 
anterograde and retrograde transport within the axons, dendrites and synapses of 
neurons.1-4 Studies in mouse models support the essential functions of KIF genes 
in the development and functioning of the nervous system. Mice with homozygous 
knockout mutations in Kif1a, 1b, 2a, 3a, 3b, 4a, 5a and 5b show various neurological 
phenotypes including structural brain anomalies, decreased brain size, loss of 
neurons, reduced rate of neuronal apoptosis and perinatal lethality due to 
neurological problems.4-12 The embryonic lethality of knockout mice for Kif5b, Kif3a 
and 3b, and Kif2a suggest that these Kif genes have an important function in 
general development as well.5, 7, 8, 13 Overexpression of Kif17 in mice resulted in 
enhanced spatial learning.14 
Several KIF genes have previously been implicated in the pathogenesis of neuro-
degenerative and neurodevelopmental disorders in humans. An overview is shown 
in Table 1. 
Table 1   KIF genes implicated in neurodegenerative and neurodevelopmental 
diseases in humans.
KIF gene Disease Inheritance Reference
KIF1A (MIM 
601255)
Hereditary spastic paraplegia type 30 
(MIM 610358)
Hereditary sensory neuropathy, type IIC
(MIM 614213)
Non-syndromic ID
AR
AR
AD 
4, 15, 16
KIF1B (MIM 
605995)
Charcot-Marie-Tooth disease , type 2A1 
(MIM 118210)
Multiple Sclerosis (MIM 126200)
AD
Susceptibility 
locus
11, 17
KIF5A (MIM 
602821) 
Hereditary spastic paraplegia type 10 
(MIM 604187)
AD 4, 18
KIF7 (MIM 611254) Acrocallosal syndrome (MIM 200990)
Hydrolethalus syndrome (MIM 614120)
Joubert syndrome 12 (MIM 200990)
Syndromic ID
AR
AR
AR
AR
19-21
KIF21A (MIM 
608283)
Congenital opthalmoplegia  (MIM 
135700)
AD 22
AR: autosomal recessive; AD: autosomal dominant
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in two unaffected males (Figure 1). The mutation is located in the large Xp22q13 
linkage interval. Further analysis of the effect on RNA expression showed an effect 
on splicing, including skipping of exon 15 (Figure 2). 
This result let us suggest that KIF4A is a novel candidate XLID gene. KIF4A belongs 
to the class of the N5-kinesins and is highly expressed in differentiated young 
neurons. It consists of a N-terminal motor domain, a central stalk domain and a 
C-terminal C-domain.24 Previous studies showed that KIF4A has various functions 
and plays a role in chromosome condensation and midzone spindle pole formation 
essential for cytokinesis and chromosome segregation during mitosis,9, 25-27 as well 
Reports that relate KIF genes to intellectual disability (ID) rare. Putoux et al. identified 
homozygous mutations in KIF7 (MIM 611254) in patients with acrocallosal syndrome 
(MIM 200990) and hydrolethalus syndrome (MIM 614120)19, and homozygous 
mutations in the same gene were also found in Joubert syndrome 12 (MIM 
200990).20 In these ciliary disorders ID is part of the phenotype. Najmabadi et al. 
identified a homozygous missense mutation in KIF7 in a consanguineous family 
with ID, clubfeet, cataract, hearing loss and midface hypoplasia, detected by 
targeted sequencing of exons from homozygous linkage intervals.21 More recently 
the first dominant de novo missense mutation in a KIF gene (KIF1A) was found in a 
patient with non-syndromic ID.16
Here we report the identification of mutations in KIF4A (MIM 300521) and KIF5C 
(MIM 604593) in an X-linked ID family, presenting with mild to moderate ID and 
epilepsy, and in a sporadic patient with severe ID, microcephaly and epilepsy, 
respectively. In addition we studied the effects on synaptic function of these KIF 
genes using a knock-down system in rat primary neurons. 
We searched for the causative mutation in a family (family 1) with five affected 
males in different generations (Figure 1), suggesting X-linked recessive inheritance. 
In the index patient we performed massive parallel sequencing after a targeted 
enrichment of all X-chromosome specific exons, as described by Kalscheuer et al.23 
The affected patients presented with mild to moderate ID, were able to speak 
simple sentences and lived and worked in sheltered places. Four of the five 
individuals had epilepsy that manifested at later childhood or adolescent age and 
comprised complex partial and generalized seizures (both absences and 
tonic-clonic seizures). Head circumferences were small to low-normal (0.6th-10th 
centile). Facial dysmorphisms were mild and non-specific. A CT-scan of the brain in 
two of the probands (III:7 at age 53 years and IV:3 at age 7 years) had shown central 
atrophy of both lateral hemispheres and wide posterior horns, respectively. Previous 
genetic investigations in this family included conventional karyotyping, genome-wide 
array analysis by the 2.7M Affymetrix array platform, DNA analysis of FMR1 (MIM 
309550) and ARX (MIM 300382), and a metabolic screen. The results did not 
provide an explanation for their phenotype. Linkage analysis indicated  two intervals 
that could contain the pathogenic mutation, one of 70 cM on Xp22q13 and the other 
of 30 cM on Xq23q27, with a LOD-score of 1.8 (LOD-scores were calculated based 
on an X-linked recessive inheritance pattern with complete penetrance).
Targeted sequencing of the X-chromosome specific exons revealed a likely 
pathogenic in-frame mutation (c.1489-8_1490delins10 ((p.? - exon skipping)) in 
KIF4A (NM_012310.4). We subsequently confirmed the mutation by Sanger 
sequencing and found that it co-segregated with the phenotype in all affected 
males (a DNA sample of the uncle was not available). Three females from three 
generations were shown to be carriers of this mutation, but the mutation was absent 
Figure 1   Pedigree of family 1.
This figure shows the X-linked pedigree of family 1 with 5 affected males over 3 generations. The mutation 
in KIF4A was shown to co-segregate in affected males (III:5, III:6, III:7 and IV:3, a DNA sample of II:5 was 
not available) and was not present in two unaffected males (III:3 and III:8). Females II:1, III:1 and IV:2 were 
carriers.
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family 1 showed no increased level of aneuploid cells which is in agreement with 
the observation in most other studies that mitosis is not significantly disturbed.9, 25, 26
Patient 2 was recently identified in a large family-based exome sequencing project 
performed by our group in a series of 100 patients with sporadic ID (see chapter 
5.2).29 In short, she was born after an uncomplicated pregnancy and delivery with 
normal growth parameters. She had a severe developmental delay, did not acquire 
the ability to speak and could only walk with support since the age of 9 -10 years. 
First seizures manifested at the age of 6 months. Her behavior was characterized 
by severe automutilation. During clinical evaluation at the age of 12 years she had 
a normal height (-1 SD), but a very dystrophic build and secondary microcephaly 
(head circumerference: 49 cm (< -2.5 SD)). In addition she had small hands and 
feet. She had stereotypic hand movements and a slight hypertonia. There were no 
evident facial dysmorphisms. Because of the observed Angelman- and Rett-like 
syndrome phenotype, DNA analysis of MECP2 (MIM 300005), FOXG1 (MIM 164874), 
CDKL5 (MIM 300203), UBE3A (MIM 601623) and 15q11q13 methylation tests were 
performed, which were all normal. Subsequent 250k SNP array analysis, DNA 
analysis of ARX, and a metabolic screen revealed no abnormalities as well. 
Family-based exome sequencing revealed a highly conserved (PhyloP 6.1) de novo 
c.11465A>C mutation in KIF5C (NM 004522.1), predicting a p.(Glu237Lys) substitution. 
The Grantham score of 56 indicated a moderate physicochemical difference.
KIF5C belongs to the class of N-1 kinesins together with KIF5A and KIF5B. KIF5C is 
specifically expressed in nervous tissue.1, 13, 30 Mice with a homozygous knockout of 
KIF5C are viable and do not show gross abnormalities in the nervous system, 
except from a smaller brain size and relative loss of motor neurons to sensory 
neurons. This was explained by a high similarity between the three KIF5s and 
functional redundancy among these three KIF5s.13 Deletion of KIF5C was reported 
in several patients with the 2q23.1 microdeletion syndrome.31, 32 The mutation in 
KIF5C in the present patient 2 is a missense mutation affecting the motor domain of 
the KIF5C protein, and thus is in contrast to the other cases, not likely leading to 
haploinsufficiency. It might rather have a dominant negative effect resulting in 
abnormal heavy chain dimerization. 
A growing body of work suggest that many ID genes impinge on synaptic function 
and as such contribute the pathophysiology of the disorder.33 In particular the 
balance between excitatory and inhibitory synaptic input seems to be disturbed in 
common neurodevelopmental disorders including ID, autism and schizophrenia. 
Therefore, to find further supportive evidence that KIF4A and KIF5C are involved in 
the ID phenotypes of family 1 and patient 2 we performed functional studies at the 
level of synaptic function in hippocampal neurons. 
Primary hippocampal neuron cultures were prepared from embryonic day 18 (E18) 
old rats as previously described.34 Cultures were maintained in Neurobasal media 
as in regulation of activity-dependent neuronal survival and apoptosis, thereby 
regulating the number of neurons during murine brain development.9 After dissociation 
from an enzymatic protein called poly (ADP-ribose) polymerase 1 (PARP1), which 
prevents apoptosis, KIF4A moves into the neurites, where it possibly transports 
cargoes essential for neuronal development, such as the adhesion molecule L1 
which is required for axon formation and synapse development.9, 28 Although KIF4A 
was shown by several studies to be involved in spindle pole organization, most 
studies concluded that KIF4A deficient cells show a normal mitotic division. 
Aneuploidy analysis in cultured blood lymphocytes from one of the patients of 
Figure 2   RNA expression studies in cell-lines of patients from family 1 with a 
mutation in KIF4A and control cell-lines, showing effect on splicing.
This figure illustrates that the KIF4 mutation affects the acceptor splice site of exon 15 leading to a skip of 
exon 15 (186 bp in length). RNA was isolated from a cell-line from an affected family member and a 
healthy control person. Primers for PCR analysis were designed at exon 13/14 and exon 16/17 bounderies 
and cDNA was synthesized. Lane 1 shows the band of the patient (mt), which is about 180 bp shorter in 
length as compared to the band in a healthy control (c), due to skipping of exon 15.
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The amplitude of mEPSCs and mIPSCs is directly related to the postsynaptic 
strength, whereas the frequency is correlated to the presynaptic release properties 
and/or the amount of functional synapses. KIF4A knockdown resulted in a significant 
decrease in mEPSC amplitude and a significant increase in mEPSC frequency 
compared to control siRNA (KS-test, P<0.001), suggesting that the development of 
excitatory synapses is hampered in neurons lacking KIF4A (Figure 3A-C). In 
contrast, knockdown of KIF5C resulted in a significant increase in both amplitude 
and frequency of mESPCs (Figure 3A-C, KS-test, P<0.001), indicating that loss of 
KIF5C promotes excitatory synapse formation. This is somehow surprising since 
interfering with all KIF5 isoenzymes via the kinesin light chain was reported to 
decrease excitatory synaptic function.37 This result is thus indicative for a specific 
function of KIF5C at excitatory synapses. For both KIF4A and KIF5C, we did not 
observe any changes in the kinetics of mEPSCs, indicating that the composition 
and/or function of the glutamate receptors mediating the mEPSCs, e.g. AMPARs, 
was unchanged (Figure 3D, E). Next we measured mIPSCs, a response from 
quantal release of single GABAA vesicles. Down-regulation of KIF4A decreased 
mIPSC frequency but not amplitude, indicating that KIF4A affects presynaptic 
GABAA release and /or inhibitory synapse formation without affecting the amount 
GABAA-receptors (GABAARs) at inhibitory synapses (Figure 4A-C). For KIF5C the 
effects on mIPSCs were much more pronounced. Loss of KIF5C showed a decrease 
in amplitude and frequency of mIPSC compared to control conditions (Figure 
4A-C). This is in accordance with recent studies in which down-regulation of the 
KIF5 family in cortical neurons resulted in a decreased inhibitory input by regulating 
the trafficking of GABAARs at inhibitory synapses.35, 37 Knocking down KIF4A and 
KIF5C did not change the kinetics of mIPSCs indicating that they are not involved 
in the trafficking of a specific GABAAR subtype (Figure 4D, E). Together our data 
show that both KIF4A and KIF5C are important proteins that regulate synapse 
development. In particular KIF5C is a critical molecule in controlling the tight 
balance between excitatory and inhibitory inputs during development since 
knocking down KIF5C diminished inhibitory and increased excitatory synaptic 
efficacy. A disturbed balance between excitatory and inhibitory drive could explain 
the presence of epilepsy in the patients. 
In summary, our studies support the involvement of the kinesin superfamily 
members genes KIF4A and KIF5C in the ID phenotypes of the presented patients. 
Identification of other patients with mutations in these genes should further confirm 
the role of KIF4A and KIF5C in ID phenotypes and may give further insights in the 
clinical spectrum. At the functional level we found that both KIF4A and KIF5C may 
contribute to the pathophysiology of ID by altering the balance between excitatory 
and inhibitory synaptic efficacy leading to changed neuronal excitability. As such 
(GIBCO-Invitrogen) supplemented with B27, penicillin, streptomycin, and L-glutamine. 
Hippocampal neurons (6 DIV) were transfected with a mix of 3 siRNAs (5 nM) 
targeting KIF4A or KIF5C, and a fluorescently labeled scrambled siRNA using 
Lipofectamine 2000. All experiments were performed 3 days after transfection. The 
following validated siRNA’s were obtained from Sigma Aldrich: KIF4A; SASI_
Rn02_00290987  5’- CUAAUGACUUCUGUAGCUU-3’;  SASI_Rn02_00290988 5’- 
CAUCUAGAACUGAAACCUA-3’; SASI_Rn02_00290989 5’- CAACCUAGAGGAAA-
CAUUA-3’. KIF5C; SASI_Rn02_00231705 5’- GGUUACAAUGGGACAAUUU-3’; 
SASI_Rn02_00231706 ; 5’- GCUUCUAGCUUCCACCAGA-3’; SASI_Rn02_00231707 
5’- CAGAGAACUCCAGACUCUU-3’. The BLOCK-iT fluorescent oligo (Invitrogen) 
that is not homologous to any known genes was used as transfection efficiency 
detector and a negative control. Each siRNA was tested in hippocampal neurons 
and validated using quantitative PCR. 
No reports are available on the synaptic function of KIF4A, whereas KIF5 was 
recently reported to be involved in regulating both glutamatergic and GABAergic 
synaptic transmission in striatal and cortical neurons.35-37 However the specific 
contribution of KIF5C has not been determined yet. To this end we examined the 
impact of KIF4A and KIF5C knockdown on both miniature excitatory, and inhibitory 
postsynaptic currents (mEPSC and mIPSC, respectively) in rat hippocampal 
neurons during a period of increased synaptogenesis, using validated siRNA’s. 
Whole-cell recordings were obtained with Multiclamp 700B amplifiers (Axon 
Instruments). To monitor the effects of KIF4A and KIF5C knockdown on synaptic 
transmission, hippocampal cultures were transfected with siRNAs at 6DIV. Three 
days later, whole-cell recordings were obtained from transfected neurons under 
visual guidance using epifluorescence and transmitted light illumination. The 
recording chamber was perfused with artificial cerebrospinal fluid (ACSF) 
containing 119 mM NaCl, 2.5 mM KCl, 4 mM CaCl2, 4 mM MgCl2, 26 mM NaHCO3, 
1 mM NaH2PO4, 11 mM glucose (pH 7.4), and gassed with 5% CO2/95% O2. 
Recordings were made at 30°C. Patch recording pipettes (3–5 MΩ) were filled with 
intracellular solution containing 115 mM cesium methanesulfonate, 20 mM CsCl, 
10 mM HEPES, 2.5 mM MgCl2, 4 mM Na2ATP, 0.4 mM Na3GTP, 10 mM sodium 
phosphocreatine, and 0.6 mM EGTA (pH 7.25).
Spontaneous responses were recorded at −60 mV in ACSF containing 2.5 mM 
CaCl2 and 1.2 mM MgCl2 at 30°C. mEPSCs were recorded in the presence of 1 μM 
TTX and 0.1 mM picrotoxin, whereas mIPSCs were recorded in the presence of 10 
μM CNQX and 100 μM APV. Five to 10 min of recordings were analyzed from each 
cell. Data were acquired at 5 kHz, filtered at 2 kHz, and analyzed using the Mini 
Analysis Program (Synaptosoft). All data are reported in a cummulative plot. 
Statistical significance was determined by the Kolmogorov-Smirnov test (KS-test). 
Significance was set to P < 0.01.
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microtubule transport pathway may be an evolving ID pathway, and other genes 
encoding microtubule transport proteins may well be potential candidates for 
involvement in ID phenotypes as well.  
they can be added to the growing list of ID genes that influence synaptic functioning.33 
Of interest, we recently reported the involvement of another component of the 
microtubule transport pathway in two patients with a similar ID phenotype. Both 
patients had a conserved de novo mutation in dynein, cytoplasmic 1, heavy chain 1 
(DYNC1H1, MIM 600112), encoding a component of the cytoplasmic dynein 1 motor 
protein complex.38 Therefore, our present and previous findings indicate that the 
Figure 4   Effect of KIF4A and KIF5C on mIPSC.
(A) Representative whole-cell current traces  (mIPSC) of a control neuron or a neuron transfected with 
siRNAs against KIF4A or KIF5C at holding potential of −60 mV. Scale bars: 16 s and 25 pA (B, C) 
Cumulative probability histograms of mIPSC amplitude and inter-event intervals in control (n=7 neurons), 
KIF4A siRNA treated neurons (n=10 neurons) and KIF5C siRNA treated neurons (n=8 neurons). (D, E) 
Average rise (D) and decay time (E) of mIPSCs of control neurons and neurons treated with siRNAs 
targeting KIF4A or KIF5C.  Differences between control and KIF4A siRNA are statistically significant for the 
displayed inter-event interval cumulative distributions but not for the mIPSC amplitude. Differences 
between control and KIF5C siRNA are statistically significant for the displayed mIPSC amplitude and 
inter-event interval cumulative distributions (P < 0.001, using Kolmogorov-Smirnov test). Error bars 
indicate S.E.M. Histograms show means + S.E.M. 
Figure 3   Effect of KIF4A and KIF5C on mEPSC.
(A) Representative whole-cell current traces  (mEPSC) of a control neuron or a neuron transfected with 
siRNAs against KIF4A or KIF5C at holding potential of −60 mV. Scale bars: 1.2 s and 20 pA (B, C) 
Cumulative probability histograms of mEPSC amplitude and inter-event intervals in control (n=39 
neurons), KIF4A siRNA treated neurons (n=30 neurons) and KIF5C siRNA treated neurons (n=34 neurons). 
(D, E) Average rise (D) and decay time (E) of mEPSCs of control neurons and neurons treated with siRNAs 
targeting KIF4A or KIF5C.  Differences between the conditions for the displayed mEPSC amplitude and 
inter-event interval cumulative distributions are statistically significant (P < 0.001, using Kolmogorov-
Smirnov test). Error bars indicate S.E.M. Histograms show means + S.E.M. 
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In chapters 3-5, various specific findings resulting from our studies were highlighted. 
This chapter describes the general overview of the results in the total study cohort, 
which is described in chapter 2.
  
6.1  Diagnostic phase 
A general overview of the results in the diagnostic phase is shown in Table 1. In total, 
in 178 of 234 index patients (76.1%) the diagnostic tests revealed an abnormal finding. 
In 43 cases (18.4%) the identified variants were (likely) pathogenic and in 55 (23.5%) of 
the cases the clinical relevance of the findings was unknown.  
Criteria that were used to assess pathogenicity are described in chapter 2 of this 
thesis. In the 18.4% of cases with a (likely) diagnosis, the majority (about 2/3) was 
explained by a copy number variation (CNV). Monogenic defects and metabolic 
abnormalities accounted for the other cases. 
(Likely) pathogenic findings
In 12.4% of all individuals a (likely) pathogenic chromosomal aberration was 
detected. A detailed overview is shown in  table 2. (Likely) pathogenic chromosomal 
copy number variations (CNVs) included well-known microdeletion syndromes, 
such as 1qter microdeletion syndrome (OMIM 612337), Sotos syndrome (5q35 
Table 1   General overview of abnormal findings in the diagnostic phase.
Abnormal finding (Likely) 
pathogenica
Unknowna (Likely) non-
pathogenica 
Total Na 
Chromosomal CNV 29 (12.4) 16 (6.8) 11 (4.7)  56 (23.9)
Monogenic defect 11 (4.7)   0 (0)   3 (1.3)  14 (6.0)
Homozygous region 
(>3 Mb)
  0b (0) 21 (9.0)   0 (0)  21 (9.0) 
Metabolic 
abnormality
  3c (1.3) 18 (7.7) 66 (28.2)  87 (37.2)
Total N (%) 43 (18.4) 55 (23.5) 80 (34.2) 178 (76.1)
CNV: copy number variation
a number (%) of 234 index participants
b  in 1 patient (09-0038) a ‘pathogenic’ homozygous region was found, which was explained by a mosaic 
trisomy. This patient was included in the chromosomal CNV group
c  all mitochondrial disorders, not otherwise specified, because further investigations (in skin biopsy) were 
not possible
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Table 2   (Likely) pathogenic chromosomal copy number variations detected in the  
total cohort (N= 29).
Case
number
Patient ID Phenotype Sex CNV Chromosomal 
region
Start-End Mb 
positions (Hg19)
Size/Gene content Inheritance Chromosomal analysis References 
1 08-0009 Sev. ID; D; MC; GR 
growth retardation; 
N; E
F Loss 1qter 244.55-249.14 4.4 Mb/>40 genes De novo 250k SNP array analysis 16
2 09-0018 Mild ID; CA M Loss 1p21.3 97.55-98.96 1.41 Mb/3 genes De novo 250k SNP array analysis 17
3 09-0044
09-0046 
(sibs)
Mild ID; F; N M Loss 1p21.3 97.72-99.48 1.7 Mb/6 genes Inherited (parents 
not tested)
250k SNP array analysis 17
4 11-0021 Mod.ID; D; CA; N M Gain 1q12q21.1 144.04-145.71 1.7 Mb/17 genes Unknown (father 
not available)
250k SNP array analysis 18-20
Decipher:
Case  numbers 250709 
and  255915 
5 10-0059 Mild ID, anxiety 
disorder
F Loss 2p16.3 51.02-51.48 455kb/1 gene 
(NRXN1)
De novo 2.7M array analysis 21, 22
Decipher: 
Case numbers 
951,250904, 251242  
6 09-0068 Mod. ID;
D; CA
M Loss 2q37.3 242.01-242.36 350 kb/8 genes NT (parents not 
available)
250k SNP array analysis 23
7 11-0028 Sev. ID;
GR; D; E
M loss 3p25.3 8.42-9.58 1.16 Mb/12 genes NT (parents not 
available)
250k SNP array analysis 24
Decipher: 
Case number 248715
8 09-0042 Sev.ID;
GR; E
MC; D
M loss
gain
3p26.3 
14q31.1q32.33
(t(3;14)) 
0.73-1.66
81.83-107.29
1.6 Mb/3 genes
~25 Mb/>50 genes
Maternal balanced 
translocation
250k SNP array analysis 25-28
9 08-0012 Sev. ID; GR;
MC; Hypogonadism; 
Hearing loss;
Behaviour problems
F loss 3q24q25.4 143.14-159.39 16.2 Mb/>30 genes NT (parents not 
available)
Initially routine cytogenetic
analysis by G-banding; 
Further delineation by 250k 
SNP array analysis
29
10 10-0042 Sev. ID; GR; 
Small hands and 
feet; E;D
F loss 4q21.21q21.23 79.93-85.12 5.2 Mb/>32 genes De novo 2.7M array 30
Decipher: 
Case numbers 252386, 
994 
11 09-0075 Sev. ID; MC; 
Behaviour problems;
Kyphoscoliosis;
M loss 5q35.2q35.3 175.57-176.89 1.3 Mb/~20 genes, 
including NSD1 
(Sotos syndrome)
De novo 250k SNP array analysis 31
12 10-0099 Mild ID; 
High myopia; GR; 
MC; Psychiatric 
problems
F gain 7q36.1 151.79-152.50 710 kb/6 genes NT (parents not 
available)
250k SNP array analysis Decipher:
 Case number 255588
Case in personal 
database
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Table 2   Continued.
Case
number
Patient ID Phenotype Sex CNV Chromosomal 
region
Start-End Mb 
positions (Hg19)
Size/Gene content Inheritance Chromosomal analysis References 
13 08-0030 Sev. ID; MC; E;
D; Depigmentation 
spots
M loss 7q22.1 98.76-100.80 2 Mb/>70 genes Unknown (father 
not available)
250k SNP array analysis Decipher:
Case numbers 854, 
256143, 248317, 253694, 
252368. 
Ecaruca: case numbers 
4328, 290, 2852, 2521, 
1720 
14 09-0038 Mild ID;
IUGR;
Cardiac arrhythmia;
Kyphoscoliosis;
Dolichocephaly
M gain Low grade 
mosaic trisomy 
9, uniparental 
disomy 9
Large homozygous 
stretches chromosome 
9 
Total chromosome 9 
(mosaic)
NT 250k SNP array
FISH buccal swap: low 
mosaic pattern trisomy 9
32-34 
15 11-0022 Mod. ID; CA;E M gain 12p11.23 27.29-27.79 500 kb/ 4 genes De novo 250k SNP array Decipher
Case number 256785 
Two overlapping cases 
with overlapping 
phenotype in our personal 
database (inherited)
16 09-0025 Sev. ID; MC;
Small hands and 
feet; N; Behaviour 
problems;
CA;E
F loss 14q12 29.83-31.73 1.9 Mb/8 genes De novo 250k SNP array 35-37
Decipher: 
Case numbers 3810, 
248405, 2060, 251718
17 09-0028 Mild ID,
D; CA
M gain 15q11.2-q15.1
(marker 
chromosome 
15, 3 copies 
BP1-BP6)
22.75 – 35.21 12.7 Mb/>tens of 
genes
Maternal 250k SNP array
Additional MLPA
38
18 09-0048 Mild ID; D F gain 15q11.2q13.1 23.70-28.53 4,8 Mb/ 19 genes Unknown (parents 
not available)
250k SNP array
Additional conventional 
karyotyping
39, 40
19 11-0033 Mild ID; Fa M gain 15q13.2q13.3 30.91-32.51 1.58 Mb/ 13 genes Paternal 250 k SNP array 40
Decipher: Multiple 
overlapping gains 
20 10-0039 Mod.ID; D; CA F loss 17p11.2 16.76-20.43 3,7 Mb/tens of genes De novo 2.7M array OMIM 182290 (Smith-
Magenis Syndrome)
21 09-0060 Sev. ID M loss 16q23.3q24.1 82.85-84.49 1,64 Mb/13 genes Unknown (parents 
not available)
250k  SNP array -
22 10-0060 Mild ID; CA M gain 17q12 34.38-36.45 1.8 Mb/ 25 genes maternal 250k SNP array 41
Decipher:
Case numbers 2843 and 
1718 
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In only three patients (1.3%) a pertinent metabolic cause of ID could be established, 
in all three cases a mitochondrial disorder. The mitochondrial defects could not be 
further specified, because the parents, the legal representatives and/or the patients 
themselves were reluctant to give permission for a skin or muscle biopsy for further 
investigations. 
In the general overview of the yield of this cohort study (table 1) only molecularly 
confirmed genetic diagnoses were taken into account. For example, one patient 
had an evident clinical diagnosis of Gomez-Lopez-Hernandez syndrome (OMIM 
601853), though the underlying genetic cause has not been elucidated. In contrast 
with most previous cohort studies1-6, we have not included such patients in 
the general overview of positively diagnosed patients. Rather, the Gomez-Lopez- 
Hernandez syndrome patient was moved to the diagnostic related research phase 
of our study. 
Findings with unknown clinical relevance
In 23.5% of the patients the diagnostic tests revealed an abnormal finding with 
unknown clinical relevance. The chromosomal aberrations with unknown significance 
microdeletion, OMIM 177550), Smith-Magenis syndrome (17p11.2 microdeletion, 
OMIM 182290), 15q13 microdeletion (OMIM 612002) and microduplication 
syndromes (OMIM 608636), 17q21.31 microdeletion syndrome (OMIM 610443) and 
22q13 microdeletion syndrome (OMIM 606232) (case numbers 1, 11, 18-21, 23 and 
24). In addition, several more rarely reported CNVs, and novel CNVs (case numbers 
2 and 3) were included in the group of (likely) pathogenic CNVs. 
In about 4.7% of the patients a monogenic defect was identified as the cause of ID. 
Monogenic defects are summarized in table 3.
Table 2   Continued.
Case
number
Patient ID Phenotype Sex CNV Chromosomal 
region
Start-End Mb 
positions (Hg19)
Size/Gene content Inheritance Chromosomal analysis References 
23 08-0025 Mod. ID; D; E F loss 17q21.31 43.74-44.24 460 kb/4 genes De novo 250k SNP array 42
24 09-0049 Sev. ID; D; 
CA; GR; E
M loss
gain
20p13
20q13.33
0.60-1.12
59.95-62.38
1,06 Mb/21 genes
2,46 Mb/>50 genes
Inherited (balanced 
rearrangement in 
mother)
250k SNP array 43
25 10-0048 Sev.ID; D; N; E M loss 22q13.32q13.33 49.40-51.20 1.8 Mb/ tens of 
genes
Unknown (parents 
not available)
2.7M array 44, 45
OMIM 606232 (Phelan- 
Mc Dermid syndrome) 
26 10-0055 Sev. ID; D; 
CA; Fa
M Loss 22q13.32q13.33 49.03-51.18 2.12 Mb/ tens of 
genes
Inherited (identical 
deletion in affected 
brother)
250k SNP array 44, 45
OMIM 606232 (Phelan- 
Mc Dermid syndrome) 
27 11-0008 Mild ID; D M gain 22q11.22q11.23 23.07-24.96 1.9 Mb/43 genes Maternal (learning 
difficulties)
250k SNP array 46, 47
Decipher: 
Case numbers 251348, 
2727 
28 09-0085 Sev. ID; GR; D; CA M loss Xp22.31p22.33 0.14-6.41 6.4 Mb/20 genes Maternal (learning 
difficulties)
250k SNP array 48-50
29 09-0015 Mod. ID; N M loss Xq22.2 102.958 – 102.977 19 kb/2 genes maternal Cytoscan HD array 51
NT= not tested. Sev./Mod./Mild ID: severe/moderate/mild ID; D: dysmorphism; MC: microcephaly; MaC: 
macrocephaly; (IU)GR: (intra-uterine) growth retardation/short stature; CA: congenital anomaly; Fa: ID in 
family; N: neurological features; E: epilepsy. 
Classifications of findings in each individual patient in this cohort were based on careful consideration of 
the full picture of the criteria for assessment of clinical relevance as mentioned in Chapter 2, Table 4. 
None of the criteria was absolute and each criterion was considered in perspective to the other criteria, 
the currently available information in literature and databases, and the phenotype of the patient. 
Microdeletions and microduplications that can be considered as a strong risk factor for ID but have 
sporadically been reported in healthy controls or are inherited, such as  15q13 microdeletions and 
duplications, were either classified as (likely) pathogenic or as of unknown clinical significance depending 
on the phenotype of the respective patient.
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(Likely) non-pathogenic findings
In about one third (34.2%) we detected abnormal findings that are unlikely to have 
an association with the ID phenotype. These (likely) non-pathogenic chromosomal 
CNVs are summarized in table 6. The majority of (likely) non-pathogenic findings 
resulted from the metabolic screen and included non-specific, benign, inconsistent 
and/or iatrogenic abnormal values of metabolites in urine or serum that did not 
have an apparent relation with the ID phenotype. For example, mildly increased 
levels of alanine due to pharmacotherapy with sodium valproate were frequently 
observed.  
are summarized in table 4. Homozygous regions ≥3 Mb were arbitrarily put into this 
category in table 1, with the argument that these regions are candidate regions for 
the localization of autosomal recessive (AR) ID genes, but this is not necessarily the 
case. An overview of detected homozygous regions is shown in table 5.  
Table 3   Monogenic defects identified by specific DNA diagnostic tests in  
diagnostic phase of the study.
Case
number
Patient id Sex Phenotype Gene/ Accession number Mutation Inheritance Clinical relevance
1 08-0034 M Sev. ID; D; GR; MC; CA; E ATRX/NM_000489.3 p.Ser1772Phe Maternal Pathogenic
(OMIM 301040, ATRX syndrome)
2 09-0006 F Mod. ID; D; N EHMT1/NM_024757.3 c.3087+1G>T in intron 
20 (dss)
De novo Pathogenic
(OMIM 610253, Kleefstra syndrome)
3 09-0008 M Mild ID;  D; N FGFR3/NM_00142.3. p.Pro250Arg NT Pathogenic 
(OMIM 602849, Muenke syndrome)
4 09-0020 M Sev. ID; N; E; Fa MECP2/NM_004992.2 p.Ser411fs Maternal Pathogenic (OMIM 312750, Rett syndrome) 
5 09-0026 M Mod. ID; D; GR; CA MID1/NM000381.3 IVS7/exon 8 NT Pathogenic (OMIM 300000, Opitz GBBB syndrome)
6 09-0040 M Sev.ID; D; MC TCF4/NM_001083962.1 p.Arg580Gln De novo Pathogenic (OMIM 610954, Pitt-Hopkins syndrome)
7 09-0043 M Sev. ID; D RAI1/NM_030665.3 Variation intron 5 Maternal Non pathogenic
8 09-0051 M Sev.ID; D; GR; CA MCT8/NM_006517.4 Synonymous NT Non pathogenic
9 09-0084 M Sev. ID; E SCN1A/NM_001202435.1 p.Ser1768Arg De novo Pathogenic
(OMIM 607208, Dravet syndrome)
10 10-0001 M Mild ID; N DMPK/NM_001081562.1 >150 (CTG)n repeats in 
3`UTR
Maternal Pathogenic
(OMIM 160900, Myotonic Dystrophy)
11 10-0003 F Sev.ID; D: N; E CDKL5/ NM_003159.2 splice site mutation 
intron 7
De novo Pathogenic
(OMIM 300672, Rett syndrome variant with infantile 
spasms)
12 10-0006 M Sev.  ID; N; E SCN1A/NM_001202435.1 p.Glu1176fs De novo Pathogenic
(OMIM 607208, Dravet Syndrome)
13 10-0018 M Sev. ID; GR RAI1/NM_030665.3 p.Pro242Leu NT Non pathogenic (found in healthy controls)
14 10-0054 F Mod. ID; D; Fa RSK2/NM_004586.2 Intronic, affects splicing, 
exon 5 is skipped. p.?
NT Pathogenic  
(OMIM 303600, Coffin-Lowry syndrome)
NT= not tested.  Sev./Mod./Mild ID: severe/moderate/mild ID; D: dysmorphism; MC: microcephaly; MaC: 
macrocephaly; (IU)GR: (intra-uterine) growth retardation/short stature; CA: congenital anomaly; Fa: ID in 
family; N: neurological features; E: epilepsy. Dss: donor splice site. IVS: intron intervening sequence
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Table 4   CNV’s with unknown clinical relevance (N=16).
Case
number
Patient ID Phenotype Sex CNV Chromosomal 
region
Start-End Mb 
positions (Hg19)
Size/Gene content Inheritance SNP array platform References 
1 09-0021 Sev.ID; D; GR; CA; N F gain 1q21.1 145.51-145.71 200 kb/~10 genes Maternal 250k SNP array 18-20
Multiple overlapping cases 
reported in Decipher
2 09-0007*a Mod. ID; MC; GR F gain 2p12p11.2 81.09-84.69 3.6 Mb/3 genes, 
including SUCLG1
Unknown (parents 
not available)
250k SNP array SUCLG1 (OMIM 245400): 
involved in autosomal 
recessive mitochondrial 
DNA depletion syndrome
3 10-0008 Sev. ID; D; MC; N F Mosaic 
gain
2q34 209.42-210.45 1,03 Mb/2 genes, 
including MAP2 
(disrupted)
Unknown (parents 
not available)
250k SNP array MAP2 (OMIM 157130): 
microtubule associated 
protein, important in 
neurogenesis52
4 10-0023 Sev.ID; MC; GR M gain 3p14.1 65.90-66.79 991 kb/3 genes (1 
disrupted)
Unknown, but 3 
unaffected sibs do 
not carry this gain
250k SNP array -
5 11-0035 Mod. ID; GR; N F gain 5q31.2 138.52-139.61 1 Mb/ > 10 genes Unknown (parents 
not available)
250k SNP array Overlapping gain in female 
girl with developmental 
delay in personal database 
(inheritance unknown)
6 11-0032 Sev. ID; D; GR;
CA; E
M gain 5q35.2 172.87-174.57 1.7Mb/ 7 genes 
(including MSX2)
Paternal 250k SNP array analysis 53, 54
7 10-0017 Mild familial ID 
(affected female sib)
M gain 9p13.3 33.56-34.51 950 kb/ 15 genes (2 
disrupted)
Paternal 250k SNP array OMIM 604366: DNAI1  
(AR Kartagener syndrome)
Decipher:  
Case number 251082 
(inherited from normal 
parent)
8 10-0074 Mod. ID; D F gain 10p15.1 4.86-5.23 365 kb/ 6 genes
(1 disrupted)
Maternal 250k SNP array Decipher: Case number 
255355
9 11-0029 Mild ID; D F gain 14q32.11 89.10-89.45 350 kb / 2 genes (1 
disrupted)
Maternal 250k SNP array -
10 10-0068 Mild ID; D; MC M gain 15q26.3 100.00-100.59 600 kb/ 5 genes 
(including MEF2A)
Maternal (learning 
difficulties)
250k SNP array Decipher:
Case number 248272, 
253919 (much larger, 
though overlapping 
11 09-0069 Mild ID; CA; N;  E M gain 17q25.3 80.87-81.01 180 kb/2 genes Unknown (father 
not available)
250k SNP array -
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6.2  Diagnostic related research phase 
Fifty of the 191 (26.2%) patients in whom the diagnostic phase of the study did not 
reveal a molecular diagnosis were included in further studies in the second, 
diagnostic related research phase of the study. Various subgroups of undiagnosed 
patients were considered for further analyses, mainly by various next generation 
sequencing (NGS) approaches (in 47 patients), including 1) patients with sporadic 
ID, an IQ<50 and availability of both parental samples, 2) patients with familial ID, 
compatible with an X-linked (XL) and/or autosomal recessive (AR) pedigree, and 
availability of DNA samples of a sufficient number of affected and non-affected 
family members. Patients with genomic variants of unknown clinical significance 
(except for homozygous regions) were excluded from further NGS studies (see also 
chapter 2).
Table 4   Continued.
Case
number
Patient ID Phenotype Sex CNV Chromosomal 
region
Start-End Mb 
positions (Hg19)
Size/Gene content Inheritance SNP array platform References 
12 11-0022*b Mod. ID; CA M gain 18q12.2q13 37.19-37.50 320 kb/2 genes 
(disrupted)
Paternal 250k SNP array Decipher:
Case number 251555 (this 
patient has in addition 
another small gain of 
unknown significance
13 10-0046 Mod. ID;
D; CA
M gain 20p12.2 9.73-9.88 150 kb/1 gene (PAK7 
disrupted)
Unknown (parents 
not available
2.7M array Internal database: in  2 
patients with MCA, in one 
inherited from parent. In 
other unknown inheritance. 
PAK7*c may have important 
function in brain55 
14 10-0098 Sev. ID; GR; 
MC; CA
M loss 22q11.21q11.22 21.98-22.98 1 Mb/14 genes Unknown (parents 
not available)
250k SNP array 46, 56
Decipher: 
Case numbers: 250737, 
4625, 2748 
15 08-0010 Sev.ID; D; GR;
CA; E
F gain 22q11.23 25.08-25.23 150kb/2 genes Unknown (father 
not available)
250k SNP array -
16 08-0031 Mod. ID; N M gain 22q11.23 23.68-24.98 1.3 Mb/~25 genes Maternal 250k SNP array 47
Decipher: 
Case number 251348
NT= not tested. Sev./Mod./Mild ID: severe/moderate/mild ID; D: dysmorphism; MC: microcephaly; MaC: 
macrocephaly; (IU)GR: (intra-uterine) growth retardation/short stature; CA: congenital anomaly; Fa: ID in 
family; N: neurological features; E: epilepsy
*a Based on metabolic investigations, this patients was diagnosed with a mitochondrial disorder. It is 
unknown whether the gain with proximal breakpoint through the gene SUCLG1 has a causal role
*b This patients has a (likely) pathogenic CNV as well (see Table 2)
*c PAK7 is alternatively called PAK5, which may be confusing
Classifications of findings in each individual patient in this cohort were based on careful consideration of 
the full picture of the criteria for assessment of clinical relevance as mentioned in Chapter 2, Table 4. 
None of the criteria was absolute and each criterion was considered in perspective to the other criteria, 
the currently available information in literature and databases, and the phenotype of the patient. 
Microdeletions and microduplications that can be considered as a strong risk factor for ID but have 
sporadically been reported in healthy controls or are inherited, such as  15q13 microdeletions and 
duplications, were either classified as (likely) pathogenic or as of unknown clinical significance depending 
on the phenotype of the respective patient.
304 305
chapter 6 general overview of results
6
Table 5   Homozygous regions detected (N=21).
Case
number
Patient id Familial ID Chromosomal region Size Known ID associated genes Consanguinity Further evaluation
1 08-0015 Yes, but NA Multiple More and larger homozygous 
regions. In total 135 Mb
Multiple Likely No
2 08-0032 Yes, but NA Multiple More and larger homozygous 
regions
Multiple Likely No
3 08-0035 Yes 14q12 4.9 Mb FOXG1 (OMIM 164874) Yes Targeted NGS (including FOXG1), followed by 
WES
4 09-0029 No Multiple More and larger homozygous 
regions
Multiple Likely No
5 09-0036 Unknown*a 19p13.12, in overlap with 
milder affected brother
6.2 Mb CC2D1A (OMIM 610055) No Sequencing CC2D1A
6 09-0039 Yes, but NA 17p12p11.2 8,8 Mb 6 (1 AD, 5 AR)
ALDH3A2 (OMIM 609523)
B9D1 (OMIM 614144)
ATPAF2 (OMIM 608918)
RAI1 (OMIM 607642
TTC19 (OMIM 613814 )
COX10 (OMIM 602125)
No Clinical: phenotype does not fit with involvement 
of these genes
Metabolic screen revealed no indication for 
mitochondrial disorder (ATPF2, TTC19, COX10)
7 09-0050 No Multiple, including large on 
chromosomes 1 and 9
18,1 Mb
12,9 Mb
Multiple Yes Trio based WES
8 09-0058 No 5q33.1q34 14 Mb Multiple (>50 genes) No Trio based WES
9 09-0061 Yes Multiple, some overlapping More and larger homozygous 
regions
Multiple Yes  WES
10 10-0024 No 5qter and multiple small 8 Mb Multiple Possibly No
11 10-0032 No 2q33.1q34
8q22.1q22.3
8q23.1q24.11
10,5 Mb 
7,4 Mb 
11,7 Mb 
7 mitochondrial disease genes
MKS3 (OMIM 607361)
COH2 (OMIM 216550)
TRPS1 (OMIM 604386)
Unknown Metabolic screen revealed metabolic defects  
that might be indicative for a mitochondrial 
disorder. Further evaluation was not possible
12 10-0034 Yes 5q14.3q21.1 11,7 Mb (~40 genes) 1 AD ID gene:  
MEF2C (OMIM 600662)
No No
13 10-0056 Yes Multiple, some overlapping in 
affected sister
More and larger homozygous 
regions
Yes WES
14 10-0076 Yes 3p21.31p21.1 8 Mb 7, mostly AR metabolic 
disorders
No Metabolic screen was not indicative for  
metabolic disorder
WES
15 10-0078 No Diverse More and larger homozygous 
regions
Multiple Yes No
16 10-0094 No 1q23.3q25.1 12,7 Mb TMCO1(OMIM 614123) 
DARS2 (OMIM 610956)
No Clinical: phenotype does not fit with involvement 
of these genes
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be plausible novel ID genes and thus likely pathogenic. In three patients pathogenic 
mutations in known ID genes were found, including PDHA (Pyruvate dehydrogenase 
E1-alpha deficiency, OMIM 312170), GRIN2A (Epilepsy with neurodevelopmental 
defects, OMIM 613971) and LRP2 (Donnai-Barrow syndrome, OMIM 222448). 
Donnai-Barrow syndrome is an AR syndromic form of ID. The patient with a de novo 
mutation in LRP2 had in addition a rare paternally-inherited, predicted pathogenic 
variant. Analyses to show that the de novo event occurred on the maternal haplotype 
were inconclusive, but based on the phenotype of the patient this was considered 
to be causative (see chapter 5.2). This illustrates that other patients with a 
suspected AD cause of ID that are selected for a family based WES approach may 
have AR ID as well. However, in the series of 100 ID trios the analyses for AR causes 
did not reveal any additional AR causes.  
Pathogenic mutations in novel recurrent ID genes were detected in three patients 
and included mutations in DYNC1H1 (see chapter 5.1)8, GATAD2B and CTNNB1. 
Patients with mutations in these genes showed overlap in phenotype, which further 
confirmed a causal relation of these genes with the observed ID phenotypes. 
Mutations in DYNC1H1 and GATAD2B were identified in single patients from the 
cohort described in chapter 2 of this thesis, but were recurrently found in patients 
from other in house series. Mutations in CTNNB1 were identified in two patients 
from this cohort. In one of them (A10-0040) the mutation was identified by 
family-based WES. The second patient was not included in family-based WES 
studies (because parental samples were not available), but was included in a series 
Homozygosity mapping
Families of three patients with familial ID and who carried a significant homozygous 
region (table 5) were further analyzed by homozygosity mapping to assess the 
relevance of the homozygous region. In cases that all affected individuals in one 
family shared the same homozygous region, candidate genes in the overlapping 
homozygous regions were selected for Sanger sequencing. No mutations were 
found (see table 5). 
WES in patients with sporadic ID and suspected autosomal 
dominant (AD) inheritance
Thirty-eight patients with likely sporadic autosomal dominant (AD) ID were included 
in a larger project applying a family based whole exome sequencing (WES) 
approach in 100 patient-parent trios to identify de novo mutations causing severe 
ID (see chapter 5.2).7 
In two patients with a clinically recognizable syndrome WES was applied as well. 
They were not included in the 100 trios project. In 22 (55%) one or more de novo 
mutations (confirmed by Sanger sequencing) were identified. Family based WES in 
the total of 40 patients has led to the identification of 14 (35%) (likely) pathogenic de 
novo mutations leading to a pertinent or plausible diagnosis (see table 7). In the 
diagnostic related research phase of this study, mutations in known ID genes and 
novel recurrent ID genes were considered to be pathogenic beyond any doubt. De 
novo mutations in genes with a biological link to an ID pathway were considered to 
Table 5   Continued.
Case
number
Patient id Familial ID Chromosomal region Size Known ID associated genes Consanguinity Further evaluation
17 10-0104 Yes 1p13.3p12 (overlapping with 
homozygous region in two 
affected sisters)
12,4  Mb ALX3 (OMIM 606014)
TSHB (OMIM 188540)
Yes Clinical: phenotype does not fit with involvement 
of these genes
18 11-0009 No 4q26 4.3 Mb PRSS12 (OMIM 606709) No Sequencing of PRSS12 
19 11-0012 Yes , NA Diverse More and larger homozygous 
regions
Several Yes No
20 11-0019 No Diverse More and larger homozygous 
regions (in total 5% genome)
Several Yes No
21 11-0037 No Diverse More and larger homozygous 
regions
Several Likely No
NA: not available *a cause of ID might be of different origin
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Table 6   (Likely) non-pathogenic CNVs (N=11).
Case
number
Patient ID Phenotype Sex CNV Chromosomal 
region
Start-End Mb 
positions (Hg19)
Size/Gene content Inheritance Chromosomal analysis References 
1 08-0011 Sev. ID; GR; CA F gain 2q31.1 179,70-180,12 400 kb/2 genes Inherited 
Segregation in non 
affected family 
members
250k SNP array -
2 08-0021 Mod. ID; N M loss 1q41 215,94-216,12 180 kb/1 gene 
(USH2A, OMIM 
608400)
Unknown (parents 
not available)
250k SNP array -
3 08-0034*a Sev. ID; D; GR; 
MC; CA; E
M gain 6q11.1 61,97-62,72 753 kb/2 genes Maternal (healthy 
mother)
250k SNP array Decipher: 
Case numbers 250628, 
257521 
4 09-0019 Mild ID; D M loss 6q12 67,18-67,90 720 kb/no genes Unknown (parents 
not available)
250k SNP array -
5 09-0030 Mod. ID; D; GR; Fa F loss 5q23.1 119,86-199,99 130 kb/ 1 gene Inherited 
Segregation in non 
affected sister
250k SNP array -
6 09-0041 Sev. ID; D; MC; E M loss 6p25.1 4,26-4,46 200 kb/ no genes Unknown (mother 
not available)
250k SNP array DGV: Larger overlapping 
deletions in controls 
7 09-0082 Sev.ID; CA; N; E M gain 14q13.2 35,38-35,83 450 kb/ 6 genes Unknown (parents 
not available)
250k SNP array Decipher: 
Case number 253275: 
larger (2.37 Mb) 
overlapping gain inherited 
from normal parent
8 09-0028*b Mild ID; D; CA M gain 18q22.1 65.65-66.45 800 kb/2 genes Paternal 250k SNP array -
9 10-0018 Sev. ID; GR M gain 21q21.1 18,78-19,07 290 kb/4 genes Maternal 250k SNP array Decipher: 
Case numbers 257242, 
253459 (no phenotype 
reported)
10 10-0052 Mod. ID; E F gain Xq28 148,26-148.73 460 kb/ 6 genes Unknown (parents 
not available)
250k SNP array 50
11 11-0021 Mod.ID; D; CA; N M gain 22q13.31 45,79-46,26 470 kb/ 4 genes Maternal 250k SNP array DGV : Slightly smaller 
overlapping CNVs in 
controls
DGV: Database of Genomic Variants; NT= not tested. 
Sev./Mod./Mild ID: severe/moderate/mild ID; D: dysmorphism; MC: microcephaly; MaC: macrocephaly; 
(IU)GR: (intra-uterine) growth retardation/short stature; CA :congenital anomaly; Fa: ID in family; N: 
neurological features; E: epilepsy
*a This patient was diagnosed with ATRX syndrome
*b This patients has a second, pathogenic CNV (see table 2, number 17)
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Next generation sequencing (NGS) in familial cases of ID
Seven patients with familial ID were included in NGS studies. In four patients with a 
suspected X-linked (XL) cause of ID, sequencing of the X-exome was performed 
followed by segregation analysis of the variants in family members. X-exome 
sequencing revealed a likely pathogenic mutation in one of those families. A 
mutation in the gene KIF4A (OMIM 300521) segregated with the phenotype in 
affected family members, comprising mild to moderate ID and epilepsy (see 
chapter 5.3). 
In three patients with possible AR or XL ID, WES was performed. In one of the two 
families with a suspected AR mode of inheritance, an overlapping homozygous 
that was screened for recurrent mutations in plausible novel ID genes that initially 
had been identified in patients included in family-based WES (see chapter 5.2).7 
Eight patients had de novo mutations in plausible novel ID genes based on a 
biological link to an ID pathway. Two of these eight genes (MYT1L and KIF5C) were 
previously reported to be involved in microdeletions associated with ID.9-13 Though 
the deletions comprising these genes cause haploinsufficiency, it is not likely that 
the missense mutation in KIF5C affecting the motor domain of the KIF5C protein 
results in loss-of-function. The phenotypic effect of this mutation is likely to be 
caused by other mechanisms (see chapter 5.3). Table 7 gives an overview of 
(likely) pathogenic de novo mutations identified by WES in patients with sporadic ID.
Table 7   (Likely) pathogenic de novo mutations identified by WES in a total  
of 40 patients.
Case
number
Patient id Gene Accession number cDNA level Protein level PhyloP
score
Grantham
score
Comment
1 08-0002 KIAA0467 NM_015284 c. 3208C>T p.Arg1070X 1.2 1000 Plausible novel ID gene57, 58 
2 08-0006 DYNC1H1 NM_001376.4 c.11465A>C p.Glu1518Lys 6 56 Novel recurrent ID gene (chapter 5.2)8
3 09-0002 MLL3 NM_170606.2 c.4441C>T p.Arg1481X 6.2 1000 Plausible novel ID gene59
4 09-0003 GRIN2A NM_000833.3 c.1655C>G p.Pro522Arg 5.4 103 Known ID gene60 (OMIM 613971) 
5 09-0023 PDHA NM_000284.3 c.328delinsAGA p.Pro110ArgfsX71 - - Known ID gene (OMIM 312170)
6 10-0010 ASH1L NM_018489.2 c.2170G>T p.Ala724Ser 1.5 99 Plausible novel ID gene. ASH1L is a histon methytransferase (OMIM 
607860)  Other histon methyl transferase genes have been implicated in ID 
phenotypes, such as EHMT161 
7 09-0079 GATAD2B NM_020699.2 c.1408C>T p.Gln470X - - Recurrent novel ID gene (see chapter 5.2)7 
8 10-0040 CTNNB1 NM_001904.3 c.1272_1275del p.Ser425ThrfsX11 - - Recurrent novel ID gene (see chapter 5.2)7
9 10-0065 PPP2R5D NM_006245 c.157C>T p.Pro53Ser 1.9 74 Plausible novel ID gene. PPP2R5D is highly expressed in adult brain and is 
implicated in control of cell growth and division (OMIM* 601646)
10 09-0034 KIF5C NM_004522.1 c.709G>A p.Glu237Lys 6.1 56 Plausible novel ID gene (see chapter 5.3)
11 09-0058 COL4A3BP NM_001130105.1 c.797C>G p.Ser266Cys 6.1 112 Plausible novel ID gene. Lethal phenotypic in zebrafish embryo62 (OMIM 
604677)
12 10-0022 LRP2* NM_004525.2 c.12437del p.Gly4146GlufsX2 - - Known AR ID gene (Donnai-Barrow syndrome; OMIM 222448)
13 10-0064 EEF1A2 NM_001958.2 c.208G>A p.Gly70Ser 5.5 56 Plausible novel ID gene. Causes lethal, neurologic phenotype in mice63
(OMIM 602959)
14 10-0108 MYT1L NM_015025.2 c.2636+1G>A p.?  - Exon skipping 5.7 - Possible novel ID gene13
* This patient has in addition a rare inherited missense mutation in LRP2, which is predicted to be 
deleterious
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6.3   Total yield of diagnostic phase and diagnostic 
related research phase
In the diagnostic phase 43 diagnoses were established, resulting in a diagnosis in 
18.4% of the participants. In the diagnostic related research phase a pertinent or 
plausible diagnosis was established in 18 additional cases, including in 17 out of 47 
(36.2%) patients that received NGS analyses. In one patient a recurrent mutation in 
the novel ID gene CTNNB1 was found. This patient was included in a screening 
cohort for recurrent mutations in novel ID genes (see chapter 5.2).
The total yield of (likely) molecular diagnoses of the first phase (18.4%) and of the 
NGS studies in second phase of the study in our cohort of individuals with so far 
unexplained ID sums up to 54.6% (18.4+36.2%). Because only 47 of the 191 
patients (24.6%) who remained undiagnosed in the first phase of the study were 
selected for NGS studies in the second phase, this resulted in a diagnostic yield of 
26.1% (61 out of 234) in the total cohort. 
6.4   Comparison between patients with and without 
a diagnosis
Table 9 shows a comparison of the phenotypic characteristics between patients 
with and patients without an established diagnosis. Only the presence of the feature 
facial dysmorphism differed significantly between the groups with and without a 
diagnosis. In the group of patients with a (likely) diagnosis a significant higher 
number of individuals had facial dysmorphism. 
There were no significant differences in distribution of gender, age and level of ID 
between the two groups. 
region was previously detected by 250k SNP array analysis (see table 5), which 
served as a guide for the selection of potential causative DNA variants following 
WES. In 2 of the 3 families WES revealed a (likely) pathogenic mutation. In a family 
with two affected brothers (A10-0076) a missense (c.1658A>T (p.V553E)) mutation 
in the X-linked ID gene OPHN1 was found. The phenotype of these brothers, 
comprising moderate ID, cerebellar hypoplasia, mild spasticity and mild facial 
dysmorphism was comparable to other patients with mutations in this gene (OMIM 
300486). Interestingly, this is the first missense mutation reported, suggesting that 
the predicted amino acid substitution affects an important domain of the OPHN1 
protein. In the second family (10-0104) comprising of three affected sisters a 
homozygous missense mutation (c.484G>A (p.Gly162Arg)), in a plausible novel ID 
gene (SLC6A17) was identified. This gene is located in the overlapping homozygous 
region detected in these patients. The mutation segregated with the phenotype, 
consisting of moderate-severe ID, behaviour problems, mild facial dysmorphism 
and a progressive tremor. The involved gene is specifically expressed in the 
neuronal synapse. The SLC6A17 protein is a member of the SLC6 family of 
transporter proteins for neurotransmitters, amino acids, and osmolytes like betaine, 
taurine, and creatine.14, 15 The mutation predicts a substitution of a conserved amino 
acid in a transmembrane domain of SLC6A17, and therefore a causal relation with 
the phenotype is very likely. 
(Likely) pathogenic mutations identified in familial ID are summarized in table 8.
Table 8   (Likely) pathogenic mutations in familial ID identified by X-exome  
sequencing or WES.
Case
number
Patient id Approach Gene Accession number cDNA level Protein level PhyloP
score
Grantham
score
Comments
1 10-0075 X-exome 
sequencing
KIF4A NM_012310.4 c.1489-
8_1490delins10
p.? skipping of 
exon15
0.98 ? See chapter 5.3
2 10-0076 WES OPHN1 NM_002547.2 c.1658A>T p.Val553Glu 2.3 121 Known ID gene (OMIM 300486)
3 10-0104 WES SLC6A17 NM_001010898.2 c.484G>A p.Gly162Arg 6.3 125 Member of the SLC6 family of transporter proteins for 
neurotransmitters, expression in neuronal synapse14, 15 
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The basic motivation of the studies described in this thesis is to increase the 
number of aetiological diagnoses in people with intellectual disability (ID), which is 
of major importance for affected individuals and their families.  Before the era of the 
genome-wide array analysis and next generation sequencing (NGS) technologies, 
in 50%-70% of the people with ID the cause remained unexplained.1-6 Moreover, 
many individuals living in residential settings of health care providers for people 
with ID, especially adults, have not received a present-day genetic diagnostic 
assessment.7  Therefore, our studies focused on this large group of mainly adult 
individuals with unexplained ID (see chapter 2). 
7.1   Yield of present-day genetic diagnostic 
assessment
This study
This study was divided into two phases, reflecting the progress in genetic diagnostic 
technologies during the course of this project. During the first phase, referred to as 
the diagnostic phase of the study, we applied genetic diagnostic technologies that 
are now routinely used in clinical genetic practice. Patients included in our study 
cohort, of whom the majority were adults, had not yet received such a present-day 
genetic diagnostic assessment. Forty-three patients (18.4%) were diagnosed in the 
diagnostic phase of the study. Genome-wide array studies accounted for the major 
part of diagnoses (12.4%), which is in line with the results of previous studies 
assessing the diagnostic yield of genome-wide array analysis8-10 and with the 
prediction of Baker et al.7 that in 8-12% of the adults with idiopathic ID genome-wide 
array analysis would reveal a diagnosis. DNA diagnostic testing of specific genes 
based on clinical evaluation led to the diagnosis in 4.7% of the patients. Most 
diagnoses comprised ID syndromes for which the causative genes were identified 
recently, such as Pitt-Hopkins and Kleefstra syndrome.11, 12 This illustrates that 
clinical investigations in the light of present-day knowledge are a powerful tool in 
diagnostics of ID and underlines the value of periodic re-evaluation of patients with 
hitherto unexplained ID. This is facilitated by documentation of collective expertise 
in medical literature and databases, such as the Database of Chromosomal 
Imbalance and Phenotype in Humans using Ensembl Resources (DECIPHER), the 
European Cytogeneticists Association Register of Unbalanced Chromosome 
Aberrations (ECARUCA), and the Database of Genomic Variants (DGV).
The yield of metabolic screening in this study was very low (1.3%). This is in line with 
previous studies that also showed a relative low yield of metabolic investigations 
and a high percentage of abnormalities of non-specific and unknown significance. 
Therefore, selective and targeted metabolic testing has been recommended.2, 13-15 
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people with ID, might be roughly estimated by extrapolating our study results. We 
made some assumptions to calculate this estimation. Firstly, we assumed that at 
least 50% of the cases of ID remained unexplained before the genome-wide array 
analysis era.1-6 Secondly, we consider it likely that our study cohort is composed of 
individuals from this group of 50% unexplained cases of ID. This assumption is 
supported by the fact that none of the participants had received genome-wide 
array analysis. Extrapolation of the yield in the diagnostic phase of the present 
study (18.4%) to the total population of people with ID would then result in a 9.2% 
(18.4*0.5) increase in the total number of patients with explained ID to approximately 
59% (9.2%+50%). Extrapolation of the yield of additional NGS studies in the 
diagnostic related research part of the study would lead to an additional 18.1% 
(36.2*0.5) increase in diagnoses to more than 75%. 
Several remarks should be made. First, our study cohort may not be representative 
for the total population of people with ID. The cohort as presented in chapter 2, is 
composed of a selected population. Because most patients were recruited from 
residential settings of service providers, adult patients and patients with a moder-
ate-severe ID (IQ <50) were overrepresented. The overrepresentation of patients 
with an IQ<50 might have led to an increased yield, though we did not observe a 
significant difference in the distribution of the level of ID between the group of 
patients with and without a diagnosis (see chapter 6, table 9). Secondly, we used 
the selection criterion that one or more other features than just ID had to be present 
This study confirms that unselected metabolic testing of individuals with unexplained 
ID has a very low yield. Therefore, it is advisable to reserve metabolic studies for 
patients with a clinical suspicion, such as marked hypotonia and coarse facial 
features.
It is important to realize that the aforementioned numbers are based on a cohort of 
patients selected for previously unexplained ID. Therefore, easily identifiable and 
highly recognizable syndromes, such as trisomy 21, large microscopically visible 
structural chromosomal aberrations, Fragile X syndrome and frequent metabolic 
disorders such as phenylketonuria are not represented in this cohort (except for 
microscopically visible chromosomal aberrations in a few patients that had not yet 
received microscopic chromosomal analysis). 
The introduction of next generation sequencing techniques (NGS) in research offered 
a great promise for providing diagnoses in patients who remained undiagnosed in 
the first diagnostic phase of the study.16-24 Therefore, in the second, diagnostic 
related research phase of the study, we selected 47 of these 191 (24.6%) unsolved 
patients for NGS studies. The majority of them had sporadic ID and were included 
in a large family based whole exome sequencing project (WES) (chapter 5.2). 
Seven patients represented probands from ID families compatible with X-linked 
(XL) or autosomal recessive (AR) inheritance pattern. All together, NGS studies 
revealed a likely diagnosis in 17/47 (36.2%) of the included patients (see figure 1). 
As described in Chapter 6 the total yield of (likely) molecular diagnoses in 
individuals with so far unexplained ID sums up to 54.6% (18.4+36.2%). Forty-three 
individuals (18.4%) were diagnosed in the first diagnostic phase of the study. Due 
to the selection criteria we used, only about one quarter of the patients without a 
diagnosis in the first phase of the study were candidates for further NGS studies in 
the second phase of the study. For example, individuals with an IQ above 50, with 
an unknown copy number variation (CNV), with consanguineous parents, and/or 
individuals of whom one or both of the parents were not available, were excluded 
for the family based WES approach. 
In total, in 61 participants a likely molecular diagnosis was established. In the total 
cohort of 234 participants this resulted in a diagnostic yield of 26.1%, however as 
explained above, only a small subset of the participants were included in further 
NGS studies. It is likely that more diagnoses would have been established without 
excluding these groups.
Extrapolation of results 
The impact of the application of present-day advanced genetic diagnostic technologies 
on the elucidation of genetic causes of unexplained ID in the total population of 
Figure 1   Yield in the diagnostic and diagnostic related research phase
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and enables careful counselling of family members regarding prognosis, natural 
course of the disease and life expectancy. Chapter 4 includes a detailed up-to-date 
phenotypic and molecular overview of a large group of patients with Kleefstra 
syndrome of various ages (chapter 4.1) and a detailed phenotypic characterization 
of adults with Angelman- and Rett-like syndromes (chapter 4.2).
7.3  Identification and definition of novel ID syndromes
Since ID is an extremely heterogeneous disorder, it is expected that many underlying 
genetic defects are still to be elucidated. Therefore, one of the objectives of this 
study was to identify and define novel genetic syndromes with ID. In chapter 3.2 
the identification and definition of two novel microdeletion syndromes is described. 
By studying the genes in the shortest region of overlap, we identified candidate 
genes for the phenotype. The results of our studies in patients with 16q24.3 
microdeletion syndromes (chapter 3.2.1) were subsequently further confirmed by 
others.25-27 Recently, one of the candidate genes in this syndrome, ANKRD11, was 
shown to be involved in KBG syndrome (OMIM 148050).28 Sirmaci et al., identified 
in 7 patients from 5 families with KBG syndrome mutations in ANKRD11 by WES. 
The patients with a microdeletion in chromosomal region 16q24.3 described by us 
and others showed indeed phenotypic similarities, but did not show the full clinical 
presentation of KBG syndrome. 
Chapter 3.2.2 describes the clinical and molecular characterization of the novel 
1p21.3 microdeletion syndrome and the identification of the microRNA gene MIR137 
as likely contributor to the ID phenotype. This was supported by expression studies 
of downstream targets of MicroRNA137 (MIR137) as well as by expression studies 
of Mir137 in the mouse cortical synapse.  
The identification of novel ID associated genes by NGS approaches is described in 
chapter 5. Chapter 5.1 reports the identification and definition of a novel ID 
syndrome in a child and an adult patient. Their phenotypes included severe ID, 
signs of neuronal migration defects and motor problems. WES revealed in these 
two patients recurrent de novo mutations in the novel ID gene dynein, cytoplasmic 
1, heavy chain 1 (DYNC1H1) (OMIM 600112), which is also known in association 
with neurological phenotypes, including Charcot-Marie-Tooth disease and spinal 
muscular atrophy.29, 30 Although these patients show some clinical overlap with the 
patients from our study, their phenotype is notoriously different, because in the 
patients from our study the cognitive phenotype is much more prominent, whereas 
in the patients with Charcot-Marie-Tooth disease and spinal muscular atrophy the 
neurological phenotype is most prominent. Future detection of additional variants 
in this gene in other patients may shed more light on the genotype-phenotype 
(see chapter 2, table 2). Although these additional findings could be very subtle, 
patients with additional findings to ID are overrepresented in our cohort as well. 
Within our study population we only observed a significant difference in the 
presence of facial dysmorphisms between the groups with and without diagnosis. 
In the group with an established likely diagnosis the number of individuals with 
facial dysmorphisms was significantly higher (chapter 6, table 9). There was also 
no significant difference in the number of positive selection criteria. However, the 
differences and the numbers in each group might be too small to reach significance. 
In the second phase of the study only a subset of the patients was selected for NGS 
studies. Application of NGS in the total group of patients that remained undiagnosed 
in the diagnostic phase of the study, might have resulted in a lower diagnostic rate 
of NGS studies, because we have now excluded individuals with an IQ between 50 
and 70 from family based exome sequencing. 
Despite of these limitations, our results may give a reasonable indication of the 
promising yield of the present-day advanced and rapidly developing genetic 
diagnostic repertoire. Furthermore, the application of WES in an increasing number 
of patients with ID, as well as in healthy controls will shed more light on the clinical 
significance of hitherto unknown variants. Some variants currently classified as 
“significance unknown” may turn out to be either pathogenic or non-pathogenic 
when more WES data become available. This may lead to establishment of 
additional diagnoses in patients with variants of currently unknown clinical 
significance. Furthermore, recurrent findings in additional patient series and/or 
functional studies may further confirm likely causative mutations. Therefore, the 
diagnostic rate of exome sequencing will likely further increase in the near future. 
7.2   Further phenotypic delineation of known  
ID syndromes
During this study we performed an extensive phenotypic description of all 
participating patients. This has resulted in the collection of a wealth of data on 
phenotypes of rare genetic disorders with ID. Moreover, the cohort we studied is 
unique, in the sense that more than 45% of the patients had an age above 40 years, 
and more than 80% were adults, while previous reports of rare genetic ID syndromes 
mainly involved children (see chapter 2). As a consequence, clinical characteristics 
including associated health and behaviour issues and recognizable facial features 
are generally well studied in children, but not in adults. Often little is known about 
evolution of phenotypes across life span. We have collected valuable data on 
progression of phenotypes in rare genetic ID syndromes. Information on health and 
social outcomes is necessary for adequate management and follow-up of patients 
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Collection of these molecular data in association with corresponding phenotypes 
in central databases, such as DECIPHER, ECARUCA and DGV importantly 
contributes to the assessment of clinical relevance of these CNVs.32-34 Nevertheless, 
the clinical significance of many CNVs cannot be clarified at the moment, as is 
illustrated by the detection of CNVs of unknown clinical significance in 6.8% of the 
patients in the present cohort study (chapter 6). 
Chapter 3.2.3 describes the interpretation of clinical relevance of X-chromosomal 
copy number variations (X-CNVs) detected by genome-wide array analysis in a 
large cohort of patients who were referred to our diagnostic centre for the evaluation 
of ID or other cognitive disorders. This provides a resource for clinicians and 
laboratory specialist for the interpretation of X-CNVs that are picked up by genome 
wide array platforms in a routine diagnostic setting.
Likewise the genome-wide array analysis studies, the application of WES in this 
study revealed several genetic variations with an unclear pathogenicity, as reported 
in chapter 5.2 and chapter 6. In analogy with the developments after the 
introduction of genome-wide array analysis, future large scale application of NGS 
technologies both in research and diagnostics may clarify the pathogenicity of 
several currently unknown or ambiguous variants. This highlights the importance of 
storage of molecular data in combination with detailed phenotypic data in central 
databases.31, 35 More and more recurrent variants in patients and controls will be 
identified. Phenotype-genotype studies of these recurrent variants will shed more 
light on hitherto unknown variants.
7.5   Implementation in clinical practice: Outpatient 
clinic ‘’Zeldzaam’’ (‘’Unique’’)
Genetic causes of ID are very heterogeneous. Therefore, each single genetic 
disorder with ID is mostly very rare. As a consequence, available information on 
clinical presentation, including associated health and behaviour problems, 
prognosis and course of life, is scarce. Yet, this information is very important in care 
and counselling of people with ID and their families. The detailed clinical information 
of the participating, mainly adult individuals with ID collected during this study is 
thus highly valuable. It importantly contributes to the insight and knowledge of rare 
genetic disorders with ID and facilitates care and counselling of affected individuals 
and their families. Several previous reports have shown that identification of the 
underlying cause of ID contributes to specific management of patients with rare 
genetic causes of ID. Studies of cognitive behavioural profiles may guide specific 
correlations and may clarify these important differences in phenotype. Furthermore, 
this may lead to further broadening and characterization of the phenotypic 
spectrum. Chapter 5.2 describes the identification of recurrent de novo mutations 
in two other newly identified ID genes, including CTNNB1 and GATAD2B. Detailed 
phenotype-genotype comparisons may result in the definition of novel ID 
syndromes. Chapter 5.2 also reports the identification of potential novel ID genes 
of which the causal role and impact on the phenotype should be further confirmed 
by recurrent findings in additional patients. As more sequence data become 
available after the implementation of NGS in diagnostics of ID, more recurrent 
mutations may be identified and may enable comparison and definition of 
corresponding phenotypes. With this, close collaboration between clinicians and 
laboratory specialists is of major importance. Chapter 5.3 describes the 
identification of mutations in two plausible novel ID genes from the kinesin family 
group (KIF genes), KIF4A and KIF5C, in an X-linked family and a sporadic patient, 
respectively. Their ID phenotypes are detailed and functional studies provided 
further evidence for a causal role of these genes in ID. Previous reports that relate 
KIF genes to human ID phenotypes are rare. KIF4A, KIF5C and also DYNC1H1 are 
all genes involved in the microtubule transport pathway. This suggests that the 
microtubule transport pathway may well be an evolving ID pathway.
7.4  Challenges in clinical interpretation
The technological advances in the elucidation of genetic causes of ID go along with 
the detection of a large number of variants that are difficult to interpret. This 
confronts us with the challenging task to determine the clinical relevance of these 
unknown variants. These uncertainties are a major challenge in the counselling of 
patients and their families. Prediction of prognosis and recurrence risk can be very 
difficult in these situations and may require identification of additional cases for 
detailed phenotype-genotype comparison, extensive family studies, and functional 
and biochemical analyses in animal or cellular models. Furthermore, prenatal 
testing can only be considered when the assessment of clinical relevance is 
sufficiently confident. In addition to unknown variants, an increased risk of incidental 
findings that are not related to ID but have medical implications for individuals with 
ID and/or their parents may also complicate counselling and can give rise to ethical 
issues.22, 31
In the past several years the wide application of genome-wide array analysis in 
research and diagnostics of ID has provided and continues to provide a wealth of 
data on recurrent genomic CNVs, both in patients and in control individuals. 
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7.6  Future prospects
With the introduction of WES in the diagnostics of ID, extensive phenotyping will 
become increasingly less important in guiding diagnostics, and the success of 
identification of clinical recognizable ID syndromes will no longer be highly 
dependent on clinical expertise on syndrome recognition.31 However, this does not 
implicate that phenotyping is no longer important, but rather means that the 
diagnostic approach will shift from a ‘’phenotype first’’ to a ‘’genotype first’’ 
approach (reverse phenotyping). In the near future, mapping of the genomic profile 
of individuals with ID may be the first step in the diagnostic process. Subsequent 
clinical investigations will be essential in the interpretation of detected genomic 
variants and to correlate these to the clinical presentation of the patient. Moreover, 
in-depth clinical investigations, including standardized psychometric cognitive 
testing, physical examinations, and longitudinal investigations during follow-up will 
stay beyond dispute for management and insight in prognosis of individuals with a 
specific genetic defect. The results of such studies derived from patient cohorts 
sharing similar molecular defects, and phenotypic features, will be mandatory for 
future trials in which the phenotypic effects of drugs will be assessed in clinical 
trials. As a consequence, the value of detailed clinical characterization of genetic 
disorders with ID in counselling and care of patients and their families will become 
increasingly important. 
The reverse phenotyping approach may have several advantages in the care of 
patients with ID and their families. Incriminating and invasive diagnostic tests -such 
as lumbar puncture-, wrong diagnoses and delay in diagnosis may be prevented. 
Instead, identification of the underlying genetic defect in an early phase enables 
personalized medicine and specific management by anticipation on associated 
comorbidity and behavioural problems from the beginning. 
Another consequence of the ‘’genotype first’’ approach will be a broadening of the 
clinical spectrum of known ID syndromes, since genetic defects may be detected 
in patients with nonspecific phenotypes who would not have been selected for 
specific genetic tests on clinical grounds.
Mutations outside the coding regions that cause ID remain to be defined. It is 
expected that the application of WES techniques in research and diagnostics of ID 
will be rapidly followed-up by whole genome sequencing (WGS).31 This will enable 
the detection of disease causing variants in non-coding regulatory sequences, 
such as intronic variants, as well. These variants may lead to altered expression of 
genes and elucidate novel epigenetic ID causing mechanisms. Epigenetic 
mechanisms have already been shown to play a role in several ID syndromes.43
behavioural and pharmacological interventions. Several studies have reported 
specific behaviour profiles in certain ID syndromes. It was shown that patients with 
Kleefstra syndrome might develop a regressive behavioural phenotype at 
adolescent/adult age of which clinicians and care-takers should be aware of. This 
is described in chapter 4.1.1 and also in previous publications from our group.36, 37 
During this study we diagnosed two brothers with Phelan-McDermid syndrome 
(22q13 deletion syndrome). Psychiatric evaluation of these brothers showed that in 
addition to delayed speech and perseverations with autistic-like features, the psy-
chopathological phenotype of Phelan-McDermid syndrome may also comprise 
atypical bipolar disorders. The latter may have implications for the treatment 
regime. As the symptoms of these patients remitted under maintenance therapy 
with a mood stabilizer, compounds from this class may be considered in the 
treatment of fluctuating challenging behaviours in patients with ID and, more 
specifically, those with Phelan-McDermid syndrome in whom an (atypical) bipolar 
disorder may be present.38  Previous studies in adults with Prader-Willi syndrome 
highlighted medical, psychiatric and behavioural issues that are important for the 
general management of patients with Prader-Willi syndrome.39-41 Catarino and 
others showed that establishment of the diagnosis in adult patients with SCN1A 
mutations enabled a specific anti-epileptic treatment strategy leading to better 
seizure control, improvement of cognitive functioning and quality of life.42 In an adult 
female diagnosed during this study with a deletion in the chromosomal region 
3q24-q25.4, an associated hypogonadotrophic hypogonadism was observed, for 
which she was subsequently treated with bisphosphonates to prevent osteoporotic 
complications, which can be very disabling (chapter 3.1.1). 
For this study we established in collaboration with the department of primary care, 
chair ‘’Health care for people with ID’’, a multidisciplinary outpatient clinic (see 
chapter 2). After completion of the clinical evaluations in the patients from the 
study cohort, this outpatient clinic continued under the name ‘’Zeldzaam’’ (or 
‘’Unique’’ in English). Outpatient clinic ‘’Zeldzaam’’ aims to implement the acquired 
knowledge and insights on rare genetic disorders with ID in clinical practice. 
Moreover, the systematic follow-up of patients in this multidisciplinary setting that 
bundles the expertise of the clinical geneticist and the specialist ID physician, 
facilitates a further increase of our experience, provides additional data on medical 
and psychiatric comorbidity and may generate new research questions as well.
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Summary
Intellectual disability (ID) has a major personal and social impact. It affects at least 
120.000 people in the Netherlands and is associated with significant more 
psychiatric and physical comorbidity. Until recently, the cause of ID remained 
unknown in 50-70% of the affected individuals. Knowing the cause is of major 
importance in care and counselling of patients and families, and provides insight in 
comorbidity, associated behaviour problems, prognosis and recurrence risk. It 
precludes further unnecessary, often incriminating testing, and fruitless 
interventions, and instead enables specific anticipation on associated health and 
behavioral problems, since the extreme clinical and molecular heterogeneity goes 
along with diverse presentations and variable needs. 
In recent years, advances in genetic technologies have provided great new 
opportunities for the elucidation of genetic causes of ID and the currently available 
genetic diagnostic repertoire is rapidly developing. In this study, state of the art 
genetic diagnostic technologies and a multidisciplinary clinical approach bundling 
the expertise of the clinical geneticist, specialist ID physician and other academic 
medical specialists were applied to identify genetic causes of ID. The aims of this 
study as defined in chapter 1.6 included the identification of genetic causes of ID 
in individuals with previously unexplained ID, the detailed delineation of 
corresponding phenotypes, assessment of the diagnostic potential of the 
present-day genetic diagnostic repertoire and implementation of the gained 
insights in clinical practice. 
In chapter 2 the study organization and design, and the study cohort are described. 
This study was embedded in the Dutch research Consortium ‘‘’Sterker op Eigen 
Benen/Stronger on Your Own Feet’’, which is a collaboration between three large 
service providers for people with ID (Pluryn, Dichterbij and Siza) and the Radboud 
University Medical Centre in Nijmegen, the Netherlands. The 253 participants of the 
study, mainly adults with unexplained ID, were recruited from these service 
providers. The study comprised two phases. In the first phase, we performed in all 
participants clinical investigations followed by phenotype guided genetic diagnostic 
tests and standard tests that are currently routinely used in clinical genetic practice. 
About 25% of the participants undiagnosed in the first phase of the study, were 
included in further next generation sequencing (NGS) studies in the second phase 
of the study.
In chapter 3 rarely reported and novel syndromes associated with microscopic 
and submicroscopic chromosomal aberrations are described. In chapter 3.1.1 
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mutations in known ID genes, novel recurrent ID genes and plausible novel ID 
genes. The added yield of (likely) molecular diagnoses of both study phases was 
54.6% (18.4% in first phase, 36.2% in NGS studies in the second phase). The 
specific findings are summarized in tables 2-8 in chapter 6.
Chapter 7.1 reflects on the total results of this study. The total yield of likely 
diagnoses of this study sums up to more than 50% (54.6%). In addition these results 
are extrapolated to the total population of people with ID to illustrate the great 
promising opportunities of the present-day, rapidly developing genetic diagnostic 
repertoire and the impact on the total population of people with ID. This predicts 
that application of the currently available genetic diagnostic repertoire may lead to 
an increase in explained ID from 50% in the past to over 75%. 
Chapters 7.2-7.5 discuss the continuous importance of detailed phenotyping, 
though a shift from a ‘’phenotype first’’ to a ‘’genotype first’’ approach can be 
foreseen, which might have great advantages for patients. In chapter 7.5 the 
implementation of study results in clinical practice are discussed, illustrated by our 
outpatient clinic ‘’Unique (Zeldzaam)’’. Finally, chapter 7.6 reflects on future 
prospects, such as the development of intervention strategies for the treatment of 
cognitive dysfunction targeting common underlying pathways involved in ID. 
three patients with overlapping interstitial 3q24q25 deletions were presented, who 
helped to delineate the critical region containing the gene(s) responsible for the 
Wisconsin syndrome phenotype. Chapter 3.1.2 reports two patients with 
overlapping deletions in chromosomal region 8p12p21, revealing two candidate 
genes for congenital heart defects, which are sometimes observed in ID patients 
with a deletion overlapping this region. Chapters 3.2.1 and 3.2.2 report clinical 
and molecular characteristics of two novel microdeletion syndromes, including four 
patients with 16q24.3 microdeletions (3.2.1) and five patients with 1p21.3 
microdeletions (3.2.2). Study of the genes in the shortest regions of overlap 
revealed candidate genes involved in the ID phenotype, including ZNF778 and 
ANKRD11 in 16q24.3 microdeletion syndrome and MIR137 in chromosome 1p21.3 
microdeletions. Chapter 3.2.3 deals with the clinical interpretation of X-chromosomal 
copy number variations (X-CNVs) identified by genome-wide array analysis.
In chapter 4 detailed further phenotypic delineations of the well-known ID 
syndromes Kleefstra syndrome (4.1) and Angelman-and Rett like syndromes (4.2) 
are described, including the evolution of the phenotypes at adulthood.
In chapter 5 the results of application of NGS studies in patients with sporadic ID 
and familial ID are reported, which has led to the identification of known and novel 
genes involved in ID, and the definition of novel ID syndromes. In addition several 
novel candidate ID genes were identified. Chapter 5.1 describes two patients with 
de novo mutations in the novel ID gene DYNC1H1, presenting with a similar 
phenotype, comprising severe ID and variable neuronal migration defect, and thus 
representing a novel ID syndrome. Chapter 5.2 reports the results of diagnostic 
exome sequencing using a family-based approach in patients with sporadic ID, 
which resulted in a definite diagnosis in 16%, mostly comprising de novo mutations. 
Amongst these were three novel ID genes with recurrent mutations in patients with 
similar phenotypes. In addition de novo mutations in several potential novel ID 
genes were identified. 
In chapter 5.3 the clinical characteristics of individuals with mutations in the kinesin 
superfamily (KIF) genes KIF4A and KIF5C are reported. Functional studies at the 
synapse of rat primary neurons further confirmed the involvement of KIF4A and 
KIF5C in the ID phenotypes of reported patients.
In chapter 6 the total results of this study are described. In the first phase of the 
study a (likely) genetic diagnosis was established in 18.4%, comprising in 12.4% 
chromosomal aberrations, in 4.7% monogenic defects and in 1.3% metabolic 
disorders. NGS studies in the second phase of the study in sporadic and familial ID 
revealed a (likely) diagnosis in 36.2% of the included individuals, comprising 
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Samenvatting
Verstandelijke beperking (VB) heeft een grote persoonlijke en maatschappelijke 
impact. In Nederland leven tenminste 120.000 mensen met een VB en zij hebben 
significant meer psychische en lichamelijke comorbiditeit. Tot voor kort bleef bij 
50-70% van de mensen met een VB de oorzaak onduidelijk. Het weten van de 
oorzaak is van groot belang bij de counselling en de zorg voor mensen met een VB 
en hun familieleden. Het geeft bijvoorbeeld inzicht in comorbiditeit, geassocieerde 
gedragsproblemen, prognose en herhalingskans en kan een einde maken aan 
zinloze, en vaak belastende onderzoeken, en niet werkzame therapieën. In plaats 
daarvan kan gericht ingespeeld worden op specifieke geassocieerde gezondheids- 
en gedragsproblemen, omdat de grote klinische en moleculaire heterogeniteit van 
VB gepaard gaat met een verscheidenheid aan klinische presentaties en wisselende 
behoeften. 
De afgelopen jaren hebben ontwikkelingen in genetische technologie geleid tot 
veelbelovende nieuwe mogelijkheden voor het opsporen van genetische oorzaken 
van VB en de beschikbare mogelijkheden voor genetische diagnostiek van VB 
ontwikkelen zich razendsnel. Tijdens het onderzoek beschreven in dit proefschrift 
werd enerzijds gebruik gemaakt van de meest moderne genetische technieken in 
de diagnostiek van VB en daarnaast van een multidisciplinaire klinische benadering 
waarbij de expertises van de klinisch geneticus, de arts voor verstandelijk 
gehandicapten (AVG) en andere academisch medisch specialisten gebundeld 
werden in de zoektocht naar genetische oorzaken van VB. De doelen van deze 
studie, zoals gedefinieerd in hoofdstuk 1.6, omvatten de identificatie van 
genetische oorzaken van VB in individuen met een tot dan toe onverklaarde VB, het 
gedetailleerd beschrijven van de bijbehorende klinische kenmerken (fenotypes), 
het vaststellen van de diagnostische mogelijkheden van het huidige arsenaal aan 
technieken voor genetische diagnostiek, en tot slot de implementatie van de 
verworven kennis in de klinische praktijk.
In hoofdstuk 2 worden de organisatie en opzet van deze studie, en het onder-
zoekscohort beschreven. Deze studie vond plaats binnen het consortium ‘’Sterker 
op Eigen Benen’’ dat een samenwerking is tussen drie grote instellingen voor 
mensen met een VB in Nederland (Pluryn, Dichterbij and Siza) en het Radboud 
Universitair Medisch Centrum in Nijmegen, Nederland. De 253 deelnemers, 
voornamelijk volwassenen met een onverklaarde VB, werden binnen deze 
instellingen geworven. De studie was verdeeld in twee fasen. In de eerste fase 
werden alle deelnemers klinisch onderzocht op onze multidisciplinaire polikliniek in 
aanwezigheid van een klinisch geneticus en een AVG. Aansluitend werd op indicatie 
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wisselende presentatie van een neuronale migratiestoornis en vertegenwoordigen 
een nieuw syndroom met VB. In hoofdstuk 5.2 worden de resultaten van exoom 
sequensen met een trio (ouders-kind) georiënteerde benadering in de diagnostiek 
van patiënten met een sporadische VB beschreven, hetgeen resulteerde in een 
zekere diagnose in 16%, voornamelijk tengevolge van de novo mutaties. Daarbij 
zaten drie nieuwe genen voor VB waarin additionele mutaties werden gevonden in 
niet-gerelateerde patiënten met een vergelijkbaar fenotype. Daarnaast werden 
diverse de novo mutaties gevonden in nieuwe kandidaat genen voor VB. In 
hoofdstuk 5.3 worden de klinische kenmerken van individuen met een mutatie in 
de kinesine superfamilie (KIF) genen KIF4A en KIF5C beschreven. Functionele 
studies in de synapsen van primaire neuronen van ratten hebben geleid tot verdere 
bevestiging van betrokkenheid van deze genen bij het ontstaan van VB.
In hoofdstuk 6 worden de totaal resultaten van dit onderzoek beschreven. In de 
eerste fase van het onderzoek werd een (waarschijnlijke) genetische diagnose 
vastgesteld bij 18.4%, betreffende in 12.4% een chromosoomafwijking, in 4.7% een 
monogene afwijking, en in 1.3% een metabole stoornis. NGS onderzoek in de 
tweede fase van de studie bij patiënten met een sporadische of een familiaire vorm 
van VB bracht bij 36.2% van de geïncludeerde individuen een (waarschijnlijke) 
moleculaire diagnose aan het licht. De totale opbrengst van (waarschijnlijke) 
moleculaire diagnoses in beide fasen van de studie komt daarmee op 54.6% (18.4% 
in de eerste fase plus 36.2% in de tweede fase). Specifieke bevindingen staan 
opgesomd in de tabellen 2-8 van hoofdstuk 6. 
In hoofdstuk 7.1 worden de totaalresultaten van deze studie besproken. Bij elkaar 
opgeteld is de opbrengst aan waarschijnlijke diagnoses van beide fasen van de 
studie meer dan 50% (54.6%). Daarnaast worden de resultaten behaald in dit 
studiecohort doorgetrokken naar de totale populatie van mensen met een VB om 
de enorme potentie van de huidige, zich snel ontwikkelende mogelijkheden voor 
genetische diagnostiek voor VB en de impact hiervan te illustreren. Dit laat zien dat 
het percentage mensen met een verklaarde VB, dat voorheen rond de 50% lag, 
door de toepassing van het huidig beschikbare genetisch diagnostisch arsenaal 
kan oplopen tot meer dan 75%. 
Daarnaast wordt in hoofdstuk 7 (7.2-7.5) het blijvende belang van gedetailleerde 
fenotypering uitgebreid toegelicht, hoewel er een verschuiving wordt voorzien van 
een ‘’fenotype eerst’’ naar een ´´ genotype eerst´´  benadering, hetgeen mogelijk 
grote voordelen voor patiënten heeft. Daarnaast wordt in hoofdstuk 7.5 de 
implementatie van deze onderzoeksresultaten in de klinische praktijk aan de hand 
van onze polikliniek Zeldzaam geïllustreerd. Tot slot wordt in hoofdstuk 7.6 vooruit 
gekeken naar toekomstige ontwikkelingen, zoals de ontwikkeling van therapeutische 
gerichte genetische diagnostiek aangevraagd. Tevens werd bij alle deelnemers de 
standaard genetische diagnostiek verricht die momenteel routinematig worden 
gebruikt in de klinisch genetische diagnostiek van VB. Ongeveer een kwart van de 
deelnemers zonder diagnose in de eerste fase van de studie werd geïncludeerd in 
vervolgstudies in de tweede fase van de studie, waarin met name verschillende 
next generation sequencing (NGS) benaderingen werden toegepast. 
In hoofdstuk 3 worden zeldzame en nieuwe beelden die veroorzaakt worden door 
microscopische en submicroscopische chromosoomafwijkingen beschreven. In 
hoofdstuk 3.1.1 worden drie patiënten met overlappende interstitiële deleties van 
de chromosomale regio 3q24q25 beschreven. Het klinisch en moleculair onderzoek 
bij deze patiënten heeft bijgedragen aan de afgrenzing van het kritische gebied dat 
de gen(en) bevat die verantwoordelijk worden gehouden voor het fenotype van het 
Wisconsin syndroom.
Hoofdstuk 3.1.2 beschrijft twee patiënten met overlappende deleties van de 
chromosomale regio 8p12p21, op basis waarvan twee kandidaatgenen voor 
aangeboren hartafwijkingen geïdentificeerd werden, welke naast een VB bij deze 
patiënten vaker beschreven worden. Hoofdstukken 3.2.1 en 3.2.2 beschrijven de 
klinische en moleculaire kenmerken van twee nieuwe microdeletie syndromen, 
vastgesteld bij respectievelijk vier patiënten met een microdeletie van chromosoom 
16q24.3 (3.2.1), en vijf patiënten met een microdeletie van chromosoom 1p21.3 
(3.2.2). Bestudering van de genen gelegen in de overlappende gebieden van deze 
microdeleties, bracht kandidaatgenen betrokken bij de fenotypes aan het licht, 
namelijk ZNF778 en ANKRD11 in het 16q24.3 microdeletie syndroom en MIR137 in 
chromosoom 1p21.3 microdeleties. Hoofdstuk 3.2.3 behandelt de klinische 
interpretatie van kopienummerveranderingen (CNVs) van het X-chromosoom, opgepikt 
met genoomwijd submicroscopisch chromosomenonderzoek.
In hoofdstuk 4 wordt het fenotypisch spectrum van bekende syndromen met VB, 
namelijk Kleefstra syndroom (4.1) en Angelman- en Rett-achtige syndromen (4.2) 
gedetailleerd besproken, inclusief de evolutie op volwassen leeftijd.
In hoofdstuk 5 worden de resultaten van het toepassen van het recent in de 
diagnostiek geïntroduceerde NGS onderzoek bij sporadische patiënten met VB en 
bij patiënten met familiaire VB beschreven. Dit heeft geleid tot het vaststellen van 
bekende en nieuwe genen betrokken bij VB, en de beschrijving van nieuwe 
syndromen met VB. Daarnaast werden verschillende nieuwe kandidaat genen voor 
VB gevonden. Hoofdstuk 5.1 beschrijft twee patiënten met de novo mutaties in een 
nieuw gen geassocieerd met VB, genaamd DYNC1H1. Zij presenteerden zich met 
een vergelijkbaar fenotype dat gekenmerkt werd door een ernstige VB en een 
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interventies voor VB die ingrijpen op gemeenschappelijke onderliggende pathways 
betrokken bij VB.
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Appendix (Color Figures)
Figure 1   Facial appearance of patient 1 at 60 years (b-c) and at younger  
adult age (a), of patient 2 at age 13 years (d-e) and of patient 3 at 
age 18 years (f-g) Note the coarse face, prominent nose, full lower 
lip, large mouth and unusually shaped, bushy eye brows.
a b
d
f
e
g
c
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Figure 1   Photographs of two patients with a 8p12p21 deletion.  
A-B Patient 1 at 9 months of age, showing long dark eye lashes, 
arched eyebrows, inverted epicanthal folds, a long and smooth 
philtrum, thin lips, downturned corners of the mouth and over folded 
upper helices of the ears. C-F Patient 2 at age of 12 months  
(C), 20 months (D) and 33 months (E-F), showing mild facial 
dysmorphic features, including thin upper lip, a full hooked nose  
and narrow palpebral fissures.
Figure 1   Facial profiles of patients 1-4. A-C: Patient 1 at several ages from  
6 years (A) to 22 years (B-C). D-F: Patient 2 at the age of 3 years  
(D) and at the age of 8 years (E-F). G-H: Patient 3 at the age of  
7 years. I-J: Patient 4 at the age of 8 years and 10 months.   
Facial features comprise high forehead/frontal bossing and large 
ears (all patients), broad mouth, long smooth philtrum and pointed 
chin (patient 1-3). Note the change in facial phenotype in patient 1  
at adult age, showing a long and oval face with full upturned nose, 
retrognathia and pronounced groove in the chin.
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Figure 1   Facial appearance of patients 1, 2, 4 and 5. 
Figures A-B show patient 1 at age 42 years, figures C-D patient 2  
at age 38 years, figures E-F patient 4 at 34 years and  
figures G-H patient 5 at age 18 years. Note the minor facial 
dysmorphic features, including long ears, deeply set eyes, full tip  
of the nose and thick lower lip.
Figure 3   A–V Facial profiles of patients with a 9q34.3 deletion, including 
patient 1 at age 2 years (A) and 5 years (B), patient 2 at age 9 
months (C), 2 years (D) and 6 years (E), patient 4 at age 5 years  
(F, G), patient 5 at age 11 years (H, I), patient 6 at age 1 year (J) and 
2 years (K), patient 7 at age 9 months (L), patient 8 at different 
childhood ages (M–O), patient 10 at young childhood age (P, Q), 
patient 11 at age 3 years (R, S) and 5 years (T, U) and patient 12 at 
age 5 years (V). The highly recognizable facial features comprise 
hypertelorism, midface hypoplasia, prognathism, prominent 
eyebrows, cupid bow or tented upper lip and everted lower lip.
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Figure 4   A–W Facial appearance of patients with an EHMT1 mutation, 
including patient 17 at age 2 years (A, B), patient 18 at age 1 year 
(C) and 6 years (D, E), patient 19 at age 3 years (F, G), patient 20 at 
age 41 years (H, I), patient 21 at age 5 years (J, K), patient 24 at age 
2 years (L, M) and 10 years (N), patient 25 at childhood age (O), 
during teenage (P), and age 32 years (Q, R), patient 26 at age 2 
years (S) and age 10 years (T, U), patient 27 at age 11 years (V, W). 
Facial characteristics are similar to Kleefstra syndrome patients with 
a 9q34.3 deletion.
Figure 1   Photograph of family 1. The proband (left) with his younger brother 
and his mother. Note the characteristic facial appearance of 
Kleefstra syndrome in the proband and the mild facial features in  
the mother. The younger brother shows marked hypotonia.
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Figure 2   Photographs of family 2. The proband at the age of 2 months (a),  
3 years (b), 4 years and 6 months (c, d) and 5 years (e), and her 
mother (f, g). Note the hypertelorism, broad and depressed bridge  
of the nose, flared nostrils (a, b, d, e), mild midface hypoplasia  
(c) and broad mouth with full lips in the proband (b, d, e).  
The mother has marked obesity and minor dysmorphic features, 
including a hypoplastic midface, small palpebral fissures, a 
depressed nasal bridge and anteverted nares (f, g).
Figure 4   Mosaic pattern detection in family 1 and 2. The results for 4 control 
probes and exons 1, 2, 5, 8, 10, 13, 16, 19, 21, 24 and 26 of the EHMT1 
gene are indicated. (a) and (b) indicate the results of the MLPA analysis 
in the proband and the mother of family 1, showing mosaicism for the 
9q34.3 deletion in both blood lymphocytes (a) and fibroblasts (b) of the 
mother. Note that a lower percentage of the fibroblasts carries the 9q 
deletion as compared to the lymphocytes. (c)-(e) show the results of the 
FISH analysis on cells derived from buccal swabs in the proband and 
the mother of family 2. (c) shows only one red signal, indicating the 
deletion of probe RP11-417A4 (red color) in chromosome region 9q34.3 
in the proband. (d) and (e) show mosaicism in the mother with a normal 
signal pattern for probe RP11-417A4 in (d) (two red signals) and only 
one red signal in (e), indicative for a loss in 9q34.4 in this cell. The 
centromere 9 probe is labeled green and shows a normal FISH pattern 
(two signals) in (c)-(e).
Chapter 4.1.2 Chapter 4.1.2
362 363
appendix appendix
Figure 1   Clinical pictures, A and B show the typical facial features of  
Kleefstra syndrome in patient 1. Note the midface hypoplasia, 
arched eyebrows and prognathism. C and D show the typical facial 
appearance of Pitt Hopkins syndrome in patient 2. Note the coarse 
face with prognathism, broad mouth with down turned corners and 
large nose. E-H show patient 3 with a mutation in MECP2 (E-F) and 
his carrier sister (G-H). I-J show patient 4 in whom we identified a 
mutation in CDKL5. Note her coarse face. K-N show patient 5 (K-L) 
and 6 (M-N) with Dravet syndrome. O-P show patient 7 with 
 Phelan-McDermid syndrome. Note the long face and full lips.  
Q-T show the brother pair with Phelan-McDermid syndrome.  
Note the long face, prominent chin and large ears in both brothers.
Figure 2   Schematic representation of human DYNC1H1 and mutations  
in patient 1, 2 and the axonal (type 2) form of Charcot-Marie-Tooth 
(CMT2) disease family reported in Weedon et al.22 together with  
the mutations of known mouse models.
Schematic representation of the mapped exome sequencing reads visualized using the Integrative 
Genomics Viewer (IGV) browser for patient 1 (panel A) and patient 2 (panel B), respectively. The upper 
part shows the per-base coverage, with coverage represented in gray indicating the wild-type base, 
whereas colored bases indicate the detection of variants. Also, a representation (part of) of exon 61 and 
exon 22 are provided for orientation. Individual sequence reads for patient 1 and patient 2 both show a 
heterozygous variant, which was followed up by Sanger sequencing, confirming the de novo occurrence 
in both patients. In panel (C), the DYNC1H1 protein is visualized according to Weedon et al. with the 
N-terminal region indicated by a gray horizontal bar, and the stem domain shown on above (amino acids 
53-1867). The residues involving DYNC1H1 dimerisation (300-1140) are shown by a pink bar. The 
C-terminal motor domain (amino acids 1868-4646) is shown in purple colour, with the seven ATPase 
domains represented by circles and the stalk region by a horizontal bar. The equivalent positions of 
mutations in three mouse models, Loa, Swl, and Cra1, are shown below the representation. Note that the 
human protein contains two additional glycine residues at position 7 relative to mouse Dync1h1, that is 
numbering of equivalent residues in human DYNC1H1 is 2 higher than in mouse models. The three 
mutations reported in patients, including p.(His3822Pro) in patient 1, p.(Glu1518Lys) in patient 2, and p.
(His306Arg) reported by Weedon et al. are  indicated with arrows according to their relative positions of 
the functional domains of the DYNC1H1 protein. 
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Figure 3   Schematic overview of GATAD2B mutations.
Schematic representation of GATAD2B, with its domain structure based on Alamut2.0. In addition, the 
mutations identified in this gene are indicated with their respective location at protein level. aa denotes 
amino acid number.
Clinical comparison of patients with mutations in GATAD2B – Two patients were shown to have a de 
novo mutation, p.(Gln470*) and p.(Asn195Lysfs*30) respectively, in the transcriptional repressor 
GATAD2B. Phenotypic comparison of these two patients was highly suggestive for a related genetic 
cause. They both had severe developmental delay with delayed motor milestones, only limited speech 
and overlapping facial features.
Figure 4   Schematic overview of CTNNB1 mutations.
Schematic representation of CTNNB1, with its domain structure based on Alamut2.0. In addition, the 
mutations identified in this gene are indicated with their respective location at protein level. aa denotes 
amino acid number
Clinical comparison of patients with mutations in CTNNB1 – Two patients were shown to have a de 
novo loss-of-function mutation in CTNNB1, including a p.(Arg515*) nonsense mutation and a p.
(Ser425Thrfs*11) frameshift mutation. For a third patient, carrying a p.(Gln309*) nonsense mutation, only 
maternal DNA was available for testing its segregation and was found to be absent. All patients presented 
with similar features comprising severe ID with absent or very limited speech, microcephaly and spasticity 
due to which the ability to walk was severely impaired.
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